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Summary	  	  In	   the	  protozoan	  parasite	  Trypanosoma	  brucei	  gene	   expression	   is	  mostly	   regulated	  on	  the	  post-­‐transcriptional	  level.	  C3H	  zinc	  fingers	  have	  shown	  to	  play	  an	  important	  role	  in	  this	  process.	  So	  far,	  all	  described	  C3H	  zinc	  finger	  in	  Trypanosoma	  brucei	  have	  shown	  to	  stabilize	  their	  targets.	  	  This	  work	  focuses	  on	  the	  zinc	  finger	  protein	  ZC3H32.	  A	  large-­‐scale	  isolation	  of	  free	  and	  membrane-­‐bound	  polyribosomes	   from	  proyclic	  and	  bloodstream	  trypanosomes,	  which	  is	   also	   described	   in	   this	   thesis,	   suggested	   that	   this	   protein	   associates	   with	  polyribosomes.	   However,	   small-­‐scale	   polyribosome	   isolations	   followed	   by	   Western	  blotting	   revealed	   that	   only	   a	   minor	   fraction	   of	   it	   is	   actually	   associated	   with	  polyribosomes.	  	  Immunofluorescence	   showed	   that	   ZC3H32	   localizes	   to	   the	   cytoplasm.	   A	   yeast-­‐two-­‐hybrid	  screen	  identified	  it	  as	  a	  putative	  binding	  partner	  of	  MKT1.	  This	  interaction	  was	  confirmed	  by	  co-­‐immunoprecipitation.	  	  RNAi,	  as	  well	  as	  knock-­‐out	  studies,	  showed	  that	  ZC3H32	  is	  essential	  in	  the	  bloodstream	  form.	  Northern	  blotting,	  as	  well	  as	  a	  SILAC	  screen	  by	  Urbaniak	  et	  al.	   indicate	   that	   it	   is	  also	  enriched	  in	  this	  life-­‐cycle	  stage	  as	  compared	  to	  procyclics.	  	  Artificial	   tethering	   of	   ZC3H32	   to	   a	   reporter	   RNA	   lead	   to	   the	   RNA’s	   degradation,	  suggesting	   that	   this	   protein	   has	   a	   destabilizing	   effect.	   Tethering	   of	   ZC3H32	   fragments	  revealed	   that	  both	   its	  N-­‐terminal,	  as	  well	  as	   its	  C-­‐terminal	   region	  are	  able	   to	  generate	  this	  destabilization	  effect,	  while	   the	  middle	  region,	  containing	  the	  zinc	   finger	  domains,	  can’t.	  RNA	  isolation	  from	  polyribosomal	  fractions	  showed	  that	  tethering	  of	  ZC3H32	  also	  decreases	  the	  translation	  of	  the	  reporter	  RNA.	  	  High-­‐throughput	  sequencing	  of	  poly-­‐A+	  RNA	  from	  a	  ZC3H32-­‐RNAi	  cell	  line	  revealed	  20	  RNAs	   that	   were	   up-­‐regulated	   upon	   ZC3H32	   knock-­‐down	   and	   thus	   might	   be	   putative	  targets.	   The	   upregulation	   was	   confirmed	   for	   three	   of	   these	   candidate	   RNAs.	   The	  majority	   of	   the	   putative	   ZC3H32	   targets	   play	   a	   role	   in	   the	   trypanosome’s	   energy	  metabolism	   and	  15	   of	   them	  are	   up-­‐regulated	   in	   procyclics.	   These	   results	   suggest	   that	  ZC3H32	   might	   be	   involved	   in	   the	   stage-­‐specific	   regulation	   of	   these	   RNAs	   in	   the	  bloodstream	  form.	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1.1	  Kinetoplastids	  	  
	  
Trypanosoma	   brucei	   are	   protozoan	   parasites	   of	   the	   order	   Kinetoplastida.	   This	   order,	  named	  after	   the	  kinetoplast,	   a	  granule	  containing	   the	  mitochondrial	  genome,	  diverged	  early	  from	  the	  eukaryotic	  lineage	  (Sogin,	  Gunderson	  et	  al.	  1989).	  	  
Trypanosoma	   brucei	   are	   transmitted	   by	   tsetse	   flies	   (Glossina	   genus).	   Parasites	   of	   the	  subspecies	  T.	  b.	  rhodesiense	  and	  T.	  b.	  gambiense	  can	  infect	  humans,	  while	  the	  subspecies	  	  
T.	  b.	  brucei	  causes	  an	  illness	  in	  cattle	  known	  as	  nagana.	  Other	  parasitic	  trypanosomatids	  include	  Trypanosoma	  cruzi,	  which	  causes	  Chagas	  disease	  (or	  American	  trypanosomiasis)	  and	  the	  parasites	  of	  the	  Leishmania	  genus.	  	  	  




Fig.	  1:	  Life	  cycle	  of	  Trypanosoma	  brucei,	  taken	  from	  (Kramer	  2012)	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1.3	  Antigenic	  variation	  in	  the	  bloodstream	  form	  	  In	  the	  bloodstream	  of	  the	  mammalian	  host,	  trypanosomes	  are	  shielded	  by	  a	  dense	  coat	  of	   variant	   surface	   glycoproteins	   (VSGs),	   approximately	   10	   million	   per	   cell	   (Rudenko	  2011).	   Because	   of	   this	   high	   density,	   VSG	   represents	   about	   7-­‐10%	   of	   the	   cells	   total	  protein.	  	  Trypanosomes	  possess	  about	  1000	  VSG	  variants,	  of	  which	  about	  5%	  are	  fully	  functional.	  The	   remaining	   genes	   are	   pseudogenes	   (Marcello	   and	   Barry	   2007).	   There	   are	   ten	   to	  twenty	  VSG	  expression	  sites,	  each	  containing	  one	  VSG	  gene	  as	  well	  as	  several	  expression	  site	  associated	  genes	  (reviewed	  by	  (Rudenko	  2011)).	  These	  expression	  sites	  are	  located	  at	  telomeres.	  	  The	  other	  VSG	  genes	  are	  either	  localized	  at	  the	  subtelomeric	  regions	  (150-­‐250	  genes)	  or	  at	   the	   telomeres	   of	  minichromosomes	   (1250-­‐1400	   genes)	   (De	   Lange	   and	   Borst	   1982,	  Van	  der	  Ploeg,	  Cornelissen	  et	  al.	  1984,	  Weiden,	  Osheim	  et	  al.	  1991).	  Opposite	   to	   the	  majority	   of	   the	   protein	   coding	   genes	   of	  Trypanosoma	  brucei,	   the	  VSG	  genes,	  as	  well	  as	  the	  procyclin	  genes,	  are	  transcribed	  by	  Polymerase	  I	  (Rudenko,	  Bishop	  et	  al.	  1989).	  	  Only	  one	  VSG	  gene	  is	  transcribed	  at	  a	  time,	  the	  other	  expression	  sites	  are	  silenced.	  The	  expression	  of	  the	  active	  VSG	  site	  takes	  place	  in	  an	  extranucleolar	   locus,	  the	  expression	  site	   body	   (ESB)	   (Navarro	   and	   Gull	   2001).	   The	   monoallellic	   expression	   of	   VSG	   is	  controlled	  at	  the	  epigenetic	  level	  (reviewed	  by	  (Horn	  and	  McCulloch	  2010)):	  the	  active	  expression	   site	   is	   depleted	   of	   nucleosomes	   (Figueiredo	   and	   Cross	   2010),	   while	   the	  silenced	  ones	  are	  not.	  	  	  
	  
Fig.	   2:	   Schematic	   representation	   of	   a	   typical	   VSG	   expression	   site.	   Taken	   from	   (Rudenko	  2011).	  The	   open	   flag	   represents	   the	   Polymerase	   I	   promoter,	   the	   filled	   boxes	   the	   expression	   site	  associated	  genes	  (ESAGs).	  The	  black	  arrow	  shows	  the	  polycistronic	  transcription	  unit,	  the	  three	  triangles	  at	  the	  end	  represent	  the	  telomeric	  repeats.	  	  	  The	  VSG	  variant	   is	  exchanged	  periodically.	   In	  pleomorphic	  cells,	  approximately	  10-­‐2	   to	  10-­‐3	  trypanosomes	  switch	  per	  generation	  (Turner	  and	  Barry	  1989,	  Robinson,	  Burman	  et	  al.	  1999).	  In	  other	  words,	  0.1-­‐1%	  of	  “newborn”	  trypanosomes	  express	  a	  different	  VSG.	  	  In	  monomorphic	  cell	  lines,	  like	  the	  ones	  used	  in	  the	  experiments	  described	  in	  this	  thesis,	  these	   switches	   occur	   less	   frequent	   (10−6	   to	   10−7	   switch/trypanosome/generation)	  (Lamont,	  Tucker	  et	  al.	  1986,	  Robinson,	  Burman	  et	  al.	  1999).	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There	  are	  several	  switching	  mechanisms,	  the	  most	  common	  are	  shown	  in	  figure	  3.	  	  There	   are	   two	   principle	   mechanisms:	   recombinant	   switching	   and	   transcription	  switching.	   Transcription	   switching	  means	   that	   the	   current	   expression	   site	   is	   silenced	  and	  another	  one	  is	  activated	  (see	  fig.	  3,	  panel	  D).	  	  Recombinant	  switching,	  as	  shown	  in	  fig.	  3	  (panel	  A,	  B	  and	  C)	  means	  that	  a	  new	  VSG	  gene	  is	   inserted	   in	   the	   expression	   site.	   This	   can	   happen	   by	   three	   different	   mechanisms:	  Duplicative	   gene	   conversion	   (A),	   where	   a	   gene	   is	   copied	   into	   the	   expression	   site,	  segmental	  gene	  conversion	  (B),	  were	  different	  parts	  of	  different	  VSGs	  are	  used	  to	  make	  a	  new	   “mosaic	   VSG”	   (Marcello	   and	   Barry	   2007,	   Hall,	   Wang	   et	   al.	   2013)	   or	   telomere	  exchange	   (C),	  which	  means	   that,	   due	   to	   a	   crossover	  with	   another	   telomere,	   the	   active	  
VSG	   changes	  place	  with	  another	  VSG	  variant.	  Opposite	   to	   the	  other	   two	  recombination	  mechanisms,	  the	  gene	  copy	  of	  the	  original	  VSG	  is	  kept	  with	  this	  mechanism.	  	  	  
	  
Fig	  3:	  Most	   important	  mechanisms	   for	  VSG	   switching	   in	  Trypanosoma	  brucei.	  Taken	  from	  (Rudenko	  2011).	  
	  Upon	   differentiation,	   the	   VSG	   coat	   is	   replaced	   by	   a	   procyclin	   coat.	   This	   process	   is	  regulated	  at	  several	  levels:	  transcription	  elongation	  is	  stopped	  (Vanhamme,	  Berberof	  et	  al.	   1995)	   and	   the	   VSG	   proteins	   on	   the	   surface	   are	   cleaved	   by	   a	  glycosylphosphatidylinositol-­‐specific	   phospholipase	   C	   (GPI-­‐PLC)	   and	   a	   zinc	  metalloprotease	  (MSP-­‐B)	  (Gruszynski,	  van	  Deursen	  et	  al.	  2006).	  The	  process	  is	  also	  controlled	  on	  the	  RNA	  level.	  The	  half-­‐life	  of	  the	  VSG	  mRNA	  decreases	  from	  approximately	  4.5h	  to	  1.2h	  when	  differentiation	  is	  induced	  in	  vitro	  by	  the	  addition	  of	  cis-­‐aconitate	   and	  a	   temperature	   reduction	   from	  37°C	   to	  27°C	   (Ehlers,	   Czichos	   et	   al.	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1987).	  Regulation	  of	  VSG	  mRNA	  levels	   is	  probably	  controlled	  by	  a	  97nt	  element	  at	   the	  3’end	   of	   the	   RNA,	   which	   is	   found	   next	   to	   the	   polyadenylation	   site.	   Addition	   of	   this	  element	  to	  the	  3’UTR	  of	  a	  reporter	  RNA	  has	  lead	  to	  its	  stabilization	  in	  the	  bloodstream	  form	   and	   to	   its	   degradation	   in	   the	   procyclic	   form	   (Berberof,	   Vanhamme	   et	   al.	   1995).	  That	   indicates	   that	   there	  are	   specific	  proteins	   interacting	  with	   the	  VSG	  RNA,	  however,	  these	  binding	  partners	  are	  unknown.	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1.4	  Energy	  metabolism	  in	  trypanosomes	  	  In	   the	   bloodstream	   form,	   glucose	   is	   the	  main	   energy	   source.	   It	   is	  mainly	   degraded	   to	  pyruvate	  (Flynn	  and	  Bowman	  1973,	  Hannaert,	  Bringaud	  et	  al.	  2003),	  but	  also	  acetyl-­‐CoA	  is	  produced,	  probably	  as	  a	  starting	  product	  for	  the	  synthesis	  of	  lipids	  (Mazet,	  Morand	  et	  al.	  2013).	  Glycolysis	  mainly	   takes	  place	   in	  a	   specialized	  peroxisome-­‐like	  organelle,	   the	  glycosome	  	  (Hannaert	  and	  Michels	  1994).	  	  
	  
Fig.	  4:	  Glucose	  metabolism	   in	   the	  bloodstream	   form	  trypanosome.	  Taken	  from	  (Hannaert,	  Bringaud	  et	  al.	  2003).	  	  Enzymes:	  1:	  Hexokinase,	  2:	  Glucose-­‐6-­‐phosphate-­‐isomerase,	  3:	  Phosphofructokinase,	  4:	  Aldolase,	  5:	   Triosephosphate-­‐isomerase,	   6:	   Glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	   7:	  Phosphoglycerate	   kinase	   8:	   Glycerol-­‐3-­‐phosphate	   dehydrogenase,	   9:	   Glycerol	   kinase	   10:	  	  Phosphoglycerate	  mutase	  11:	  Enolase	  12:	  Pyruvate	  kinase	  13:	  Glycerol-­‐3-­‐phosphate	  oxidase	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In	   the	   procyclic	   form,	   the	   main	   energy	   sources	   are	   amino	   acids	   like	   proline	   and	  threonine	  (Evans	  and	  Brown	  1972,	  Cross,	  Klein	  et	  al.	  1975).	  However,	  when	  glucose	  is	  present,	   procyclics	   prefer	   it	   to	   proline	   (Lamour,	   Rivière	   et	   al.	   2005).	   Unlike	   as	   in	   the	  bloodstream	  form,	  the	  TCA	  cycle	  is	  present	  in	  this	  life	  cycle	  stage	  (see	  fig.	  5)	  but	  it	  does	  not	   operate	   as	   a	   full	   cycle,	   and	   does	   not	   contribute	   much	   to	   ATP	   production	   (van	  Weelden,	  Fast	  et	  al.	  2003).	  	  Threonine	   is	   first	   oxidized	   by	   threonine-­‐3-­‐dehydrogenase	   (TDH)	   and	   then	   split	   into	  glycine	   and	   Acetyl-­‐CoA	   by	   2,2-­‐amino-­‐3-­‐ketobutyrate-­‐coenzyme-­‐A-­‐ligase.	   Acetyl-­‐CoA	   is	  then	   converted	   to	   acetate,	   by	   acetate:succinate	   CoA-­‐transferase,	   leading	   to	   the	  production	   of	   Succinyl-­‐CoA,	   which	   is	   converted	   to	   Succinate	   by	   the	   TCA	   enzyme	  Succinate	  dehydrogenase	  in	  an	  ATP	  generating	  reaction.	  	  While	  not	  being	  a	  great	  ATP	  source,	  threonine	  is	  the	  main	  source	  for	  acetyl-­‐CoA,	  which	  is	  used	  for	  the	  synthesis	  of	  fatty	  acid	  synthesis	  (Millerioux,	  Ebikeme	  et	  al.	  2013).	  	  Proline	  is	  converted	  to	  α-­‐Ketoglutarate,	  which	  is	  also	  converted	  into	  Succinyl-­‐CoA.	  This	  yields	   either	   three	   reaction	   equivalents	   or,	   when	   glutamate:oxoglutrate	  aminotransferase	  is	  used	  for	  the	  last	  step	  of	  the	  pathway	  (conversion	  of	  Glutamate	  into	  
α-­‐Ketoglutarate),	   this	   process	   yields	   two	   reaction	   equivalents	   and	   one	   oxoacid	   gets	  converted	  into	  an	  amino	  acid	  (see	  fig.	  5).	  Opposite	   to	   the	   bloodstream	   form,	   the	   respiratory	   chain	   is	   present	   in	   procyclics.	   This	  respiratory	   chain	   is	   similar	   to	   that	   of	   other	   eukaryotes,	   however,	   additionally	   to	  complex	   I	   and	   II,	   there	   are	   two	   other	   enzymes	   donating	   electrons	   to	   the	   ubiquinone	  pool:	  glycerol-­‐3-­‐dehydrogenase	  and	  a	  rotenone-­‐insensitive	  NADH-­‐oxidoreductase	  (Fang	  and	   Beattie	   2002).	   This	   kind	   of	   NADH-­‐oxidoreductase	   can	   also	   be	   found	   in	   Archaea,	  




Fig.	   5:	   Energy	   metabolism	   in	   the	   procyclic	   trypanosome.	   Taken	   from	   (van	   Hellemond,	  Opperdoes	  et	  al.	  2005),	  modified	  from(van	  Weelden,	  van	  Hellemond	  et	  al.	  2005).	  	  Ovals:	  substrates,	  Boxes:	  end	  products.	  	  Broad	  arrows	  in	  the	  citric	  acid	  cycle	   indicate	  the	  parts	  of	  the	  citric	  acid	  cycle	  that	  are	  active	  in	  procyclics.	  	  Note:	  Acetate,	  not	  citrate,	  is	  shuttled	  out	  of	  the	  mitochondrion	  in	  trypanosomes	  (Riviere,	  Moreau	  et	  al.	  2009).	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1.5	  RNA	  transcription	  in	  trypanosomes	  	  The	   majority	   of	   protein	   coding	   genes	   in	   trypanosomes	   is	   transcribed	   in	   large	  polycistronic	   transcription	   units.	   The	   transcription	   of	   these	   units	   seems	   to	   be	  mostly	  unregulated.	  There	  is	  only	  one	  described	  RNA	  Polymerase	  II	  promoter,	  the	  promoter	  of	  the	  spliced	  leader	  RNA	  (Gilinger	  and	  Bellofatto	  2001).	  	  The	  polycistronic	  units	  are	  separated	  by	  trans-­‐splicing.	   In	   this	  process	  a	  5’	   capped,	  39	  nucleotide	  RNA,	  the	  spliced	  leader	  (SL),	  is	  attached	  to	  the	  mRNA	  (Boothroyd	  and	  Cross	  1982).	   Trans-­‐splicing	   is	   coupled	   to	   polyadenylation	   (Sather	   and	   Agabian	   1985,	   Hug,	  Hotz	  et	  al.	  1994,	  Vassella,	  Braun	  et	  al.	  1994).	  	  As	   the	   transcription	   of	   most	   genes	   is	   not	   regulated	   in	   trypanosomes,	   post-­‐transcriptional	  regulation,	  especially	  the	  control	  of	  mRNA	  levels,	  plays	  an	  important	  role	  in	  these	  parasites,	  which	  makes	  them	  a	  model	  organism	  to	  study	  these	  processes.	  	  	  
1.6	  Regulation	  of	  RNA	  stability	  in	  trypanosomes	  While	  transcription	  regulation	  is	  mostly	  absent	  in	  trypanosomes,	  mRNA	  levels	  vary	  a	  lot.	  While	  most	  of	  the	  transcripts	  are	  present	  with	  only	  three	  copies	  per	  cell	  or	  less,	  others,	  especially	   RNAs	   encoding	   the	   tubulins,	   histones,	   and	   ribosomal	   proteins	   are	   quite	  abundant,	   for	  example	  600	  copies	  of	   the	  alpha	   tubulin	  mRNA	  are	  present	  per	  cell	  and	  about	  a	  hundred	  of	  the	  mRNA	  of	  the	  ribosomal	  protein	  L28	  (Manful,	  Fadda	  et	  al.	  2011).	  Although	   some	   genes	   are	   present	   with	   more	   than	   one	   copy	   (e.g.	   tubulin,	   actin),	   this	  difference	  is	  mostly	  due	  to	  the	  regulation	  of	  RNA	  stability.	  	  Most	  mRNAs	   in	   trypanosomes	  are	  rather	  unstable,	   the	  median	  half	   life	  of	  an	  mRNA	   in	  the	  bloodstream	  form	  is	  13	  min	  and	  only	  5%	  of	  the	  RNAs	  have	  a	  half	  life	  of	  more	  than	  1h	  (Manful,	  Fadda	  et	  al.	  2011).	   In	  comparison,	   in	  mammalian	  cells	  the	  half-­‐life	  on	  mRNAs	  has	  been	  shown	  to	  range	  from	  4	  to	  10	  hours	  (Yang,	  van	  Nimwegen	  et	  al.	  2003,	  Sharova,	  Sharov	  et	  al.	  2009,	  t	  Hoen,	  Hirsch	  et	  al.	  2011,	  Clayton	  2013).	  Also,	   RNA	   patterns	   in	   trypanosomes	   change	   in	   answer	   to	   different	   environmental	  conditions	  (Najafabadi,	  Lu	  et	  al.	  2013)	  and	  between	  the	  different	  life	  cycle	  stages:	  5%	  to	  25%	  of	   all	  mRNAs	   are	  developmentally	   regulated	  between	  bloodstream	  and	  procyclic	  trypanosomes.	  (Brems,	  Guilbride	  et	  al.	  2005,	  Jensen,	  Sivam	  et	  al.	  2009,	  Kabani,	  Fenn	  et	  al.	  2009,	   Queiroz,	   Benz	   et	   al.	   2009,	   Siegel,	   Hekstra	   et	   al.	   2010,	   Kramer	   and	   Carrington	  2011).	  	  The	   stability	   of	   an	   mRNA	   is	   mainly	   determined	   by	   the	   proteins	   binding	   to	   it.	   These	  proteins	  are	  also	  called	  trans-­‐acting	  factors.	  The	  trans-­‐acting	  factors	  and	  the	  mRNA	  form	  messenger	  ribonucleoprotein	  complexes,	  short	  mRNPs.	  While	  some	  of	  the	  RNA	  binding	  proteins,	  e.g.	  the	  poly-­‐A	  binding	  proteins	  (PABP1	  and	  2),	  bind	  to	  the	  majority	  of	  mRNAs,	  others	  are	  more	  specific	  (Clayton	  2013).	  It	  is	  thought	  that	  most	  regulating	  RNA	  binding	  proteins	   in	   eukaryotes	   bind	   to	   a	   specific	   subset	   of	   functionally	   related	   RNAs	   (Keene	  2007).	  This	  has	  already	  been	  observed	  in	  trypanosomes,	  for	  example	  knock-­‐down	  of	  the	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RRM	   domain	   protein	   DRBD3	   (also	   called	   PTB1)	   influences	   mainly	   RNAs	   encoding	  transmembrane	   proteins	   (Stern,	   Gupta	   et	   al.	   2009).	   Another	   example	   is	   the	   pumilio	  protein	  Puf9,	  which	  has	  been	  shown	  to	  bind	  to	  a	  subset	  of	  mRNAs	  which	  is	  enriched	  in	  the	   late	   G0	   phase	   (Archer,	   Luu	   et	   al.	   2009).	  Most	   Puf9	   targets	   contained	   a	   consensus	  sequence	   in	   their	   3’UTR	   (UUGUAC).	   Puf9	   and	   PTB1	   both	   stabilize	   their	   target	   RNAs,	  PTB1	  is	  also	  involved	  in	  splicing	  (Stern,	  Gupta	  et	  al.	  2009).	  	  The	  binding	   site	  of	  RNA	  binding	  proteins	   is	  mostly	   found	   in	   the	  untranslated	   regions,	  especially	  the	  3’UTR,	  of	  their	  target	  RNAs.	  However,	  there	  are	  exceptions,	   for	  example,	  the	  RNA	  binding	  protein	  RBP42	  binds	  preferably	  to	  the	  coding	  region	  of	  its	  targets	  (Das,	  Morales	  et	  al.	  2012).	  	  It	   has	   been	   shown	   that	   mRNAs	   with	   similar	   functions	   share	   common	  motifs	   in	   their	  3’UTRs,	   for	   example,	   a	   uridine-­‐rich	   sequence	   (UAUUUUUU)	   has	   been	   found	   to	   be	  enriched	   in	   the	   3’UTR	   of	   procyclic	   specific	   genes	   (Mayho,	   Fenn	   et	   al.	   2006).	   Common	  regulatory	  domains,	  which	  are	  found	  in	  the	  3’UTR	  of	  many	  RNAs,	  are	  AU-­‐rich	  elements,	  short	  AREs.	  RBP	  binding	  sites	  can	  be	  quite	  short,	  as	  the	  binding	  sites	  of	  most	  RNA	  binding	  proteins	  bind	   only	   to	   a	   few	   nucleotides:	   The	   most	   common	   RNA	   binding	   domain,	   the	   RRM	  domain	  in	  eukaroytes,	  normally	  binds	  two	  to	  eight	  nucleotides.	  The	  RRM	  domain	  is	  a	  90	  amino	  acid	  long	  motif	  and	  normally	  folds	  into	  a	  βαββαββ	  structure	  (Clery,	  Blatter	  et	  al.	  2008,	  Kramer	  and	  Carrington	  2011).	  Another	  RNA	  binding	  domain	   is	   the	  Puf	  domain,	  which	   consists	   of	   40	   amino	   acid	   repeats	   and	   forms	   an	   arc-­‐like	   structure	   (Wickens,	  Bernstein	  et	  al.	  2002).	  Each	  Puf	  repeat	  binds	  to	  one	  nucleotide	  (Wang,	  McLachlan	  et	  al.	  2002).	  Usually,	  Puf	  domains	  consist	  of	  eight	  Puf	  repeats.	  Trypanosoma	  brucei	  encodes	  10	  Puf	   proteins	   (Caro,	   Bercovich	   et	   al.	   2006)	   with	   eight	   Puf	   repeats	   or	   less.	   Puf9,	   for	  example,	  has	  six	  Puf	  repeats.	  Thus,	   the	  binding	  sites	  of	   these	  proteins	  are	  probably	  no	  longer	  than	  eight	  nucleotides	  or,	  in	  the	  case	  of	  Puf9,	  shorter.	  	  mRNAs	  can	  have	  multiple	  RBP	  binding	  sites	  in	  their	  sequence,	  therefore	  they	  can	  bind	  to	  different	  RNA	  binding	  proteins	  and	  form	  different	  mRNPs.	  The	  mRNP	  composition	  can	  in	  turn	  decide	  the	  fate	  of	  the	  RNA:	  whether	  it	  is	  translated,	  degraded	  or	  stored	  in	  stress	  granules	   or	   P-­‐bodies.	   This	   allows	   flexible	   regulation	   of	   the	   mRNA	   (Keene	   and	  Tenenbaum	  2002).	  	  The	  fact	  that	  one	  mRNA	  can	  have	  several	  regulatory	  elements	  and	  is	  usually	  regulated	  by	  multiple	  factors	  makes	  the	  dissection	  of	  regulatory	  UTRs	  difficult.	  	  An	   example	   is	   the	   3’UTR	   of	   the	   procyclin	   gene	   EP1.	   Procyclin	   genes	   are	   expressed	  specifically	   in	   the	   procyclic	   form.	   Transcription	   is	   down-­‐regulated	   in	   the	   bloodstream	  form	   to	   5-­‐15%	   (Berberof,	   Pays	   et	   al.	   1991,	   Vanhamme,	   Berberof	   et	   al.	   1995)	   and	   the	  transcribed	  procyclin	  RNA	  is	  unstable	  (Berberof,	  Vanhamme	  et	  al.	  1995,	  Furger,	  Schürch	  et	  al.	  1997,	  Hotz,	  Hartmann	  et	  al.	  1997).	  	  Three	  regulatory	  elements	  have	  been	  found	  in	  this	  UTR:	  two	  stabilizing	  stem	  loops	  (LI	  and	  LIII)	  and	  a	  destabilizing	  stem	  loop	  (LII)	  (Hehl,	  Vassella	  et	  al.	  1994,	  Furger,	  Schürch	  et	  al.	  1997,	  Hotz,	  Hartmann	  et	  al.	  1997,	  Schürch,	  Furger	  et	  al.	  1997).	  These	  structures	  
1.	  Introduction	  
18	  
are	  conserved	  in	  the	  UTRs	  of	  different	  EP	  genes,	  the	  rest	  of	  the	  3’UTR	  sequences	  varies.	  The	   destabilizing	   LII	   domain	   contains	   a	   conserved	   26mer,	   while	   the	   LIII	   domain	  contains	  a	  conserved	  16mer.	  	  The	  main	  method	  used	  to	   functionally	  map	  the	  EP1	  3’UTRs	  was	   to	  add	  the	  3’UTR	  to	  a	  reporter	   RNA	   and	   check	   the	   reporter’s	   expression.	   Deletions	   of	   different	   parts	   of	   the	  UTR	   served	   to	  map	   the	   regions	   responsible	   for	  positive	   and	  negative	   regulations.	  The	  results,	  however,	  were	  difficult	  to	  interpret,	  for	  several	  reasons:	  	  mRNA	   regulation	   can	   occur	   on	  more	   than	   one	   level	   (trans-­‐splicing,	   nuclear	   transport,	  mRNA	   stability,	   mRNA	   localization,	   translation	   etc.).	   For	   example,	   deletion	   of	   the	  conserved	  16mer	   in	  the	  LIII	  domain	   leads	  to	  a	  decrease	   in	  reporter	  protein	   levels,	  but	  not	  mRNA	  levels.	  This	  suggests	  an	  effect	  on	  translation,	  however,	  it	  could	  have	  also	  been	  caused	  by	  rapid	  protein	  degradation	  (Hehl,	  Vassella	  et	  al.	  1994).	  	  Different	  deletions	   can	  have	  different	  effects	  even	   if	   they	  affect	   the	   same	  domain.	  The	  regulation	  of	  the	  EP1	  RNA	  is	  stage-­‐specific,	  it	  is	  down-­‐regulated	  in	  the	  bloodstream	  and	  up-­‐regulated	   in	   the	   procyclic	   form.	   However,	   deletions	   of	   LII	   and	   LIII	   had	   the	   same	  effects	  in	  bloodstream	  and	  procyclics.	  LII	  deletion	  lead	  to	  an	  increase,	  LIII	  deletion	  to	  a	  decrease	   of	   reporter	  mRNA	   and	   protein	   levels.	   The	   effect	   on	   the	   protein	   levels	   were	  higher,	   which	   suggests	   translational	   regulation	   (Furger,	   Schürch	   et	   al.	   1997,	   Schürch,	  Furger	  et	  al.	  1997).	  While	  deletion	  of	  the	  entire	  LII	  domain	  did	  not	  show	  a	  stage-­‐specific	  effect,	  the	  effect	  of	  deletion	  of	  a	  part	  of	  this	  domain	  was	  stage	  specific.	  This	  part	  was	  the	  conserved	  26mer.	  In	  the	  bloodstream	  form,	  a	  CAT	  reporter	  RNA	  carrying	  the	  EP1	  3’UTR	  without	  the	  26mer	  deleted	  was	  ten	  times	  more	  abundant	  than	  a	  reporter	  mRNA	  with	  a	  complete	  EP1	  3’UTR.	  However,	  deleting	  the	  26mer	  had	  no	  effect	  on	  the	  expression	  of	  the	  reporter	  RNA	  in	  procyclic	  forms.	  (Hotz,	  Hartmann	  et	  al.	  1997).	  Thus,	  it	  can	  be	  concluded	  that	  sequences	  within	  a	  regulatory	  domain	  (in	  this	  case	  LII)	  can	  influence	  the	  regulation	  of	   the	   entire	   domain.	   As	   RNA	   binding	   proteins	   bind	   only	   to	   a	   few	   nucleotides,	   these	  sequences	  can	  be	  quite	  short.	  	  The	   open	   reading	   frame	   can	   have	   an	   effect	   on	   mRNA	   levels:	   while	   reporter	   RNAs	  carrying	  the	  EP1	  3’UTR	  could	  still	  be	  detected,	  the	  EP1	  RNA	  could	  not.	  Also,	  deletion	  of	  the	   destabilizing	   domain	   had	   a	   greater	   effect	   on	   the	   EP1	  RNA	   than	   on	   the	   reporter	  constructs	  (Schürch,	  Furger	  et	  al.	  1997).	  	  The	   surrounding	   sequences	  of	   a	   regulatory	  element	  might	  be	   important.	  For	  example,	  the	  26mer	  did	  not	   show	  an	  effect	  when	  being	   inserted	   into	  another	  part	  of	   the	  3’UTR	  (Hotz,	  Hartmann	  et	  al.	  1997).	  This	  can	  either	  be	  due	  to	  the	  three	  dimensional	  structure	  of	   the	   RNA:	   a	   regulatory	   element	   might	   not	   be	   functional	   if	   it	   is	   in	   the	   wrong	  conformation.	  It	  can	  also	  be	  due	  to	  the	  crosstalk	  between	  different	  regulatory	  elements:	  For	   example,	   deletion	   of	   the	   conserved	   16mer	   in	   the	   LIII	   domain	   decreases	   the	  reporter’s	  expression	  in	  both	  bloodstream	  and	  procyclics.	  However,	  if	  the	  destabilizing	  LII	  domain	  is	  deleted	  as	  well,	  the	  deletion	  of	  the	  16mer	  had	  no	  effect.	  This	  indicates	  that	  proteins	  binding	   to	   the	  16mer	   counteract	   the	  destabilizing	   effect	   of	   the	  LII	   domain.	  A	  possible	  candidate	  protein,	  which	  could	  regulate	  this	  effect	  is	  the	  C3H	  zinc	  finger	  ZFP3,	  
1.	  Introduction	  
19	  
which	  binds	  to	  the	  EP1	  and	  GPEET	  mRNAs	  (Walrad,	  Paterou	  et	  al.	  2009).	  The	  binding	  of	  ZFP3	  is	  dependent	  on	  LII	  and	  LIII,	  which	  indicates	  that	  it	  binds	  to	  one	  of	  this	  regions.	  It	  might	  be	  possible	  that	  ZFP3	  either	  induces	  translation	  or	  prevents	  a	  negative	  regulator	  from	  binding	   (Walrad,	   Paterou	   et	   al.	   2009).	   Another	   finding	   that	   supports	   this	   is	   that	  ZFP3	  is	  associated	  with	  polyribosomes	  in	  the	  procyclic,	  but	  not	  in	  the	  bloodstream	  form	  (Paterou,	  Walrad	  et	  al.	  2006).	  	  	  It	   can	   be	   concluded	   that	   the	   effect	   of	   regular	   domains	   in	   RNA	   sequences	   depends	   on	  many	   factors;	   for	   example	   the	   cellular	   environment	   (e.g.	   different	   life	   cycle	   stages,	  environmental	  stresses	  etc),	  the	  surrounding	  sequences	  in	  the	  3’UTR	  and	  also	  the	  open	  reading	  frame	  of	  the	  gene	  itself.	  	  There	  are	  many	  ways	   in	  which	  an	  RNA	  binding	  protein	  can	   influence	   its	   target	  mRNA.	  For	  most	  RNA	  binding	  proteins	  in	  trypanosomes,	  however,	  the	  mechanism	  is	  not	  known.	  	  Stabilizing	   factors	   can,	   for	   example,	   be	   involved	   in	   trans-­‐splicing,	   like	   DRBD3	   and	  DRBD4	   (also	   called	   PTB1	   and	   PTB2)(Stern,	   Gupta	   et	   al.	   2009).	   They	   also	   can	   prevent	  destabilizing	  factors	  from	  binding,	  either	  by	  competing	  with	  them	  for	  the	  same	  binding	  site	  or	  by	  changing	  the	  mRNA’s	  confirmation.	  	  Destabilizing	  factors	  can	  also	  act	  on	  different	  stages.	  An	  example	  for	  the	  different	  ways	  in	  which	  a	  protein	  can	  influence	  RNAs	  is	  the	  yeast	  protein	  DHH1	  (DEAD	  box	  helicase	  1).	  DHH1	  can	   induce	  decapping	  by	   interacting	  with	  both	  deadenylases	  and	   the	  decapping	  enzyme	  (Coller,	  Tucker	  et	  al.	  2001,	  Fischer	  and	  Weis	  2002).	  This	  protein	  is	  also	  involved	  in	   the	   formation	   of	   P-­‐bodies	   (Coller	   and	   Parker	   2005).	   P-­‐bodies	   are	   RNA-­‐protein	  aggregates	   were	   translationally	   repressed	   RNAs	   can	   both	   be	   stored	   and	   degraded	  (reviewed	  by	  (Kulkarni,	  Ozgur	  et	  al.	  2010)).	  DHH1	  also	   inhibits	   translation	  by	  slowing	  down	  ribosome	  movement	  (Sweet,	  Kovalak	  et	  al.	  2012).	  In	  T.	  brucei,	  it	  has	  been	  shown	  that	   DHH1	   destabilizes	   and	   represses	   the	   translation	   of	   developmentally	   regulated	  mRNAs	  in	  procyclics	  (Kramer,	  Queiroz	  et	  al.	  2010).	  	  
1.7	  mRNA	  degradation	  in	  trypanosomes	  mRNA	  degradation	  starts	  usually	  with	  deadenylation.	  This	   step	   is	  mostly	   catalyzed	  by	  the	  CAF1/NOT	  complex	  (Schwede,	  Ellis	  et	  al.	  2008),	  the	  Pan2/Pan3	  complex	  (Schwede,	  Manful	  et	  al.	  2009)	  or	  by	  one	  of	  the	  three	  PARN	  deadenylases	  (Utter,	  Garcia	  et	  al.	  2011).	  This	  step	  is	  normally	  followed	  by	  decapping,	  however,	  a	  general	  decapping	  enzyme	  has,	  so	  far,	  not	  been	  found	  in	  trypanosomes.	  The	  deadenylated	  mRNA	  can	  be	  degraded	  from	  the	  3’	  end	  by	   the	  exosome	  complex	   (Estevez,	  Kempf	  et	  al.	  2001,	  Estevez,	  Lehner	  et	  al.	  2003)	  and	  from	  the	  5’	  end	  by	  the	  exoribonuclease	  XRNA	  (Li,	  Irmer	  et	  al.	  2006).	  	  RNA	  regulation	  by	  micro	  RNAs	  does	  not	  play	  a	   role	   in	  Trypanosoma	  brucei:	  While	   the	  RNAi	  machinery	  is	  present	  in	  Trypanosoma	  brucei,	   it	  serves	  mainly	  for	  the	  degradation	  of	   retroposon	   transcripts	   but	   does	   not	   seem	   to	   process	   micro	   RNAs,	   as	   an	   affinity	  purification	  of	  TbAgo1	  revealed	  none	  (Tschudi,	  Shi	  et	  al.	  2012).	  The	  fact	  that	  TbAgo1	  is	  not	  essential	  in	  trypanosomes	  also	  indicates	  that	  RNAi	  does	  not	  play	  a	  major	  role	  in	  the	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regulation	  of	  mRNA	  stability	  (Janzen,	  van	  Deursen	  et	  al.	  2006).	  	  




Fig.	  6:	  Translation	  initiation	  in	  
eucaryotes	  Taken	  from	  (Kindler,	  Wang	  et	  al.	  2005).	  The	  43S	  complex,	  consisting	  of	  the	  small	  ribosomal	  subunit,	  the	  aminoacyl-­‐tRNA	  and	  the	  initiation	  factors	  eIF1,	  1A,	  2	  and	  3	  gets	  recruited	  to	  the	  mRNA.	  This	  is	  mediated	  by	  the	  eIF4	  complex,	  consisting	  of	  eIF4A	  and	  B,	  the	  cap-­‐binding	  protein	  eIF4E	  and	  eIF4G,	  which	  binds	  to	  the	  poly-­‐A	  protein,	  which	  leads	  to	  a	  circulation	  of	  the	  mRNA.	  	  In	  Leishmania,	  however,	  the	  eIF4E	  homologue,	  not	  the	  eIF4G	  homologue,	  seems	  to	  bind	  to	  PABP	  (Zinoviev	  and	  Shapira	  2012).	  After	  recruiting	  the	  43S	  complex	  to	  the	  mRNA,	  the	  complex	  “scans”	  the	  mRNA	  for	  the	  initiation	  codon.	  The	  scanning	  is	  promoted	  by	  eIF4A	  and	  B.	  Then,	  the	  60S	  subunit	  joins	  and	  the	  initiation	  factors	  are	  released.	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1.9	  CCCH	  zinc	  finger	  proteins	  	  One	  group	  of	  RNA	  binding	  proteins	  are	  the	  CCCH	  zinc	  finger	  proteins,	  which	  bind	  RNA	  with	  a	  zinc	  finger,	  a	  small	  protein	  motif,	  which	  is	  stabilized	  by	  its	  interaction	  with	  a	  zinc	  ion.	  The	  CCCH	  zinc	  finger	  consensus	  sequence	  is	  defined	  as	  C-­‐X(4-­‐15)-­‐C-­‐X(4-­‐6)-­‐C-­‐X3-­‐H	  (Wang,	  Guo	  et	  al.	  2008)	  (C:	  cysteine,	  H:	  histidine,	  X:	  any	  amino	  acid),	  the	  most	  common	  variations	  are	  the	  C-­‐X7-­‐C-­‐X5-­‐CX3-­‐H	  and	  the	  C-­‐X8-­‐C-­‐X5-­‐C-­‐X3-­‐H	  motif	  (Kramer,	  Kimblin	  et	  al.	  2010).	  	  The	  best-­‐described	  CCCH	  protein	   is	   tristetraproline	   (TTP),	   the	   founding	  protein	  of	   the	  Tis11	  family.	  Proteins	  of	  the	  Tis11	  family	  bind	  to	  AU-­‐rich	  elements	  (AREs)	  in	  the	  3’UTR	  of	  their	  target	  RNAs.	  Most	  Tis11	  family	  members	  destabilize	  their	  targets	  by	  interacting	  with	  the	  RNA	  degradation	  machinery	  (Sanduja,	  Blanco	  et	  al.	  2011)	  (see	  fig.	  7).	  	  	  
	  
Fig.	  7:	  ARE	  mediated	  mRNA	  decay	  by	  the	  Tis11	  family	  CCCH	  zinc	  finger	  proteins	  TTP	  and	  
Brf1	  and	  2.	  Taken	  from	  (Sanduja,	  Blanco	  et	  al.	  2011).	  TTP	   can	   induce	   deadenylation	   by	   recruiting	   the	   CCR4/CAF1/NOT	   deadenylation	   complex	   by	  direct	  interaction	  with	  CCR4	  and	  the	  central	  region	  of	  the	  scaffold	  protein	  NOT1(Sandler,	  Kreth	  et	   al.	   2011).	   They	   can	   also	   recruit	   the	   PARN	  deadenylase	   complex	   via	   an	   indirect	   interaction.	  TTP	  can	  interact	  with	  components	  of	  the	  exosome	  complex,	  which	  catalyses	  3’-­‐5’	  mRNA	  decay.	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TTP	  and	  BRF	  proteins	  can	  also	  mediate	  the	   localization	  of	   the	  deadenylated	  RNAs	  to	  P-­‐bodies,	  where	  TTP	   can	   interact	  with	   the	   decapping	   complex,	   as	  well	   as	   the	   exonuclease	  XRN1,	  which	  leads	  to	  5’-­‐3’	  exonucleotic	  decay.	  	  TTP	  mediate	  the	   interaction	  between	   its	   target	  RNA	  and	  Argonaute	  proteins	  (AGO),	  which	  can	  promote	  microRNA	  dependent	  decay.	  	  TTP	  and	  BRF	  are	  also	  associated	  with	  stress	  granules.	  It	  is	  thought	  that	  these	  proteins	  facilitate	  the	   transport	   of	   RNAs	   from	   stress	   granules	   to	   P-­‐bodies.	   The	   ARE	   binding	   proteins	   TIA1	   and	  TIAR	   have	   been	   shown,	   among	   other	   functions,	   to	   be	   important	   for	   stress	   granule	   formation	  (Kedersha,	   Gupta	   et	   al.	   1999).	   An	   immunoprecipitation	   of	   myc-­‐TTP	   followed	   by	   mass	  spectrometry	  suggested	  that	  TTP	  interacts	  with	  TIAR.	  	  
Trypanosoma	  brucei	  possess	  48	  putative	  zinc	  finger	  proteins,	  most	  of	  them	  are	  unique	  to	  kinetoplastids	  (Kramer,	  Kimblin	  et	  al.	  2010).	  One	  third	  of	  these	  proteins	  possess	  one	  zinc	  finger.	  It	  was	  thought	  that,	  as	  TTP	  requires	  both	   its	   CCCH	   domains	   to	   bind	   to	   RNA,	   that	   two	   zinc	   fingers	   are	   required	   for	   RNA	  binding	   (Lai,	  Carballo	  et	  al.	  1999)	  but	   it	  was	  shown	  by	   (Michel,	  Guerrerio	  et	  al.	  2003)	  that	   one	   functional	   zinc	   finger	   can	   bind	   RNA	   specifically.	   Therefore,	   these	   proteins	  containing	  a	  single	  zinc	  finger	  could	  either	  act	  on	  their	  own	  or	  as	  homo-­‐	  or	  heterodimers.	  In	  Michel	  at	  al.’s	  study,	  a	  seven	  nucleotide	  sequence	  was	  needed	  for	  the	  binding	  of	  the	  C3H	  domain	  peptide	  (UUUAUUU).	  	  The	  binding	  site	  for	  the	  two	  zinc	  fingers	  of	  Tristetraprolin	  is	  a	  nonamer	  (UUAUUUAUU)	  (Worthington,	  Pelo	  et	  al.	  2002,	  Blackshear,	  Lai	  et	  al.	  2003)	  and	  each	  zinc	  finger	  binds	  to	  one	  UAUU	  site	  (Hudson,	  Martinez-­‐Yamout	  et	  al.	  2004).	  TTP	  related	  proteins	  are	  likely	  to	  have	  the	  same	  or	  similar	  binding	  sites	  (Brooks	  and	  Blackshear	  2013).	  	  Contrary	  to	  TTP,	  the	  zinc	  finger	  proteins	  described	  in	  Trypanosoma	  brucei	  have	  so	  far	  all	  shown	  to	  have	  a	  stabilizing	  effect	  on	  their	  mRNA	  targets.	  	  ZFP1,	   ZFP2	   and	   ZFP3,	   a	   group	   of	   small	   proteins	   (12,	   16	   and	   14kDa	   respectively)	  possessing	  only	  one	  C3H	  zinc	   finger	  each,	   seem	   to	  play	  a	   role	   in	   the	  differentiation	  of	  bloodstream	  trypanosomes	  to	  procyclics.	  	  While	   ZFP2	   knock-­‐down	   inhibits	   differentiation	   (Hendriks,	   Robinson	   et	   al.	   2001),	  knock-­‐out	   of	   ZFP1	   impairs	   the	   repositioning	   of	   the	   kinetoplast	   during	   this	   process	  (Hendriks	  and	  Matthews	  2005).	  	  These	  three	  proteins	  have	  shown	  to	  interact	  with	  each	  other	  in	  vivo	  (Paterou,	  Walrad	  et	  al.	  2006).	  	  ZFP3	   binds	   to	   EP1	   and	   GPEET	   procyclin	   RNA	   (Paterou,	   Walrad	   et	   al.	   2006,	   Walrad,	  Paterou	  et	  al.	  2009),	  as	  well	  as	  several	  transcripts	  that	  are	  up-­‐regulated	  in	  the	  stumpy	  form.	   EP1	   RNA	   and	   other	   transcripts	   seem	   to	   be	   stabilized	   by	   ZFP3,	   as	   their	   levels	  increase	  if	  ZFP3	  is	  overexpressed	  (Walrad,	  Capewell	  et	  al.	  2012).	  	  ZC3H18	   probably	   plays	   a	   role	   in	   differentiation	   as	   well,	   as	   downregulation	   of	   this	  protein,	  while	  not	  stopping	  this	  process,	  does	  slow	  it	  down	  (Benz,	  Mulindwa	  et	  al.	  2011).	  ZC3H20	  is	  up-­‐regulated	  in	  procyclics,	  in	  opposite	  to	  the	  bloodstream	  form,	  and	  has	  been	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shown	   to	   stabilize	   and	   interact	   with	   two	   RNAs	  which	   are	   also	   enriched	   in	   procyclics	  (Ling,	  Trotter	  et	  al.	  2011).	  	  ZC3H12	  has	  been	  shown	  to	  interact	  with	  the	  exonuclease	  XRNA,	  but	  artificial	  tethering	  of	  this	  protein	  to	  a	  reporter	  RNA	  lead	  to	  no	  decrease	  in	  RNA	  levels	  (Ouna,	  Stewart	  et	  al.	  2012).	  	  ZC3H11	  is	  involved	  in	  the	  heat	  shock	  response	  in	  trypanosomes.	  It	  is	  up-­‐regulated	  upon	  heat	  shock	  and	   its	  RNA	  targets	   include	  chaperones,	  e.g.	  Hsp70.	   It	  has	  been	  shown	  that	  this	  zinc	  finger	  binds	  to	  the	  Hsp70	  RNA	  via	  an	  AU-­‐rich	  element	  in	  its	  UTR	  (Droll,	  Minia	  et	  al.	  2013).	  A	  TAP	  purification	  revealed	  that	  ZC3H11	  binds	  to	  MKT1.	  It	  was	  shown	  that	  MKT1	  (see	  fig.	  8)	  interacts	  with	  PBP1,	  which	  in	  turn	  interacts	  with	  the	  poly-­‐A-­‐binding	  protein.	  It	  is	  thought	   that	   this	  mechanism	   could	   lead	   to	   the	   stabilization	   of	   the	   target	   RNA	   (Singh,	  Minia	  et	  al.	  2014).	  	  
	  
Fig.	  8:	  Putative	  mechanism	  of	  MKT1.	  Taken	  from	  (Singh,	  Minia	  et	  al.	  2014).	  	  RBP:	  RNA	  binding	  protein,	  PK:	  protein	  kinase	  (putative	  MKT1	  interaction	  partner).	  	  	  	  A	   yeast-­‐two-­‐hybrid	   screen	   identified	   16	   predicted	   RNA-­‐binding	   proteins	   as	   putative	  MKT1	  binding	  partners.	  10	  of	   these	  16	  proteins	  were	  zinc	   finger	  proteins.	  The	   screen	  also	   identified	   a	   putative	   MKT1	   binding	   motif,	   the	   “HNPY”	   consensus	   motif	  ((H/N)(D/E/N/Q)PY).	  	  Another	  binding	  partner	  found	  in	  the	  yeast-­‐two-­‐hybrid	  screen	  is	  the	  protein	  Not2,	  which	  is	  a	  part	  of	  the	  CAF1-­‐NOT	  deadenylation	  complex.	  Also,	  two	  other	  components	  of	  this	  complex	  (CAF40	  ant	  NOT1)	  were	  co-­‐purified	  with	  MKT1	  in	  a	  TAP	  purification.	  This	  indicates	  that	  MKT1	  could,	  next	  to	  RNA	  stabilization,	  also	  mediate	  RNA	  deadenylation	  and	  thus	  RNA	  decay.	  (Singh,	  Minia	  et	  al.	  2014).	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1.10	  Aims	  of	  the	  thesis	  	  The	  main	  aim	  of	  my	   first	  and	  second	  project	   (described	   in	  section	  3.1	  and	  3.2)	  was	  to	  find	   trans-­‐acting	   factors	   of	   the	   VSG	   mRNA.	   Although	   there	   is	   evidence	   that	   VSG	  expressing	  is	  regulated	  on	  the	  mRNA	  level	  (Ehlers,	  Czichos	  et	  al.	  1987),	  so	  far	  no	  trans-­‐acting	  factors	  of	  the	  VSG	  mRNA	  have	  been	  found.	  	  The	   first	   step	   was	   to	   find	   proteins	   associated	   with	   free	   and	   membrane-­‐bound	  polyribosomes	   in	   procyclic	   and	   bloodstream	   cells.	   In	   order	   to	   do	   that,	   free	   and	  membrane-­‐bound	  polyribosomes	  were	  separated	  by	  ultracentrifugation	  at	  30	  000g	  and	  the	  polyribosomes	  were	  subsequently	  purified	  by	  separation	  on	  a	  sucrose-­‐gradient.	  The	  isolated	  polyribosomes	  were	  concentrated	  and	  sent	  for	  mass	  spectrometry	  analysis.	  	  As	  VSG	  is	  the	  major	  surface	  protein	  in	  trypanosomes,	  a	  large	  percentage	  of	  membrane-­‐bound	  polyribosomes	  should	   translate	  VSG.	  Thus,	  proteins	  with	  RNA	  binding	  domains	  that	   are	   found	   exclusively	   in	   the	  membrane-­‐bound	  polyribosomes	  of	   the	   bloodstream	  form	  might	  be	  candidates	  for	  VSG	  mRNA	  binding	  proteins.	  The	   large-­‐scale	   purifications	   should	   also	   be	   helpful	   in	   order	   to	   identify	   other	   RNA	  binding	  proteins	   that	   associate	  with	  polyribosomes.	  Knowing	  whether	  a	  putative	  RNA	  binding	   protein	   is	   associated	   with	   polyribosomes	   is	   quite	   useful;	   not	   only	   does	  polyribosome	   association	   point	   towards	   a	   function	   in	   translation	   regulation,	   it	   also	  indicates	  that	  this	  protein	  is	  indeed	  binding	  to	  RNA.	  	  The	   second	  method	   that	  was	   used	   to	   try	   to	   identify	  VSG	  mRNA	   binding	   proteins	  was	  polyribosome	   purification	   followed	   by	   immunoprecipitation	   with	   a	   polyclonal	   VSG	  antibody	  (described	  in	  section	  3.2).	  	  The	  third	  project	  described	  in	  this	  thesis	  (section	  3.3)	  was	  about	  identifying	  the	  role	  of	  a	  C3H	   zinc	   finger	   protein,	   ZC3H32.	   ZC3H32	   was	   identified	   in	   the	   mass	   spectrometry	  results	   of	   the	   purification	   of	   the	  membrane-­‐bound	   polyribosomes	   of	   the	   bloodstream	  form.	  It	  was	  also	  identified	  as	  a	  putative	  binding	  partner	  of	  MKT1	  in	  a	  yeast-­‐two-­‐hybrid	  screen	  (Singh,	  Minia	  et	  al.	  2014).	  The	  main	  aims	  of	  this	  project	  were	  to	  find	  out	  whether	  this	  protein	  is	  essential,	  how	  it	  influences	  the	  mRNA	  metabolism	  of	  the	  cell	  and	  to	  find	  its	  RNA	  targets	  and	  protein	  binding	  partners.	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2.	  Materials	  and	  Methods	  
2.1	  General	  cloning	  methods	  
2.1.1	  PCR	  PCR	  was	  performed	   in	  a	  Thermocycler	  using	  GoTaq	   (promega)	  polymerase.	  The	  usual	  settings	  were:	  	  DNA	  denaturation	  at	  95°C	   for	  5	  min,	  24-­‐30	  cycles	  with	  30-­‐45	  seconds	  denaturation	  at	  95°C,	  30-­‐45	  seconds	  annealing	  at	  52-­‐55°C	  and	  1min	  elongation	  at	  72°C.	  	  	  PCR	  reaction	  mix:	  1x	  Taq	  polymerase	  buffer	  100	  pM	  fw	  primer	  	  100	  pM	  reversed	  primer	  	  20mM	  DMSO	  (optionally)	  0.4	  mM	  of	  each	  dNTP	  100	  ng	  genomic	  DNA	  0.5U	  Taq	  polymerase	  	  	  For	  long	  open	  reading	  frames,	  as	  well	  as	  for	  the	  testing	  of	  the	  knock-­‐out	  cell	  lines,	  the	  Q5	  Polymerase	   (NEB)	   was	   used.	   The	   PCR	   protocol	   was	   adusted	   according	   the	  manufacturers	  instructions.	  	  	  The	   PCR	   product	   was	   analysed	   on	   a	   1%	   agarose	   gel	   containing	   0.7µg/ml	  ethidiumbromide	   and	   purified	   either	   by	   PCR-­‐clean	   up	   or	   the	   whole	   sample	   was	  separated	  by	  electrophoresis	  and	  purified	   from	  the	  agarose	  gel.	  For	  both	  methods	   the	  Nucleospin	  ExtractII	  kit	  (Macherey-­‐Nagel)	  was	  used.	  	  	  
2.1.2	  Isolation	  of	  trypanosome	  genomic	  DNA	  About	  108	   trypanosome	  cells	  were	  harvested	  by	  centrifugation	  (2000rpm,	  10min,	  RT).	  Genomic	  DNA	  was	  isolated	  using	  the	  illustra	  GenomicPrep	  cells	  and	  tissue	  DNA	  isolation	  kit	  (GE	  Healthcare).	  The	  isolated	  DNA	  was	  stored	  at	  –20°C.	  	  
2.1.3	  Agarose	  gel	  electrophoresis	  1%	  agarose	  Gels	  were	  prepared	  by	  dissolving	  1g	  ultrapure	  agarose	  in	  100ml	  TAE	  buffer	  in	  a	  microwave.	  After	  cooling	  down,	  10µl	  ethidiumbromide	  (70µg)	  were	  added	  and	  the	  gel	  mix	  was	  poured	  in	  a	  tray.	  6x	  DNA	  loading	  dye	  was	  added	  to	  a	  final	  concentration	  of	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1x	   and	   the	   DNA	   was	   separated	   at	   100-­‐170V.	   Visualisation	   was	   done	   using	   a	   UV	  Transilluminator.	  	  	  TAE	  buffer:	  40mM	  Tris-­‐HCl	  1mM	  EDTA	  (pH	  8.0)	  0.11%	  Acetic	  acid	  	  	  DNA	  loading	  dye:	  	  10mM	  Tris.HCl	  (pH=7.6)	  60mM	  EDTA	  0.09%	  Bromphenolblue	  0.09%	  Xylenecyanole	  FF	  60%	  glycerin	  
2.1.4	  Restriction	  endonuclease	  digest	  	  The	  reaction	  was	  performed	  in	  the	  buffer	  recommended	  by	  the	  manufacturer	  (NEB).	  In	  case	  of	  a	  double	  digest,	  which	  means	  that	  two	  enzymes	  were	  used	  simultaneously,	   the	  buffer	  which	  resulted	  in	  the	  highest	  activity	  of	  both	  enzymes	  was	  used.	  BSA	  was	  added	  if	  recommended.	  2-­‐5U	  of	  enzyme	  was	  used	  to	  digest	  1µg	  DNA.	  Usually,	  15µl	  purified	  PCR	  product	  or	  5µl	  plasmid	  preparation	  were	  digested	  with	  1µl	  restriction	  enzyme	  solution.	  The	   reaction	   was	   incubated	   for	   at	   least	   2h	   at	   the	   recommended	   temperature.	   If	   two	  temperatures	  were	  recommended,	  the	  digest	  was	  incubated	  for	  1h	  at	  the	  first,	  then	  for	  1h	  at	  the	  second	  temperature.	  	  After	   digestion,	   the	   DNA	  was	   purified	   either	   by	   PCR	   clean-­‐up	   or	   by	   gel	   extraction,	   as	  described	  before.	  Digested	  vectors	  were	  dephosphorylated	  first	  (see	  below).	  	  
2.1.5	  Dephosphorylation	  of	  5’ends	  Dephosphorylation	   was	   performed	   to	   prevent	   self-­‐ligation	   of	   a	   digested	   vector.	   The	  reaction	  was	  performed	  by	  adding	  1U	  alkaline	  phosphatase	   (Roche,	  1U/µl)	   and	  1µl	  of	  the	  respective	  buffer	  to	  the	  restriction	  digest	  and	  incubating	  for	  10-­‐15min	  at	  37°C.	  	  
2.1.6	  Klenow	  cleavage	  of	  DNA	  	  In	  order	  to	  get	  blunt	  ends	  after	  a	  restriction	  endonuclease	  digest	  the	  plasmid	  or	  the	  DNA	  fragment	  was	  treated	  with	  Klenow,	  Large	  Fragment	  of	  DNA	  Polymerase	  I	  (USB).	  2	  -­‐	  4µg	  DNA	   were	   blunted	   with	   1µl	   (5U)	   Klenow	   in	   a	   reaction	   including	   one	   volume	   of	   10x	  Klenow	  buffer	  and	  0.5mM	  of	  each	  dNTP.	  	  
2.1.7	  Ligation	  of	  DNA	  fragments	  PCR	  fragments	  or	  inserts	  excised	  from	  plasmids	  were	  ligated	  into	  digested	  vectors	  using	  1U	   DNA	   ligase	   (NEB,	   1U/µl)	   in	   a	   10µl	   reaction	   in	   the	   appropriate	   buffer.	   Insert	   and	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vector	  were	   ligated	   in	  a	  molar	   ratio	  of	  approximately	  1:5.	  The	  reaction	  was	   incubated	  for	  2-­‐16h	  at	  16°C.	  
2.1.8	  Transformation	  of	  competent	  cells	  	  50µl	  DH5α	  or	  BL21	  cells	  were	  thawed	  on	  ice	  and	  incubated	  on	  ice	  for	  5-­‐20min	  with	  10µl	  of	  the	  ligation	  reaction	  mix.	  Then	  the	  bacteria	  were	  heat-­‐shocked	  for	  90	  seconds	  at	  42°C,	  chilled	  for	  two	  minutes	  on	  ice	  and	  grown	  in	  200µl	  LB	  medium	  (without	  antibiotics)	  at	  37°C	  for	  30	  minutes.	  The	  transformation	  was	  plated	  out	  on	  LB	  plates	  with	  ampicillin	  and	  incubated	  at	  37°C	  over	  night.	  	  	  Luria	  Bertani	  (LB)	  Medium:	  10	  g/l	  Tryptone	  5	  g/l	  Yeast	  extract	  10	  g/l	  NaCl	  	  LB	  Medium	  +	  Agar	  (LB-­‐Agar)+	  Ampicillin	  LB	  Medium	  15	  g/l	  Bacto-­‐Agar	  	  100	  µg/ml	  ampicillin	  	  Ampicillin	  stock	  solution:	  10mg/ml	  ampicillin 
50% ethanol  
2.1.9	  Screening	  of	  transformed	  bacteria	  by	  colony	  PCR	  A	  PCR	  mastermix	  was	  prepared	  as	  described	  in	  2.2.1	  (without	  DMSO).	  	  10-­‐20	   colonies	   of	   one	   transformation	   were	   picked	   from	   an	   ampicillin	   plate	   using	   a	  yellow	   pipette	   tip,	   resuspended	   partially	   in	   10µl	   water	   and	   mixed	   with	   15µl	   PCR	  mastermix.	  The	  rest	  of	  the	  culture	  was	  used	  to	  inoculate	  2ml	  LB	  medium	  with	  ampicillin.	  10µl	   of	  pure	  water	  was	  used	  as	   a	  negative	   control.	  Alternatively,	  10-­‐20	   cultures	  were	  picked	   the	  day	  before	  and	  grown	  over	  night	   in	  2ml	  LB	  medium	  with	  ampicillin.	  2µl	  of	  each	  bacteria	  culture	  were	  added	  to	  23µl	  PCR	  mastermix.	  	  PCR	  was	  performed	  as	  described	  before.	  The	  PCR	  products	  were	  analyzed	  on	  an	  agarose	  gel.	  Positive	  clones	  were	  grown	  over	  night,	  or	  respectively	  the	   liquid	  culture	  was	  used	  directly	  for	  a	  plasmid	  preparation.	  	  
2.1.10	  Plasmid	  preparation	  2-­‐4ml	  LB	  media	  with	  ampicillin	  was	  inoculated	  with	  bacteria	  and	  grown	  over	  night.	  The	  plasmid	   preparation	   was	   done	   using	   the	   NucleoSpinPlasmid	   kit	   (Macherey-­‐Nagel)	  according	  to	  the	  manufacturers	  instructions.	  The	  plasmid	  preparation	  was	  screened	  for	  the	   desired	   vector	   by	   restriction	   digest.	   The	   vector	   was	   then	   checked	   by	   sequencing	  performed	  by	  GATC	  Biotech.	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For	   higher	   plasmid	   concentrations,	   which	   are	   needed	   for	   the	   transformation	   of	  trypanosomes,	  a	  12ml	  culture	  was	  inoculated	  and	  grown	  over	  night.	  6ml	  of	  this	  culture	  were	   spun	   down	   in	   an	   eppendorf	   tube	   and	   the	   cell	   pellet	   was	   used	   for	   a	   plasmid	  preperation.	   After	   elution	   of	   the	   plasmid	   DNA,	   the	   column	   was	   reused	   for	   the	  preparation	   of	   the	   rest	   of	   the	   culture.	   The	   two	   eluates	   were	   pooled	   and	   the	   plasmid	  concentration	  was	  measured	  using	  a	  nanodrop.	  	  
2.1.11	  Ethanol	  precipitation	  of	  DNA	  The	  DNA	  was	  mixed	  with	  1/10	  volume	  of	  3M	  sodium	  acetate	  and	  2.5	  volumes	  of	  ethanol.	  The	  mixture	  was	  incubated	  for	  at	  least	  45min	  at	  -­‐20°C.	  The	  precipitate	  was	  spun	  down	  in	  a	  microfuge	  at	   top	   speed	   for	  15min	  at	  4°C.	  The	   supernatant	  was	  discarded	  and	   the	  pellet	  air-­‐dried.	  If	  the	  DNA	  was	  used	  for	  the	  transformation	  of	  trypanosomes,	  the	  drying	  was	  done	  in	  a	  laminar	  flow	  hood.	  	  	  
2.2.	  Cell	  culture	  methods	  	  
2.2.1	  Cultivation	  of	  bloodstream	  trypanosomes	  Bloodstream	   trypanosomes	   were	   cultivated	   in	   HMI-­‐9	   medium	   at	   37°C	   in	   a	   humid	  athmosphere	  with	  5%	  CO2	  in	  a	  Heraeus	  incubator.	  In	  order	  to	  allow	  gaseous	  exchange,	  the	  caps	  of	  the	  flasks	  were	   loosely	  tied.	  Bloodstream	  cells	  were	  kept	  at	  concentrations	  around	  	  5.105	  cells/ml	  and	  not	  exceeeding	  2.106	  cells/ml.	  	  	  HMI-­‐9	  medium	  	  Iscove’s	  modified	  Dulbecco’s	  medium	   17.66	  g/l	  NaHCO3	  	   	   	   	   	   3.024	  g/l	  Hypoxanthine	   	   	   	   	   136	  mg/l	  Sodium	  pyruvate	   	   	   	   110	  mg/l	  Thymidine	   	   	   	   	   39	  mg/l	  Bathocuprono	  disulfonic	  acid	  disodium	  salt	   28	  mg/l	  pH	  =	  6.3	  The	  media	  was	  filter-­‐sterilized	  and	  stored	  at	  –20°C	  in	  450ml	  aliquots.	  	  Additional	  components	  (added	  prior	  to	  use):	  Heat-­‐inactivated	  FCS*	  (Biochrom)	   10%	  (v/v)	  	  Penicillin/Streptomycin	  (Sigma)	   50U/ml	  (5ml	  of	  a	  5000U/ml	  stock	  solution	  L-­‐Cysteine-­‐HCL.	  H2O	  	   	   1.5mM	  	  
β-­‐Mercaptoethanol	  (Sigma)	  	   0.14%	  (7µl)	  *Heat	  inactivation	  of	  FCS	  was	  done	  for	  30min	  at	  55°C	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For	  cryopreservation	  500µl	  of	  cells	  in	  a	  logarithmic	  state	  of	  growth	  (5-­‐10.105	  cells/ml)	  were	  transferred	  to	  cryovials	  and	  mixed	  with	  500µl	  of	  HMI-­‐9	  medium	  containing	  20%	  glycerol.	   To	   freeze	   the	   cells	   gradually,	   the	   cryovials	  were	  wrapped	   in	   a	   thick	   layer	   of	  paper,	  left	  at	  	  -­‐80°C	  for	  at	  least	  one	  day	  and	  then	  transferred	  to	  cryoboxes	  in	  a	  liquid	  N2	  tank.	  	  To	   restart	   the	   culture,	   the	   cells	  were	   thawed	   at	   4°C	   or	   at	   room	   temperature,	  washed	  once	  with	  HMI-­‐9	   and	   then	   resuspended	   in	  10-­‐20ml	  HMI-­‐9	   containing	   the	   appropriate	  antibiotics.	  	  
2.2.2	  Stable	  transfection	  of	  bloodstream	  trypanosomes	  1-­‐2.107	   cells	   in	   a	   logarithmic	   state	   of	   growth	   (5-­‐10.105	   cells/ml)	   were	   spun	   down	   at	  2000rpm	  for	  8	  min	  at	  room	  temperature.	  The	  cell	  pellet	  was	  suspended	  in	  10ml	  ice-­‐cold	  cytomix	  and	  centrifuged	  as	  before.	  Then	  the	  cells	  were	  resuspended	   in	  500µl	  cytomix,	  transferred	   to	   a	  BTX	   electroporation	   cuvette	   and	  mixed	  with	   10µg	   linearised	  plasmid	  DNA.	  Electroporation	  was	  done	  with	  a	  single	  1.5kV	  pulse	  at	  a	  resistance	  of	  24	  Ohm	  using	  a	   BTX	   electroporator.	   The	   cells	  were	   transferred	   to	   20ml	   prewarmed	  HMI-­‐9	  medium	  containing	   the	   appropriate	   antibiotics	   for	   the	   used	   cell	   line	   and	   diluted	   until	   the	  concentration	  was	   lower	   than	  5.105	   cells/ml.	  The	  next	  day,	   the	   cells	  were	  diluted	   to	  a	  concentration	  of	  2.105	  cells/ml	  and	  the	  appropriate	  selective	  antibiotic	  was	  added	  (for	  concentration	  see	  2.3.3).	  The	  cells	  were	  distributed	  into	  a	  24-­‐well	  plate	  (1ml	  per	  well).	  Stable	   clones,	   which	   could	   be	   collected	   after	   a	  minimum	   of	   4	   days,	   were	   diluted	   and	  grown	  for	  further	  analysation.	  	  	  Cytomix	  (1l):	  0.76g	  EGTA	  9g	  KCl	  0.022g	  CaCl2.	  2H2O	  	  8.66ml	  K2HPO4	  (1M)	  1.34ml	  KH2PO4	  	  (1M)	  pH=7.6	  (adjust	  with	  KCl)	  	  
2.2.3	  Stable	  transfection	  of	  bloodstream	  trypanosomes	  –	  Amaxa	  system	  1-­‐2.107	   cells	   in	   a	   logarithmic	   state	   of	   growth	   (5-­‐10.105	   cells/ml)	   were	   spun	   down	   at	  2000rpm	   for	   8	   min	   at	   room	   temperature.	   The	   cell	   pellet	   was	   resuspended	   in	   200µl	  Amaxa	   buffer,	   transferred	   to	   a	   BTX	   electroporation	   cuvette	   and	   mixed	   with	   10µl	  	  linearised	   plasmid	   DNA	   solution	   (conc.	   appr.	   1µg/µl).	   The	   transfection	   was	   done	  according	  to	  (Schumann	  Burkard,	  Jutzi	  et	  al.	  2011),	  using	  program	  X-­‐001	  of	  the	  Amaxa	  Nucleofector.	  The	  antibiotic	  selection	  was	  done	  as	  described	  in	  2.3.2.	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Amaxa	  buffer:	  90mM	  sodium	  phosphate	  	  5mM	  potassium	  chloride	  	  0.15mM	  calcium	  chloride	  	  50mM	  HEPES,	  pH	  7.3	  	  
	  
2.2.4	  Antibiotics	  used	  for	  selection	  	  	  	   	  	   Bloodstream	   	  	   procyclics	   	  	  Antibiotic	  	   Stock	  	   added	  vol./	  100ml	  media	   final	  conc.	   added	  vol./	  100ml	  media	   Final	  conc.	  Phleomycin	   5mg/ml	   4µl	   0.2µg/ml	   4µl	   0.2µg/ml	  G148	  	  (Neomycin)	   50mg/ml	   10µl	   5µg/ml	   30µl	   15µg/ml	  Hygromycin	  B	   50mg/ml	   30µl	   15µg/ml	   100µl	   50µg/ml	  Blasticidin	   5mg/ml	   100µl	   5µg/ml	   200µl	   10µg/ml	  Puromycin	   1mg/ml	   20µl	   0,2µg/ml	   100µl	   1µg/ml	  
Table	   1:	   Concentration	   of	   stock	   solutions	   and	   final	   concentration	   in	   the	  media	   of	   antibiotics	  used	  for	  selection	  
2.2.5	  Cultivation	  of	  procyclic	  trypanosomes	  Procyclic	   trypanosomes	  were	  cultivated	   in	  MEM-­‐Pros	  medium	   in	  a	  climatised	  room	  at	  27°C.	  Cells	  were	  diluted	  to	  a	  concentration	  no	  lower	  than	  5.105	  cells/ml	  and	  grown	  up	  to	  5.106	  cells/ml.	  	  	  
Mem-­‐PROS	  (Minimum	  essential	  medium	  for	  procyclic	  trypanosomes	  ):	  CaCl2.2H2O	   265mg/l	  Kcl	   400mg/l	  MgSO4.7H2O	   200mg/l	  NaCl	   6.8g/l	  NaH2PO4.	  H2O	   140g/l	  HEPES	   7.14g/l	  L-­‐Arg-­‐HCl	   126mg/l	  L-­‐Cys-­‐Cys	   240mg/l	  L-­‐Gln	   292mg/l	  L-­‐His-­‐HCl.H2O	   42mg/l	  L-­‐Ile	   52mg/l	  L-­‐Leu	   52mg/l	  L-­‐Lys	   73mg/l	  L-­‐Met	   15mg/l	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L-­‐Phe	   100mg/l	  L-­‐Thr	   48mg/l	  L-­‐Trp	   10mg/l	  L-­‐Tyr	   100mg/l	  L-­‐Val	   46mg/l	  L-­‐Pro	   600mg/l	  Adenosine	   12mg/l	  Ornithine.HCl	   10mg/l	  
Table	  2:	  contents	  of	  MEM-­‐Pros	  
	  1l	  of	  a	  10x	  MEM-­‐PROS	  mixture	  (Biochrom)	  containing	  the	  mentioned	  components	  was	  mixed	  with	   4l	  water.	   The	   pH	  was	   adjusted	   to	   7.4	   using	  NaOH.	   Then,	   4l	  water,	   100ml	  MEM	  non-­‐essential	  amino	  acids,	  100ml	  MEM	  vitamins	  (SIGMA)	  and	  100mg	  phenol	  red	  were	  added.	  The	  pH	  was	  again	  adjusted	  to	  7.4,	  the	  media	  was	  sterilized	  by	  filtration	  and	  stored	  in	  450ml	  aliquots	  at	  –20°C.	  	  Additional	  components	  which	  were	  added	  prior	  to	  use:	  Heat-­‐inactivated	  FCS*	  (Biochrom)	   10%	  (v/v)	  	  Hemin	  	   	   	   	   7.5mg/l	  (1.5ml	  of	  a	  2.5	  g/l	  stock	  solution)	  Penicillin/Streptomycin	  (Sigma)	   50U/ml	  (5ml	  of	  a	  5000U/ml	  stock	  solution)	  *Heat	  inactivation	  of	  FCS	  was	  done	  for	  30min	  at	  55°C	  	  For	  cryopreservation,	  approximately	  2ml	  of	  cells	  in	  the	  logarithmic	  state	  of	  growth	  (1-­‐2.106	   cells/ml)	   were	   spun	   down	   and	   resuspended	   in	   500µl	   media.	   The	   cells	   were	  transferred	   to	   cryovials	   and	  mixed	  with	  Mem-­‐Pros	  medium	   containing	   20%	   glycerol.	  Freezing	   and	   thawing	   was	   identical	   to	   bloodstream	   trypanosomes.	   Thawed	   procyclic	  trypanosomes	   were	   washed	   once	   with	   Mem-­‐Pros	   medium	   and	   transferred	   to	  conditioned	   Mem-­‐Pros	   medium.	   Conditioned	   Mem-­‐Pros	   medium	   was	   obtained	   by	  spinning	  down	  a	  culture	  of	  procyclic	  1313	  cells	  and	  supplying	  the	  supernatant	  with	  the	  appropriate	  antibiotics.	  
	  
2.2.6	  Stable	  transfection	  of	  procyclic	  trypanosomes	  	  1-­‐2.107	   cells	   in	   a	   logarithmic	   state	   of	   growth	   (1-­‐2.106	   cells/ml)	   were	   spun	   down	   at	  2000rpm	   for	   8min	   at	   room	   temperature.	   The	   supernatant	   was	   kept	   as	   conditioned	  medium.	   The	   cell	   pellet	   was	   suspended	   in	   10ml	   cold	   ZFPM	   (Zimmerman post-fusion 
medium)	   and	   spun	   down	   as	   before.	   The	   cells	   were	   resuspended	   in	   500µl	   ZFPM	   and	  mixed	  with	  10µg	  linearised	  plasmid	  DNA.	  Electroporation	  was	  performed	  as	  described	  for	  bloodstream	  cells	  (see	  2.3.2).	  The	  cells	  were	  transferred	  to	  a	  culture	  flask	  with	  5ml	  Mem-­‐Pros	   medium,	   containing	   the	   appropriate	   antibiotics	   for	   the	   cell	   line	   used	   and	  grown	   over	   night.	   The	   next	   day,	   the	   cells	   were	   diluted	   to	   a	   concentration	   of	   2.105	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cells/ml	   using	   the	   conditioned	   medium	   and	   the	   appropriate	   selective	   antibiotic	   was	  added.	   The	   cells	   were	   transferred	   to	   a	   24wells	   plate.	   Stable	   clones	   were	   obtained	  approximately	  7	  days	  later.	   	  	  5xZFPM:	  38.57	  g	  NaCl	  2.98g	  KCl	  7.12g	  Na2HPO4	  .2H2O	  1.02g	  KH2PO4	  0.536g	  magnesiumacetate	  (C4H6	  O4	  Mg.	  4H2O)	  0.066	  CaCl.2H2O	  
2.2.7	  Induction	  of	  RNAi	  constructs	  with	  tetracycline	  The	   Tn10	   tet	   repressor	   gene	   is	   integrated	   in	   the	   genome	   of	   the1313	   514	   cell	   lines	  (procyclic	   and	   bloodstream)	   and	   expressed	   constitutively.	   The	   Tet	   repressor	   binds	   to	  promoter	   regions	   containing	   the	   two	   appropriate	   operation	   sites	   and	   blocks	   the	  expression	  of	  the	  respective	  gene.	  When	  tetracycline	  is	  added,	  it	  binds	  to	  the	  repressor,	  which	  detaches	  itself	  from	  the	  promoter,	  thus	  allowing	  gene	  expression.	  This	  system	  is	  used	  for	  induced	  gene	  expression	  in	  trypanosomes.	  	  Here,	  the	  p2T7TAblue	  vector	  was	  used,	  which	  contains	  two	  Tet-­‐inducible	  promoters	  on	  each	  side	  of	  the	  inserted	  gene.	  Upon	  adding	  of	  tetracycline,	  this	  leads	  to	  the	  expression	  of	  two	  complementary	  RNA	  strands,	  which	  form	  a	  double-­‐stranded	  RNA.	  The	  presence	  of	  this	  double-­‐stranded	  RNA	  complementary	  to	  the	  target	  gene	  leads	  RNA	  interference	  and	  thus	  inhibits	  its	  expression.	  	  In	   order	   to	   observe	   the	   effects	   of	   the	   knockdown	   of	   the	   target	   gene,	   cell	   growth	  was	  monitored	  up	   to	  7	  days.	  Bloodstream	  cells	  were	  diluted	   to	  a	   starting	   concentration	  of	  5.104	  cells/ml,	  procyclics	   to	  5.105.	   Induction	  of	   the	  Tet	  promoter	  was	  done	  by	  adding	  tetracycline	  to	  a	  final	  concentration	  of	  0.1µg/ml	  (0.02µl/ml	  of	  a	  5µg/µl	  stock	  solution	  or	  1µl/ml	   of	   a	   1:50	   dilution).	   After	   one	   day,	   the	   cells	   were	   counted,	   re-­‐diluted	   to	   this	  concentration	  and	  the	  cell	  number	  and	  the	  dilution	  ratio	  were	  documented.	  
2.3	  General	  methods	  for	  protein	  analysis	  
2.3.1	  Extraction	  of	  total	  protein	  0.2	   -­‐	   1.107	  cells	   were	   harvested	   at	   2000rpm	   for	   8min	   at	   room	   temperature.	   The	   cell	  pellet	  was	  resuspended	  in	  2xLaemmli	  buffer	  and	  boiled	  for	  5min	  at	  95°C.	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2.3.2	  SDS-­‐PAGE	  The	  samples	  were	  loaded	  on	  a	  10%	  or	  a	  15%	  PAA	  gel	  and	  run	  at	  80-­‐150V.	  A	  mini protean 
electrophoresis apparatus (BioRad) was used to make and run the PAA gels.	  	  2x	  Laemmli-­‐buffer:	  125	  mM	  Tris-­‐Cl	  pH=6.8	  4%	  SDS	  15mM	  EDTA	  10%	  β-­‐Mercaptoethanol	  20%	  glycerol	  0.1%	  bromphenolblue	  	  seperation	  gel	  	  10-­‐15%	  polyacrylamide	  	  25%	  	  	  	  	  	  1.5M	  Tris-­‐Hcl,	  pH	  8.8	  1%	   	  	  SDS	  (10%	  stock	  solution)	  1%	   	  	  APS	  (10%	  stock	  solution)	  0.05%	  	  	  TEMED	  	  stacking	  gel	  4%	   polyacrylamide	  	  25%	   1M	  Tris-­‐HCl,	  pH	  6.8	  1%	   	  	  SDS	  (10%	  stock	  solution)	  1%	   	  	  APS	  (10%	  stock	  solution)	  0.1%	   	  	  TEMED	  	  Running	  buffer:	  3.03g	  Tris	  14.42g	  glycine	  1g	  SDS	  +	  millipore	  water	  until	  volume	  equals	  1l	  
2.3.3	  Western	  blotting	  The	   proteins	   were	   transferred	   to	   a	   nitrocellulose	   transfer	   membrane	   (Whatman,	  Schleicher	  &	  Schuell)	  using	  a	  biorad	  apparatus.	  Blotting	  was	  done	  in	  1x	  blotting	  buffer,	  which	  was	  stirred	  using	  a	  magnetic	  stirrer,	  at	  4°C	  at	  100V	  for	  1-­‐3	  hours.	  	  	  The	  blot	  was	  washed	  once	  with	  water,	   stained	  with	  ponçeau,	  destained	  with	  PBS	  and	  blocked	   for	   at	   least	   1h	  with	   5%	   skimmed	  milk	   powder	   in	   TBS-­‐T.	   All	   incubations	   and	  washing	   steps	   were	   performed	   with	   gentle	   agitation	   at	   room	   temperature,	   except	  incubations	  over	  night,	  which	  were	  done	  at	  4°C.	  The	  blot	  was	  incubated	  with	  the	  primary	  antibody	  for	  at	  least	  1	  hour.	  Antibodies	  were	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dissolved	   in	   5%	   milk	   in	   an	   appropriate	   ratio.	   To	   remove	   the	   unbound	   primary	  antibodies,	   the	  blots	  were	  washed	  3	   times	   for	  5	  min	  with	  1xTBS-­‐T.	  Then	   the	  blot	  was	  incubated	   for	   at	   least	   an	   additional	   hour	   with	   a	   horseradish-­‐peroxidase	   conjugated	  secondary	  antibody.	  Before	  detection,	  the	  blot	  was	  washed	  three	  times	  for	  10	  min	  with	  1xTBS-­‐T.	  	  
The protein bands were detected using the Western lightning Plus or Ultra ECLT detection 
reagents (Perkin Elmer). The blots were either exposed on ECL films for 1-30min or analysed 
using the LSA-4000 (usual settings: increment, 10sec exposure time, standard exposure). 
If necessary, the antibodies were removed using stripping buffer and new antibodies were 
applied. 	  	  Blotting	  Buffer:	  3.03g	  Tris	  14.4g	  glycine	  200ml	  methanol	  millipore	  water	  until	  volume	  equals	  1l	  
 
TBS-T: 
50 mM Tris 
150 mM NaCl 
0.05% Tween 20 
 Stripping	  buffer:	  25mM	  glycine	  1%SDS	  adjusted	  to	  pH:2	  with	  HCl	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2.3.4	  Gel	  staining	  methods	  
Colloidal	  Coomassie:	  The	  gel	  was	  fixed	  for	  at	  least	  1h	  in	  fixing	  solution.	  Then	  it	  was	  stained	  for	  at	  least	  15min	  in	  colloidal	  coomassie	  stain.	  After	  staining,	  the	  gel	  was	  washed	  in	  bi-­‐distilled	  water	  until	  the	  bands	  were	  visible.	  	  	  Coomassie	  brilliant	  blue	  stock:	  	  5g	  Coomassie	  	  100ml	  millipore	  water	  	  Colloidal	  coomassie	  dye	  stock	  (500ml):	  	  50g	  ammoniumsulfat	  	   	   	   	  6	  ml	  phosphoric	  acid	  (85%)	  10ml	  Coomassie	  brilliant	  blue	  stock	  	  Colloidal	  coomassie	  dye:	  100ml	  Colloidal	  coomassie	  dye	  stock	  25ml	  methanol	  
2.3.5	  TCA	  precipitation	  1/5	  volume	  of	  100%	  TCA	  was	  added	  to	  the	  protein	  solution.	  The	  mixture	  was	  vortexed	  and	  incubated	  at	  -­‐20°C	  overnight.	  The	  precipitate	  was	  spun	  down	  for	  15min	  at	  room	  temperature.	  The	  pellet	  was	  washed	  by	  adding	  3	  volumes	  of	  the	  original	  sample	  volume	  of	  acetone,	  incubating	  the	  mixture	  for	  10min	  at	  room	  temperature	  and	  then	  spinning	  down	  as	  before.	  The	  supernatant	  was	  removed	  and	  the	  pellet	  was	  dried	  for	  10min	  and	  then	  either	  stored	  at	  -­‐20°C	  or	  dissolved	  in	  1x	  Laemmli	  buffer.




2.4.1	  Preparation	  of	  cell	  lysate	  for	  Immunoprecipitation 1-­‐2.108	   bloodstream	   cells	  were	  harvested	   at	   a	   density	   of	   approximately	   1.106cells/ml.	  The	   cells	  were	   spun	  down	  at	  2300g	  at	  4°C	   for	  10min	  and	  washed	   twice	  with	   ice-­‐cold	  PBS.	  The	   cell	   pellets	  were	   snap-­‐frozen	   in	   liquid	  nitrogen	  and	   stored	  at	   -­‐80°C.	  The	   cell	  pellet	  was	  thawed	  on	  ice	  and	  dissolved	  in	  300µl	  lysis	  buffer.	  	  If	  needed,	  0.5µg/µl	  RNAseA	  or	  6µl	  RNAseIN	  (RNase	  Inhibitor,	  promega)	  were	  added	  to	  the	  lysis	  buffer.	  	  Cell	  breakage	  was	  performed	  by	  passing	  the	  cells	  approximately	  50	  times	  through	  a	  21	  gauge	  needle.	  The	  lysate	  was	  spun	  at	  13.000g	  for	  5min	  at	  4°C	  to	  remove	  the	  cell	  debris.	  Before	  the	  IP,	  the	  NaCl	  concentration	  of	  the	  cleared	  lysate	  was	  increased	  to	  100-­‐150mM.	  	  
2.4.2	  Immunoprecipitation	  30-­‐50µl	  α-­‐V5,	  α-­‐myc	  (both	  from	  abgene)	  or	  GBP	  beads	  were	  washed	  three	  times	  with	  IP	  buffer.	   The	   cleared	   lysate	   was	   added	   to	   the	   beads	   and	   incubated	   for	   2h	   on	   a	   rotary	  shaker	  at	  4°C.	  	  The	  supernatant	  was	  removed	  by	  spinning	  the	  beads	  at	  2000rpm	  at	  4°C.	  Then	  the	  beads	  were	  washed	  three	  to	  five	  times	  with	  IP	  buffer.	  The	  beads	  were	  boiled	  with	  10µl	  4x	  Laemmli.	  	  The	  samples	  were	  then	  analysed	  on	  a	  Western	  blot.	  	  
 Lysis	  buffer:	  10mM	  Tris-­‐Cl	  10mM	  NaCl	  0.2%	  IGEPAL	  2mM	  DTT	  complete	  protease	  inhibitor	  (Roche)	  pH=7.4	  	  Wash	  buffer:	  10mM	  Tris-­‐Cl	  100-­‐150mM	  NaCl	  0.1%	  IGEPAL	  pH=7.4
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2.5	  Preparation	  of	  total	  RNA	  and	  Northern	  blotting	  
2.5.1	  Preparation	  of	  total	  RNA	  Total	   RNA	   was	   isolated	   from	   2-­‐10.107	   cells.	   Bloodstream	   cells	   were	   harvested	   at	   a	  density	   of	   0.5-­‐1.106	   cells/ml,	   procyclic	   cells	   at	   a	   density	   of	   1-­‐6.106cells/ml.	   The	   cells	  were	  pelleted	  by	  centrifugation	  (10min,	  2000rpm)	  and	  the	  cell	  pellet	  was	  resuspended	  in	  1ml	  pegGOLD	  TriFastTM	  (Peqlab,	  GmbH)	  and	  incubated	  for	  5	  min	  at	  room	  temperature.	  0.2ml	  of	  chloroform	  was	  added	  to	  the	  samples.	  The	  tubes	  were	  shaken	  for	  15	  seconds,	  incubated	  at	  room	  temperature	  for	  2-­‐3minutes	  and	  centrifuged	  in	  a	  microfuge	  at	  4°C	  for	  10min	   at	   full	   speed.	   The	  mixture	   separates	   into	   a	   lower	   organic	   phase,	   an	   interphase	  and	  an	  upper	  aqueous	  phase,	  which	  contains	  the	  RNA.	  The	  aqueous	  phase	  is	  transferred	  into	   a	   fresh	   tube	   and	   the	   RNA	   is	   precipitated	   by	   adding	   0.5ml	   isopropyl	   alcohol.	   The	  samples	  are	   incubated	  for	  10min	  at	  room	  temperature	  and	  then	  centrifuged	  at	  4°C	  for	  20min	   at	   12.000rpm.	   The	   supernatant	   was	   removed	   and	   the	   cell	   pellet	   washed	   with	  75%	  ethanol.	  After	  the	  wash,	  the	  RNA	  was	  pelleted	  by	  centrifugation	  at	  4°C	  for	  5min	  at	  10.000rpm.	  	  The	  pellet	  was	  air-­‐dried	  for	  5-­‐10min	  and	  dissolved	  in	  10µl	  sterile	  water.	  	  
2.5.2	  Northern	  blotting	  of	  total	  RNA Before	   loading,	   10µg	   RNA	   was	   mixed	   with	   RNA	   loading	   mic	   (50%	   formamid,	   6.5%	  formaldehyde,	  1xMOPS	  buffer,	  total	  volume:	  20-­‐30µl)	  and	  denaturated	  by	  incubation	  at	  65°C	   for	   15min.	   After	   denaturation,	   6x	   sample	   dye	   (15%	   ficoll)	   and	   1µl	   ethidium	  bromide	   solution	   (1mg/ml)	   were	   added	   and	   the	   RNA	   was	   loaded	   on	   a	   1%	   agarose/	  formaldehyde	  gel	   (0,5M	  Formaldehyde,	  1%	  Agarose,	  1xMOPS).	  The	  gel	  was	  run	  at	  15-­‐20mV	  over	  night	  or	  for	  approximately	  4	  hours	  at	  60mV	  using	  1x	  MOPS	  as	  running	  buffer.	  The	  gel	  was	  washed	  2	  times	  with	  water	  (10min)	  and	  once	  with	  10xSSC	  (15min).	  	  The	  RNA	  was	  transferred	  to	  a	  Nytran	  N	  membrane	  using	  the	  Turbo	  blotter	  system	  and	  10xSSC	  as	  blotting	  buffer.	  Blotting	  was	  either	  done	  over	  night	  or	  for	  at	  least	  4	  hours.	  	  After	  blotting,	  the	  RNA	  was	  cross-­‐linked	  to	  the	  membrane	  using	  a	  UV	  Stratalinker	  1800.	  	  The	  membrane	  was	  then	  washed	  for	  15min	  in	  5%	  acetic	  acid	  and	  stained	  with	  methylen	  blue	   stain	   (0.04%	   methylen	   blue,	   0.5M	   sodium	   acetate,	   pH:	   5.2).	   The	   blot	   was	   pre-­‐hybridized	   for	   at	   least	   2h	   at	   65°C	   in	   a	   hybridization	   tube	   using	   approximately	   10ml	  hybridization	  solution	  (5xSSC,	  0,5%	  SDS,	  1%	  Denhard's,	  0.1mg/ml	  salmon	  sperm).	  	  The	   	  32P-­‐dCTP-­‐labeled	   probe	   was	   made	   using	   	   the	   Prime-­‐It	  ®	   RmT	   Random	   Primer	  Labeling	  Kit	  (Stratagene).	  The	  probe	  was	  purified	  using	  the	  Quiagen	  nucleotide	  removal	  kit	   and	   added	   to	   10ml	   hybridization	   mix.	   Hybridization	   was	   performed	   at	   65°C	  overnight	   on	   a	   spinning	  wheel.	   The	   blot	  was	  washed	   1	   time	   for	   10min	  with	   2x	   SSC+	  0.1%SDS	  and	  two	  times	  for	  10-­‐20min	  with	  1xSSC+	  0.1%SDS	  at	  65°C.	  	  The	  blot	  was	  then	  exposed	  to	  a	  phosphoimager	  screen	  for	  at	  least	  one	  hour.	  	  Non-­‐radioactive	  detection	  (used	  only	  for	  VSG)	  was	  done	  using	  the	  DIG	  RNA	  labeling	  kit,	  as	   well	   as	   the	   DIG	   RNA	   detection	   kit	   from	   Roche,	   according	   to	   the	   manufacturers’	  instructions.	  The	  hybridization	  temperature	  was	  60°C.	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2.6	  Tethering	  assay	  	  	  (PhD	  Thesis,	  Dorothea	  Droll,	  modified).	  To	   determine	   the	   effect	   of	   different	   ZC3H32	   protein	   construct,	   two	   chloramphenicol	  acetyl	  transferase	  (CAT)	  reporter	  constructs	  were	  used.	  One	  contained	  the	  BoxB	  domain	  from	  phage	   lambda	   in	   its	   3’UTR,	   the	  other	  one	  did	  not.	   The	  BoxB	   is	   bound	  by	   the	  λN	  peptide,	  which	  was	   fused	   to	   the	  myc-­‐tagged	   ZC3H32	   protein	   constructs	   (see	   2.14	   for	  plasmids).	  Thus,	  the	  λN-­‐ZC3H32-­‐myc	  construct	  was	  tethered	  to	  the	  reporter	  RNA.	  CAT	  was	  chosen	  as	   reporter	  as	   the	  CAT	   transcript	   can	  easily	  be	  detected	  on	  Northern	  Blot	  and	  the	  protein	  expression	  can	  be	  assayed	  with	  an	  enzymatic	  reaction	   in	  the	  CAT	  assay.	  	  CAT	   transfers	   an	   acetyl	   group	   from	   radioactively	   labeled	   14C	   butryl	   CoA	   to	  chloramphenicol.	  After	  uptake	  of	   an	   acetyl	   group,	   chloramphenicol	  will	   become	  water	  insoluble	  and	  move	  from	  the	  aqueous	  phase	  of	  the	  reaction	  solution	  to	  the	  upper	  non-­‐aqueous	   phase	   of	   the	   scintillation	   solution	   (Econofluor-­‐2,	   Perkin	   Elmer).	   With	   time,	  more	  and	  more	  acetyl-­‐chloramphenicol	  (and	  therefore	  radioactive	  14C)	  will	  move	  to	  the	  upper	  phase,	  which	  will	  be	  measured	  by	  the	  scintillation	  counter.	  
2.6.1	  Sample	  preparation	  and	  determination	  of	  protein	  concentration	  	  The	   expression	   of	   the	   λN-­‐ZC3H32-­‐myc	   construct	   was	   induced	   24hours	   prior	   to	  harvesting	  by	  adding	  tetracycline.	  For	  one	  sample	  ≥107	  cells	  were	  taken	  and	  spun	  down	  at	  2,000	  rpm	  for	  10	  minutes.	  	  Pellets	  were	  transferred	  to	  a	  microfuge	  tube,	  centrifuged	  at	  3,000	  rpm	  for	  2	  minutes	  and	  washed	  using	  cold	  1x	  PBS.	  The	  cell	  pellet	  can	  be	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  For	  lysis	  300	  μl	  of	  CAT	  assay	  buffer	  was	  added	  followed	  by	  freeze-­‐thawing	  three	  times	   in	   liquid	   nitrogen.	   After	   centrifugation	   at	   13,000	   rpm	   at	   4°C	   for	   3	  minutes,	   the	  supernatant	  was	  transferred	  to	  a	  new	  tube	  and	  can	  be	  stored	  at	  -­‐	  80°C	  until	  use.	  The	  Bradford	  assay	  is	  used	  to	  determine	  the	  total	  protein	  concentration	  of	  a	  sample.	  The	  assay	   is	   based	   on	   the	   proportional	   binding	   of	   the	   Coomassie	   Blue	   dye	   to	   proteins.	  Coomassie	   bound	   to	   protein	   has	   an	   absorption	  maximum	   at	   595	   nm.	   The	   higher	   the	  protein	  concentration,	  the	  higher	  the	  absorption	  at	  595	  nm	  will	  be.	  	  Bradford:	  0,	  5,	  10,	  15,	  20μg	  of	  BSA	  (0.5	  μg/μl	  stock)	  in	  800μl	  for	  standard	  curve	  50	  μl	  of	  each	  protein	  sample	  +750μl	  water	  all	  +	  200μl	  Bradford	  reagent	  (Biorad),	  mix,	  incubate	  ca.	  5	  min	  and	  measure	  absorption	  at	  595nm	  in	  photometer.	  	  
2.6.2	  The	  CAT	  Assay	  	  For	   this	  assay,	  equal	  amounts	  of	  protein	  were	   taken	   for	  each	  sample	  and	  scaled	  up	   to	  50μl	  using	  100	  mM	  Tris-­‐HCl,	  pH	  7.8.	  After	  addition	  of	  200	  μl	  100	  mM	  Tris-­‐HCl,	  pH7.8,	  2	  μl	  chloramphenicol	  (40	  mg/ml),	  10	  μl	  14C-­‐butryl	  CoA	  (box	  21C	  in	  -­‐80°C)	  and	  finally	  4	  ml	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scintillation	   cocktail	   (in	   fume	   hood,	   Econofluor-­‐2),	   the	   samples	   were	   measured	   in	   a	  scintillation	   counter	   (Beckman	   LS6000IC)	   using	   program	   #7,	   measuring	   14C.	   Samples	  were	  measured	  at	  appropriate	  time	  intervals,	  every	  12	  to	  16	  minutes	  or	  as	  required.	  The	  increase	  of	  14C	  signal	   in	  the	  scintillation	  fluid	   is	  proportional	  to	  the	  amount	  of	  enzyme	  present	   in	   the	   sample.	   Therefore	   after	   blotting	   the	   data	   the	   slope	   in	   the	   linear	   range	  (before	  saturation)	  can	  be	  compared	  between	  the	  different	  samples	  and	  the	  relative	  CAT	  protein	  amount	  calculated.	  	  
2.7	  CLIP	  (Crosslinking	  and	  Immuoprecipitation)	  	  	  Protocol	   from	  Bhaskar	  Anand	   Jha,	   (Jha,	  Fadda	  et	  al.	  2014)	   	   a	   combination	  of	   the	  PAR-­‐CLIP	   (Hafner,	   Landthaler	   et	   al.	   2010,	   Hafner,	   Landthaler	   et	   al.	   2010)	   and	   the	   CLIP	  protocol	  (Ule,	  Jensen	  et	  al.	  2005)	  with	  slight	  modifications.	  	  
2.7.1	  Crosslinking	  The	  cells	  were	  spun	  down	  at	  room	  temperature	  at	  2000rpm	  for	  10min,	  resuspended	  in	  25ml	  medium	  and	  put	   on	   big	   petri	   disk.	   The	   cells	  were	   crosslinked	   twice,	   on	   a	  metal	  plate	   (for	   reflection)	   with	   a	   Stratalinker	   2400	   (Strategene,	   Germany)	   at	   4000	   x	   100	  microjoule/cm2,	  spun	  down	  at	  3000rpm	  at	  4°C,	  washed	  twice	  with	  PBS,	  frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C.	  	  Cells	  lines	  used:	  bs	  1313	  514,	  density	  appr.	  1.106	  cells/ml,	  250-­‐300ml	  “WT”	  bs	  1313	  2332	  2487	  2488,	  density	  appr.	  1.106	  cells/ml,	  250-­‐300ml	  “Z32”	  pc	  1313	  myc-­‐UBP1	  from	  B.	  Jha	  as	  positive	  control	  “UBP1”	  	  
2.7.2.	  Cell	  lysis	  The	  cell	  pellets	  were	  dissolved	  in	  250µl	  lysis	  buffer	  and	  incubated	  on	  ice	  for	  10min.	  The	  cell	  lysis	  was	  checked	  under	  the	  microscope.	  The	  lysate	  was	  cleared	  twice	  in	  order	  to	  remove	  the	  cell	  debris	  for	  5min	  at	  13000rpm.	  	  	  
2.7.3.	  RNAse	  T1	  treatment	  RNAse	   T1	   was	   added	   to	   the	   sample	   (2U/µl)	   and	   the	   sample	   was	   incubated	   22°C	   for	  10min,	  shaking	  at	  800rpm	  and	  then	  kept	  on	  ice	  for	  5min.	  
2.7.4 Immunprecipitation	  75	  or	  100µl	  myc	  beads	  were	  used	  per	  IP	  (75µl	  for	  250ml	  cells,	  100µl	  for	  300ml).	  The	   beads	   were	   washed	   5x	   with	   PBS	   (1000rpm)	   and	   once	   with	   IP	   wash	   buffer.	   The	  lysate	  was	  added	  and	  the	  IP	  was	  rotated	  for	  1-­‐2h	  at	  4°C	  (program	  F5,	  10rpm)	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Then	  the	  supernatant	  was	  removed	  and	  the	  IP	  was	  washed	  3x	  with	  IP	  Wash	  buffer	  and	  2x	  with	  High	  Salt	  Wash	  buffer	  (1000rpm,	  4°C)	  
2.7.5	  Phosphatase	  treatment	  The	   beads	   were	   resuspended	   in	   1	   bead	   volume	   of	   2xNEB3	   (1:5	   dilution	   of	   original	  NEB3)	  supplied	  with	  2µl	  (80U)	  RNAsIN.	  Calf	  intestinal	  phosphatase	  was	  added	  to	  a	  final	  conc	  of	  0.5U/µl	  (conc.	  stock	  solution:	  10U/µl).	  	  	  The	  beads	  were	  incubated	  for	  10min	  at	  37°C,	  shaking	  at	  800rpm	  and	  then	  washed	  twice	  with	  1ml	  phosphatase	  wash	  buffer.	  	  
2.7.6	  Phosphonucelotidekinase	  (PNK)	  treatment	  	  The	  beads	  were	  washed	  twice	  with	  cold	  PNK	  buffer.	  	  The	  following	  steps	  were	  done	  in	  the	  isotope	  lab	  with	  appropriate	  shielding.	  1	  bead	  volume	  of	  PNK	  buffer	  was	  added	  to	  beads,	  together	  with	  1/10	  bead	  volume	  PNK	  and	  3.3-­‐5µl	  yATP	   (33-­‐50µCi).	  The	   reaction	  was	   incubated	   for	  20min	  at	  37°C	  and	   then	  washed	  three	  times	  with	  PNK	  buffer.	  The	  beads	  were	  resuspended	  in	  20µl	  4x	  NuPAGE	  LSD	  sample	  buffer	  (Invitrogen),	  with	  500mM	  DTT	  and	  boiled	  for	  5min	  at	  95°C.	  This	  elution	  step	  was	  done	  twice.	  	  The	   eluates	   were	   loaded	   on	   a	   on	   a	   4-­‐12%	   NuPAGE	   Bis-­‐Tris	   gel	   together	   with	   5µl	  prestained	  protein	  marker.	  For	   the	   first	   CLIP	   experiment,	   the	   two	   elutions	  were	   loaded	   in	   separate	  wells,	   for	   the	  following	  two	  experiments	  the	  two	  elutions	  (of	  each	  bead	  sample)	  were	   loaded	  in	  one	  well.	  	  The	  gel	  was	  run	  at	  200V	  for	  50min	  in	  1x	  NuPAGE	  MOPS	  SDS	  running	  buffer	  (Invitrogen).	  Then	  the	  gel	  was	  wrapped	  in	  saran	  wrap	  and	  exposed	  to	  a	  phosphoimager	  screen	  for	  at	  least	  one	  hour.	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2.7.7	  Buffers	  	  
Lysis buffer  







compl. Inhibitor, Roche   0.5 tablet/ml 
  
IP wash buffer  
HEPES pH 7.5 50mM 
KCl 150mM 
NP-40 0.05% 
DTT 0.5mM  
RNASIN 1600U 
compl. Inhibitor, Roche   1 tablet/10ml 
  
High salt wash buffer   
HEPES pH 7.5 50mM 
KCl 500mM 
NP-40 0.05% 
DTT 0.5mM  
RNASIN 1600U 
compl. Inhibitor, Roche   1 tablet/10ml 
  
Phosphatase wash buffer  






polynucelotide kinase buffer  
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2.8	  Web	  resources	  Kinetoplastid	   databases	   with	   expression	   data	   and	   user	   comments:	   TriTrypDB	  http://tritrypdb.org	  GeneDB;	  www.genedb.org	  NCBI	  databases,	  e.g.	  BLAST	  NCBI	   	  http://blast.ncbi.nlm.nih.gov/Blast.cgi	  	  
2.9	  Polyribosome	  isolation	  
2.9.1	  Cycloheximide	  treatment	  	  Bloodstream	  cells:	  Bloodstream	   cells	   (d=1.106	   cells/ml)	   cells	   were	   given	   into	   centrifuge	   flasks	   and	  cycloheximide	  was	  added	  to	  a	  concentration	  of	  25	  µg/ml.	  The	  cells	  were	  incubated	  for	  1min	  at	  room	  temperature	  and	  then	  chilled	  in	  a	  dry	  ice	  ethanol	  bath.	  The	  cells	  were	  then	  spun	  down	  (4°C,	  2,300g,	  20min),	  transferred	  to	  Eppendorf	  tubes	  and	  spun	  down	  again	  at	  2,300g	  for	  2min.	  The	  pellet	  was	  either	  used	  immediately	  or	  resuspended	  in	  freezing	  buffer,	  wrapped	  in	  cold	  paper	  and	  kept	  at	  -­‐70°C.	  	  Procyclic	  cells:	  	  Procyclic	   cells	   (d=4.106	   cells/ml)	   were	   spun	   down	   (RT,	   2,300rpm,	   10min)	   and	  resuspended	   in	  20-­‐50ml	  of	  medium	   (app.	   1/20	  of	   the	   former	   volume).	   Cycloheximide	  was	  added	  to	  a	  concentration	  of	  100	  µg/ml,	  the	  cells	  were	  incubated	  for	  5min	  at	  room	  temperature,	   chilled	  on	   ice	  and	  spun	  down	  (4°C,	  2,300rpm,	  8min).	  The	  cell	  pellet	  was	  either	  used	  immediately	  or	  resuspended	  in	  freezing	  buffer,	  wrapped	  in	  cold	  paper	  and	  kept	  at	  -­‐70°C.	  	  	  Before	  preparation	  of	  cell	  lysates,	  the	  pellets	  were	  thawed	  on	  ice	  and	  washed	  twice	  (4°C,	  2min,	  3000rpm)	  with	  wash	  buffer.	  	  Then	  the	  cells	  were	  lysed,	  either	  by	  the	  method	  described	  in	  2.9.2	  (total	  cell	   lysate)	  or	  2.9.3	   (separation	   of	   cytosolic	   and	   membrane-­‐bound	   fractions).	   The	   used	   buffer	   was	  taken	  from	  (Hanas,	  Linden	  et	  al.	  1975,	  Brecht	  and	  Parsons	  1998)	  	  
2.9.2	  Preparation	  of	  total	  cell	  lysate	  Cell	  lysates	  were	  prepared	  on	  ice.	  	  The	  cell	  pellet	  was	  resuspended	  in	  lysis	  buffer	  containing	  0,2%	  NP-­‐40	  and	  lysed	  using	  a	  gauge	  needle	   at	   4°C	   (put	   at	   least	   50	   times	   through	   the	   gauge	  needle).	   The	   lysate	  was	  cleared	  by	  centrifugation	  (4°C,	  4,500rpm,	  5min)	  and	  given	  on	  the	  sucrose	  gradient.	  	  
2.9.3	  Separation	  of	  free	  and	  membrane-­‐associated	  fractions	  Cell	  lysates	  were	  prepared	  at	  4°C.	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Acid	  ethanol-­‐washed	  glass	  beads	  (300µg/ml	  lysis	  buffer)	  were	  washed	  twice	  with	  wash	  buffer.	   The	   cell	   pellet	  was	   resuspended	   in	   lysis	   buffer	   (without	   NP-­‐40/IGEPAL)	   and	  added	   to	   the	   beads.	   Cell	   lysis	   was	   accomplished	   by	   vortexing	   in	   intervals	   of	   30sec	  following	  10	  sec	  chilling	  on	  ice	  (total	  vortexing	  time:	  20min).	  Lysis	  was	   checked	  under	   a	   glass	   slide.	   The	   lysate	  was	   cleared	   twice	   by	   centrifugation	  	  (4°C,	   4,500rpm,	   5min).	   Then	   the	   membrane	   fraction	   was	   separated	   by	  ultracentrifugation	  (4°C,	  30000g,	  20min,	  Rotor:	  S45A).	  The	  supernatant	  (“free”	  fraction)	  was	   taken	   and	   the	   pellet	   ("membrane-­‐bound"	   fraction)	   resuspended	   in	   lysis	   buffer	  containing	  0,2%	  Triton-­‐X	  (detergent	  to	  lyse	  the	  membranes).	  Triton-­‐X	  (use	  10%	  Triton-­‐X	  stock	  solution)	  was	  added	  to	  a	  final	  concentration	  of	  0,2%	  to	  the	  supernatant	  ("free"	  fraction).	  The	  "free"	  fraction	  was	  given	  on	  a	  sucrose	  gradient.	  The	  membranes	  in	  the	  membrane-­‐bound	  fraction	  were	  dissolved	  by	  pulling	  the	  pellet	  through	  a	  gauge	  needle	  followed	  by	  short	  vortexing.	  The	  membrane	  fraction	  was	  cleared	  by	  ultracentrifugation	  (4°C,	  30000g,	  20min,	  Rotor:	  S45A).	  The	  supernatant	  was	  given	  on	  a	  sucrose	  gradient.	  	  
2.9.4	  Preparation	  of	  sucrose	  gradients	  The	   lighter	   sucrose	   fraction	   (15%)	  was	   underlayed	  with	   the	   heavier	   sucrose	   solution	  (50-­‐55%)	  and	  rotated	  in	  the	  gradient	  maker	  (Gradient	  Master,	  Biocomp)	  for	  2min	  at	  an	  angle	  of	  45°.	  	  Alternatively,	   the	  gradients	  were	  sealed	  with	  parafilm	  and	  turned	  horizontally	   for	   two	  hours.	  Gradients	  were	  prepared	   in	  Beckmann	  polyallomer	   tubes	  with	   a	   volume	  of	  14x89mm	  (12ml	  gradient,	  1ml	  lysate)	  or	  11x60cm	  (4,8ml	  gradient,	  0,2	  ml	  lysate).	  	  15%-­‐50%	  sucrose	   gradients	  were	  made	   for	   optimal	   resolution	  of	   fractions.	   15%-­‐55%	  sucrose	  gradients	  were	  used	  for	  a	  higher	  concentrated	  polyribosome	  fractions.	  	  Gradients	  were	  frozen	  at	  -­‐70°C	  and	  thawed	  approximately	  1h	  prior	  to	  use	  at	  4°C.	  	  
2.9.5	  Sucrose	  gradient	  centrifugation	  and	  separation	  of	  fractions	  Sucrose	   gradient	   centrifugation	   was	   done	   at	   4°C,	   either	   at	   36000rpm	   for	   2,5h	   or	   at	  40,000rpm	  for	  2h.	  For	  14x89mm	  tubes	  the	  SW41	  rotor,	   for	  11x60mm	  tubes	  the	  SW60	  rotor	  was	  used.	  	  The	  fractions	  were	  collected	  and	  the	  OD260	  profile	  measured	  using	  an	  ISCO	  160	  gradient	  former.	  	  Fractions	  can	  be	  collected	  every	  minute	  (volume	  app.	  1,2ml),	  every	  30	  sec	  (volume	  app.	  0,6ml),	  every	  22	  seconds	  (for	  Western	  blots,	  resulted	  in	  appr.	  10	  fractions	  with	  a	  volume	  of	  appr.	  0.4ml)	  or	  every	  15	  seconds	  (for	  Northern	  blots,	  appr.	  14	  fractions,	  volume	  appr.	  0.3ml).	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2.9.6	  Concentration	  (for	  mass	  spectrometry	  samples)	  	  The	   samples	  were	   diluted	   1:4	  with	   gradient	   buffer	  without	   sucrose	   and	   concentrated	  using	   Centricon	   tubes	   (Molecular	   cut-­‐off:	   100kDa).	   After	   the	   desired	   volume	   was	  reached	  the	  samples	  were	  precipitated	  with	  TCA.	  For	  direct	  TCA	  precipitation,	  the	  samples	  were	  also	  diluted	  1:4	  with	  gradient	  buffer.	  	  	  
2.9.7	  Sample	  preparation	  for	  Western	  and	  Northern	  blotting	  For	   a	  Western	   blot,	   300-­‐400ml	   bloodstream	   cells	   (density	   approximately	   1.106)	  were	  used	   for	   total	   polyribosomes	   and	   the	   double/triple	   amount	   for	   separated	   free	   and	  membrane	  bound	  polyribosomes.	  5-­‐15	  times	  less	  was	  loaded	  in	  the	  first	  three	  fractions,	  as	  these	  contained	  a	  lot	  of	  proteins.	  For	  the	  rest	  of	  the	  fractions,	  30-­‐50µl	  were	  loaded	  on	  the	   gel.	   In	   order	   to	   prevent	   the	   samples	   from	   solidification	   (due	   to	   the	   high	   sucrose	  content),	  the	  samples	  were	  kept	  warm	  during	  the	  loading	  of	  the	  Western	  blot.	  For	   RNA	   isolation,	   the	   samples	   were	   mixed	   with	   3	   parts	   peqGOLD	   TriFastFL	   and	  processed	  according	  to	  the	  manufacturer’s	  description.	  	  
2.9.8	  Solutions	  	  Stock	  solutions:	  
2xPolyribosome	  buffer:	  20mM	  Tris	  (pH:	  7,4-­‐7,5)	  20mM	  MgCl2	  600mM	  KCl	  	  	  
200mg/ml	  Heparin	  (dissolved	  in	  water,	  stored	  at	  -­‐20°C)	  
	  
1M	  DTT	  (dissolved	  in	  water,	  stored	  at	  -­‐20°C)	  
	  
5mg/ml	  Leupeptin	  (dissolved	  in	  water,	  stored	  at	  -­‐20°C)	  
	  
100mg/ml	  Cycloheximide	  (dissolved	  in	  ethanol,	  stored	  at	  -­‐20°C)	  	  Buffers:	  	  
Freezing	  buffer	  (1ml):	  	  1x	  Polyribosome	  buffer	  200mM	  Sucrose	  (0,0684g)	  10%	  Glycerol	  (100µl)	  100	  µg	  Cycloheximide	  (1	  µl)	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Lysis	  buffer:	  1x	  Polyribosome	  buffer	  (10mM	  Tris	  (pH:	  7,4-­‐7,5),	  10mM	  MgCl2,	  300mM	  KCl)	  200mM	  Sucrose	  1	  tablet/5ml	  complete	  protease	  inhibitor	  (Roche,	  without	  EDTA)	  2mM/ml	  DTT	  0,4mg/ml	  Heparin	  	  10µg/ml	  Leupeptine	  100µg/ml	  Cycloheximide	  	  for	  total	  lysate	  only:	  0,2%	  NP-­‐40	  ddH2O	  until	  final	  volume	  
	  
Wash	  buffer	  (5ml):	  	  2,5	  ml	  2x	  Polyribosome	  buffer	  	  0,342g	  sucrose	  (final	  conc.:	  200mM)	  ddH2O	  until	  final	  volume	  
Gradient	  buffer:	  0%,	  15%,	  50%	  or	  55%	  sucrose	  0,5	  volumes	  2x	  Polyribosome	  buffer	  2mM/ml	  DTT	  (1:500)	  400µg/ml	  heparin	  (1:500)	  10µg/ml	  leupeptin	  (1:500)	  ddH2O	  until	  final	  volume	  	  
10%	  Triton-­‐X	  0,5	  volume	  2x	  Polyribosome	  buffer	  0,2	  volumes	  1M	  sucrose	  0,2	  volumes	  ddH2O	  0,1	  volume	  Triton-­‐X	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2.10	  Polyribosome	  isolation	  followed	  by	  immunoprecipitation	  	  
2.10.1	  VSG222	  pull-­‐down	  	  VSG222	  clonal	  selection	  In	  order	  to	  get	  a	  monoclonal	  population	  of	  VSG222	  expressing	  cells,	  bs1313	  cells	  were	  diluted	  to	  a	  concentration	  of	  12.5	  cells/ml	  and	  plated	  out	  on	  a	  96well	  plate.	  40µl	  were	  given	  in	  each	  well,	  thus,	  statistically	  there	  were	  0.5	  cells/well.	  The	  cells	  were	  left	  to	  grow	  for	  ten	  days,	  then	  protein	  samples	  were	  collected.	  VSG222	   expression	   was	   tested	   by	   Western	   blotting,	   the	   cell	   line	   with	   the	   strongest	  VSG222	  expression	  (VSG222	  WT11)	  was	  used	  for	  the	  following	  experiment.	  	  Antibody	  purification	  (protocol	  from	  AG	  Melchior,	  ZMBH)	  1ml	   VSG222	   polyclonal	   antibody	   was	   mixed	   with	   2ml	   PBS	   and	   supplemented	   with	  EDTA-­‐free	  Protease	   Inhibitor	   (Roche,	   1	   tablet	   in	  3.5	  ml	  PBS).	  The	   solution	  was	  mixed	  with	   2ml	   ProteinA	   beads,	   which	   were	   washed	   with	   50ml	   PBS.	   The	   beads	   and	   the	  antibody	  solution	  were	  incubated	  over	  night	  rotating	  at	  4°C.	  	  The	   following	   day,	   the	   column	   was	   washed	   with	   60ml	   PBS	   with	   500mM	   NaCl.	   The	  antibody	   was	   eluted	   15x	   with	   1ml	   elution	   buffer	   (200mM	   acetic	   acid,	   500mM	   NaCl,	  pH=2.7,	  adjusted	  with	  NaOH).	  Each	  eluate	  was	  mixed	  with	  200µl	  1M	  Tris-­‐Cl	  (pH=11)	  in	  order	  to	  neutralize	  the	  solution.	  Samples	  of	  the	  eluates	  were	  given	  on	  a	  dot	  blot.	  The	  dot	  blot	   was	   stained	   by	   ponceau	   in	   order	   to	   check	   whether	   the	   eluates	   still	   contained	  protein.	  At	  the	  15th	  elution,	  no	  protein	  could	  be	  detected,	  thus,	  the	  elution	  was	  stopped.	  	  The	   eluates	   were	   concentrated	   using	   four	   centricon	   columns	   (10kDa	   cut-­‐off).	   After	  concentration,	   in	   order	   to	   change	   the	   buffer,	   sterile	   PBS	   (20ml)	   was	   added	   to	   the	  columns.	  The	  samples	  were	  concentrated	  until	  the	  volume	  was	  1ml.	  In	  order	  to	  store	  the	  antibody,	  it	  was	  mixed	  1:2	  with	  glycerol.	  Thus,	  1µl	  of	  the	  purified	  antibody	  corresponds	  to	  0.5µl	  of	  the	  original	  antibody.	  	  	  Polyribosome	  isolation	  and	  immunoprecipitation	  Polyribosomes	   were	   isolated	   as	   described	   in	   2.9.	   Approximately	   8.108	   bs1313	   cells	  (selected	   for	   VSG222	   expression)	   were	   used.	   The	   polyribosome	   fractions	   were	   taken	  and	   split	   into	  5	  parts.	   300µl	  were	  used	   as	   Input	   sample,	   600µl	  were	  used	   for	   each	   IP	  (1.7.108	  cells	  each).	  	  Two	   IPs	   were	   done	   with	   100µl	   ProteinA	   beads	   mixed	   with	   10µl	   purified	   VSG222	  antibody.	  One	  was	  incubated	  (rotating	  at	  4°C)	  for	  1h,	  the	  other	  one	  for	  30min.	  The	  other	  two	   IPs	   were	   done	   with	   200µl	   Protein	   A	   beads,	   mixed	   with	   10µl	   and	   20µl	   purified	  antibody.	  Both	  of	  these	  IPs	  were	  incubated	  for	  1h.	  After	  the	  incubation,	  the	  supernatant	  was	   removed	   and	   300µl	   (half	   of	   the	   supernatant,	   corresponds	   to	   0.85.108	   cells)	  were	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taken	   as	   RNA	   sample.	   In	   order	   to	   elute	   the	   RNA,	   the	   pellets	   were	   mixed	   with	   750µl	  Trifast.	  	  	  
2.10.2	  VSG118	  pull-­‐down	  	  Antibody	  purification	  75µl	  VSG118	  antibody	  was	  purified	  as	  described	  before	  (2.10.1).	  In	  order	  to	  determine	  how	  much	  of	  the	  original	  antibody	  corresponds	  to	  the	  purified	  antibody,	  a	  dot	  blot	  was	  made,	  probed	  with	  anti-­‐rabbit	  and	  the	  signal	  was	  quantified.	  The	  quantification	  showed	  that	  2.5µl	  of	  the	  purified	  antibody	  corresponded	  to	  1µl	  unpurified	  antibody.	  	  	  Polyribosome	  isolation	  and	  immunoprecipitation	  6.108	  bloodstream	  wild	  type	  cells	  expressing	  VSG118	  were	  used	  for	  this	  experiment.	  	  Polyribosomes	  were	  isolated	  was	  described	  in	  2.9.	  600µl	  polyribosomes	  were	  used	  for	  each	  IP.	  300µl	  of	  the	  polyribosomes	  were	  used	  as	  polyribosome	  sample	  for	  the	  Northern	  blot,	  30µl	  were	  used	  as	  protein	  sample.	  	  3	   aliquots	   of	   100µl	   ProteinA	   beads	   were	   mixed	   with	   2.5µl,	   5µl	   and	   12.5µl	   purified	  VSG118	  antibody	   (corresponding	   to	  1µl,	  2µl	   and	  5µl	  unpurified	  antibody).	  To	  each	   IP,	  8µl	  VRCs,	  12µl	  RNAsIN	   (promega)	  and	  0.6µl	   cycloheximide	  were	  added.	  The	   IPS	  were	  rotated	   for	   2	   hours	   at	   4°C	   and	   then	   washed	   1x	   with	   Wash	   buffer	   and	   2x	   with	  polyribosome	  buffer.	  300µl	  of	   the	   flow-­‐through	  was	  taken	  as	  RNA	  and	  30µl	  as	  protein	  sample.	  	  1/20	  of	  the	  pellet	  was	  taken	  as	  a	  protein	  sample,	  the	  rest	  mixed	  with	  Trifast	  in	  order	  to	  elute	  the	  RNA.	  	  The	  protein	  samples	  were	  analysed	  by	  Western,	  the	  RNA	  samples	  by	  Northern	  blotting.	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2.11	  Peptide	  antibody	  against	  VSG118	  The	   following	   sequence	  was	   chosen	   for	   the	   production	   of	   a	   peptide	   antibody	   against	  VSG118	  (by	  the	  manufacturers	  of	  the	  antibody):	  	  CKMS	  KELK	  ATAM	  RAAN	  DAKL	  KITE	  	  The	   protein	   sequence	   is	   24	   amino	   acids	   long	   and	   starts	   at	   position	   47	   of	   the	  VSG118	  protein.	  The	  antibodies	  were	  raised	   in	   two	  rabbits,	  with	  an	   immunization	  of	  90days,	  by	  Pierce	  custom	  antibodies	  (Thermo	  scientific)	  
2.12	  VSG118	  Immunoprecipitation	  with	  cells	  in	  vivo	  labeled	  with	  35S	  methionine	  
2.12.1	  Preparation	  of	  protein-­‐A	  beads	  1st	   experiment:	   six	   aliquots	   of	   100µl	   Protein	  A	   beads	  were	   incubated	  with	   1µl,	   5µl	   or	  10µl	  VSG118	  antibody	  (received	  from	  J.	  Banks)	  or	  the	  peptide	  antibody	  (see	  2.11).	  The	  beads	   were	   incubated	   with	   the	   antibody	   in	   1xPolyribosome	   wash	   buffer	   (see	   2.10)	  overnight,	  rotating	  at	  4°C.	  	  Prior	  to	  the	  immunoprecipitation,	  the	  beads	  were	  washed	  3x	  with	  500µl	  wash	  buffer.	  2nd	   experiment:	   five	   aliquots	   of	   ProteinA	   beads	   were	   used.	   1µl,	   4µl	   and	   8µl	   VSG118	  antibody	   were	   mixed	   with	   200µl,	   200	   µl	   and	   300µl	   ProteinA	   beads.	   10µl	   and	   20µl	  VSG118	  peptide	  antibody	  were	  mixed	  with	  300µl	  ProteinA	  beads	  each.	  The	  beads	  and	  antibodies	  were	  incubated	  with	  500µl	  PSB	  wash	  buffer	  for	  4	  hours	  at	  room	  temperature	  and	  washed	  4x	  with	  1ml	  wash	  buffer	  prior	  to	  the	  experiment.	  
2.12.2	  In	  vivo	  labeling	  of	  cells	  All	   centrifugations	   were	   done	   at	   room	   temperature.	   All	   steps	   after	   the	   adding	   of	   35S	  methionine	  were	  performed	  with	  appropriate	  shielding.	  1st	  experiment:	  3.107	  bs1313	  3850	  cells	  were	  spun	  down	  at	  2500rpm,	  transferred	  to	  a	  1.5ml	  Eppendorf	  tube	  and	  washed	  twice	  with	  1xPBS.	  Then	  the	  cells	  were	  resuspended	  in	  400µl	  labeling	  medium.	  6µl	  35S	  methionine	  solution,	  with	  an	  activity	  of	  about	  60µCi,	  was	  added.	  The	   cells	  were	   incubated	   for	  1h	  at	  37°C.	  Then	   the	   cells	  were	  pelleted	  and	  washed	  three	  times	  with	  1x	  polyribosome	  wash	  buffer	  (see	  2.9.9).	  2nd	  experiment:	  2.5.107	  VSG118	  expression	  cells	  were	  used.	  The	  labeling	  was	  done	  like	  in	  the	  first	  experiment,	  using	  60µCi	  of	  35S	  methionine,	  despite	  the	  lower	  amount	  of	  cells.	  	  	  
2.12.3	  Immunoprecipitation	  and	  gel	  electrophoresis	  1st	  experiment:	  The	  cell	  pellet	  was	  dissolved	  in	  500µl	  lysis	  buffer	  and	  incubated	  on	  ice	  for	   30min,	   with	   occasional	   vortexing.	   Then	   the	   cell	   debris	   was	   spun	   down	   at	   room	  temperature	  (5	  min,	  5.000rpm).	  A	  10µl	  sample	  was	  taken	  (input)	  and	  80µl	  of	  the	  lysate	  was	  given	  on	  each	  of	  the	  six	  bead	  aliquots.	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The	  IPs	  were	  rotated	  for	  2	  hours	  at	  4°C.	  Then	  the	  beads	  were	  spun	  down	  at	  2000rpm	  for	  2min	  at	  room	  temperature	  and	  the	  supernatant	  was	  removed.	  The	  beads	  were	  washed	  once	  with	  1ml	  wash	  buffer	  and	  then	  mixed	  with	  15µl	  4x	  Laemmli.	  A	  15µl	  sample	  from	  the	  supernatant	  was	  also	  mixed	  with	  4x	  Laemmli.	  The	  samples	  were	  kept	  at	  -­‐20°C	  and	  separated	  on	  a	  12%	  PAA	  gel	  the	  next	  day.	  	  2nd	   experiment:	   The	   cells	   were	   lysed	   in	   200µl	   lysis	   buffer	   for	   30min	   on	   ice	   with	  occasional	  vortexing.	  The	  lysate	  was	  cleared	  for	  10min	  at	  10,000rpm,	  a	  5µl	  input	  sample	  was	  taken.	  For	  each	  IP,	  40µl	  of	  the	  lysate	  was	  mixed	  with	  60µl	  60%	  sucrose	  (in	  order	  to	  mimic	  the	  sucrose	  concentration	  in	  the	  polyribosome	  samples)	  and	  mixed	  with	  one	  bead	  aliquot.	  	  The	   IPs	   were	   rotated	   for	   1	   hour	   at	   4°C.	   The	   beads	   were	   spun	   down	   and	   a	   20µl	  supernatant	  sample	  was	  taken	  and	  mixed	  with	  7µl	  4x	  Laemmli.	  The	  pellets	  were	  washed	  with	  500µl	  wash	  buffer	  and	  mixed	  with	  4x	  Laemmli.	  The	  samples	  were	  kept	  at	  4°C	  and	  separated	  on	  a	  12%	  PAA	  gel	  the	  next	  day.	  	  	  The	   PAA	   gels	  were	   fixed	   for	   1	   hour	   in	   a	  mix	   of	   60%	  water,	   30%	  methanol	   and	   10%	  acetic	  acid	  and	  then	  incubated	  with	  enhance	  solution	  (Perkin	  Elmer)	  for	  another	  hour.	  The	  gels	  were	  washed	  with	  water	  and	  dried	  for	  3	  hours	  at	  65°C	  using	  a	  vacuum	  dryer.	  Then	  the	  gels	  were	  exposed	  to	  an	  x-­‐ray	  film	  for	  at	  least	  3	  hours.	  
2.13	  Indirect	  Immunofluorescence	  The	   immunofluorescence	   was	   performed	   according	   to	   the	   EMBO/TDR	   protocol.	   The	  anti-­‐myc	  and	  the	  anti-­‐V5	  antibody	  from	  abgene	  (mouse,	  1:500)	  were	  used.	  The	  Olympus	  CellR	  microscope	  was	  used	  for	  image	  acquisition.	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2.14	  Plasmids	  and	  Primers	  
2.14.1	  Plasmids	  
pHd 
number description provided by Result section 
1781 pHD1744 +PUF3 ORF (TAP-tag-HYG) Dr. S. Archer 3.1.4 
1783 pHD1744 +PUF6 ORF (TAP-tag-HYG) Dr. S. Archer 3.1.4 
2161 Bla V5 + RBP29 ORF + UTR   3.1.4 
2162 Bla V5 + ZC3H29 ORF+ UTR   3.1.4 
2332 pHd1700 + ZC3H32 ORF   3.3 
2343 Bla-V5 Z32 ORF +UTR    3.3 
2375 P2T7TABlue ZC3H32   3.3.3 
2437 pHd2412 + ZC3H32 ORF from AA 83-
655    3.3.6 
2438 pHd2412 + ZC3H32 ORF from AA 211-
655    3.3.6 
2439 pHd2412 + ZC3H32 ORF from AA 1-158    3.3.6 
2482 pHd2412 + ZC3H32 ORF AA 1-253   3.3.6 
2483 pHd2412 + ZC3H32 ORF AA 1-274   3.3.6 
2484 pHd2412 + ZC3H32 ORF AA 1-362   3.3.6 
2485 pHd2412 + ZC3H32 ORF AA 274-655   3.3.6 
2486 pHd2412 + ZC3H32 ORF AA 362-655   3.3.6 
2487 ZC3H32 KO - in 1748 (BLA resistance)   3.3.4 
2488 ZC3H32 KO - in 1747 (PURO 
resistance)   3.3.4 
2527 Bla-v5+ Not2 ORF + UTR   3.3.9 
2573 pHd1701 + Tb927.7.2780   3.3.10 
2575 phd1701 + DRBD2   3.3.10 
2579 pHd1912 + ZC3H28 fragment (N-term. 
YFP-tag)   3.3.10 
2580 pHd2412 + ZC3H32 AA 362-538   3.3.6 
2581 pHd2412 + ZC3H32 AA 1-253   3.3.6 
2582 pHd2412 + ZC3H32 AA 1-145   3.3.6 
2594 pHd2412 + ZC3H32 AA 146-362   3.3.6 
2595 pHd2412 + ZC3H32 AA 146-538   3.3.6 
1995 pHD1912+MKT1 fragment (N-term. 
YFP-tag) Dr. D. Droll 3.3.2 






integrates in front of VSG121 in the 
VSG121 (MITat1.6) expression site. 
After integration you get the following: 
ESAG1 -VSG118 ORF with VSG221 
intergenic regions - blasticidin resistance 
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VSG121  The vector is linearised for 




p2676 (Kelly, Reed et al. 2007) Puro 
resistance replaced with Bla stuffer + tag 
cut out, VSG222  inserted   
3.2.1 
 
2607 P2T7 VSG118, for non radioactive probe   3.2.2 
Table	  3:	  Plasmids	  used	  for	  the	  work	  described	  in	  this	  Thesis.
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Fig.	  9:	  Maps	  of	  plasmids	  used	  for	  VSG	  project	  (Result	  section	  3.2)	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Fig.	  10:	  Vector	  maps	  of	  plasmids	  used	  for	  the	  ZC3H32	  project	  (Result	  section	  3.3),	  as	  well	  as	  for	  tagging	  proteins	  found	  in	  the	  mass	  spectrometry	  results	  (Result	  section	  3.1)	  	   	  




number name sequence 
used for 
pHD 
3819 rvORFZC3H29Apa1 ATAgggcccGATAGCAACCGTGGAATA 2162 
3820 fwORFZC3H29Xho1 CAGctcgagATGACACAGGTCATCACG 2162 
3821 fwUTRZC3H29Sac2 CACccgcggATGTATTTGTTAAACGAG 2162 
3822 rvUTRZC3H29Xba1 CACtctagaGTTAATGGGCAATAACTA 2162 
3823 fwORFrbp29Xho1 GAGctcgagATGGCGCATGTTGGACAG 2161 
3824 rvORFrbp29Apa1 ATAgggcccTGCTCGCAGTATTGCTGG 2161 
3825 fwUTRrbp29Sac2 CACccgcggGAGCCTAGAAAATAGATA 2161 
3826 rvUTRrbp29Xba1 ATAtctagaCCGTTCGGCGCTTGCCTT 2161 
4350 VSG118hind3revshort ATCaagcttCTAGTTCTGTGTGTGTT 2607 
4414 vsg118wosskpn1fw TatggtaccACAAACAATCACGGC 2607 
3854 VSG rev 2nd Apa1 AGCgggcccTCTGATTTGTTGTATCCGAAC 2606 

























4501 ZC3H32Hind3fw GCGaagcttATGTCTGGCACTAATCAC 2332 
4678 Z32UTRRvXbaI GCGtctagaGATGTTTTCCTTCCCCTT 2343 
4679 Z32UTRfwSac2 CATccgcggACTCACTCATACATCTAA 2343 
4681 Z32ORFrvApa1 ATAgggcccAAGCCAGAATATCATCT 2343 
4682 Z32ORFfwXho1 CATctcgagATGTCTGGCACTAATCAC 2343 
4747 ZC3H32 RNAi fw GAAGAAGAGGACGCTGATGG 2375 
4748 ZC3H32 primer rv ACTGCGAAGGGTTGCTAAGA 2375 
4978 Z32.83.fw.asc1 TATGGCGCGCCtaTCTTTTGAGGTTCAC 2437 




Z32-538-rvHpa1 CATgttaacGCAACTGCGACTAGCCTGACT 2439 
2580 
2595 
5069 Z32 KO rv Sac2 3'UTR ataCCGCGGtcctgacttggttcgtta 
2487 
2488 
5070 Z32 KO fw Xho1 5'UTR tatCTCGAGttcaggaaattgtgtcgt 
2487 
2488 
5071 Z32 KO rv hind 3 5'UTR ataAAGCTTgatgttttccttccccttc 
2487 
2488 
5072 Z32 KO fw Xba1 3'UTR cgcTCTAGAttgtgcctcgttaccatggt 
2487 
2488 
5073 Z32.274.fw.asc1 TATGGCGCGCCtaGTCGACTTCACATGG 2485 
5074 Z32.274.rvHpa1 GAGgttaacCTGCATCCATGTGAAGTCGAC 2483 
5075 Z32teth253rvHpa1 GAGgttaacGGCAGTTGGTAACTGCGA 2581 
5076 Z32teth362rvHpa1 GAGgttaacAGCTAAGTACCGCGGTATCAC 
2484 
2594 
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5077 Z32teth362fwAsc1 TATGGCGCGCCtaGTGATACCGCGGTAC 
2486 
2580 
5148 Z32gatewayfw AAAGCAGGCTCCATGtctggcactaatcac 2507 
5149 Z32 gateway rv GTACAAGAAAGCTGGGTTtcatctctgtttctgcgt 2507 
5245 PDH E1 fw TCATCTGCTGCACTTGGTTC probe 
5244 PDH E1 rv AGCATAACGACGGGATTGTC probe 
5243 PPDK fw GCGGACGGTAACAAGAACAT probe 
5242 PPDK rv AGCTCCTTTAGGTCCGAAGC probe 
5241 IDH fw AAGACGGAGGATCGTGTGAC probe 
5240 IDH rv CTTGAAACGCCCATCGTAAT probe 
5239 MCP 9 fw CAAGGCAACAAAGGGGAATA probe 
5238 MCP 9 rv CTTGATTCCGTGCTCACTCA probe 
5269 Not2 UTR fw Sac2 tatccgcggacagtaaatgaagaagtg 2527 
5454 DRBD2 fw Hind3 TATaagcttCAAGGAGGAAATATGTTCGAC 2575 
5455 DRBD2 rv BamH1 ATAggatccTCATGAAGTGGATTTATTGTC 2575 
5436 Tb927.7.2780 fw Hind3 gctaagcttTCTAAAGCTCCTTCGCAACCAGCC 2573 
5435 





ZC3H28 fw Mlu1 
GCGacgcgttaTATTCTAGCGAAAAGGAGAAG 
2579 
5437 ZC3H28 rv Hpa1 TATgttaacTCACGAACGACCCGGATGCTT 2579 



























3854 VSG rev 2nd Apa1 AGCgggcccTCTGATTTGTTGTATCCGAAC 2605 
3855 VSG fw 2nd Xho1 atactcgagATGCAGATGCGGCTGTGG 2605 	  
Table	  4:	  Primers	  used	  for	  the	  work	  described	  in	  this	  thesis.	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3.	  Results	  
3.1	  Mass	  Spectrometry	  of	  free	  and	  membrane	  bound	  polyribosomes	  	  The	  aim	  of	   this	  project	  was	   to	   identify	  proteins	  associating	  with	  polyribosomes	   in	   the	  bloodstream	  and	  the	  procyclic	  form	  of	  Trypanosoma	  brucei.	  This	  was	  done	  for	  two	  reasons:	  Polyribosome	  association	  of	  a	  candidate	  protein	  can	  give	  a	  hint	  towards	   its	  role	   in	  the	  RNA	   metabolism	   of	   the	   parasite.	   There	   are	   many	   putative	   RNA	   binding	   proteins	   in	  
Trypanosoma	  brucei.	  If	  a	  candidate	  protein,	  e.g.	  a	  protein	  with	  an	  RRM	  or	  a	  zinc	   finger	  domain,	  is	  found	  on	  the	  polyribosomes,	  this	  would	  indicate	  that	  this	  protein	  can	  indeed	  bind	  to	  RNA.	  Also,	  polyribosome	  association	  points	  towards	  a	  stabilizing	  role,	  instead	  of	  a	  role	  in	  RNA	  degradation.	  	  The	  second	  aim	  was	  to	  find	  proteins	  binding	  to	  the	  VSG	  mRNA.	  As	  VSG	  is	  the	  major	  surface	  protein	  and	  makes	  out	  about	  10%	  of	  the	  cell’s	  total	  protein,	  the	   polyribosomes	   at	   the	   ER	   should	   be	   enriched	   with	   VSG	   mRNPs.	   Thus,	   it	   was	  concluded	   that	   RNA	   binding	   proteins	   found	   exclusively	   in	   the	   membrane-­‐bound	  polyribosome	   of	   the	   bloodstream	   form	  were	   likely	   candidates	   for	  VSG	  mRNA	   binding	  proteins.	  	  Therefore,	   the	   polyribosomes	   of	   the	   bloodstream,	   as	  well	   as	   the	   procyclic	   form,	  were	  separated	  into	  free	  and	  membrane-­‐bound	  polyribosomes.	  	  	  To	   obtain	   the	  membrane-­‐bound	   fraction,	   the	   lysis	  was	   done	  without	   detergent,	   using	  glass	   beads	   and	   vortexing.	   The	   membrane	   fraction	   was	   separated	   from	   the	   cytosolic	  fraction	  by	  centrifugation	  at	  30,000g.	  Subsequently,	  the	  pellet	  (membrane	  fraction)	  and	  the	   supernatant	   (free	   fraction)	   were	   treated	   with	   Triton-­‐X	   in	   order	   to	   lyse	   the	  membranes	  (for	  a	  more	  precise	  description	  see	  2.9).	  	  The	  polyribosomes	  were	  isolated	  by	  sucrose	  gradient	  centrifugation.	  The	  two	  fractions	  were	  loaded	  on	  two	  different	  sucrose	  gradients,	  thus,	  membrane-­‐bound	  polyribosomes	  and	   free	   polyribosomes	  were	   isolated	   separately.	   Using	   an	   ISCO	  160	   gradient	   former,	  the	   fractions	  were	   collected	  and	   the	  polyribosome	  profile	  was	   recorded	  by	  measuring	  the	  absorption	  at	  254nm.	  	  	   	  




Fig.	  11:	  Scematic	  representation	  of	  a	  sucrose	  gradient	  centrifugation.	  A:	  Taken	  from	  (Spriggs,	  Stoneley	  et	  al.	  2008)	  	  B:	   examples	   for	   polyribosome	   gradients	   of	   free	   polyribosomes	   (made	   from	   the	   cytosolic	  fraction)	  and	  membrane-­‐bound	  polyribosomes	   (made	   from	  the	  membrane	   fraction).	  Note	   that	  the	  preribosomal	  subunits	  (40S	  and	  60S)	  are	  almost	  exclusively	  found	  in	  the	  cytosolic	  fraction.	  	  
	  
3.1.1	  Methods	  and	  pre-­‐trials	  	  The	   first	   polyribosome	   isolation,	   followed	   by	  mass	   spectrometry	   of	   the	   polyribosome	  fractions,	  was	  done	  as	  a	  pre-­‐trial,	  in	  order	  to	  see	  how	  much	  sample	  is	  needed	  in	  order	  to	  see	   RNA-­‐binding	   proteins.	   1.8.109	   procyclic	   cells	  were	   used.	   The	   polyribosomes	  were	  concentrated	  using	  centricon	  columns.	  	  The	  concentration	  of	  the	  polyribosomal	  fractions	  using	  centricon	  columns	  turned	  out	  to	  take	   more	   time	   than	   expected	   (approximately	   5	   hours),	   due	   to	   the	   high	   sucrose	  concentration	  of	  the	  samples.	  	  The	   amount	   of	   protein	   was	  measured	   using	   the	   Bradford	   assay.	   The	   total	   amount	   of	  protein	  was	  384µg	  for	  the	  free	  polyribosomes	  and	  128µg	  were	  loaded	  on	  the	  gel.	  For	  the	  membrane	  bound	  polyribosomes,	  the	  total	  amount	  of	  protein	  was	  83,3µg	  and	  52µg	  were	  loaded	  on	  the	  gel.	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Fig.	  12:	  Results	  of	   first	  mass	   spectrometry	  of	   free	  and	  membrane	  bound	  polyribosomes	  
from	   procyclics	   A:	   Coomassie-­‐stained	   gel	   for	  mass	   spectrometry	   B:	   Polyribosome	   profile	   for	  free	  polyribosomes	  C:	  Polyribosome	  profile	   for	  membrane-­‐bound	  polyribosomes.	  Note:	  Before	  fraction	  5	  (free	  polyribosomes)	  and	  4	  (membrane-­‐bound	  polyribosomes)	   the	  sensitivity	  of	   the	  machine	  was	  set	  too	  high	  (1	  instead	  of	  2),	  therefore,	  the	  absorption	  for	  the	  protein	  peak,	  as	  well	  as	  the	  40S,	  60S	  and	  80S	  peak,	  was	  to	  high	  to	  be	  measured.	  	  	  	  D:	   mass	   spectrometry	   results	   for	   the	   membrane-­‐bound	   polyribosomes.	   126	   proteins	   were	  identified	   in	   total.	   E:	   mass	   spectrometry	   results	   for	   the	   free	   polyribosomes.	   155	   different	  proteins	  were	  identified.	  	  The	  proteins	  labeled	  as	  contaminants	  include	  cytosceletal	  and	  mitochondrial	  proteins,	  proteins	  which	  have	   a	   function	   in	   the	   glucose	  metabolism	  and	   the	   citric	   acid	   cycle,	   in	   the	   cell	   cycle,	   in	  vesicular	   transport,	   in	   lipid	  and	   fatty	   acid	   synthesis	   as	  well	   as	   in	   the	   synthesis	  of	  purines	  and	  pyrimidines	  (for	  a	  complete	  list:	  see	  Suppl.	  6.1)	  	  The	   mass	   spectrometry	   (see	   fig.	   12)	   results	   contained	   a	   lot	   of	   ribosomal	   proteins,	  proteins	  involved	  in	  translation	  but	  only	  very	  few	  RNA	  binding	  proteins.	  	  In	   the	   free	  polyribosomes,	   the	  cap-­‐binding	   initiation	   factor,	  eIF4E4,	  was	   found.	  As	   this	  protein	  should	  be	  present	  only	  once	  on	  each	  polyribosome,	  we	  concluded	  that,	   for	   the	  free	  polyribosomes,	  we	  loaded	  enough	  material	  to	  see	  proteins	  binding	  to	  mRNAs	  with	  only	  a	  single	  copy.	  	  In	   order	   to	   see	   RNA	   binding	   proteins,	   however,	   which	   are,	   opposite	   to	   translation	  initiation	  factors,	  not	  found	  on	  every	  RNA,	  we	  would	  need	  more	  material.	  As	  one	  third	  of	  the	  material	  for	  free	  polyribosomes	  was	  loaded	  on	  a	  gel	  and	  1,8.109	  cells	  were	  used,	  this	  would	  correspond	  to	  6.108	  cells.	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A	  protein	  that	  would	  bind	  the	  VSG	  RNA	  would	  bind	  to	  approximately	  10%	  of	  the	  total	  RNA,	   but	   probably	   to	   50%	   of	   the	   RNA	   transcribed	   on	   the	   membrane-­‐bound	  polyribosomes.	  	  	  Comparison	   of	   the	   gradients	   from	   the	   free	   and	   membrane	   bound	   polyribosomes	   in	  bloodstream	   cells	   (see	   fig.	   14	   A	   and	   C,	   the	   height	   of	   the	   polyribosome	   peak	   was	  compared)	  showed	  that	   there	  are	  approximately	  three	  times	  more	   free	  polyribosomes	  than	  membrane	  bound	  ones.	  	  Therefore,	  in	  order	  to,	  theoretically,	  be	  able	  to	  see	  a	  protein	  binding	  to	  the	  VSG	  mRNA,	  we	  need	  at	  least	  6	  times	  more	  material,	  which	  would	  correspond	  to	  3,6.109	  cells	  for	  the	  membrane	  bound	  polyribosome	  isolation.	  	  In	   order	   to	   have	   enough	   material,	   for	   the	   first	   mass	   spectrometry	   for	   the	   free	  polyribosomes,	  I	  used	  5,6.109	  bloodstream	  cells	  (see	  fig.	  14,	  A	  and	  B).	  	  For	  the	  preparation	  of	  the	  membrane	  bound	  polyribosomes	  double	  as	  many	  cells	  were	  used	  (1,06.1010	  cells)	  (result	  see	  fig.	  15).	  In	   this	   second	   large-­‐scale	  preparation,	   the	   cytosolic	   fraction	   (free	  polyribosomes)	  was	  distributed	   over	   three	   different	   gradients,	   two	   15-­‐50%	   and	   one	   15-­‐55%	   gradient,	   in	  order	  to	  avoid	  overloading	  of	  the	  gradient	  (see	  fig.	  15,	  C-­‐E).	  	  The	  membrane	  fraction	  was	  loaded	  on	  15-­‐55%	  gradient	  (see	  fig.	  15,	  A).	  	  However,	   after	   reviewing	   the	   results	   of	   the	   free	   and	   the	   membrane-­‐bound	  polyribosomes,	   it	   was	   seen	   that	   much	   less	   proteins	   were	   obtained	   in	   the	   free	  polyribosomes	   than	   in	   the	   results	   from	   the	   membrane-­‐bound	   ones	   (112	   proteins	   as	  compared	   to	   394).	   Therefore,	   the	   mass	   spectrometry	   of	   the	   bloodstream	   free	  polyribosomes	   was	   repeated	   using	   the	   free	   polyribosomal	   fractions	   from	   the	   larger	  polyribosome	  preparation	  (see	  fig.	  15	  C-­‐E).	  	  As	  already	  mentioned,	   the	   concentration	  of	   the	   samples	  using	   centricon	  columns	   took	  quite	  a	   long	  time,	  due	  to	  the	  high	  sucrose	  concentration.	  Also	  TCA	  precipitation	  works	  badly	   with	   polyribosome	   samples,	   because	   the	   pellets	   did	   not	   dissolve	   well	   in	   the	  Laemmli	  buffer,	  as	  compared	  to	  “normal”	  protein	  samples	  (e.g.	   the	  Flow-­‐through	  of	  an	  immunoprecipitations),	  and	  were	  larger	  due	  to	  the	  sucrose.	  	  As	  can	  be	  seen	  in	  fig.	  13,	  however,	  even	  though	  the	  centricon	  concentration	  takes	  time	  and	   even	   if	   the	   samples	   are	   frozen	   in	   between,	   the	   majority	   of	   polyribosomes	   stays	  intact,	  although	  some	  seem	  to	  fall	  apart	  into	  monosomes.	  	  Also,	   due	   to	   the	   molecular	   cut-­‐off	   of	   100kDa,	   this	   method	   serves	   as	   an	   additional	  purification	  step.	  However,	  material	  also	  gets	   lost	  during	  this	  step,	   this	  can	  be	  seen	  by	  the	  fact	  that	  the	  peaks	  in	  gradient	  B	  are	  not	  as	  high	  as	  expected.	  	  As	   the	   samples	   concentrate	   slower	   due	   to	   the	   sucrose	   content,	   I	   tried	   shortening	   the	  spin	   time	   by	   diluting	   the	   samples	   with	   sucrose-­‐free	   polyribosome	   buffer.	   Although	  leading	   to	   a	   larger	   volume,	   a	  1:4	  dilution	  did	   reduce	   the	   concentration	   time.	  Also,	   the	  diluted	  concentrate	  could	  be	  TCA	  precipitated.	  Thus,	  for	  the	  large-­‐scale	  preparation	  for	  the	  bloodstream-­‐form	  polyribosomes,	  a	  combination	  of	  both	  methods	  was	  chosen.	  The	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samples	   were	   diluted	   1:4,	   with	   sucrose-­‐free	   polyribosome	   buffer	   (see	   Materials	   and	  Methods),	   then	   concentrated	   using	   centricon	   columns.	   The	   concentrate	   was	   then	  precipitated	  with	  TCA.	  	  	  For	  the	  procyclic	  preparation	  1,35.1010	  cells	  were	  used.	  Again	  four	  gradients	  were	  made.	  	  The	  membrane	  fraction	  was	  given	  on	  a	  15-­‐55%	  gradient	  (see	  fig.16,	  A),	  as	  well	  as	  half	  of	  the	   cytosolic	   fraction	   (see	   fig.	   16,	   C).	   The	   polyribosome	   fractions	   from	   these	   two	  gradients	   were	   concentrated	   with	   centricons	   directly	   after	   fractionation	   and	   the	  concentrate	  was	  sent	  for	  mass	  spectrometry.	  The	  other	  half	  of	  the	  cytosolic	  fraction	  was	  split	  on	  two	  15-­‐50%	  gradients	  (not	  shown),	  these	  were	  not	  used	  for	  mass	  spectrometry.	  	  As	  the	  final	  volume	  of	  both	  the	  free	  and	  the	  membrane-­‐bound	  polyribosomes	  was	  small	  enough	   to	   be	   loaded	   on	   a	   gel,	   no	   TCA	   precipitation	   was	   done	   after	   the	   centricon	  concentration.	   However,	   the	   remaining	   sucrose	   in	   the	   sample	   destroyed	   the	  chromatograph’s	  column,	  therefore	  this	  method	  is	  not	  recommendable.	  	  	  
	  
Fig.	  13:	  Concentration	  of	  polyribosome	   fractions	  with	  Centricon	  A:	  polyribosome	  gradient	  (15-­‐50%),	   with	   free	   poyribosomes,	   made	   with	   2.4.109	   procyclic	   cells.	   Fractions	   6,7,8	   and	   9	  (polyribosomes,	  shown	  in	  red)	  were	  pooled,	  45%	  of	  the	  pooled	  polyribosomes	  were	  frozen	  over	  night	   at	   80°C	   and	   concentrated	   with	   a	   centricon	   column	   the	   next	   day.	   The	   concentracte	   was	  given	   on	   a	   new	   gradient,	   which	   is	   seen	   in	   B:	   Polyribosome	   gradient	   with	   sample	   after	  concentration	  with	  centricon	  column	  (MW:100kDa).	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Fig.	   14:	   Results	   of	   first	   mass	   spectrometry	   of	   free	   polyribosomes	   from	   	   bloodstream	  
trypanosomes	   A:	   polyribosome	   gradient,	   free	   polyribosomes	   (profile	   membrane	   bound	  polyribosomes,	  see	  C.).	  Made	  with	  5,6.109	  bloodstream	  cells.	  Fraction	  16	  and	  17	  were	  diluted	  1:4	  and	  concentrated	  using	  a	  centricon	  column	  (time	  needed:	  ca.	  150min).	  The	  final	  volume	  (about	  345µl)	  was	   TCA	   precipitated,	  washed	  with	   Ethanol,	   run	   on	   a	   PAA	   gel,	   coomassie	   stained	   and	  sent	   for	   mass	   spectrometry.	   B:	   Overview	   of	   Mass	   Spectrometry	   results	   from	   concentrated	  polyribosomes	   C:	   membrane	   bound	   polyribosomes	   from	   same	   cell	   lysate	   as	   used	   in	   A	   (not	  analysed	  by	  mass	  spectrometry,	  too	  little	  material).	  	  	  	  
3.1.2	  Mass	  spectrometry	  results	  from	  the	  large	  scale	  polyribosome	  isolations	  
	  1507	  unique	  peptides	  were	  found	  in	  the	  mass	  spectrometry	  results	  of	  the	  bloodstream	  free	  polyribosomes,	  done	  with	  1,06.1010	  cells,	  and	  1859	  unique	  peptides	  were	  found	  in	  the	  membrane-­‐bound	  polyribosomes	  (for	  a	  complete	  list	  see	  suppl.	  6.1).	  This	  shows	  that,	  despite	   the	   use	   of	   additional	   material	   for	   the	   free	   polyribosomes,	   there	   was	   still	   a	  smaller	  yield	  than	  for	  the	  membrane-­‐bound	  ones.	  	  	  For	  procyclics	  (1,34.1010	  cells	  used),	  2123	  peptides	  were	  found	  in	  the	  membrane-­‐bound,	  but	  only	  423	  in	  the	  free	  polyribosomes.	  This	  shows	  that,	  for	  the	  free	  polyribosomes,	  the	  yield	   is	   very	   low,	   therefore,	   the	   data	   used	   from	   this	   preparation	   should	   be	   used	  with	  some	  caution,	  meaning,	   if	  a	  protein	   is	   found	  only	  with	   the	  procyclic	  membrane-­‐bound	  polyribosome	  data	  set,	  it	  does	  not	  necessarily	  mean	  that	  it	  cannot	  be	  present	  in	  the	  free	  polyribosomes.	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Fig.15:	  Large	  scale	  isolation	  of	  bloodstream	  free	  and	  membrane-­‐bound	  polyribosomes	  	  A:	   polyribosome	  profile	   of	   the	  membrane	  bound	  polyribosomes.	   Fractions	   shown	   in	   red	  were	  concentrated	  with	  a	  centricon	  column,	  then	  TCA	  precipitated	  and	  sent	  for	  mass	  spectrometry.	  	  B:	   Overview	   of	   proteins	   found	   by	   mass	   spectrometry	   (bloodstream	   membrane-­‐bound	  polyribosomes).	  C,	  D,	  E:	  polyribosome	  profiles	   for	   free	  polyribosomes.	  Fractions	   shown	   in	   red	  were	   concentrated	   with	   a	   centricon	   column,	   then	   TCA	   precipitated	   and	   sent	   for	   mass	  spectrometry.	   F:	   Overview	   of	   proteins	   found	   by	   mass	   spectrometry	   (bloodstream	   free	  polyribosomes)	  .	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Fig.16:	  Large	  scale	  isolation	  of	  procyclic	  free	  and	  membrane-­‐bound	  polyribosomes	  	  A:	  Polyribosome	  profile	   of	   the	  membrane	  bound	  polyribosomes.	   Fractions	   shown	   in	   red	  were	  concentrated	  with	  a	  centricon	  column	  and	  sent	  for	  mass	  spectrometry.	  	  B:	   Overview	   of	   proteins	   found	   by	   mass	   spectrometry	   (procyclic	   membrane-­‐bound	  polyribosomes)	  	  C:	   polyribosome	  profile	   of	   the	   free	   polyribosomes.	   Fractions	   shown	   in	   red	  were	   concentrated	  with	  a	  centricon	  column	  and	  sent	  for	  mass	  spectrometry.	  	  D:	  Overview	  of	  proteins	  found	  by	  mass	  spectrometry	  (procyclic	  free	  polyribosomes)	  .	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3.1.3	  Mass	  spectrometry	  results	  –	  Proteins	  involved	  in	  translation	  	  In	  the	  mass	  spectrometry	  results	  of	  the	  isolated	  polyribosomes,	  3%	  to	  9%	  of	  the	  found	  proteins	  have	  already	  been	  shown	  to	  have	  a	  function	  in	  translation	  or	  are	  homologues	  of	  proteins	  having	  a	  function	  in	  translation	  in	  other	  organisms	  (see	  fig.	  15	  and	  16).	  These	  proteins	  are	  summarized	  in	  table	  5.	  	  The	  poly-­‐A	  binding	  proteins	  were	  found	  in	  all	   isolations,	  as	  well	  as	  elongation	  factor	  1	  gamma	  and	  TbRACK1,	  a	  WD-­‐repeat	  protein	   that	  binds	   to	  eEF1A	  and	  has	  already	  been	  shown	  to	  be	  associated	  with	  polyribosomes	  (Regmi,	  Rothberg	  et	  al.	  2008).	  All	  eight	  TCP	  proteins,	   the	  subunits	  of	   the	  TRiC	  complex,	  were	   found	   in	   the	  bloodstream	  membrane	  bound	   polyribosomes.	   The	   TRiC	   complex	   is	   involved	   in	   folding	   of	   the	   nascent	  polypeptides	  (Frydman,	  Nimmesgern	  et	  al.	  1994).	  Some	  of	  the	  TCP	  proteins	  were	  found	  in	  the	  other	  purifications	  as	  well.	  	  In	   the	   samples	   from	   the	   bloodstream	   form,	   the	   trypanosome	   homologue	   to	   Bfr1	  was	  found,	  a	  protein	  which	  is	  associated	  with	  polyribosomes	  in	  yeast	  (Lang,	  Li	  et	  al.	  2001).	  We	  also	   found	   the	  T.	  brucei	   homologues	  of	   the	  DEAD-­‐box	  helicase	  DED1,	  DED1-­‐1	   and	  DED1-­‐2,	  whose	  homologues	  in	  Leishmania	  were	  shown	  to	  be	  associated	  with	  translation	  initiation	  factors	  (Zinoviev,	  Leger	  et	  al.	  2011,	  Zinoviev,	  Akum	  et	  al.	  2012).	  	  Elongation,	  initiation	  and	  termination	  factors	  were	  found	  as	  well,	  but	  not	  to	  comparable	  amounts	   in	   all	   purifications,	  which	   shows	   a	  major	   flaw	   in	   these	   results.	   For	   example,	  according	   to	   the	   mass	   spectrometry	   results,	   the	   translation	   initiation	   factors	   eIF4E3,	  eIF4E4,	   eIF4G3	   and	   eIF4G4	   seem	   to	   be	   differentially	   distributed	   between	   free	   and	  membrane-­‐bound	   polyribosomes	   in	   the	   bloodstream	   form:	   while	   eIF4E3	   and	   G4	   are	  found	  exclusively,	  or	  with	  more	  unique	  peptides,	  in	  the	  mass	  spectrometry	  results	  of	  the	  membrane-­‐bound	  polyribosomes,	  eIF4E3	  and	  G4	  seem	  to	  be	  mainly	  associated	  with	  free	  polyribosomes.	   This	   would	   have,	   to	   a	   certain	   extent,	   matched	   the	   results	   of	   (Freire,	  Dhalia	  et	  al.	  2011),	  as	  they	  showed	  that	  E3	  binds	  G3	  and	  G4,	  while	  E4	  binds	  only	  G3,	  as	  well	  as	  that	  these	  initiation	  factors	  are	  associated	  with	  polyribosomes.	  	  In	  order	  to	  check	  whether	  this	  difference	  was	  genuine,	  I	  made	  Western	  blots	  from	  free	  and	   membrane-­‐bound	   polyribosomes.	   The	   polyribosome	   fractions	   were	   pooled	   and	  concentrated	  with	  centricon	  columns	  (see	  fig.	  17).	  The	  elongation	  factors	  were	  detected	  using	  antibodies	  from	  (Freire,	  Dhalia	  et	  al.	  2011).	  However,	  these	  Western	  blots	  showed	  that	   the	   distribution	   of	   these	   proteins	   does	   not	   differ	   between	   free	   and	   membrane-­‐bound	  polyribosomes	  (see	  fig.	  17),	  at	  least	  not	  to	  a	  detectable	  extent.	  	  
Protein name 
Protein accession 
number Number of unique peptides 
    bs free  bs mb pc mb pc free A pc free B  
Bfr1 Tb927.10.14150 3 6       
DED1-1 Tb927.10.14550 3 9 3     
DED1-2 Tb09.211.3510   9 5     
EF1α Tb927.10.2100 9 10 9   1 
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EF1β Tb927.4.3570 2   3     
EF1γ Tb11.01.4660 4 1 10 2 1 
EF2 Tb927.10.4560 10   45 8   
EIF  Tb11.01.3420     6     
EIF2γ Tb11.01.4830     3     
eIF2α Tb927.3.2900     2     
EIF3  Tb11.01.1370     5     
EIF3 subunit 7 Tb927.6.4370     7     
EIF3a Tb927.7.6090 8   16     
EIF3b Tb927.5.2570     6     
EIF3c Tb927.10.8270 1   13     
EIF3c Tb927.10.8290 1         
EIF3g Tb927.4.1930 5         
eIF3L Tb927.10.4640     6     
EIF4A1 Tb09.160.3270 6 6 8     
EIF4E3 Tb11.01.3630 1 3       
EIF4E4 Tb927.6.1870 10 3 2   1 
EIF4G3 Tb927.8.4820 14   5   1 
EIF4G4 Tb11.01.2330   3       
EIF5 Tb927.10.2770   5 4     
ERF1  Tb11.22.0012   1 4     
ERF3  Tb11.02.4030     3     
IF2 Tb927.2.3780     2     
PABP1 Tb09.211.0930 24 11 25 4 1 
PABP2 Tb09.211.2150 28 21 24 6 1 
RBG1 Tb927.10.6800   3       
TbRACK1 Tb11.01.3170 15 14 15 8 1 
TCP 1 γ  Tb927.8.3150   2 17     
TCP 1 α  Tb11.01.8510     18   1 
TCP 1 β Tb11.42.0003     16   1 
TCP 1 δ Tb927.10.1060     17 2   
TCP 1 ε  Tb11.01.5860     15   1 
TCP 1 η Tb09.211.2570     11   1 
TCP 1 θ  Tb927.10.8190 2   17   1 
TCP 1 ζ  Tb11.02.0750 1   14     
Table	  5:	  Proteins	  involved	  in	  translation	  found	  in	  the	  mass	  spectrometry	  results.	  	  bs	   free:	   bloodstream	   free	   polyribosomes	   (see	   fig.	   15	   C,D,E	   and	   F),	   bs	   mb:	   bloodstream	  membrane-­‐bound	   polyribosomes(see	   fig.	   15	   A+B),	   pc	   mb:	   procyclic	   membrane-­‐bound	  polyribosomes	  (see	  fig.	  16	  A+B),	  pc	  free	  A:	  procyclic	  free	  polyribosomes,	  2nd	  mass	  spectrometry	  results	  (see	  fig.	  16,	  B+C),	  pc	  free	  B:	  procyclic	  free	  polyribosomes,	  1st	  mass	  spectrometry	  results	  (see	  fig.	  12	  A,	  B,	  E).	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Fig.	  17:	  eIF4E3	  and	  G4	  are	  not	  exclusively	  associated	  with	  free	  and	  eIF4E4	  and	  G3	  are	  not	  
with	  membrane	  bound	  polyribosomes	  A:	   Polyribosome	   profiles,	   free	   and	   membrane	   bound	   polyribosomes,	   from	   bloodstream	  trypanosomes	  B:	  Western	  blots	  made	  with	  samples	  from	  polyribosome	  isolation	  shown	  in	  A.	  	  PP:	  protein	  peak.	  Fraction	  1	  and	  2	  of	  each	  gradient	  were	  pooled,	  1/100	  was	  used	  as	  sample	  per	  Western	  blot.	  	  40S,	  60S,	  80S:	  Fraction	  3	  (40S),	  fraction	  4	  (60S)	  and	  fraction	  5	  (80S)	  were	  concentrated	  using	  a	  microcon	  column,	  1/10	  of	  the	  concentrated	  samples	  was	  used	  per	  Western	  blot.	  	  Poly:	   Polyribosomes,	   Fractions	   6-­‐8	   were	   pooled	   and	   concentrated	   using	   a	   centricon	   column.	  1/10	  of	  the	  concentrate	  was	  used	  per	  Western	  blot.	  	  C:	  Same	  experiment,	  different	  polyribosome	  isolation.	  V5-­‐ZC3H29	  was	  used	  as	  loading	  control.	  	  PP:	  protein	  peak.	  1/100	  of	  the	  non-­‐concentrated	  protein	  peak	  fractions	  was	  loaded.	  	  40S:	  1/16	  of	  non-­‐concentrated	  40S	  fraction	  was	  loaded,	  	  80S:	  60S	  and	  80S	   fractions	  were	  combined	  and	  concentrated	  using	  a	  microcon	  column	  (peaks	  were	  not	  clearly	  separated	  into	  two	  fractions	  in	  these	  profiles),	  	  poly:	   polyribosome	   fractions	   were	   combined	   and	   concentrated	   using	   two	  microcon	   columns.	  1/16	  of	  the	  concentrated	  sample	  was	  loaded	  on	  the	  Western	  blots.	  	  D:	  Northern	  blot	  probed	  against	  the	  VSG	  mRNA	  with	  samples	  made	  from	  the	  protein	  peak	  (PP)	  and	  the	  polyribosomes	  from	  both	  the	  gradients	  shown	  in	  A,	  free	  and	  membrane-­‐bound	  (mb),	  in	  order	  to	  show	  the	  proper	  separation	  of	   free	  and	  membrane-­‐bound	  polyribosomes	  (VSG	  mRNA	  should	  localize	  to	  the	  membrane-­‐bound	  polyribosomes).	  	  E:	  The	  signals	  from	  the	  Western	  blots	  were	  quantified.	  The	  signal	  was	  added	  up	  separately	  for	  free	   and	   membrane-­‐bound	   polyribosomes.	   Then	   the	   percentage	   of	   the	   total	   signal	   was	  calculated	  for	  each	  fraction	  (PP,	  40S,	  60S	  	  80S	  and	  polyribosomes).	  	  F:	  quantification	  of	  Western	  blots	  shown	  in	  C.	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3.1.4	  Testing	  of	  polyribosome	  association	  of	  RNA	  binding	  proteins	  	  In	  the	  mass	  spectrometry	  results	  of	  the	  isolated	  polyribosomes,	  2%	  to	  8%	  of	  the	  found	  proteins	  (see	  fig.	  15	  and	  16)	  are	  either	  shown	  to	  bind	  RNA	  or	  have	  RNA	  binding	  domains	  (see	  3.1.5,	  table	  6).	  	  In	   order	   to	   test	   whether	   these	   RNA	   binding	   proteins	  were	   genuinely	   associated	  with	  polyribosomes	   and	   not	   just	   contaminants,	   I	   used	   tagged	   versions	   of	   four	   candidate	  proteins	  and	  tested	  their	  movement	  through	  a	  sucrose	  gradient	  by	  Western	  blot.	  	  As	  the	  goal	  was,	  initially,	  to	  find	  proteins	  associated	  with	  the	  VSG	  mRNA,	  the	  four	  chosen	  candidate	  proteins	  were	  RNA	  binding	  proteins	  exclusively	  associated	  with	  bloodstream	  membrane-­‐bound	   polyribosomes.	   These	   candidates	   were	   the	   zinc	   finger	   protein	  ZC3H29,	   which	   was	   found	   with	   two	   unique	   peptides	   in	   the	   membrane-­‐bound	  polyribosomes,	   the	   pumilio-­‐domain	   proteins	   Puf3	   and	   Puf6	   (2	   and	   3	   unique	   peptides	  respectively)	   and	   the	   RRM-­‐domain	   protein	   RBP29	   (4	   unique	   peptides).	   ZC3H29	   and	  RBP29	  were	  endogenously	  V5-­‐tagged,	  while	  for	  Puf3	  and	  Puf6	  exogenously	  TAP-­‐tagged	  versions	  were	  used.	  RBP29	  was	  clearly	  not	  associated	  with	  polyribosomes,	  as	  it	  localizes	  to	  the	  nucleus	  (see	  fig.	  18).	  	  As	  was	  shown	  by	  Western	  blot,	  the	  other	  three	  proteins	  were	  mainly	  not	  associated	  with	  polyribosomes	   either	   but	   seem	   to	   trail	   down	   the	   gradient	   in	   a	   similar	   fashion	   as	   the	  negative	  control,	  trypanothione	  reductase	  (see	  fig.	  19	  for	  ZC3H29,	  fig.	  20	  for	  Puf6	  and	  fig.	  21	  for	  Puf3).	  	  However,	  as	  Puf6	  and	  Puf3	  were	  exogenously	  expressed,	  it	  cannot	  be	  ruled	  out	  that	  the	  expression	  levels	  of	  the	  tagged	  protein	  is	  higher	  than	  the	  endogenous	  protein	  levels	  and	  that	  therefore	  there	  is	  a	  large	  pool	  of	  superfluous	  protein,	  which	  would	  not	  bind	  to	  RNA	  targets	   and	   thus	   not	   be	   associated	   with	   polyribosomes.	   This	   could	   lead	   to	   a	   larger	  amount	   of	   protein	   found	   in	   the	   first	   fractions	   and	   thus	   might	   cause	   a	   false	   negative	  result.	  Stabilization	  of	  the	  polyribosomes	  by	  UV-­‐crosslinking	  the	  RNAs	  to	  the	  proteins	  did	  not	  lead	  to	  an	  increase	  of	  either	  ZC3H29	  or	  Puf6	  protein	  levels	  in	  the	  higher	  fractions	  (see	  fig.	  22	  for	  ZC3H29	  and	  fig.	  23	  for	  Puf6).	  Also,	  dissociation	  of	  polyribosomes	  did	  not	  lead	  to	   a	   shift	   of	   the	   ZC3H29	   and	  Puf6	   signal	   to	   the	   lower	   fractions.	   This	   speaks	   against	   a	  specific	  association	  with	  polyribosomes.	  As	   these	   proteins	   were	   all	   found	   in	   the	   membrane-­‐bound	   sample,	   it	   was	   tested	   for	  ZC3H29	   whether	   this	   protein	   accumulates	   in	   the	   membrane-­‐bound	   polyribosomes.	  However,	   the	   amount	  of	   ZC3H29	   found	   in	   the	  membrane-­‐bound	  polyribosomes	   is	  not	  higher	  than	  the	  amount	  found	  in	  the	  free	  polyribosomes	  (see	  fig.	  24).	  	  In	  order	  to	  check	  whether	  any	  of	  these	  proteins	  binds	  to	  the	  VSG	  mRNA,	  RNA	  was	  pulled	  down	   by	   immunoprecipitation,	   either	   with	   V5-­‐beads	   (ZC3H29	   and	   RBP29)	   or	   IgG	  beands	  (Puf6	  and	  Puf3).	  The	  RNA	  level	  of	  VSG	  was	  then	  checked	  by	  qPCR.	  However,	  the	  results	  were	  inconclusive	  and,	  as	  it	  was	  discovered	  later	  that	  these	  proteins	  were	  mainly	  not	  associated	  with	  polyribosomes,	  the	  testing	  was	  stopped.	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Fig.	  18:	  V5-­‐RBP29	  localizes	  to	  the	  nucleus,	  V5-­‐ZC3H29	  to	  the	  cytoplasm	  	  Localization	  of	  V5-­‐RBP29	  and	  V5-­‐ZC3H29	  using	   immunofluorescence	  against	   the	  V5-­‐tag.	  DAPI	  was	  used	  to	  stain	  the	  nucleus.	  	  
	  
Fig.	  19:	  ZC3H29	  is	  mainly	  not	  associated	  with	  polyribosomes.	  	  A:	  Polyribosome	  profile	   and	  Western	  blot	  using	  bloodstream	  cells	   expressing	  V5-­‐ZC3H29.	  TR:	  trypanothione	   reductase,	   negative	   control	   S9:	   ribosomal	   protein	   S9	   (small	   subunit),	   positive	  control.	  B:	   Summary	  of	   the	  quantified	   results	  of	   three	  Western	  blots	  made	  with	   samples	   from	  three	  different	   gradients	   (as	   shown	   in	  A,	   but	  with	  different	   loading	  order).	   The	  quantification	  was	  done	  with	  respect	  to	  the	  differential	   loading	  (3µl	   in	  the	  first,	  10µl	   in	  the	  second	  and	  third	  fraction,	  30µl	  of	  the	  others).	  	  
	   3.	  Results	  
74	  
	  
Fig.	   20:	  Puf3	   is	  mainly	  not	   associated	  with	  polyribosomes.	  A:	  Sucrose	  gradient	  made	  with	  bloodstream	  cells	  expressing	  TAP-­‐tagged	  Puf6	  and	  quantification	  results	  of	  a	  Western	  blot	  made	  with	   samples	   from	   this	   gradient.	   TR:	   trypanothione	   reductase,	   negative	   control	   G3:	   eIF4G3	  (translation	   initiation	   factor)	   positive	   control.	   B:	   Summary	   of	   the	   quantified	   results	   of	   three	  Western	  blots	  made	  from	  samples	  of	  three	  different	  gradients.	  The	  quantification	  was	  done	  with	  respect	  to	  the	  differential	  loading	  (2µl	  in	  the	  first	  and	  second,	  10µl	  in	  the	  third	  fraction,	  30µl	  of	  the	  others).	  	  
	  
Fig.	  21:	  Puf3	  is	  mainly	  not	  associated	  with	  polyribosomes.	  A:	  Sucrose	  gradient	  and	  Western	  blot	   quantification	   using	   bloodstream	   cells	   expressing	   TAP-­‐tagged	   Puf3.	   TR:	   trypanothione	  reductase,	   negative	   control,	   S9:	   ribosomal	   protein	   S9	   (small	   subunit),	   positive	   control.	   The	  quantification	  was	  done	  with	  respect	  to	  the	  differential	  loading	  (1µl	  in	  the	  first	  and	  second,	  10µl	  in	  the	  third	  fraction,	  30µl	  of	  the	  others).	  	  




Fig.	  22:	  Polyribosome	  dissociation	  has	  no	  influence	  ZC329	  migration	  through	  the	  gradient	  Sucrose	   gradients	   of	   V5-­‐ZC3H29	   cells	   which	   were	   treated	   with	   cycloheximide	   prior	   to	   UV	  crosslinking	   in	   comparison	   to	   cell	   lysates	   treated	  with	  RNAseA	  A:	  Sucrose	  gradient	  profiles	  of	  crosslinked	   and	   RNAseA	   treated	   samples.	   B:	   Western	   blots	   probed	   against	   V5-­‐ZC3H29,	   TR	  (trypanothione	   reductase)	   and	   S9	   (ribosomal	   protein	   S9)	   C:	   quantification	   of	   Western	   blots,	  differential	  loading	  was	  taken	  into	  account.	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Fig.	  23:	  Polyribosome	  dissociation	  has	  no	  influence	  Puf6	  migration	  through	  the	  gradient	  Sucrose	   gradients	   of	   TAP-­‐Puf6	   cells	   which	   were	   treated	   with	   cycloheximide	   prior	   to	   UV	  crosslinking	  in	  comparison	  to	  cell	  lysates	  treated	  with	  RNAseA	  	  A:	   Sucrose	   gradient	   profiles	   of	   crosslinked	   and	   RNAseA	   treated	   samples.	   B:	   Western	   blots	  probed	   against	   TAP-­‐Puf6	   (with	   anti-­‐PAP),	   TR	   (trypanothione	   reductase)	   and	   S9	   (ribosomal	  protein	  S9)	  C:	  quantification	  of	  Western	  blots,	  differential	  loading	  was	  taken	  into	  account.	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Fig.	  24:	  ZC3H29	  is	  mainly	  not	  associated	  with	  membrane-­‐bound	  polyribosomes.	  	  A:	   Polyribosome	   profiles	   of	   free	   and	  membrane-­‐bound	   polyribosomes	  B:	  Western	   blots	  made	  with	   samples	   from	   polyribosome	   isolation	   shown	   in	   A.	   Probed	   against	   V5-­‐ZC3H29,	   TR	  (trypanothione	   reductase)	   and	   S9	   (ribosomal	   protein	   S9).	   C:	   quantification	   of	   ZC3H29	   signal	  from	  Western	  blots	  shown	  in	  fig.	  16	  and	  partially	  in	  D.	  	  mb:	  membrane-­‐bound	  PP:	  protein	  peak.	  1/100	  of	  unconcentrated	  protein	  peak	  fractions	  was	  loaded.	  	  40S:	  1/16	  of	  unconcentrated	  40S	  fraction	  was	  loaded,	  	  80S:	  60S	  and	  80S	  fractions	  were	  combined	  and	  concentrated	  using	  a	  microcon	  column	  	  polysomes:	   polyribosome	   fractions	   were	   combined	   and	   concentrated	   using	   two	   microcon	  columns.	  	  1/16	  of	  the	  concentrated	  samples	  was	  loaded	  on	  the	  Western	  blots.	  	  D:	  Two	  of	  the	  five	  Western	  blots	  (made	  from	  the	  same	  samples)	  used	  for	  the	  quantification	  seen	  in	  C.	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I	   also	   checked	   the	   polyribosome	   association	   of	   DHH1,	   which	   was	   found	   in	   the	   mass	  spectrometry	  results	  of	   the	  bloodstream	  free	  and	  membrane-­‐bound	  polyribosomes,	  as	  well	  as	  in	  the	  procyclic	  membrane-­‐bound	  polyribosomes	  (see	  table	  6).	  DHH1	  has	  been	  shown	  to	  be	  associated	  with	  polyribosomes	  in	  yeast	  (Sweet,	  Kovalak	  et	  al.	  2012).	  It	  also	  has	  been	  shown	  that	  this	  protein	  is	  responsible	  for	  the	  regulation	  of	  RNA	  translation	  in	  trypanosomes	   (Kramer,	   Queiroz	   et	   al.	   2010).	   As	   a	   DHH1	   antibody	   was	   available	  (Hartmann,	  Benz	  et	  al.	  2007),	   tagging	  of	   this	  protein	  as	  well	  as	  making	  new	  polysome	  gradients	   was	   not	   necessary.	   I	   used	   protein	   samples	   of	   already	   existing	   polysome	  gradients,	  made	  from	  cells	  that	  were	  crosslinked	  and	  treated	  with	  cycloheximide	  prior	  to	  harvesting	  (for	  profiles	  see	  fig.	  22,	  23	  and	  34).	  	  As	   expected,	   DHH1	   is	   enriched	   in	   the	   polyribosomal	   fractions,	   as	   compared	   to	   the	  negative	  control,	  trypanothione	  reductase	  (see	  fig.	  25).	  	  	  
Fig.	  25:	  DHH1	  associates	  with	  
polyribosomes	  A:	   polyribosome	   profile,	   made	   with	  cells	   expressing	   TAP-­‐tagged	   Puf6	  (same	   profile	   as	   shown	   in	   fig.	   23).	  Cells	   were	   treated	   with	  cycloheximide	   and	   crosslinked	   with	  UV	  light	  prior	  to	  harvesting.	  	  B:	   Corresponding	   Western	   blot,	  probed	   against	   DHH1,	   TR	  (trypanothione	   reductase,	   negative	  control),	   TxNPX	   (tryparedoxin	  peroxidase,	  negative	  control)	  and	  S9	  (ribosomal	   protein	   S9,	   positive	  control)	  	  C:	   This	   experiment	   was	   done	   three	  times.	   The	   average	   and	   standard	  deviation	   of	   the	   quantifications	   of	  the	   DHH1	   and	   the	   TR	   signals	   from	  the	  three	  Western	  blots	  are	  shown.	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3.1.5	  Summary	  of	  the	  mass	  spectrometry	  results	  of	  RNA	  binding	  proteins	  	  The	   first	   four	   RNA	   proteins	   I	   tested	   (Puf6,	   Puf3,	   RBP29,	   ZC3H29)	   showed	   no	  polyribosome	  association,	  at	   least	  not	  to	  a	  detectable	  extent.	  For	  the	  ZC3H32	  project,	   I	  tested	  the	  polyribosome	  association	  for	  this	  zinc	  finger	  protein	  as	  well	  (see	  3.2.2,	  fig.	  34),	  although	  it	  was	  found	  with	  only	  one	  unique	  peptide	  in	  the	  mass	  spectrometry	  results	  of	  the	   membrane-­‐bound	   polyribosomes.	   ZC3H32	   also	   showed	   no	   detectable	   association	  with	   polyribosomes.	   I	   later	   tested	   DHH1,	  which	  was	   found	   in	   the	  mass	   spectrometry	  results	   of	   three	   polyribosome	   preparations	   (see	   table	   6).	   DHH1	   was	   found	   in	   the	  polyribosome	  fractions	  to	  a	   larger	  extent	  than	  the	  negative	  control	  (see	  fig.	  25),	  which	  strongly	  suggests	  that	  it	  associates	  with	  polyribosomes.	  	  Nine	  other	  RNA	  binding	  proteins	  that	  were	  found	  in	  the	  mass	  spectrometry	  results	  were	  shown	  not	   to	  be	  associated	  with	  polyribosomes	  by	  different	  people	   (see	   table	  6).	  This	  shows	  that	   in	   the	   large-­‐scale	  polyribosome	  isolation	  method	  proteins	  present	   in	  a	   low	  amount	  in	  the	  polyribosomes	  are	  detected.	  The	  main	   problem,	   as	   can	   be	   seen	   in	   figures	   19-­‐24,	   is,	   that	   there	   are	  many	   abundant	  proteins,	   for	   example	   trypanothione	   reductase,	   which	   trail	   down	   the	   gradient	   and	  contaminate	  the	  polyribosome	  samples.	  	  Nevertheless,	  the	  obtained	  data	  can	  still	  be	  useful.	  However,	  precautions	  must	  be	  taken.	  A	   protein	   found	   in	   only	   one	   of	   the	   samples	   is	   probably	   not	   associated	   with	  polyribosomes	  unless	  it	   is	  a)	  specific	  for	  one	  life	  cycle	  stage	  or	  b)	  present	  with	  a	  lot	  of	  peptides	   (more	   than	   6	   (value	   for	   Puf2,	   which	   was	   tested	   negative)),	   like	   Ago1.	   Also,	  abundant	  proteins	  are	  more	  likely	  to	  be	  contaminants	  then	  non-­‐abundant	  proteins	  (see	  calculations,	  3.1.6).	  	  Out	  of	  the	  five	  RNA	  binding	  proteins,	  which	  were	  found	  in	  three	  of	  the	  five	  samples	  (all	  except	  the	  procyclic	  free	  polyribosomes,	  which	  yielded	  fewer	  unique	  peptides	  than	  the	  other	   three),	   four	   were	   indeed	   found	   in	   the	   polyribosomes.	   The	   only	   exception	   was	  DRBD3	  (also	  called	  PTB1),	  which	  was	  found	  not	  to	  be	  associated	  with	  polyribosomes	  by	  (Fernandez-­‐Moya,	   Garcia-­‐Perez	   et	   al.	   2012).	   However,	   the	   results	   on	   DRBD3	   are	  inconsistent:	  In	  the	  same	  study,	  Fernandez-­‐Moya	  et	  al.	  found	  ribosomal	  proteins	  in	  eight	  TAP-­‐purifications	  of	  DRBD3.	  Although	   ribosomal	  proteins	   are	  often	   contaminatants	   in	  affinity	  purifications	   (Ouna,	  Stewart	  et	  al.	  2012),	  Fernandez-­‐Moya	  et	  al.	  did	  not	  detect	  ribosomal	   contaminations	   in	   the	   TAP	   purifications	   of	   two	   other	   proteins	   (RRP44	   and	  PABP2),	  suggesting	  that	  this	  interaction	  is	  genuine.	  Why	  the	  TAP	  purification	  of	  PABP2,	  which	  is	  polyribosomal	  associated	  (Kramer,	  Bannerman-­‐Chukualim	  et	  al.	  2013),	  did	  not	  yield	  ribosomal	  proteins	  is	  another	  question.	  	  Also,	  it	  has	  been	  shown	  that	  DRBD3	  is	  involved	  in	  trans-­‐splicing	  and	  localizes	  partially	  to	  the	   nucleus	   (Stern,	   Gupta	   et	   al.	   2009,	   Fernandez-­‐Moya,	   Garcia-­‐Perez	   et	   al.	   2012).	  Fernandez-­‐Moya	  et	  al.	  use	  1%	  octyl-­‐glucoside	   to	   lyse	   the	  cells	   (protocol	  adapted	   from	  (Kramer,	  Queiroz	   et	   al.	   2010)).	   This	  might	  have,	   at	   least	   to	   a	   certain	   extent,	   lysed	   the	  nuclei.	   If	   this	   happened,	   the	   DRBD3	   proteins,	   which	   were	   formerly	   localized	   to	   the	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nucleus,	  would	  be	  present	  in	  the	  cleared	  cell	  lysate.	  This	  in	  turn	  would	  lead	  to	  a	  larger	  percentage	  of	  DRBD3	  in	  the	  protein	  fraction	  of	  the	  polysome	  gradients.	  	  D.	   Inchaustegui	   found	   DRBD3	   in	   the	   polyribosomes	   of	   procyclic	   cells,	   but	   exclusively	  after	   crosslinking	   the	   cells	   (D.	   Inchaustegui,	   unpublished	   data).	   This	   suggests	   that	  DRBD3	  associates	  with	  polyribosomes,	  but	  the	  association	  is	  unstable.	  	  To	  sum	  this	  up,	  the	  currently	  available	  data	  on	  DRBD3	  rather	  suggests	  that	  the	  fraction	  of	  this	  protein	  that	  localizes	  to	  the	  cytoplasm	  associates	  with	  polyribosomes.	  This	  means	  that	   all	   five	   proteins,	  which	   have	   been	   found	   in	   all	   three	   preparations	   and	   have	   been	  tested	  for	  polyribosome	  association,	  are	  indeed	  associated	  with	  polyribosomes.	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B   
AGO1 Tb927.10.10850     21     
 positive (Djikeng, Shi et al. 2003; 
Shi, Chamond et al. 2009) 
NOT5 Tb927.3.1920 4 9       signal too weak 
DHH1 Tb927.10.3990 2 4 6     positive 
DRBD3/  
PTB1 Tb09.211.0560 2 5 2     
negative (Fernandez-Moya, Garcia-
Perez et al. 2012), positive (D. 
Inchaustegui, unpublished data) 
DDX60 Tb927.3.2600     8   1  n.d. 
MKT1 Tb927.6.4770 3 2 2      positive (Singh, Minia et al. 2014) 
PUF2 Tb927.10.12660   6       negative (B. Anand, PhD Thesis) 
ALBA4/ 
ALBA3  Tb927.4.2030 1 2 2 1   
 positive* (Mani, Guttinger et al. 
2011) 
RBP42 Tb927.6.4440 3 1 2      positive (Das, Morales et al. 2012) 
ZC3H41 Tb11.46.0009     5      n.d. 
PUF6 Tb927.10.11760   4        negative 
RPB29 Tb927.10.13720   3        negative, nuclear 
PUF1 Tb927.10.4430   2        negative (Luu, Brems et al. 2006) 
PUF3 Tb927.10.310   2        negative 
ZC3H29 Tb09.211.1130   2        negative 
DBP2 Tb927.10.6630   2        n.d. 
PARN-3 Tb09.211.4350     2      n.d. 
RBP11 Tb927.8.4450 2          n.d. 
NOT2 Tb927.6.850 2          n.d. 
ZC3H18 Tb927.7.2140   1        n.d. 
ZC3H30 Tb927.10.1540   1        signal too weak 
ZC3H32 Tb927.10.5250   1        negative 
PBP1 Tb927.8.4540   1        positive (Singh, Minia et al. 2014) 
SUB2 Tb927.10.540   1       
 nuclear (Serpeloni, Moraes et al. 
2011)  
Table	  6:	  RNA	  binding	  proteins	  found	  in	  the	  mass	  spectrometry	  results.	  	  bs	   free:	  bloodstream	   free	  polyribosomes	   (see	   fig.	   14	  C,D,E,F),	   bs	  mb:	  bloodstream	  membrane-­‐bound	  polyribosomes(see	   fig.	  14	  A+B),	  pc	  mb:	  procyclic	  membrane-­‐bound	  polyribosomes	  (see	  fig.	  15	  A+B),	  pc	  free	  A:	  procyclic	  free	  polyribosomes,	  2nd	  mass	  spectrometry	  results	  (see	  fig.	  15,	  B+C),	  pc	  free	  B:	  procyclic	  free	  polyribosomes,	  1st	  mass	  spectrometry	  results	  (see	  fig.	  11	  A,	  B,	  E).	  	  Color	  coding:	  Red:	  This	  protein	  associates	  with	  polyribosomes,	  blue:	  This	  protein	  is	  mainly	  not	  associated	  with	  polyribosomes,	  green:	  Results	  are	  unclear	  (see	  text).	  signal	   too	   weak:	   the	   association	   with	   polyribosomes	   could	   not	   be	   determined,	   because	   the	  Western	  blot	  signal	  from	  the	  tagged	  cell	  line	  was	  too	  weak.	  	  *:	  ALBA3	  was	  found	  to	  be	  partially	  associated	  with	  polyribosomes,	  while	  ALBA4	  is	  not.	  However,	  these	  two	  proteins	  cannot	  be	  distinguished	  by	  mass	  spectrometry	  (Mani,	  Guttinger	  et	  al.	  2011).	  Proteins	  written	  in	  bold	  were	  tested	  for	  polyribosome	  association	  by	  myself	  (see	  figures	  19-­‐	  25	  or	  respectively,	  3.3.2	  for	  the	  results	  on	  ZC3H32).	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3.1.6	  RNA	  binding	  proteins	  in	  polyribosomes	  	  As	   five	  of	   the	   six	  RNA	  binding	  proteins	   I	   tested	  were	   found	  not	   to	  be	  associated	  with	  polyribosomes,	  at	  least	  not	  to	  a	  detectable	  extent,	  it	  was	  questioned	  whether	  it	  is	  likely	  to	  detect	  an	  RNA	  binding	  protein	  on	  the	  polyribosomes.	  	  Because	  of	  this,	  I	  made	  the	  following	  calculation:	  	  A	   bloodstream	   trypanosome	   cell	   contains	   approximately	   20	   000	   RNAs	   (Haanstra,	  Stewart	  et	  al.	  2008).	  In	  comparison,	  the	  levels	  of	  putative	  RNA	  binding	  proteins	  are	  quite	  high.	  The	  are	  4x105	  RBP10	  proteins	  per	  cell	  (PhD	  Thesis,	  Martin	  Wurst),	  PUF5	  proteins	  are	   present	   at	   less	   than	   5x104	   proteins	   per	   cell	   (Jha,	   Archer	   et	   al.	   2013)	   and	   PUF2	  proteins	  are	  present	  at	  approximately	  1.5x104	  proteins	  per	  cell	  (PhD	  Thesis,	  B.Jha).	  	  For	   my	   calculations,	   I	   assumed	   that	   the	   normal	   protein	   levels	   of	   other	   RNA	   binding	  proteins	  are	  similar,	  meaning	  in	  a	  range	  from	  5x104	  to	  5x105.	  I	   also	   considered	   that	   very	   abundant	   proteins,	   for	   example	   trypanothione	   reductase,	  tend	   to	   trail	   down	   the	   gradient	   and	   therefore	   are	   also	   partially	   found	   in	   the	  polyribosome	  fractions.	  Using	  the	  quantifications	  of	  the	  trypanothione	  reductase	  signal	  from	  six	  Western	  blots	  of	  polyribosome	  gradients	  (made	  with	  non-­‐crosslinked	  cells),	   I	  calculated	  that,	  on	  average,	  2%	  of	  the	  trypanothione	  reductase	  protein	  pool	  is	  found	  on	  the	  polyribosome	  fractions.	  	  In	  order	  to	  prove	  that	  a	  protein	   is	  really	  associated	  with	  polyribosomes	  and	  not	   just	  a	  contamination,	   a	   larger	   percentage	   than	   2%	   of	   this	   protein	   should	   be	   present	   in	   the	  polyribosomes.	  	  Assuming	   now	   that	   a	   protein	   binds	   to	   5%	   of	   the	   RNA,	   which	   would	   be	   1000	   RNA	  molecules	  per	   cell,	   and	   there	  are	  1x105	  copies	  of	   this	  protein	  per	   cell,	   only	  1%	  of	   this	  protein	  would	  be	  bound	  to	  RNA	  and	  therefore	  could	  be	  found	  on	  the	  polyribosomes.	  	  This	  would	  be	  nearly	  impossible	  to	  detect	  by	  Western	  blot.	  	  The	   percentage	   of	   protein	   bound	   to	   RNA	   gets	   larger	   if	   there	   is	   less	   protein	   per	   cell,	  however,	  as	  these	  proteins	  are	  not	  abundant	  they	  are	  hard	  to	  detect	  on	  a	  Western	  blot	  to	  start	  with	  (see	  fig.	  26,	  A).	  	  The	  percentage	  also	  increases	  if	  a	  protein	  has	  more	  RNA	  targets	  and	  also	  if	  each	  target	  RNA	  is	  bound	  by	  more	  than	  one	  copy	  of	  the	  protein	  (see	  fig.	  26,	  B).	  If	  six	  or	  more	  copies	  of	   a	   protein	   bind	   to	   each	   target	   RNA	   and	   these	   target	   RNAs	   are	   currently	   being	  translated,	  it	  should	  be	  possible	  to	  detect	  this	  protein	  in	  the	  polyribosomes.	  	  Considering,	   however,	   that	   probably	   the	   majority,	   but	   not	   all	   of	   the	   target	   RNAs	   are	  found	  on	   the	  polyribosomes	  (see	   fig.	  26,	  C)	  or	  bound	   to	   their	  protein	  binding	  partner,	  the	  percentage	  is	  even	  less	  than	  shown	  in	  figure	  26	  A	  and	  B.	  	  Regarding	   these	   results,	   in	   the	   future,	   if	   no	   antibody	   is	   available,	   only	   endogenously	  tagged	  proteins	  should	  be	  used	  in	  order	  to	  test	  polyribosome	  association.	  For	  example,	  I	  used	  exogenously	  expressed	  TAP-­‐tagged	  Puf6	  and	  Puf3	  constructs	  that	  are	  transcribed	  by	  PolI,	  which	  probably	   lead	   to	  higher	  protein	   levels.	  That	  might	  have	  diminished	   the	  percentage	   of	   protein	   found	   on	   the	   polyribosomes	   and	   thus	   lead	   to	   a	   false	   negative	  result.	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In	  conclusion,	  it	  is	  no	  problem	  to	  detect	  RNA	  binding	  proteins	  with	  multiple	  RNA	  targets,	  like	   translation	   initiation	   factors	   or	   PABP,	   in	   the	   polyribosomes.	   However,	   proteins	  binding	   to	   only	   a	   small	   pool	   of	   target	   RNAs	   (less	   than	   10%)	   cannot	   be	   shown	   to	   be	  associated	   with	   polyribosomes	   using	   this	   method,	   especially	   if	   only	   one	   copy	   of	   this	  protein	  binds	  to	  each	  target	  RNA.	  	  
	  
Fig.	   26:	   Diagrams	   illustrating	   the	   possibility	   to	   detect	   an	   RNA	   binding	   protein	   on	   the	  
polyribosomes	  by	  Western	  blot	  Background:	   %	   trypanothione	   reductase	   found	   in	   polyribosomes.	   On	   average,	   2%	   of	  trypanothione	  reductase	  is	  found	  in	  the	  polyribosomes	  (fractions	  after	  the	  80S	  peak).	  The	  data	  was	  taken	  from	  six	  Western	  blots	  from	  six	  different	  polyribosome	  gradients	  (for	  quantifications	  see	  fig.	  19	  and	  20).	  If	  the	  fraction	  of	  a	  protein	  that	  associates	  with	  the	  polyribosome	  is	  not	  larger	  than	   this	   background,	   its	   polyribosome	   association	   probably	   cannot	   be	   detected	   by	  Western	  blotting.	  A:	  percentage	  of	  protein	  bound	  to	  RNA	  (“bound	  protein”)	  plotted	  against	  proteins	  per	  cell	   times	  105.	  B:	  percentage	  of	  protein	  bound	  to	  RNA	  plotted	  against	   the	  number	  of	  proteins	  bound	  to	  each	  target	  RNA.	  C:	  percentage	  of	  protein	  bound	  to	  RNA	  plotted	  against	  the	  percentage	  of	  the	  target	  RNA	  found	  on	  polyribosomes.	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3.2	  VSG	  mRNP	  pull-­‐down	  
3.2.1	  Plan	  of	  experiment	  The	  aim	  of	  these	  experiments	  was	  to	  pull	  down	  proteins	  binding	  to	  the	  VSG	  mRNA.	  For	  this,	  it	  was	  planned	  to	  pull-­‐down	  the	  VSG	  mRNP	  using	  antibodies	  binding	  to	  the	  nascent	  polypeptide.	  In	  order	  to	  get	  rid	  of	  most	  of	  the	  mature	  VSG,	  which	  would	  compete	  with	  the	   nascent	   polypeptide	   for	   the	   antibody,	   the	   pull-­‐down	   would	   be	   done	   with	   the	  polyribosome	  fractions,	  as	  the	  majority	  of	  the	  mature	  VSG	  is	  found	  in	  the	  protein	  peak.	  The	   antibody-­‐bound	   mRNPs	   would	   then	   be	   precipitated	   using	   protein-­‐A	   beads.	   The	  enrichment	  of	  VSG	  mRNPs	  in	  the	  precipitates	  was	  checked	  by	  Northern	  blot,	  however,	  in	  the	  following	  shown	  experiment	  no	  enrichment	  of	  VSG	  mRNA	  was	  observed.	  	  
	  
Fig.	  27:	  Schematic	  representation	  of	  mRNA	  pull-­‐down.	  	  
3.2.2	  VSG222	  cell	  line	  For	   the	   VSG	   pull-­‐down	   experiments,	   it	   was	   planned	   to	   create	   a	   cell	   line	   expressing	  VSG222	   under	   antibiotic	   selection.	   However,	   the	   creation	   of	   this	   cell	   line	   failed	   (for	  plasmid	  see	  2.13.1,	  table	  2	  and	  fig.	  9),	  no	  clones	  were	  obtained.	  In	  order	  to	  continue	  with	  these	  experiments,	  a	  mainly	  VSG222	  expression	  cell	  line	  was	  obtained	   using	   clonal	   selection.	   For	   this,	   bs1313	   cells	   were	   diluted	   down	   to	   12.5	  cells/ml	  and	  distributed	  on	  a	  96	  well/plate.	  40µl	  were	  used	  per	  well,	  resulting	  into,	  on	  average,	  0.5	  cells/well.	  	  The	   cells	   were	   checked	   by	   Western	   blot,	   the	   clone	   with	   the	   strongest	   signal	   when	  probed	  with	  the	  VSG222	  antibody	  was	  chosen.	  In	   order	   to	   prevent	   RNA	  degradation	   from	  RNAses	   in	   the	   antibody,	   the	   antibody	  was	  purified	  by	  binding	  to	  protein-­‐A	  beads	  and	  then	  eluting	  it	  at	  pH	  2.7	  (see	  Materials	  and	  Methods	  2.10.1).	  However,	  the	  first	  mRNP	  pull-­‐downs	  did	  not	  show	  an	  enrichment	  of	  VSG222.	  The	  yield	  also	  did	  not	  increase	  with	  the	  double	  amount	  of	  antibody	  (20µl).	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Fig.	  28:	  VSG222	  RNA	  did	  not	  accumulate	  in	  the	  precipitate	  after	  the	  mRNP	  pull-­‐down.	  	  Four	  different	  Immunoprecipitation	  were	  made	  with	  the	  polyribosomal	  fractions	  of	  one	  gradient.	  Different	   amounts	   of	   antibody	   (10µl	   or	   20µl)	   	   and	   beads	   (100µl	   or	   200µl)	   were	   used.	   The	  incubation	  time	  of	  the	  Immunoprecipitations	  was	  1hour,	  with	  the	  exception	  of	   IP2	  (1/2	  hour).	  The	  total	  volume	  of	  pooled	  polyribosomes	  was	  approximately	  2.8ml.	  600µl	  were	  used	  for	  each	  IP,	  300µl	  were	  used	  for	  the	  Input	  sample.	  For	  exact	  protocol,	  see	  2.10.1	  A:	  Northern	  blot,	   probed	   against	  VSG222	   (DIG-­‐labeled	  probe)	   and	   tubulin	   (32P	   labeled	  probe)	  Input:	   Sample	   from	   the	   pooled	   polyribosome	   fractions	   that	   were	   used	   for	   the	  Immunoprecipitation.	  The	  volume	  of	   the	   Input	   sample	  was	  300µl,	  which	   corresponds	   to	  appr.	  0.85.108	  cells.	  	  U:	  Unbound	  fractions.	  300µl	  samples	  were	  used,	  which	  corresponds	  to	  appr.	  0.85.108	  cells.	  	  P:	  Precipitate.	  Trifast	  was	  added	  to	  the	  ProteinA	  beads	  after	  the	  immunoprecipitation	  in	  order	  to	  elute	  the	  bound	  RNAs.	  The	  samples	  correspond	  to	  appr.	  1.7.108	  cells.	  	  B:	  quantification	  of	  Northern	  blot	  shown	  in	  A.	  The	  VSG	  signal	  was	  divided	  by	  tubulin	  signal	  (neg.	  control,	   grey	   columns)	   and	   the	   ribosomal	   RNA	   signal	   (from	   the	   methylen	   blue	   stain,	   black	  columns).	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3.2.3	  VSG118	  antibody	  pull-­‐downs	  In	  order	  to	  get	  a	  cell	  line	  in	  which	  the	  expression	  of	  a	  single	  VSG	  was	  maintained	  by	  drug	  selection,	   a	   plasmid	   from	   Mark	   Carrington	   was	   used	   which	   should	   express	   VSG118	  under	  drug	  control	  (pHD	  3850,	  for	  vector	  map	  see	  2.14,	  figure	  9).	  	  A	  VSG118	  antibody	  was	  received	  from	  J.Banks.	  	  It	  was	  planned	   to	  make	  another	  VSG118	  antibody,	  but	   the	  His-­‐tagged	  protein	  was	  not	  expressed	  enough	  for	  purification.	  	  A	  VSG118	  peptide	  antibody	  was	  made,	  but	  this	  antibody	  gave	  a	  lot	  of	  background	  on	  a	  Western	  blot.	  It	  was	  also	  not	  useful	  in	  the	  immunoprecipitations	  (see	  fig.	  29	  and	  30).	  The	  created	  cell	   line	  expressed	  a	  VSG	   that	  was	   recognized	  by	   the	  antibody	  and	  pulled	  down	  by	  it	  with	  high	  affinity.	  The	  pull-­‐down	  was	  done	  with	  35S-­‐labeled	  cells,	  in	  order	  to	  get	  rid	  of	  the	  background	  signal	  from	  the	  antibody	  (see	  fig.	  29A).	  	  However,	   the	  RNA	  could	  not	  be	  detected	  with	  VSG118	   probes,	  neither	   radioactive	  nor	  non-­‐radioactive	   probes.	   Thus,	   it	   was	   concluded	   that	   these	   cell	   lines	   did	   not	   express	  VSG118	  but	  are	  false	  positives.	  	  I	   tried	  to	   identify	   the	  unknown	  VSG	  by	  making	   first	  strand	  cDNA,	  do	  a	  PCR	  for	   the	  2nd	  strand	  using	  the	  VSG	  consensus	  sequence	  and	  then	  cloning	  the	  DNA	  into	  the	  P2T7	  blue	  Plasmid.	  However,	  I	  did	  not	  receive	  any	  usable	  clones.	  	  Then	  I	  received	  a	  VSG118	  expressing	  cell	  line	  from	  Markus	  Engstler	  (called	  VSG118	  cells	  in	  the	  following	  figures).	  The	  cell	  line	  was	  used	  for	  the	  mRNP	  pull-­‐down.	  However,	  also	  no	  enrichment	  of	  VSG	  mRNA	  was	  observed	  after	   the	  VSG	  pull-­‐down	  (fig.	  30	  A+B).	  The	  pull-­‐down	  was	  also	  not	  so	  successful	  on	  the	  protein	   level	  (fig.	  30	  C).	  A	  pull-­‐down	  with	  35S-­‐labeled	   cells	   was	   also	   not	   successful,	   but	   it	   remains	   unclear	   whether	   this	   was	  because	   of	   faults	   in	   the	   experiment	   or	   whether	   VSG118	   is	   not	   pulled	   down	   by	   its	  antibody.	   Another	   change	   in	   the	   IP	   procedure,	   in	   opposite	   to	   the	   first	   35S	   labeling	  experiment	   (see	   fig.	   29A)	  was	   that	   the	   sucrose	   concentration	  was	   adjusted	   to	  30%	   in	  order	   to	  mimic	   the	   sucrose	   concentration	   in	   the	   polyribosome	   fractions.	   Therefore,	   it	  might	  be	  possible	  that	  the	  pull-­‐down	  does	  not	  work	  in	  this	  sucrose	  concentration.	  This	  would	  be	  a	  huge	  disadvantage	  as	  well.	  	  But	   it	   was	   possible	   to	   pull-­‐down	   at	   least	   a	   part	   of	   the	   VSG	   protein	   in	   an	  immunoprecipitation	  with	  a	  different	  buffer,	  as	  used	  by	  (Schutz,	  Kieval	  et	  al.	  1977).	  	  	  It	  might	  be	  possible	   to	  pull	  down	  the	  VSG	  mRNP	  with	  these	  cells,	  but	   this	  method	  still	  requires	  a	  lot	  of	  adjustment	  in	  order	  to	  work	  properly.	  	  I	   tried	  to	  transfect	  these	  cells	  once	  with	  Mark	  Carrington’s	  3850	  plasmid,	  but	  received	  no	  clones.	  However,	  if	  this	  project	  would	  be	  picked	  up	  again,	  I	  would	  recommend	  to	  try	  again	  to	  make	  this	  cell	  line,	  as	  the	  VSG118	  cells	  switch	  quickly	  (within	  two	  weeks)	  when	  cultured	  and	  then	  the	  VSG	  cannot	  be	  detected	  by	  Northern	  blot	  anymore.	  	  	  
	   3.	  Results	  
87	  
	  
Fig.	   29:	  Pull-­‐down	   of	   VSG	   protein	   using	   the	   VSG118	   antibody	   and	   the	   VSG118	   peptide	  
antibody	  A	  and	  B:	  IP-­‐experiments	  using	  cells	  labeled	  with	  35S-­‐methionine	  labeling.	  A:	  pull-­‐down	  with	  the	  bs1313	   3850	   cell	   line	   in	   polyribosome	   buffer.	   1µl,	   5µl	   and	   10µl	   were	   used	   of	   the	   VSG118	  antibody	  (labeled	  1,5,10),	  1µl,	  10µl	  and	  20µl	  were	  used	  from	  the	  peptide	  antibody	  (labeled	  1P,	  10P	  and	  20P).	  The	  antibody	  was	  mixed	  with	  proteinA	  beads	  (100µl).	  5.106	  cells	  were	  used	  per	  IP.	  	  B:	   Same	   experiment,	   done	  with	   the	   VSG118	   cell	   line,	   in	   30%	   sucrose.	   1µl,	   4µl	   and	   8µl	   of	   the	  VSG118	  antibody	  were	  used	   (labeled	  1,4,8),	   10µl	   and	  20µl	  of	   from	   the	  peptide	  antibody	  were	  used	  (labeled	  10P	  and	  20P).	  5.5.106	  cells	  were	  used	  per	  IP.	  No	  enrichment	  of	  VSG	  was	  observed.	  	  C:	  Western	  blot	  with	  unlabeled	   cells.	   Pull-­‐down	  with	  VSG118	   cell	   line	  with	  different	  buffer	   as	  used	  by	  (Schutz,	  Kieval	  et	  al.	  1977).	  1µl	  and	  2µl	  were	  used	  of	  the	  VSG118	  antibody.	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Fig	  30:	  mRNP	  pull-­‐down	  with	  VSG118	  cells.	  	  6.108	  cells	  were	  used	  for	  this	  experiment.	  A:	  Northern	  blot	  probed	  against	  VSG	  118.	  	  bs	   1313:	   Wild	   type	   cells	   expressing	   mainly	   VSG222,	   Input:	   cleared	   lysate,	   before	   sucrose	  gradient	   centrifugation,	   Polys:	   sample	   of	   the	   pooled	   polyribosome	   fractions.	   The	   remaining	  polyribosomes	   were	   split	   in	   three	   parts	   and	   3	   IPs	   (with	   100µl	   Poly-­‐A	   beads	   and	   different	  amounts	   of	   VSG118	   antibody)	   were	   made:	   A:	   2,5µl	   VSG	   118	   antibody,	   B:	   6,25µl	   VSG	   118	  antibody,	  C:	  12,5µl	  VSG	  118	  antibody	  	  Corr.	  to	  cells:	  loaded	  RNA	  amount	  corresponds	  to	  X	  .	  107	  cells.	  600µl	  of	  the	  pooled	  polyribosomes	  were	   used	   per	   IP,	   this	   corresponds	   to	   1.7.108	   cells.	   300µl	   samples	   were	   used	   for	   the	  polyribosomes	   and	   unbound	   mRNA	   samples,	   this	   corresponds	   to	   8.6.107	   cells.	   U:	   Unbound	  fraction,	  supernatant	  after	  the	  immunoprecipitation.	  Bound:	  RNA	  bound	  to	  the	  beads.	  	  B:	   quantification	   of	   Northern	   blot:	   The	   VSG118	   signal	   was	   divided	   by	   the	   total	   RNA	   amount	  loaded	  on	  the	  Northern	  blot	  (measured	  by	  nanodrop)	  and	  normalized	  to	  the	  input.	  	  C:	  Western	  blot	  made	  from	  samples	  from	  the	  same	  IP.	  30µl	  from	  the	  pooled	  polyribosomes	  and	  the	   unbound	   fractions	   and	   1/20th	   of	   the	   beads	   was	   taken	   as	   samples	   (corresponds	   to	   appr.	  8.5.106	  cells/lane).	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3.3	  The	  role	  of	  ZC3H32	  
3.3.1.	  Structure	  and	  expression	  ZC3H32	   is	   a	   655	   amino	   acid	   long	   zinc	   finger	   protein	   with	   three	   CCCH	   zinc	   finger	  domains,	  two	  conventional	  7-­‐5-­‐3	  C3H	  domains	  (see	  fig.	  31)	  and	  one	  unconventional	  9-­‐5-­‐3	  C3H	  domain	  (Kramer,	  Kimblin	  et	  al.	  2010).	  These	  zinc	  finger	  domains	  are	  conserved	  among	  kinetoplastids	  (T.	  b.	  brucei,	  T.	  cruzi,	  L.	  major).	  	  ZC3H32	  was	  found	  to	  be	  a	  potential	  binding	  partner	  of	  MKT1	  (Singh,	  Minia	  et	  al.	  2014)	  which	  was	  suggested	  by	  the	  results	  of	  a	  TAP	  purification	  and	  a	  yeast	  two	  hybrid	  assay.	  As	  shown	  by	  (Singh,	  Minia	  et	  al.	  2014),	  ZC3H32	  carries	  the	  binding	  motive	  for	  MKT1,	  the	  HNPY	  motif,	  in	  this	  case	  being	  HTNNPY.	  This	  motif	  is	  conserved	  between	  T.	  brucei	  and	  T.	  
cruzi,	  but	  not	  from	  T.	  brucei	  to	  L	  .major.	  Initially,	   it	  was	  thought	  that	  ZC3H32	  would	  stabilize	  mRNAs	  with	  a	  similar	  mechanism	  as	  the	  one	  proposed	  for	  ZC3H11	  (as	  described	  by	  (Singh,	  Minia	  et	  al.	  2014))	  see	  1.7,	  fig.	  8),	  namely	  by	  binding	  MKT1,	  which	  binds	  PBP1,	  which	  in	  turn	  binds	  the	  poly-­‐A	  binding	  protein,	   which	   binds	   to	   the	   poly-­‐A	   tail	   and	   thus	   protects	   the	   RNA	   from	   degradation.	  However,	  this	  hypothesis	  was	  soon	  abandoned,	  as	  ZC3H32	  seems	  to	  destabilize	  mRNAs	  rather	  than	  to	  stabilize	  them	  (see	  3.3.8).	  The	  SILAC	  proteomic	  analysis	  by	  (Urbaniak,	  Guther	  et	  al.	  2012)	  showed	  that	  the	  protein	  level	  of	  ZC3H32	  is	  approximately	  17	  times	  higher	  in	  the	  bloodstream	  form	  as	  compared	  to	   the	  procyclic	   form.	  The	   results	   from	   (Siegel,	  Hekstra	  et	   al.	   2010)	   indicated	   that	   the	  
ZC3H32	  RNA	   is	  approximately	   two	   fold	  enriched	   in	   the	  bloodstream	   form.	  Sequencing	  results	  form	  our	  lab	  (Fadda,	  Ryten	  et	  al.	  2014)	  also	  show	  an	  enrichment	  of	  the	  ZC3H32	  RNA	  in	  the	  bloodstream	  from	  (2.5	  to	  3.9	  fold).	  Northern	  blot	  analysis	  showed	  that	  this	  up-­‐regulation	  is	  indeed	  present	  (see	  fig.	  32).	  	  Thus,	  it	  can	  be	  concluded	  that	  ZC3H32	  is	  differentially	  regulated	  during	  the	  life	  cycle	  and	  seems	  to	  play	  a	  bigger	  role	  in	  the	  bloodstream	  form	  as	  compared	  to	  procyclics.	  ZC3H32	  was	  found	  in	  the	  mass	  spectrometry	  results	  from	  the	  bloodstream	  membrane-­‐bound	  polyribosomes,	  however,	  only	  one	  unique	  peptide	  was	  found.	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Fig.	  31:	  Structure	  of	  TbZC3H32	  and	  alignment	  of	  its	  trypanosomtid	  homologues	  	  A:	   Schematic	   structure	   of	   TbZC3H32,	   with	   zinc	   finger	   domains	   as	   determined	   by	   (Kramer,	  Kimblin	   et	   al.	   2010).	   Conventional	   7-­‐5-­‐3	   zinc	   finger	   domains	   (CCCH)	   are	   shown	   in	   red,	   the	  unconventional	  9-­‐5-­‐3	  zinc	  finger	  domain	  (CCCH*)	  is	  shown	  in	  orange.	  The	  MKT1	  binding	  motive	  (HNPY	  motive)	   is	   shown	   in	  blue.	  B:	  Alignment	  of	  ZC3H32	  homologues	   from	  T.	  b.	  brucei,	   strain	  427	  to	  T.	  cruzi	  and	  L.	  major.	  Identical	  amino	  acid	  residues	  are	  shown	  in	  black,	  similar	  residues	  in	  grey.	  Zinc	  finger	  domains	  are	  again	  shown	  in	  red	  or	  orange	  and	  the	  HNPY	  motive	  in	  blue.	   	  The	  alignment	  was	  done	  using	  CLUSTALW	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  (http://npsa-­‐pbil.ibcp.fr/cgi-­‐bin/npsa_automat.pl?page=/NPSA/npsa_clustalw.html),	   and	   the	  BOXSHADE	   software	   (http://mobyle.pasteur.fr/cgi-­‐bin/portal.py#forms::boxshade)	   and	   then	  edited	  using	  Microsoft	  excel.	  	  
	  
Fig.	  32:	  ZC3H32	  is	  up-­‐regulated	  in	  the	  bloodstream	  form	  	  Comparison	  of	  ZC3H32	  RNA	   levels	  between	  bloodstream	  wildtype	  (bs)	  and	  procyclic	  wildtype	  (pc).	  The	  7SL	  RNA,	  as	  well	  as	  the	  methylene	  blue	  stain,	  was	  used	  as	  loading	  control.	  
	  
3.3.2	  Localization	  of	  ZC3H32	  In	  order	  to	  find	  out	  the	  localization	  of	  ZC3H32,	  cells	  expressing	  C-­‐terminally	  myc-­‐tagged	  ZC3H32,	   as	  well	   as	  wild	   type	   cells,	  were	   analysed	   by	   immunofluorescence.	   A	   cell	   line	  expressing	   the	   tethering	   construct,	   which	   is	   N-­‐terminally	   tagged	  with	   the	  λN-­‐peptide	  and	   C-­‐terminally	   tagged	   with	   two	  myc-­‐tags,	   was	   also	   analyzed,	   because	   this	   cell	   line	  showed	   a	   stronger	   expression	   of	   the	  myc-­‐tagged	   construct	   as	   compared	   the	   ZC3H32-­‐myc	  cell	  line.	  This	  was	  tested	  by	  Western	  blot.	  	  The	   myc-­‐tagged	   constructs	   were	   ectopically	   expressed,	   under	   the	   control	   of	   a	   Tet	  promoter.	  The	  expression	  was	  induced	  24h	  before	  the	  cells	  were	  harvested	  and	  fixed	  to	  the	  glass	  slides.	  	  As	   can	   be	   seen	   in	   fig.	   32,	  myc-­‐tagged	   ZC3H32	   localizes	   to	   the	   cytoplasm.	  As	   the	  myc-­‐tagged	  version	  of	  ZC3H32	  is	  functional	  (see	  section	  3.3.6),	  this	  strongly	  suggests	  that	  the	  untagged	  protein	  is	  cytosolic	  as	  well.	  λN-­‐ZC3H32-­‐myc	  also	  localizes	  to	  the	  cytoplasm.	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Fig	  32:	  ZC3H32	  localizes	  to	  the	  cytoplasm	  	  Immunofluorescence	  with	  wild	  type,	  ZC3H32-­‐myc,	  and	  λN-­‐ZC3H32-­‐myc	  cells.	  	  	  ZC3H32	   is	   probably	   not	   associated	   with	   the	   polyribosomes.	   The	   mass	   spectrometry	  results	  of	  the	  large-­‐scale	  polyribosome	  preparation	  suggested	  it	  to	  be	  in	  the	  membrane-­‐bound	  fraction	  of	  the	  bloodstream	  polyribosomes	  (see	  table	  6).	  However,	  it	  was	  shown	  by	  Western	  blotting	  (see	  fig.	  34)	  that	  only	  a	  minor	  fraction	  of	  the	  V5-­‐tagged	  version	  of	  this	   protein	   is	   found	   in	   the	   polyribosomes,	   less	   than	   compared	   to	   a	   negative	   control.	  Also,	   when	   the	   polyribosomes	   are	   dissociated	   by	   RNAseA	   treatment,	   the	   migration	  pattern	  of	  ZC3H32	  on	   the	  Western	  Blot	  does	  not	   change,	   in	  opposite	   to	   the	  migration	  pattern	   of	   the	   ribosomal	   protein	   S9	   (see	   fig.	   34D	   and	   G).	   Cycloheximide	   treatment	  followed	   by	   UV-­‐crosslinking	   prior	   to	   harvesting	   the	   cells,	   which	   should	   stabilize	   the	  RNA-­‐protein	  interaction,	  also	  did	  not	  change	  the	  pattern.	  	  This	   strongly	   suggests	   that	   the	  majority	   of	   the	   ZC3H32	  protein	   is	   not	   associated	  with	  polyribosomes.	  However,	  as	  calculated	  in	  3.1.6,	  it	  might	  be	  that	  a	  fraction	  of	  the	  ZC3H32	  pool	   is	   associated	   with	   polyribosomes,	   but	   this	   fraction	   might	   be	   too	   small	   to	   be	  recognized	  on	  a	  Western	  blot.	  




Fig	  34:	  ZC3H32	  is	  mainly	  not	  associated	  with	  polyribosomes	  A:	  Polyribosome	  profile	  of	  V5-­‐ZC3H32	  cells.	  B:	  Western	  Blot	  made	  with	  samples	  of	  the	  fractions	  from	   the	   polyribosome	   gradient	   shown	   in	  A.	   3-­‐10µl	  was	   loaded	   per	   lane	   (the	   total	   volume	   of	  each	   fraction	   is	   approximately	   400µl)	   A	   smaller	   amount	   of	   sample	  was	   loaded	   from	   the	   first	  three	   in	  order	   to	  compensate	   for	   the	   large	  amount	  of	  protein	  present	   in	   those.	  Trypanothione	  reductase	   was	   used	   as	   a	   negative	   control,	   the	   ribosomal	   protein	   S9	   as	   a	   positive	   control.	   C:	  Western	   Blot	   with	   samples	   from	   a	   polyribosome	   gradient	   with	   V5-­‐ZC3H32	   cells	   which	   were	  treated	  with	  cycloheximide,	  followed	  by	  UV-­‐crosslinking	  prior	  to	  harvesting.	  When	  the	  cells	  are	  harvested	  with	  UV-­‐crosslinking,	  more	  cells	  are	  lost	  than	  without.	  Therefore,	  a	  larger	  amount	  of	  material	  was	  loaded	  on	  this	  blot	  in	  comparison	  to	  B	  and	  D.	  D:	  Western	  Blot	  with	  samples	  from	  a	  polyribosome	  gradient	  with	  V5-­‐ZC3H32	  cells	  that	  were	  treated	  with	  RNAseA	  after	  lysis.	  E,	  F	  G:	  quantifications	  of	  Western	  Blots	  B,	  C,	  D	  respectively.	   	  Percentage	  calculations	  take	  the	  unequal	  loading	  into	  account.	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3.3.3	  ZC3H32	  interacts	  with	  MKT1	  	  	  A	  yeast-­‐two-­‐hybrid	  assay	  with	  MKT1,	  as	  well	  as	  the	  mass	  spectrometry	  results	  of	  a	  TAP	  purification	  of	  MKT1,	  suggested	  ZC3H32	  as	  a	  putative	  binding	  partner	  of	  MKT1	  (Singh,	  Minia	  et	  al.	  2014).	  However,	  Co-­‐Immunoprecipitation	  of	  ZC3H32	  (V5	  or	  myc	  tagged)	  and	  YFP-­‐MKT1,	   showed	   that	   only	   a	   very	   small	   proportion	   of	   the	   ZC3H32-­‐protein	   pool	  interacts	  with	  MKT1.	  	  This	  interaction	  is	  also	  observed	  when	  the	  RNA	  is	  degraded	  using	  RNAseA.	  This	  shows	  that	   the	   interaction	   between	   ZC3H32	   and	   MKT1	   is	   not	   dependent	   on	   mRNA.	   It	   also	  proves	   that	   these	   two	   proteins	   genuinely	   interact	   and	   are	   not	   just	   found	   on	   different	  binding	  sites	  of	  the	  same	  target	  mRNAs.	  	  	  
	  
Fig.	  35:	  ZC3H32	  interacts	  with	  MKT1,	  even	  in	  the	  presence	  of	  RNAse	  inhibitor	  	  *	  marks	  the	  antibody	  which	  was	  used	  for	  the	  precipitation	  (e.g.	  α-­‐myc	  in	  a	  pull	  down	  with	  α-­‐myc	  beads,	  α-­‐GFP	  in	  a	  pull	  down	  with	  GBP	  beads).	  GBP:	  GFP	  binding	  peptide,	  binds	  to	  GFP	  and	  YFP.	  	  Antibody	  recognizing	  the	  tagged	  ZC3H32	  (either	  V5	  or	  myc	  tagged)	  is	  written	  in	  bold	  A:	  Western	  blot	  of	   affinity	  purification	  of	  YFP-­‐MKT1	  and	  V5-­‐ZC3H32	  with	  GBP-­‐beads	   (bind	   to	  YFP-­‐tag).	   lys:	   lysed	   cells,	   I:	   Input	   (cell	   lysate	   cleared	   by	   centrifugation),	   U:	   unbound	   fraction,	  supernatant	  after	  IP,	  B:	  bound	  fraction	  (boiled	  beads).	  S9	  was	  used	  as	  control.	  The	  GFP	  antibody	  recognizes	  the	  YFP-­‐tag.	  	  B:	  Western	  blot	  of	  Co-­‐IP	  of	  V5-­‐ZC3H32	  and	  YFP-­‐MKT1	  with	  V5-­‐beads.	  S9	  was	  used	  as	  control.	  	  C:	   Western	   blot	   of	   affinity	   purification	   of	   YFP-­‐MKT1	   and	   V5-­‐ZC3H32	   with	   GBP-­‐beads	   in	   the	  presence	  of	  RNAseA	  (+RNAseA)	  or	  RNAse	  Inhibitor	  (+Inh)	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3.3.4	  MKT1	  does	  not	  interact	  with	  the	  CAF-­‐NOT	  deadenylation	  complex	  component	  NOT2	  	  NOT2,	   which	   is	   a	   part	   of	   the	   CAF1-­‐NOT	   deadenylation	   complex,	   was	   suggested	   as	   a	  binding	  partner	  for	  MKT1	  in	  a	  yeast-­‐two-­‐hybrid	  screen	  (Singh,	  Minia	  et	  al.	  2014).	  Two	  other	  components	  of	  this	  complex	  (CAF40	  and	  NOT1)	  were	  co-­‐purified	  with	  MKT1	  in	  a	  TAP	  purification	  (Singh,	  Minia	  et	  al.	  2014).	  This	  suggested	  an	  association	  of	  MKT1,	  and	  thus,	   possibly,	   ZC3H32,	   with	   the	   CAF1-­‐NOT	   deadenylase	   complex.	   However,	   this	  interaction	  could	  not	  be	  confirmed	  by	  co-­‐immunoprecipitation	  (see	  fig.	  36).	  	  
	  
Fig.	  36:	  MKT1	  does	  not	  interact	  with	  NOT2	  *	  marks	  the	  antibody	  which	  was	  used	  for	  the	  precipitation	  (e.g.	  α-­‐myc	  in	  a	  pull	  down	  with	  α-­‐myc	  beads,	  α-­‐GFP	  in	  a	  pull	  down	  with	  GBP	  beads)	  A:	  Western	  blot	  of	  a	  co-­‐affinity	  purification	  with	  YFP-­‐MKT1	  and	  V5-­‐NOT2	  with	  GBP-­‐beads	  (GBP	  binds	   to	   the	   YFP-­‐tag).	   I:	   Input	   (cell	   lysate	   cleared	   by	   centrifugation),	   U:	   Unbound	   fraction,	  Supernatant	  after	  IP;	  B:	  Bound	  fraction	  (boiled	  beads).	  S9	  was	  used	  as	  negative	  control.	  	  B:	  Western	  blot	  of	  Co-­‐IP	  with	  YFP-­‐MKT1	  and	  V5-­‐Not2	  V5-­‐beads.	  S9	  was	  used	  as	  negative	  control.	  	  	  
3.3.5	  ZC3H32	  is	  essential	  in	  the	  bloodstream	  form	  The	  RNAi	  screen	  from	  Alsford	  et	  al.	  (Alsford,	  Glover	  et	  al.	  2005)	  suggested	  that	  ZC3H32	  is	  essential	  in	  the	  bloodstream	  form,	  but	  not	  in	  procyclics.	  In	  order	  to	  test	  that,	  ZC3H32	  was	  knocked	  down	  in	  bloodstream	  and	  proyclic	  cells.	  	  Knock-­‐down	   of	   ZC3H32	   in	   the	   bloodstream	   form	   lead	   to	   a	   growth	   defect	   (see	   fig.	   37,	  growth	   curve	   A	   and	   D,	   Northern	   blot	   C	   and	   Western	   blot	   E).	   The	   knock-­‐down	   was	  confirmed	  by	  Northern	  blotting	  (see	  fig.	  37	  C).	  	  The	   decrease	   of	   ZC3H32	   on	   the	   protein	   level	   was	   shown	   with	   a	   Western	   blot,	   by	  inducing	   RNAi	   in	   bloodstream	   cells	   expressing	   endogenously	   V5-­‐tagged	   ZC3H32.	   The	  protein	   levels	  dropped	  to	  approximately	  a	   tenth	  of	   the	  original	   level	  after	  one	  day.	  No	  protein	  or	  RNA	  samples	  could	  be	  collected	  for	  day	  two	  and	  three,	  as	  there	  was	  almost	  no	  cell	  growth.	  The	  protein	  levels	  increased	  on	  day	  four,	  synchronously	  with	  the	  recovery	  of	  the	  cells.	  	  Poly-­‐A+	   RNA	   isolated	   from	   the	   RNAi	   cell	   line	   shown	   in	   A	   and	   C	   was	   sent	   for	   high-­‐throughput	  sequencing	  (see	  3.3.11).	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The	  RNAi	  in	  procyclics	  was	  not	  successful	  (data	  not	  shown).	  	  Six	  clones	  were	  tested,	  but	  none	   of	   them	   showed	   any	   significant	   reduction	   of	   the	   ZC3H32	   RNA	   levels,	   which	   are	  already	  low	  in	  this	  life	  cycle	  stage.	  	  
	  
Fig.	  37:	  ZC3H32	  is	  essential	  in	  bloodstream	  form	  trypanosomes.	  	  A:	  Cumulative	  growth	  curve	  of	  bloodstream	  cells	  with	  RNAi	  against	  ZC3H32	  	  B:	  Cumulative	  growth	  curve	  of	  bloodstream	  cells	  with	  ZC3H32	  RNAi	  expressing	  V5-­‐ZC3H32.	  The	  average	  and	  standard	  deviation	  of	  three	  clones	  is	  shown.	  	  C:	  Northern	  blot	  corresponding	  to	  growth	  curve	  A	  with	  samples	  from	  wildtype	  bloodstream	  cells	  (WT)	  and	  ZC3H32	  RNAi	  cells,	  induced	  for	  24h	  (RNAi)	  D:	  Western	   blot	   with	   V5-­‐ZC3H32	   cells,	   with	   (clone	   1-­‐3)	   and	  without	   RNAi	   (-­‐).	   Samples	   were	  taken	   before	   induction,	   one	   day	   after	   induction	   (quantification	   shown	   in	   bold)	   and	   after	   the	  recovery	   of	   the	   cells	   (4-­‐6	   days).	   The	   quantification	   was	   normalized	   to	   the	   parental	   cell	   line	  (RNAi	  -­‐	  ).	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3.3.6	  Knock-­‐out	  cell	  lines	  In	  order	  to	  test	  whether	  the	  C-­‐terminally	  myc-­‐tagged	  ZC3H32	  protein,	  as	  well	  as	  the	  N-­‐terminally	  V5-­‐tagged	  version,	  were	  functional,	  knock-­‐out	  cell	  lines	  were	  created.	  	  In	   the	   cell	   lines	  expressing	   the	  endogenously	  expressed	  V5-­‐ZC3H32,	   the	  non-­‐modified	  copy	   of	   the	   ZC3H32	   gene	   was	   knocked	   out,	   using	   a	   knock-­‐out	   plasmid	   carrying	   a	  puromycin	  resistance	  (plasmids	  see	  2.14).	   In	   the	  cell	   lines	  expressing	   the	  exogenously	  expressed	  ZC3H32-­‐myc,	  one	  copy	  of	   the	  gene	  was	  knocked	  out	   first.	  Two	  clones	  were	  selected,	   the	   expression	   of	   the	   inducible	   myc-­‐tagged	   version	   was	   induced	   by	   adding	  tetracycline	   and	   the	   cell	   lines	   were	   transfected	   with	   the	   other	   knock-­‐out	   vector.	   The	  induction	   was	   done	   just	   prior	   to	   the	   transfection.	   The	   clones	   received	   from	   this	  transfection	  were	  maintained	  in	  medium	  containing	  tetracycline.	  	  It	  was	  possible	  to	  create	  both	  single	  knock-­‐out	  V5-­‐ZC3H32	  cell	  lines,	  as	  well	  as	  double-­‐knock	  out	  myc	  tagged	  cell	  lines.	  	  The	  knock-­‐outs	  were	  confirmed	  by	  PCR	  (see	  fig.	  38).	  Two	  different	  sets	  of	  primers	  were	  used	  for	  the	  confirmation	  of	  the	  knock-­‐outs.	  One	  set	  binds	  in	  the	  ORF	  of	  ZC3H32	  (see	  fig.	  38,	   shown	   in	   red).	   As	   every	   cell	   line	   possesses	   either	   the	   inducible	   ZC3H32-­‐myc,	   the	  endogenous	   ZC3H32	   or	   V5-­‐ZC3H32,	   this	   PCR	   should	   be,	   and	   was,	   positive	   for	   each	  genomic	  DNA	  sample.	  	  The	  forward	  primer	  of	  the	  other	  set	  binds	  in	  the	  5’UTR	  of	  ZC3H32,	  the	  reverse	  one	  in	  the	  ORF	  (see	  fig.	  38,	  shown	  in	  black).	  This	  PCR	  yielded	  no	  product	  in	  the	  double	  knock-­‐out	  cell	  lines,	  as	  these	  do	  not	  possess	  the	  endogenous	  ZC3H32.	  	  The	   V5-­‐ZC3H32	   cell	   line	   possesses	   both	   a	   non-­‐modified	   endogenous	   copy	   and	   V5-­‐
ZC3H32,	   in	  which	  the	  sequence	  of	  the	  V5-­‐tag,	  the	  blasticidin	  resistance	  gene,	  as	  well	  as	  two	  UTRs,	  are	  inserted	  between	  the	  ORF	  and	  the	  5’UTR.	  Therefore,	  for	  this	  cell	  line,	  the	  PCR	  yields	  two	  products:	  A	  shorter	  one	  corresponding	  to	  the	  unmodified	  ZC3H32	  locus	  (predicted	  size:	  1109bp),	  and	  another,	  longer	  PCR	  product,	  corresponding	  to	  V5-­‐ZC3H32	  (predicted	  size:	  2130bp).	  For	  the	  V5-­‐ZC3H32	  single	  knock-­‐out	  cell	  lines,	  possessing	  only	  the	  tagged	  endogenous	  ZC3H32,	  the	  PCR	  yields	  only	  the	  larger	  product	  corresponding	  to	  the	  tagged	  version.	  Thus,	  the	  single	  knock-­‐out	  is	  confirmed.	  	  	  The	  fact	  that	  it	  was	  possible	  to	  create	  both	  V5-­‐ZC3H32	  single	  knock-­‐out	  cell	  lines	  as	  well	  as	  double	  knock-­‐out	  ZC3H32-­‐myc	  cell	  lines	  shows	  that	  both	  tagged	  versions	  are,	  at	  least	  partially,	   functional.	  The	  V5	  single	  knock-­‐out	   cell	   lines	  grow	  a	  bit	   slower	   than	   the	  V5-­‐tagged	  cell	  line	  still	  containing	  the	  other	  ZC3H32	  copy	  (see	  fig.	  39).	  	  The	  double-­‐knock	  out	  cell	  lines	  grow	  well	  in	  the	  presence	  of	  tetracycline,	  which	  induces	  the	  exogenous	  ZC3H32-­‐myc.	  Once	   tetracycline	   is	   removed,	  by	   spinning	  down	   the	  cells	  and	  resuspending	  them	  in	  new	  media,	  their	  growth	  is	  arrested	  (see	  fig.	  39).	  	  This	   not	   only	   shows	   that	   the	  myc-­‐tagged	   version	   is	   functional,	   but	   also	   confirms	   that	  ZC3H32	  is	  essential	  for	  cell	  proliferation	  in	  the	  bloodstream	  form.	  	  After	  about	  four	  days,	  the	  cells	  recover	  and	  re-­‐express	  the	  myc-­‐tagged	  protein	  (Fig.	  39,	  D).	  	  	  




Fig.	  38:	  Verification	  of	  single	  and	  double	  knock-­‐out	  cell	  lines	  by	  PCR	  A:	   Schematic	   presentation	   of	  WT,	   V5-­‐ZC3H32	   and	   V5-­‐ZC3H32	   single	   knock-­‐out	   cell	   lines	   The	  UTRs	  of	  ZC3H32	  are	  shown	  in	  dark,	  the	  ORF	  is	  shown	  in	  light	  grey.	  The	  zinc	  finger	  domains	  are	  shown	  in	  red	  (canonical)	  and	  orange	  (non-­‐canonical).	  The	  HNPY	  domain	  is	  shown	  in	  blue.	  The	  blasticidin	  resistance	  is	  shown	  in	  orange,	  the	  puromycin	  reistance	  is	  shown	  in	  purple,	  the	  V5-­‐tag	  is	  shown	  in	  blue.	  Black	  arrows:	  Primer	   for	  UTR+ORF	  PCR	  Red	  arrows:	  primer	   for	  ORF	  PCR.	  B:	  PCR	  results	  for	  V5-­‐ZC3H32	  cell	  lines.	  C:	  Schematic	  presentation	  of	  ZC3H32-­‐myc	  cell	  lines,	  single	  and	  double	  knock-­‐out.	  The	  myc-­‐tag	  is	  shown	  in	  mauve,	  the	  Tet-­‐operator	  and	  GPEET	  promoter	  in	  blue	  and	  red.	  D:	  PCR	  results	  for	  ZC3H32-­‐myc	  cell	  lines.	  	  




Fig.	  39:	  Growth	  of	  ZC3H32	  double	  knock-­‐out	  cell	  line	  and	  V5-­‐ZC3H32	  single	  knock-­‐out	  cell	  
line	  A:	  Cumulative	  growth	  curve	  for	  3	  ZC3H32-­‐myc	  double	  knock-­‐out	  clones	  for	  three	  days,	  with	  and	  without	  tetracycline.	  	  B:	  Western	   Blot	   with	   samples	   from	   clone	   B	   and	   C,	   with	   and	  without	   Tet.	   –Tet	   samples	  were	  collected	  24h	  after	  Tet	  removal.	  	  C:	  Cumulative	  growth	  curve	  for	  clone	  A	  for	  five	  days.	  	  D:	  Western	  blot	  with	  samples	  from	  clone	  A.	  	  E:	  Growth	  curve	  of	  the	  V5-­‐ZC3H32	  cell	  line	  and	  three	  V5-­‐ZC3H32	  single	  knock-­‐out	  cell	  lines.	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Fig.	  40:	  Expression	  of	  ZC3H32-­‐myc	  leads	  to	  higher	  
ZC3H32	  mRNA	  levels,	  but	  does	  not	  cause	  a	  growth	  
defect	  in	  procyclics	  A:	   Cumulative	   growth	   curve	   of	   procyclic	   cells	  expressing	  exogenous	  ZC3H32-­‐myc	  	  B:	  Northern	  blot	  with	  procyclic	  WT	  and	  ZC3H32-­‐myc	  cells	   (induced	   for	   24h),	   probed	   against	   ZC3H32	   and	  
7SL	  (loading	  control).	  C:	   Western	   blot	   with	   pc	   1313	   514	   (“WT”)	   and	  ZC3H32-­‐myc	  cells,	  clone	  1	  and	  4.	  ZC3H32-­‐myc	  expression	  was	  induced	  for	  24h.	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3.3.8	  Tethering	  of	  the	  ZC3H32	  protein	  to	  a	  reporter	  RNA	  leads	  to	  its	  degradation	  	  We	  wanted	  to	  see	  which	  effect	  ZC3H32	  has	  on	  the	  mRNAs	  it	   interacts	  with.	  Therefore,	  we	  used	   an	   assay	   in	  which	  we	   tethered	   the	  protein	   to	   a	   reporter	  RNA.	   Its	   interaction	  with	  MKT1,	  which	  was	  shown	  to	  stabilize	  the	  reporter	  RNA	  in	  the	  same	  assay,	  suggested	  that	  tethering	  ZC3H32	  would	  stabilize	  the	  reporter	  RNA	  as	  well.	  	  For	   the	   tethering,	   a	   fusion	  protein	  was	   created,	   containing	   the	   lambdaN	  domain	   from	  phage	   lambda	   at	   its	  N-­‐terminus	   and	   two	  myc-­‐tags	   at	   its	   C-­‐terminus.	  This	   protein	  was	  expressed	  ectopically	  and	  its	  expression	  was	  induced	  by	  adding	  tetracycline.	  The	  reporter	  RNA,	  encoding	  chloramphenicol-­‐acetyl-­‐transferase	  (CAT),	  carries	  5	  copies	  of	  the	  BoxB	  sequence	  in	  its	  3’UTR,	  to	  which	  the	  lambdaN	  peptide	  binds	  with	  high	  affinity.	  Thus,	  the	  fusion	  protein	  is	  tethered	  to	  the	  CAT	  RNA.	  As	  a	  control,	  a	  cell	   line	  containing	  the	   reporter	   RNA	   without	   the	   BoxB	   was	   used.	   	   CAT	   RNA	   levels	   were	   measured	   by	  Northern	  blotting,	  CAT	  protein	  levels	  with	  an	  enzymatic	  assay	  using	  14C-­‐labeled	  Butyryl-­‐CoA	  (description	  see	  2.6).	  	  As	   seen	   in	   fig.	   41,	   the	   tethering	   of	   ZC3H32	   to	   the	   CAT	   RNA	   leads	   to	   both	   lower	   CAT	  protein	  levels	  as	  well	  as	  lower	  CAT	  RNA	  levels,	  which	  was	  not	  the	  effect	  we	  expected.	  	  Thus,	   It	   can	   be	   concluded	   that	   tethering	   of	   Z3CH32	   to	   a	   reporter	   RNA	   leads	   to	   its	  degradation	  and	  thus	  to	  lower	  levels	  of	  the	  encoded	  protein.	  	  
	  
Fig.	  41:	  Tethering	  of	  ZC3H32	  leads	  to	  the	  degradation	  of	  the	  CAT	  RNA	  A:	  schematic	  graph	  of	  the	  tethering	  experiment.	  The	  experiments	  were	  done	  with	  three	  clones	  each.	  B:	  CAT	  assay	  results	  for	  λN-­‐ZC3H32-­‐myc	  after	  an	  induction	  of	  24	  hours.	  C:	  Northern	  blot	  probed	  against	  the	  CAT	  reporter	  RNA	  and	  7SL	  as	  control.	  	  D:	  Western	  blot	  with	  λN-­‐ZC3H32-­‐myc	  clones,	   from	   cell	   lines	   containing	   the	   CAT	   reporter	   with	   and	   without	   the	   BoxB	   copies.	   λN-­‐ZC3H32-­‐myc	  expression	  was	  checked	  using	  the	  antibody	  against	  the	  myc	  tag.	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In	   order	   to	   see	  whether	   the	   tagging	   on	   both	   ends	   has	   an	   effect	   on	   the	   activity	   of	   the	  fusion	   protein,	   another	   construct	   was	   made	   in	   which	   both	   the	   myc-­‐tag	   and	   the	   λN-­‐peptide	   were	   on	   the	   N-­‐terminus.	   The	   induction	   of	   this	   fusion	   protein	   also	   led	   to	   a	  decrease	  in	  CAT	  activity.	  	  	  
3.3.9	   The	  C-­‐	   and	   the	  N-­‐terminus	  of	   the	   ZC3H32	  protein	   seem	   to	  be	   responsible	   for	  RNA	  
degradation	  	  In	  order	  to	  find	  out	  which	  part	  of	  the	  protein	  catalyzes	  the	  effect,	   fusion	  proteins	  with	  fragments	  of	  the	  ZC3H32	  sequence	  were	  made:	  	  
	  
Fig.	  42:	  Overview	  of	  tethering	  experiments	  with	  ZC3H32	  fragments	  AA:	  amino	  acid.	  	  Numbers	  below	  AA:	  pHd	  number	  of	  plasmid.	  	  *:	  	  	  one	  clone	  (instead	  of	  three)	  was	  tested	  **:	  two	  clones	  were	  tested	  n.d.:	  not	  determined	  	  Surprisingly,	   tethering	   of	   both	   the	   C-­‐terminal	   (AA	  274	   -­‐	   655)	   and	   the	  N-­‐terminal	   half	  (AA	  1-­‐274)	   lead	   to	   a	  decrease	   in	  CAT	  activity.	  This	   indicates	   that	   ZC3H32	  might	  have	  two	  active	  domains,	  one	  in	  the	  C-­‐terminus	  and	  the	  other	  one	  in	  the	  N-­‐terminus.	  A	  145	  amino	  acid	  long	  fragment	  (AA	  1-­‐145)	  of	  the	  N-­‐terminus	  is	  sufficient	  to	  cause	  a	  decrease	  in	   CAT	   activity.	   For	   the	   C-­‐terminus,	   the	   last	   293	   Amino	   acids	   (AA	   362-­‐655)	   are	   also	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sufficient.	  Expression	  of	  a	  174	  AA	  long	  fragment	  (AA	  362-­‐538),	  which	  does	  not	  contain	  the	  HNPY	  domain,	  did	  not	  lead	  to	  a	  decrease	  in	  CAT	  activity.	  	  These	  results	   indicate	   that	   the	   first	  145,	  as	  well	  as	   the	   last	  293	  Amino	  acids,	  probably	  contain	   the	   domains	   of	   this	   protein	   that	   are	   active	   in	   decreasing	   RNA	   levels.	   They	  suggest	   also	   that	   the	   HNPY	   domain	   is	   important	   for	   the	   function	   of	   the	   C-­‐terminal	  domain.	  Tethering	  of	  the	  middle	  part	  of	  the	  protein	  (AA	  146-­‐538)	  did	  not	  lead	  to	  a	  decrease	  CAT	  activity.	   This	   part	   contains	   the	   three	   zinc	   fingers,	   which	   indicates	   that,	   for	   wild	   type	  protein,	  this	  part	  might	  be	  mainly	  responsible	  for	  the	  binding	  to	  the	  RNA	  targets,	  while	  the	  N-­‐	  and	  the	  C-­‐terminus	  are	  probably	  responsible	  for	  their	  degradation.	  	  
	  	  
Fig.	  43:	  Tethering	  of	   fragments	  AA211-­‐655	  and	  AA1-­‐538	  leads	  to	  a	  decrease	  in	  CAT	  RNA	  
levels	  The	  experiments	  were	  done	  in	  cell	  lines	  expressing	  the	  CAT	  reporter	  with	  the	  BoxB	  and	  in	  cell	  lines	  expressing	  the	  reporter	  without	  the	  BoxB.	  	  A:	  Northern	  blot	  probed	  against	  the	  CAT	  reporter	  RNA.	  The	  7SL	  RNA	  was	  used	  as	  loading	  control.	  The	   relative	   CAT	   activity	   (determined	   by	   CAT	   assay)	   is	   written	   below	   the	   Northern	   blot	  quantification.	  B:	  Chart	   showing	   the	  quantification	  of	  Northern	  blots.	  For	  each	  construct	   three	  clones	  were	  used.	  D:	  Western	  Blot	  of	  ZC3H32	  fragments.	  The	  clones	  shown	  in	  bold	  were	  used	  to	  make	  the	  samples	  for	  the	  Northern	  blots.	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Fig	  44:	  Tethering	  experiment	  with	  GFP	  (control	  construct)	  and	  ZC3H32	  fragments	  A:	   CAT	   assay	   results	   for	   λN-­‐GFP-­‐myc	   (control	   construct)	   and	   λN-­‐ZC3H32-­‐myc	   fragments.	  Arrows	   indicate	   interpretation	   of	   results,	   as	   shown	   in	   figure	   42	   (down:	   	   down-­‐regulation,	  straight:	  no	  effect).	  The	  CAT	  activity	  was	  normalized	  to	  activity	  of	  the	  WT	  +Tet	  sample.	  B:	  Western	  blots	  done	  to	  check	  construct	  expression.	  The	  myc-­‐tagged	  constructs	  were	  detected	  using	  α-­‐myc.	  AA:	  amino	  acid.	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Fig.	  45:	  Summary	  of	  CAT	  assay	  results.	  	  The	  putative	  functional	  domains	  of	  ZC3H32,	  at	  the	  C	  and	  the	  N-­‐terminus,	  are	  shown	  in	  light	  blue	  
	  
3.3.10	  Tethering	  of	  ZC3H32	  causes	  a	  decrease	  in	  CAT	  RNA	  translation	  	  In	  order	   to	   check	  whether	   tethering	  of	   the	  ZC3H32	  protein	   to	   the	  CAT	  RNA	  affects	   its	  translation,	   I	   tested	  whether	   it	   still	   co-­‐localized	  with	   the	   polyribosome	   fractions	   after	  the	  induction	  of	  the	  λN-­‐ZC3H32-­‐myc	  construct.	  	  Two	  λN-­‐ZC3H32-­‐myc	  cell	   lines	  were	  used,	   one	   containing	   the	  CAT	   reporter	  RNA	  with	  the	   BoxBs	   in	   its	   3’UTR	   and	   the	   other	   containing	   the	  CAT	   reporter	  without	   the	   BoxBs	  (negative	   control).	   λN-­‐ZC3H32-­‐myc	   expression	   was	   induced	   for	   four	   hours,	   this	   time	  span	   being	   the	   minimum	   needed	   until	   adequate	   levels	   of	   λN-­‐ZC3H32-­‐myc	   were	  detectable	  on	  a	  Western	  Blot	  (see	  fig.	  46,	  F).	  	  RNA	   was	   isolated	   from	   the	   cell	   lysate	   (Input:	   1/10th	   of	   the	   total	   input	   was	   used	   as	  sample)	  and	  from	  the	  sucrose	  gradient	  fractions	  and	  put	  on	  a	  Northern	  blot,	  which	  was	  probed	  against	  CAT,	  Histone	  H4	  (HisH4)	  and	  human	  β-­‐globin.	  HisH4	  was	  used	  as	  control,	  as	   its	   translation	   should	   be	   equal	   in	   both	   cell	   lines.	   In	   vitro	   expressed	   β-­‐globin	  RNA	  (made	  by	  I.	  Minia)	  was	  added	  to	  each	  RNA	  sample	  in	  order	  to	  check	  the	  efficiency	  of	  the	  RNA	  isolation	  in	  the	  different	  fractions.	  	  As	   can	   be	   seen	   in	   fig.46,	  while	   the	  CAT	   RNA	  without	   the	  BoxB	   localizes	   to	   the	   higher	  fractions	  (polyribosomal	  fractions)	  of	  the	  polyribosome	  gradient,	  the	  CAT	  RNA	  with	  the	  BoxB	   is	   found	   in	   similar	   levels	   in	   all	   the	   fractions.	  There	   also	   seem	   to	  be	   some	  bands	  corresponding	   to	   shorter	   CAT	   fragments,	   which	   might	   correspond	   to	   degradation	  products.	   These	   fragments	   are	   not	   visible	   in	   the	   Northern	   blots	   from	   the	   cell	   line	  carrying	  the	  CAT	  RNA	  without	  the	  BoxB.	  	  These	  results	  show	  that,	  on	  average,	   less	  ribosomes	  sit	  on	  the	  CAT	  RNA	  with	  the	  BoxB	  than	  on	  the	  one	  without	  the	  BoxB.	  This	  indicates	  that,	  upon	  tethering	  of	  λN-­‐ZC3H32-­‐myc	  to	   the	  CAT	  RNA,	   its	   translation	  decreases.	  The	  Northern	  blots	  also	   show	   that	   the	   total	  
CAT	  RNA	  level	  is	  already	  lower	  in	  the	  BoxB	  cell	  line	  as	  compared	  to	  the	  negative	  control,	  although	  the	  construct	  was	  only	  induced	  for	  4	  hours.	  Quantification	  of	   the	  CAT	   signal	  of	   four	  Northern	  blots	  of	   the	  BoxB	  cell	   line	  and	   three	  Northern	   blots	   of	   the	   control	   cell	   line,	   followed	   by	   the	   division	   with	   signal	   from	   the	  
HisH4	  RNA,	  clearly	  shows	  that	  the	  CAT	  RNA	  with	  the	  BoxB	  is	  more	  likely	  to	  be	  found	  in	  the	  lower	  fractions	  (pre-­‐ribosomal	  fractions)	  than	  the	  one	  without	  the	  BoxB	  (see	  fig.46,	  G).	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Fig.	   46:	   Tethering	   of	   ZC3H32	  
causes	   a	   decrease	   in	   CAT	   RNA	  
translation	  A+B:	   Polyribosome	   profiles	   made	  from	   cell	   line	   containing	   the	   CAT	  RNA	  with	   (A)	  and	  without	   the	  BoxB	  (B),	   harvested	   4	   hours	   after	   λN-­‐ZC3H32-­‐myc	  induction.	  	  C+D:	  Northern	  blots	  made	  from	  RNA	  isolated	   from	   the	   collected	   fractions,	   probed	   against	   CAT,	   HisH4	   and	   β-­‐globin.	   In	   vitro	  synthesized	  β-­‐globin	  RNA	  (made	  by	   I.	  Minia)	  was	  added	   to	  each	   fraction	   in	  order	   to	  check	   the	  efficiency	   of	   each	   RNA	   isolation.	   E:	   Quantification	   of	   Northern	   blots.	   The	   signal	   from	   the	  CAT	  RNA	  was	  divided	  by	  the	  signal	  from	  the	  β-­‐globin	  RNA,	  in	  order	  to	  compensate	  for	  differences	  in	  RNA	   isolation	   efficiency	   (relative	   CAT	   signal).	   Then,	   the	   signals	   from	   each	   fraction	   (without	  Input)	   were	   added	   up	   and	   the	   percentage	   of	   the	   relative	   CAT	   signal	   in	   each	   fraction	   was	  calculated.	  F:	  Western	  blot	  made	  from	  both	  cell	  lines,	  to	  check	  λN-­‐ZC3H32-­‐myc	  expression	  after	  2,4,6	   and	   8	   hours	   after	   induction.	   Trypanothione	   reductase	   was	   used	   as	   loading	   control.	   G:	  Quantification	  of	  Northern	  blots	  (4	  for	  BoxB	  cell	  line,	  3	  for	  control	  cell	  line)	  from	  replicas	  of	  the	  same	   experiment.	   The	   intensity	   of	   the	   CAT	   signal	   was	   divided	   by	   the	   HisH4	   signal	   and	  normalized	  to	  the	  input.	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3.3.11	  High-­‐throughput	  sequencing	  results	  Poly-­‐A+	   RNA	   from	   bloodstream	   cells	   expressing	   the	   ZC3H32	   RNAi	   construct	   and	  procyclic	   cells	   expressing	   ZC3H32-­‐myc	   (called	   procyclic	   overexpression),	   made	   24	  hours	  after	  the	  induction	  of	  the	  cells,	  was	  sent	  for	  high-­‐throughput	  sequencing.	  	  From	  the	  bloodstream	  RNAi	  cell	   line	   two	  different	  poly-­‐A+	  preparations	  were	  sent	   for	  sequencing.	   These	   two	   replicas	   yielded	   quite	   different	   results	   (R	   =	   0.52).	   This	   is	  surprising	   as	   the	   same	   cell	   line	   was	   used	   and	   the	   cells	   were	   induced	   for	   the	   same	  amount	   of	   time	   (24h).	   The	   level	   of	   downregulation	   seemed	   to	   be	   similar,	   the	   relative	  amount	  of	  ZC3H32	  RNA,	  as	  compared	  to	  the	  wild	  type,	  was	  0.094	  in	  the	  first	  and	  0.12	  in	  the	   second	   replica.	  However,	   it	   cannot	  be	   ruled	  out	   that	   the	   levels	   of	   ZC3H32	  protein	  differed	  in	  the	  two	  separate	  preparations.	  Also,	  small	  differences	  in	  the	  poly-­‐A+	  RNA	  or	  in	   the	   cDNA	   library	   preparation	   might	   have	   caused	   a	   difference	   in	   mRNA	   levels,	  although	  the	  same	  protocols	  were	  used.	  	  Due	  to	  the	  large	  discrepancy	  between	  the	  two	  replicas,	  only	  those	  RNAs	  were	  labeled	  as	  up-­‐regulated,	  or	  respectively,	  down-­‐regulated,	  which	  showed	  an	  increase/decrease	  of	  at	  least	  two	  fold	  in	  both	  preparations	  and	  were	  present	  on	  both	  with	  at	  least	  10rpm	  (reads	  per	  million).	  Comparison	   of	   the	   average	   results	   from	   both	   bloodstream	   RNAi	   replicas	   with	   the	  procyclic	  overexpression	  data	  showed	  a	  correlation	   factor	  of	  about	  zero	  (R=0.025,	   see	  table	  7,	  row	  2,	  only	  genes	  which	  were	  found	  with	  more	  than	  10	  rpm	  in	  both	  sequencing	  results	  were	  taken	  into	  account).	  This	  means	  that	  the	  effect	  ZC3H32	  overexpression	  has	  on	  the	  mRNA	  metabolism	  in	  procyclics	  is	  different	  from	  the	  effect	  ZC3H32	  RNAi	  has	  in	  the	   bloodstream	   form.	   However,	   the	   effect	   was	   not	   opposite,	   meaning	   that	   mRNAs	  which	  were	  up-­‐regulated	  in	  the	  bloodstream	  form	  upon	  ZC3H32	  RNAi	  were	  not	  down-­‐regulated	  in	  the	  procyclic	  form	  and	  vice	  versa.	  One	  explanation	  might	  be	  that	  other	  RNA-­‐binding	   proteins	   influence	   the	   activity	   of	   ZC3H32.	   These	   proteins	   could,	   for	   example,	  prevent	  ZC3H32	  from	  binding	  and	  thus	  limit	  its	  influence	  in	  the	  procyclic	  form.	  	  Another	  explanation	  might	  be	  that	  the	  mRNA	  levels	  in	  both	  cell	  lines	  are	  influenced	  by	  secondary	   effects.	   For	   example,	   there	   seems	   to	   be	   a	   decrease	   in	   RNAs	   coding	   for	  proteins	   involved	   in	   RNA	  metabolism	   (see	   fig.	   48).	   14	   trans-­‐acting	   factors	   are	   down-­‐regulated	  in	  both	  the	  bloodstream	  RNAi	  and	  the	  procyclic	  overexpression	  cell	  line	  (e.g.	  PUF2,	  ZFP1	  and	  ZC3H29).	  Therefore,	  any	  effect	  observed	  might	  as	  well	  be	  caused	  by	  the	  downregulation	  of	  any	  of	  these	  trans-­‐acting	  factors.	  	  Another	  secondary	  effect	  which	  surely	   influenced	  the	  mRNA	  levels	   in	   the	  bloodstream	  RNAi	   cell	   line	   is	   the	   stress	   reponse,	   as	   ZC3H32	   knock-­‐down	   causes	   a	   growth	   defect.	  Exogenous	  expression	  of	  ZC3H32-­‐myc	  in	  procyclics	  does	  not	  cause	  a	  growth	  defect	  (see	  fig.	  40),	  thus,	  it	  is	  unlikely	  that	  the	  mRNA	  levels	  of	  these	  cells	  are	  influenced	  by	  the	  stress	  response.	  	  There	   is	   a	   positive	   correlation	  between	   the	   average	  of	   the	   two	   sequencing	   replicas	  of	  bloodstream	  RNAi	  cell	   lines	  and	   the	  sequencing	  result	  of	  other	  RNAi	  cell	   lines	   (MKT1,	  RRP45,	  CAF1,	  PUF2	  and	  CTR9	  RNAi	  (see	  table	  7)).	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One	  possible	  explanation	  of	  the	  correlation	  between	  the	  MKT1	  and	  the	  ZC3H32	  dataset	  is	   that	   these	  proteins	   interact.	  Also,	   the	  MKT1	  mRNA	  seems	  to	  be	  down-­‐regulated	  two	  fold	   in	   the	  ZC3H32	  cell	   lines	  (see	  table	  7,	  row	  8,	  column	  four).	   If	  ZC3H32	  knock-­‐down	  causes	   lower	  MKT1	   RNA	   levels,	   this	   could	   influence	   the	   levels	   of	   the	   RNA	   targets	   of	  MKT1,	  thus	  causing	  a	  correlation	  between	  the	  two	  datasets.	  This	  could	  also	  explain	  the	  correlation	  between	  the	  ZC3H32	  dataset	  and	  the	  PUF2	  RNAi	  dataset,	  as	  the	  PUF2	  RNA	  is	  down-­‐regulated	  approximately	  five	  fold	  in	  the	  ZC3H32	  RNAi	  cell	  line.	  But	  this	  is	  not	  the	  case	  for	  CAF1	  and	  CTR9,	  whose	  mRNAs	  seem	  to	  be	  only	  slightly	  down-­‐regulated	  in	  this	  cell	  line,	  and	  also	  not	  for	  RRP45,	  whose	  mRNA	  is	  not	  down-­‐regulated.	  However,	  in	  these	  cell	   lines,	   the	   ZC3H32	   mRNA	   levels	   seem	   to	   have	   decreased.	   In	   the	   RRP45	   and	   CTR1	  RNAi	  cell	   line	  even	  with	  a	  factor	  of	  0.1,	  which	  is	  the	  same	  degree	  of	  decrease	  as	  in	  the	  ZC3H32	  RNAi	  cell	  lines.	  In	  the	  CAF1	  cell	  line,	  the	  ZC3H32	  mRNA	  is	  down-­‐regulated	  with	  a	  factor	  of	  0.3.	  Thus,	  for	  these	  cell	  lines	  the	  correlation	  could	  be	  caused	  by	  the	  opposite	  effect;	   if,	   for	   example,	   the	   knock-­‐down	   of	   RRP45	   decreases	   the	   level	   of	   ZC3H32,	   this	  could	  influence	  the	  target	  mRNAs	  of	  ZC3H32	  and	  thus	  cause	  a	  correlation.	  	  Another	   possible	   explanation	   is	   the	   negative	   correlation	   between	   the	   length	   of	   the	  coding	   sequence	   and	   the	   relative	   RNA	   amount	   in	   the	   sequencing	   results	   from	   the	  ZC3H32	  RNAi	  cell	  line.	  This	  means,	  that,	  when	  ZC3H32	  is	  knocked	  down,	  RNAs	  with	  long	  coding	  sequences	  are	  more	   likely	  to	  be	   less	  abundant	  than	  compared	  to	  the	  wild	  type.	  RNAs	   with	   short	   coding	   sequences,	   on	   the	   other	   hand,	   are	   more	   likely	   to	   show	  comparatively	  higher	  levels.	  	  Thus,	   short	  RNAs,	  which	   seem	   to	   be	   enriched	   in	   the	   ZC3H32	  RNAi	   cell	   line,	   are	  more	  likely	  to	  be	  false	  positives	  (see	  table	  8,	  column	  15,	  sequences	  shown	  in	  pink)	  than	  longer	  RNAs.	  The	  same	  correlation	  was	  observed	  with	  the	  majority	  of	  the	  other	  sequencing	  datasets	  (see	  table	  7,	  column	  5).	  The	  only	  exceptions	  are	  the	  datasets	  from	  the	  procyclic	  ZC3H32	  overexpression	  cell	  line	  and	  the	  ZC3H11	  RNAi	  dataset,	  which	  show	  no	  correlation	  (0.012	  and	  0.001),	  as	  well	  as	  the	  XRNA	  RNAi	  dataset,	  which	  shows	  a	  positive	  correlation	  (0.47).	  	  This	  correlation	  with	  the	  CDS	  length	  might	  also	  explain	  the	  correlation	  of	  the	  sequencing	  results	   between	   the	   ZC3H32	   cell	   line	   and	   the	   cell	   lines	   showing	   the	   same	   correlation	  (MKT1,	  RRP45,	  CAF1,	  PUF2	  and	  CTR9	  RNAi	  cell	  line).	  It	  should	  be	  mentioned	  that,	  while	  it	  would	  have	  been	  more	  informative	  to	  calculate	  the	  correlation	  between	  the	  length	  of	  the	  RNA	  and	  the	  relative	  RNA	  levels	  in	  the	  respective	  cell	   line,	   this	   was	   not	   possible,	   as	   for	   too	   many	   RNAs	   the	   length	   of	   the	   UTRs	   are	  unknown,	  and	   thus	   the	   length	  of	   the	  entire	  RNA	  cannot	  be	  determined	  with	  certainty.	  Therefore,	   the	   CDS	   length	   was	   used	   for	   the	   calculation.	   It	   is	   not	   unlikely	   that	   the	  correlation	  between	   the	  RNA	   length	  and	   the	   relative	  RNA	   levels	   in	   the	  RNAi	   cell	   lines	  might	  be	  even	  higher.	  	  An	  interesting	  observation,	  however,	  was	  that	  there	  seems	  to	  be	  a	  positive	  correlation	  (0.31)	  between	  the	  relative	  RNA	  levels	  from	  the	  ZC3H32	  bloodstream	  RNAi	  results	  and	  the	  proportions	  of	   the	  RNA	   levels	  between	  procyclics	  and	  bloodstream	  wild	   type	  cells	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(rpm	  procyclic	  WT/rpm	  bloodstream	  WT),	  meaning	  that	  if	  an	  RNA	  is	  up-­‐regulated	  in	  the	  procyclic	   form,	   as	   compared	   to	   the	   bloodstream	   form,	   it	   is	   more	   likely	   to	   be	   up-­‐regulated	  in	  the	  ZC3H32	  RNAi	  cell	  line	  (see	  fig.	  47,	  panel	  F).	  	  
	  
Table	  7:	  Comparison	  of	  different	  sequencing	  datasets.	  	  The	   correlation	   between	   the	   relative	   RNA	   levels	   (rpm	   cell	   line/	   rpm	  bloodstream	  WT)	   of	   the	  datasets	  is	  shown.	  Correlations	  higher	  than	  0.3	  are	  shown	  in	  red,	  correlations	  lower	  than	  -­‐0.3	  in	  blue.	  
Column	  2:	  datasets	  used	  for	  comparison:	  Row	  1:	  Procyclic	  ZC3H32-­‐myc	  cell	  line	  (pc	  1313	  514	  2332)	  Row	  2-­‐8:	  Other	  bloodstream	  RNAi	  cell	  lines.	  	  Row	  9:	  Correlation	  between	   the	  relative	  RNA	   levels	   in	   the	  bloodstream	  ZC3H32	  RNAi	  cell	   line	  and	   the	   proportion	   between	   procyclic	   WT	   and	   bloodstream	   WT	   sequencing	   results	   (rpm	  procyclic	  WT/rpm	  bloodstream	  WT)	  Row	  10:	  Correlation	  between	  the	  relative	  RNA	  levels	  in	  the	  bloodstream	  ZC3H32	  RNAi	  cell	  line	  and	  the	  length	  of	  the	  coding	  sequence	  (in	  base	  pairs).	  	  
Column	  3:	  Correlation	  coefficient	  R	  between	  the	  relative	  RNA	  levels	  form	  the	  sequencing	  results	  from	  the	  respective	  cell	  line	  and	  the	  average	  of	  the	  datasets	  of	  the	  two	  sequencing	  replicas	  of	  the	  ZC3H32	  RNAi	  cell	  line.	  	  
Column	  4:	  Only	  applicable	  for	  RNAi	  cell	  lines.	  Relative	  RNA	  level	  of	  the	  respective	  RNAi	  target	  in	  the	  ZC3H32	  cell	  line	  (e.g.	  MKT1:	  0.5,	  meaning	  the	  MKT1	  RNA	  is	  down-­‐regulated	  two	  fold	  in	  the	  ZC3H32	  RNAi	  cell	  line).	  Values	  below	  0.5	  are	  shown	  in	  blue.	  	  
Column	  5:	  Only	  applicable	  for	  RNAi	  cell	   lines.	  Relative	  RNA	  level	  of	  ZC3H32	   in	  the	  sequencing	  results	  from	  the	  respective	  RNAi	  cell.	  Values	  below	  0.5	  are	  shown	  in	  blue.	  In	  the	  XRNA	  cell	  line	  not	  enough	  rpms	  were	  obtained	  for	  the	  ZC3H32	  RNA.	  






rel. RNA levels 
in ZC3H32 RNAi 
rel. ZC3H32 
RNA levels  
corr. with 
CDS length 
1 pc OE 0.025     0.012 
2 XRNA RNAi -0.12 0.4  -  0.47 
3 ZC3H11 RNAi -0.07 0.5 1.2 0.001 
4 CTR9 RNAi 0.43 0.8 0.1 -0.42 
5 Puf2 RNAi 0.45 0.2 1.3 -0.51 
6 CAF1RNAi 0.46 0.6 0.3 -0.40 
7 RRP45 RNAi 0.49 1.4 0.1 -0.37 
8 MKT1 RNAi 0.59 0.5 1 -0.38 
9 pc WT/bs WT 0.31     -0.17 
10 CDS length -0.42     1 
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Fig.	  47:	  Comparison	  of	  the	  ZC3H32	  sequencing	  results	  with	  other	  sequencing	  datasets	  Scatter	  blots	  for	  the	  comparison	  of	  sequencing	  results	  from	  the	  bloodstream	  ZC3H32	  RNAi	  cell	  line	  with	  other	  sequencing	  datasets,	  the	  coding	  sequence	  length	  (G)	  and	  the	  proportions	  of	  the	  RNA	   levels	   between	   procyclics	   and	   bloodstream	   wild	   type	   cells	   (rpm	   procyclic	   WT/rpm	  bloodstream	   WT)	   (F).	   A:	   bloodstream	   MKT1	   RNAi	   cell	   line	   (Singh,	   Minia	   et	   al.	   2014)	   B:	  bloodstream	  PUF2	  RNAi	  cell	  line	  (Jha,	  Fadda	  et	  al.	  2014)	  C:	  bloodstream	  ZC3H11	  RNAi	  cell	  line	  (Droll,	  Minia	   et	   al.	   2013)	   	   D:	   bloodstream	  XRNA	  RNAi	   cell	   line	   (Manful,	   Fadda	   et	   al.	   2011)	   E:	  bloodstream	   RRP45	   RNAi	   cell	   line	   (Fadda,	   Farber	   et	   al.	   2013).	   F:	   rpm	   procyclic	   WT/	   rpm	  bloodstream	  WT	  (Fadda,	  Ryten	  et	  al.	  2014)	  G:	  coding	  sequence	  length	  




Fig.	  48:	  Overview	  of	  RNAseq	  results	  A+B:	   data	   from	   the	  bloodstream	  RNAi	   cell	   line	   (combined	   from	  both	   replicas)	  Up-­‐	   and	  down-­‐regulated	  mRNAs	  sorted	  by	  function.	  The	  threshold	  was	  a	  two	  fold	  change	  in	  comparison	  to	  the	  wild	  type	  C+D:	   data	   from	   the	   procyclic	   ZC3H32-­‐myc	   cell	   line.	   E:	   Scatter	   blot	   showing	   the	   comparison	  between	   the	   data	   from	   bloodstream	   and	   procyclic	   RNAseq	   F:	   Scatter	   blot	   showing	   the	  comparison	  between	  the	  data	  from	  the	  bloodstream	  replicas.	  For	  entire	  datasets,	  see	  table	  8	  and	  suppl.	  6.2.	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    ZC3H32          











E1 β-subunit (PDH)  
Citric acid 





genesis glyc.1 3.4 2.0 2.1 ± 0.9 - 22.6 1.4 1.8 1.4 0.4 0.4 2742 
Tb927.3.2230 
Succinyl CoA synth. α-
subunit (SCS) 
Citric acid 
cycle mito* 3.2 2.5 1.2 ± 0.3 1.4 4.4 1.6 1.3 2.9 1.7 2.4 906 
Tb927.10.12240 
short-chain 
dehydrogenase, putative - mito 2.8 2.1 - 1.8 3.6 1.8 1.2 1.8 1.0 3.6 984 
Tb927.11.900 
Isocitrate 
dehydrogenase, putative  
Citric acid 





genesis glyc.2 2.3 2.1 2.2 ± 0.5 2.2 31.4 1.4 1.3 1.1 0.3 0.4 972 
 Tb927.2.5980 heat shock protein 104  Chaperone Cy     cyt cytoplasm 2.3 2.3 - 2.1 1.0 3.7 1.4 0.7 2.2 0.7 2613 
Tb927.3.3460 
hyp. protein, (SDH5 in T 
cruzi) 
respiratory 





protein mito* 2.1 2.1 0.9 - 1.7 2.4 1.0 1.0 1.2 3.5 849 
Tb927.4.2240 hyp. protein - nn 2.0 2.0 - 1.9 1.6 1.6 1.4 2.3 2.8 1.0 1173 
Tb927.8.5270 hyp. protein - nn 2.0 2.0 - 1.8 0.6 1.7 1.2 1.0 1.0 1.3 840 
Tb927.4.3520 hyp. protein - nn 4.1 2.1 - 5.6 4.1 1.9 1.7 1.5 0.5 0.2 537 
Tb927.6.1520 
aquaporin 3, putative 
(AQP1) - 
mem-










protein mito* 2.8 2.7 - 1.2 3.6 2.1 1.9 2.3 3.1 1.3 405 
Tb927.7.210 proline dehydrogenase AA mito2 2.6 2.6 - 1.1 7.6 2.8 1.9 3.4 1.3 0.7 1671 
	   3.	  Results	  
113	  
Table	  8:	  RNAs	  enriched	  in	  the	  bloodstream	  ZC3H32-­‐RNAi	  cell	  line	  High	  throughput	  sequencing	  results.	  RNAs	  which	  were	  up-­‐regulated	  upon	  ZC3H32	  knock-­‐down	  in	  both	  sequencing	  datasets	  (A	  and	  B)	  are	  shown.	  	  pc	  OE:	  results	  from	  overexpression	  in	  procyclics;	  	  pc/bs:	  RNA	  levels	  in	  procyclic	  cells/RNA	  levels	  in	  bloodstream	  cells,	  from	  wild	  type	  cells	  	  NB:	  results	  from	  Northern	  blotting	  (see	  fig.	  49	  and	  50)	  MKT1,	  ZC3H11,	  Puf2,	  Caf1,	  RRP45:	  RNA	  sequencing	  results	  for	  these	  mRNAs	  from	  of	  MKT1,	  ZC3H11,	  Puf2,	  Caf1	  and	  RRP45	  RNAi	  cell	  lines.	  Data	  taken	  from:	  XRNA:	  (Manful,	  Fadda	  et	  al.	  2011),	  ZC3H11:	  (Droll,	  Minia	  et	  al.	  2013),	  CTR9:	  (Ouna,	  Nyambega	  et	  al.	  2012),	  PUF2:	  (Jha,	  Fadda	  et	  al.	  2014),	  CAF1	  and	  RRP45:	  (Fadda,	  Farber	  et	  al.	  2013)	  MKT1:	  (Singh,	  Minia	  et	  al.	  2014),	  procyclic	  WT/bloodstream	  WT:	  (Fadda,	  Ryten	  et	  al.	  2014)	  CDS	  length:	  coding	  sequence	  length.	  Sequences	  shorter	  than	  the	  first	  quartile	  (801bp)	  are	  shown	  in	  pink,	  shorter	  than	  the	  median	  in	  dark	  blue,	  longer	  than	  the	  median	  length	  (1276bp)	  are	  shown	  in	  dark	  green	  and	  longer	  than	  the	  third	  quartile	  (2007bp)	  are	  shown	  in	  light	  green.	  	  Localzation:	  mito:	  mitochondrion;	  glyc:	  glycosome	  *	  mitochondrial	  localisation	  predicted	  by	  MitoCarta	  1:	  (Cosenza,	  Bringaud	  et	  al.	  2002)	  2:	  localization	  determined	  by	  homology	  	  
metabolism 
Tb927.11.6700 hyp. protein - mito* 2.3 2.0 - - 1.6 1.7 1.3 1.4 3.3 3.0 399 
Tb927.10.3120 
cytochrome c oxidase 
assembly protein 
respiratory 
chain mito*2 2.0 2.2 - 0.6 2.5 1.3 1.3 1.2 0.6 0.8 699 
Tb927.10.10000 hyp. protein - nn 2.0 2.9 - 1.2 5.9 2.6 2.2 1.8 4.1 0.6 1224 
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In	  the	  bloodstream	  form,	  120	  RNAs	  were	  down-­‐regulated	  upon	  ZC3H32	  RNAi	  induction,	  while	  19	  were	  up-­‐regulated.	  In	  the	  procyclic	  form,	  93	  were	  down-­‐	  and	  140	  up-­‐regulated.	  Up	   and	   downregulation	   was	   defined	   by	   at	   least	   a	   two-­‐fold	   change	   in	   RNA	   levels	   as	  compared	   for	   the	   wild	   type.	   For	   the	   bloodstream	   RNAi	   results,	   the	   effect	   had	   to	   be	  present	  in	  both	  replicas	  in	  order	  to	  be	  definded	  as	  up/downregulation.	  Also,	  RNAs	  that	  were	   shown	   to	   be	   affected	   in	   all	   RNAi	   cell	   lines	   were	   not	   defined	   as	   up	   or	   down-­‐regulated,	  even	  if	  they	  changed	  2	  fold	  in	  both	  replicas.	  	  There	  seem	  to	  be	  more	  RNA	  level	  changes	  in	  the	  procyclic	  data,	  however,	  this	  is	  due	  to	  two	  things:	  for	  once,	  this	  sequencing	  reaction	  was	  done	  only	  once.	  Also,	  apart	  from	  two	  wild	   type	  samples,	   there	  was	  no	  other	  sequencing	  data	   from	  procyclics	  available	  (that	  means,	   from	   RNAi	   cell	   lines	   or	   cell	   lines	   in	   which	   another	   protein	   was	   exogenously	  expressed),	  with	  which	   to	   compare	   this	   data.	   Therefore,	   less	  data	   could	  be	  discarded;	  thus	  there	  seem	  to	  be	  more	  targets.	  	  What	   is	  surprising	   is,	   that,	  although	  the	  tethering	  experiments	   indicate	  that	  ZC3H32	  is	  destabilizing,	   more	   RNAs	   seem	   to	   be	   down-­‐regulated	   upon	   its	   decrease	   in	   the	  bloodstream	  form,	  while	  more	  appear	  to	  be	  stabilized	  upon	  its	  exogenous	  expression	  in	  procyclics.	  But	  this	  might	  be	  a	  secondary	  effect.	  	  What	  was	  interesting,	  however,	  was,	  that	  among	  the	  19	  stabilized	  RNAs	  (see	  table	  3)	  in	  the	   bloodstream	   form,	   11	   encode	   proteins	   localizing	   to	   the	  mitochondrion.	   Of	   the	   12	  putative	   targets,	   which	   could	   be	   linked	   to	   a	   cellular	   pathway,	   3	   were	   found	   to	   be	  associated	   with	   the	   citric	   acid	   cycle	   (note:	   one	   of	   them	   is	   a	   subunit	   of	   pyruvate	  dehydrogenase,	   which	   is	   not,	   in	   fact,	   part	   of	   the	   citric	   acid	   cycle)	   and	   three	  with	   the	  respiratory	  chain.	  	  This	   might	   a	   response	   to	   the	   stress,	   as	   the	   cells	   are	   dying	   they	   might	   increase	   their	  energy	   metabolism.	   But	   it	   could	   also	   be	   possible	   that	   ZC3H32	   down-­‐regulates	   RNAs	  encoding	  mitochondrial	  proteins	  in	  the	  bloodstream	  form.	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3.3.12	  Validation	  of	  the	  high-­‐throughput	  sequencing	  results	  by	  Northern	  blotting	  	  The	  high-­‐throughput	   sequencing	   results	   showed	   that	   the	  majority	   of	   the	  RNAs,	  which	  were	  enriched	  in	  the	  bloodstream	  ZC3H32	  RNAi	  cell	  line,	  encoded	  proteins	  found	  in	  the	  mitochondrion	   and/or	   involved	   in	   energy	   metabolism.	   In	   order	   to	   find	   out	   whether	  these	   targets	  were	   indeed	   down-­‐regulated	   upon	   ZC3H32	   knock-­‐down,	  Northern	   blots	  were	  made	  using	  both	  the	  inducible	  knock-­‐out	  cell	  lines	  and	  the	  RNAi	  cell	  line	  (the	  same	  clone	  which	  was	  also	  used	  for	  sequencing).	  	  Six	   candidate	   mRNAs	   were	   tested:	   Pyruvate	   phosphate	   dikinase	   (PPDK),	   glycosomal	  malate	   dehydrogenase	   (gMDH),	   isocitrate	   dehydrogenase	   (IDH),	   the	   alpha	   subunit	   of	  succinyl-­‐CoA	  synthetase	  (SCS),	  the	  beta	  subunit	  of	  E1	  of	  pyruvate	  dehydrogenase	  (PDH)	  and	  mitochondrial	  carrier	  protein	  9	  (MCP9).	  	  The	   expected	   upregulation	   was	   not	   much,	   as	   the	   sequencing	   results	   also	   showed	   no	  higher	  increase	  than	  3.8	  fold	  as	  compared	  to	  the	  wildtype.	  	  The	  Northern	   blots	   showed	   that,	   upon	   downregulation	   of	   ZC3H32,	   either	   by	   inducing	  RNAi	  or	  by	  stopping	   the	  expression	  of	  ZC3H32-­‐myc	   in	   the	  double	  knock-­‐out	  cell	   lines,	  the	   RNA	   levels	   of	   SCS,	   PDH	   and	   IDH	   show	   a	   slight	   increase,	   however,	   the	   results	   are	  inconclusive.	  There	  was	  no	   increase	   in	   the	  RNA	   levels	  of	  MCP-­‐9	  (see	   fig.	  49	  and	  50,	  as	  well	  as	  table	  8).	  gMDH	  and	  PPDK	  were	  shown	  to	  be	  up-­‐regulated	  at	  least	  two	  fold	  in	  two	  independent	  experiments	  (for	  gMDH,	  see	  fig.	  49	  B	  and	  D,	  for	  PPDK	  see	  fig.	  50	  A	  and	  B).	  The	   results	   of	  PDH	   also	   point	   towards	   an	   upregulation,	   upon	   knock-­‐down,	   it	  was	   up-­‐regulated	  2	  folds	  in	  the	  double	  knock-­‐out	  cell	  line	  and	  1.9	  fold	  in	  the	  RNAi	  cell	  line.	  Thus,	  it	  can	  be	  concluded,	  that	  ZC3H32	  knock-­‐down	  affects	  the	  RNA	  levels	  of	  gMDH	  and	  PPDK	  and	  probably	  PDH	  as	  well.	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Fig.	  49:	  Testing	  of	   the	  sequencing	  
results	   for	  gMDH,	  SCS	   and	   IDH	   by	  
Northern	  blot	  	  Two	   ZC3H32	   double	   knock-­‐out	   cell	  lines	   expressing	   ZC3H32	   myc	   were	  used	   (A,B,C:	   clone	  B,	   D+E:	   clone	  A),	  as	  well	  as	  the	  ZC3H32	  RNAi	  cell	  line.	  Expression	   of	   the	   exogenous	  ZC3H32-­‐myc	   was	   stopped	   by	  transferring	  the	  cells	  to	  tetracycline-­‐free	   medium.	   Samples	   were	  collected	   from	   bloodstream	   cells	  unless	   otherwise	   indicated	   (pc=	  procyclic)	   A:	   Northern	   blot	   probed	  against	   succinyl-­‐CoA	   synthetase	  alpha	   subunit,	   putative	   (SCS),	   7SL	  RNA	  was	  used	  as	  control	  in	  all	  blots	  B:	   Northern	   blot	   probed	   against	  glycosomal	   malate	   dehydrogenase	  (gMDH)	   C:	   Western	   blot	   probed	  with	   α-­‐myc	   showing	   the	   depletion	  of	  the	  exogenous	  ZC3H32	  over	  time.	  	  D:	   Second	   Northern	   blot	   probed	   against	   SCS	   and	   gMDH.	   RNAi	   (ZC3H32	   RNAi)	   samples	   were	  collected	   after	   24h	   of	   induction	   E:	   Northern	   blot	   probed	   against	   isocitrate	   dehydrogenase,	  putative	   (IDH).	   myc:	   cells	   expression	   exogenous	   ZC3H32-­‐myc	   (no	   knock-­‐out).	   Both	   myc	   and	  RNAi	  cell	  lines	  were	  induced	  for	  24h.	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Fig.	  50:	  Testing	  of	  the	  sequencing	  results	  for	  PPDK,	  PDH	  and	  MCP-­‐9	  by	  Northern	  blot	  	  For	  these	  Northerns,	  RNA	  samples	  from	  different	  cell	  lines	  were	  used:	  	  bloodstream	  and	  procyclic	  1313	  (“WT”),	  the	  ZC3H32	  RNAi	  cell	   line	  (“RNAi”,	  see	  panel	  A,	  C	  and	  E),	  	  a	  double	  knock-­‐out	  cell	  line	  (clone	  A,	  labeled	  “dKO”,	  see	  panel	  B,	  D;	  clone	  A	  was	  used)	  and	  the	   procyclic	   ZC3H32-­‐myc	   cell	   line	   (no	   knock-­‐out	   of	   ZC3H32),	   referred	   to	   as	   “ZC3H32-­‐myc”	  (A,C,E)	  and	  “myc”	  (B,D).	  	  RNAi	  was	  induced	  by	  adding	  tetracycline	  (+Tet),	  expression	  of	  the	  exogenous	  ZC3H32-­‐myc	  was	  stopped	  by	  transferring	  the	  cells	  to	  tetracycline-­‐free	  medium	  (-­‐Tet).	  	  
7SL	  RNA	  was	  used	  as	  control	  in	  all	  blots	  	  A	  and	  B:	  Northern	  blots	  probed	  against	  pyruvate	  phosphate	  dikinase	  (PPDK)	  	  C	  +D:	  Northern	  blot	  probed	  against	  pyruvate	  dehydrogenase	  E1	  beta	  subunit,	  putative	  (PDH)	  	  E:	  Northern	  blot	  probed	  against	  mitochondrial	  carrier	  protein	  9	  (MCP9)	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3.3.13	  ZC3H32	  and	  the	  degradation	  machinery	  	  As	   ZC3H32	   degrades	   RNA,	   it	   was	   thought	   that	   it	   interacts	   with	   some	   parts	   of	   the	  trypanosome	   degradation	   machinery.	   I	   therefore	   tested	   several	   proteins	   involved	   in	  mRNA	  degragation	  for	  an	  interaction	  with	  ZC3H32.	  I	  started	  with	  members	  of	  the	  CAF-­‐NOT	  complex,	  because	  there	  were	  indications	  that	  MKT1	  interacts	  with	  components	  of	  this	   complex:	   a	   yeast-­‐two-­‐hybrid	   screen	   showed	   NOT2	   as	   a	   putative	   MKT1	   binding	  partner	  while	  CAF40	  and	  NOT1	  were	  co-­‐purified	  with	  MKT1	  in	  a	  TAP	  purification	  (Singh,	  Minia	  et	  al.	  2014).	  However,	  I	  could	  not	  detect	  an	  interaction	  between	  ZC3H32	  and	  any	  of	  these	  proteins	  (see	  fig.	  51).	  	  I	  also	  tested	  the	  exoribonuclease	  XRNA	  and	  the	  exosome	  component	  RRP45	  (fig.	  52A)	  as	  well	  as	  DHH1	  (fig.	  52B),	  which	  is	  involved	  in	  translation,	  for	  an	  interaction	  with	  ZC3H32.	  XRNA	  and	  RRP45	  were	  chosen	  because	  they	  play	  a	  role	  in	  mRNA	  degradation	  and	  also	  because	  specific	  antibodies	  were	  available.	  DHH1	  was	  tested	  because	  it	  was	  also	  found	  in	  the	  TAP	  purification	  of	  MKT1	  (Singh,	  Minia	  et	  al.	  2014).	  But	  as	  the	   initial	   IP	  did	  not	  suggest	   any	   interaction	   (fig.	   52),	   I	   stopped	   testing	   these	   candidates.	   However,	   the	  interaction	   between	   ZC3H32	   and	   these	   proteins,	   as	   well	   as	   with	   the	  members	   of	   the	  CAF-­‐NOT	   complex,	   might	   be	   too	   transient	   to	   be	   observed.	   Thus,	   it	   remains	   unclear	  whether	  ZC3H32	  degrades	  RNA	  and	  how	  it	  does	  that.	  	  	  
	  
Fig.	  51:	  ZC3H32	  does	  not	  interact	  with	  the	  CAF1-­‐NOT	  complex	  *	  marks	  the	  antibody	  which	  was	  used	  for	  the	  precipitation	  (here:	  α-­‐V5,	  as	  α-­‐V5	  beads	  were	  used	  for	  all	  three	  IPs)	  The	  antibody	  recognizing	  the	  tagged	  ZC3H32	  (either	  V5	  or	  myc	  tagged)	  is	  written	  in	  bold	  A:	  V5-­‐IP	  with	  V5-­‐ZC3H32	  and	  CAF1-­‐myc.	  S9	  was	  used	  as	  control.	  	  B:	  V5-­‐IP	  with	  V5-­‐Not2	  and	  ZC3H32-­‐myc.	  S9	  was	  used	  as	  control.	  	  C:	  V5-­‐IP	  with	  V5-­‐CAF40	  and	  ZC3H32-­‐myc.	  S9	  was	  used	  as	  control.	  	  




Fig.	  52:	  ZC3H32	  does	  not	  co-­‐purify	  RRP45,	  XRNA	  and	  DHH1	  *	  marks	  the	  antibody	  which	  was	  used	  for	  the	  precipitation	  (here:	  α-­‐V5,	  as	  α-­‐V5	  beads	  were	  used	  for	  both	  IPs)	  The	  antibody	  recognizing	  the	  tagged	  ZC3H32	  (here:	  α-­‐V5)	  is	  written	  in	  bold	  A:	  V5-­‐IP	  with	  V5-­‐ZC3H32	  expressing	  cells.	  Cells	  expressing	  MKT1-­‐YFP	  were	  used	  as	  control	  cell	  line.	  (“untagged	  ZC3H32”,	  Western	  blot	  signal	  for	  YFP-­‐MKT1	  not	  shown).	  The	  Western	  blot	  was	  probed	  with	  α-­‐V5,	  α-­‐XRNA,	  α-­‐RRP45	  and	  α-­‐S9	  (negative	  control).	  The	  IPs	  were	  done	  with	  and	  without	  RNAse.	  	  D:	  V5-­‐IP	  with	  V5-­‐ZC3H32	  and	  WT	  cells	  (control	  cell	  line).	  The	  Western	  blot	  was	  probed	  with	  α-­‐DHH1	  and	  α-­‐V5.	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3.3.14	  Immunoprecipitation	  of	  ZC3H32	  followed	  by	  Mass	  spectrometry	  In	  order	  to	  find	  interaction	  partners	  of	  ZC3H32,	  two	  ZC3H32-­‐myc	  Immunoprecipitations	  were	  done	  with	  anti-­‐myc	  beads,	  one	  in	  the	  presence	  of	  RNAse	  Inhibitor,	  the	  other	  in	  the	  presence	  of	  RNAseA.	  As	  a	  control,	  an	  IP	  with	  a	  wild	  type	  cell	  line,	  also	  in	  the	  presence	  of	  RNAse	  Inhibitor,	  was	  done.	  	  The	   beads	   were	   boiled	   in	   Laemmli	   buffer	   and	   the	   eluted	   proteins	   were	   sent	   for	  comparative	   mass	   spectrometry.	   The	   control	   sample	   was	   labeled	   with	   formaldehyde	  (“light”	   labeling),	   the	   inhibitor	   sample	  with	   deuterated	   formaldehyde	   (“medium”)	   and	  the	   RNAse	   sample	   was	   labeled	   with	   deuterated	   and	   13C	   containing	   formaldehyde	  (“heavy”).	  	  The	  results	  are	  shown	  in	  table	  9.	  ZC3H32	  was	  shown	  to	  be	  enriched,	  as	  compared	  to	  the	  control,	   in	   both	   preparations,	  which	   shows	   that	   the	   pull-­‐down	  was	   successful.	   	  MKT1	  was	  not	  enriched,	  neither	  were	  any	  members	  of	  the	  degradation	  machinery.	  Some	  putative	  RNA	  binding	  proteins	  were	  found,	  though,	  for	  example	  ZC3H28,	  DRBD2,	  ZC3H41	  and	  ZC3H40.	  	  eIF4E-­‐IP	   and	  DRBD4	  are	   enriched	   in	  both	  RNAse	   and	   Inhibitor	  preparation,	   however,	  only	  with	  one	  unique	  peptide,	  which	  is	  too	  little	  for	  conformation.	  eIF4E-­‐IP	  was	  tested	  for	  interaction	  by	  Co-­‐IP	  (result	  see	  fig.	  53),	  but	  no	  interaction	  was	  seen.	  PBP1	  is	  enriched	  in	  the	  Inhibitor	  sample,	  however,	  it	  only	  shows	  one	  unique	  peptide	  as	  well	  (see	  table	  in	  suppl.	  data).	  In	   order	   to	   check	   the	   mass	   Spectrometry	   data,	   two	   candidates,	   DRBD2	   and	   the	  hypothetical	  protein	  Tb927.7.2780,	  which	  were	  both	  enriched	   in	  both	   the	  RNAse	   	  and	  the	   Inhibitor	   sample,	   were	   tested	   for	   interaction	   with	   ZC3H32.	   However,	   the	   Co-­‐IPs	  showed	  that	  there	  was	  no	  interaction.	  This	  finding,	  combined	  with	  the	  fact	  that	  MKT1,	  which	  was	  shown	  to	  interact	  with	  ZC3H32	  both	  in	  the	  presence	  and	  absence	  of	  RNAseA,	  was	   not	   found	   to	   be	   enriched	   in	   neither	   of	   the	   samples,	   shows,	   that	   the	   mass	  spectrometry	   results	   probably	   do	   not	   show	   real	   interaction	   partners	   of	   ZC3H32	   and	  thus	  cannot	  be	  used.	  	   	  










Tb927.10.5250 ZC3H32 19 300.00 300.00 
Tb927.7.2780 hyp. protein 2 300.00 300.00 
Tb09.211.4540 DRBD2 4 300.00 300.00 
Tb927.6.4870 S-adenosylmethionine 
synthetase, putative  
3 300.00 300.00 
Tb927.6.4480 valyl-tRNA synthetase, 
putative (ValRS) 
4 300.00 300.00 
Tb11.01.1170 hyp. protein, unique to 
Kinetoplastids 
5 300.00 300.00 
Tb927.4.4060  hyp. protein 2 79.770 300.000 
Tb927.10.14140  pyruvate kinase 1 
(PYK1) 6 
1.000 300.000 
Tb927.4.560 Cytoplasmic dynein 2 
heavy chain, putative 
6 300.00 66.18 
Tb927.7.1040 40S rib. protein S16 5 22.88 18.01 
Tb927.8.6260 hyp. protein, N-terminal 
leucine zipper 
4 26.71 17.61 
Tb09.160.1160 nucleolar protein 
(NOP86) 
5 29.78 15.50 
Tb927.4.450 coatomer alpha subunit, 
putative 
3 31.76 13.53 
Tb927.4.4310 Nucleoporin (TbNup64) 4 15.26 10.37 
Tb927.6.3650 ADP-ribosylation factor, 
putative 
2 14.20 10.29 
Tb11.02.4040 protein transport protein 
Sec31, putative 
3 18.12 7.33 
Tb11.02.0030 dynein heavy chain, 
putative  
11 37.66 6.74 
Tb09.211.4240 phosphoinositide-
binding protein, putative 
3 11.35 6.51 
Tb09.211.1070 ZC3H28 4 11.03 6.04 
Tb11.02.3120  malic enzyme 2 1.488 4.961 
Tb927.10.5340 40S ribosomal protein 
S18 
6 6.94 4.72 
Tb09.211.4780 Nucleoporin (Nup82) 3 15.16 4.38 
Tb11.02.1566  VSG-related, putative 5 0.953 3.966 
Tb927.10.12710 HSP110 4 33.38 3.34 
Tb927.10.14950 ZC3H40 3 17.09 3.34 
Tb11.02.4300 hyp. protein 14 300.00 1.86 
Tb927.10.10360 microtubule-associated 
protein, putative 
3 4.81 1.83 
Tb927.4.2740 hyp. protein 2 7.86 1.82 
	   3.	  Results	  
122	  
Tb927.8.1870 Golgi/lysosome 
glycoprotein 1 (tGLP1) 
2 4.84 1.52 




7 3.01 1.44 
Tb927.10.4570 elongation factor 2 11 5.17 1.43 
Tb927.3.3580 lipophosphoglycan 
biosynthetic protein 
2 17.01 1.43 
Tb927.10.8230 protein disulfide 
isomerase, putative 
6 3.81 1.36 
Tb927.10.2890 enolase 11 3.59 1.27 
Tb11.02.1120 adenylosuccinate 
synthetase, putative 
3 5.45 1.24 
Tb11.01.7010 hyp. protein (TbKap123) 4 3.57 1.15 
Tb09.211.3610 ubiquitin-activating 
enzyme e1, putative  
12 4.99 1.07 
Tb11.01.1400 glycyl-tRNA synthetase, 
putative 
2 7.11 1.02 




2 4.68 0.76 
Tb09.211.1620 hyp. protein 6 3.31 0.74 
Tb927.3.910 gamma-tubulin 2 78.45 0.16 
Tb927.7.1300 protein disulfide 
isomerase,ERp72-like, 
putative 
2 3.25 0.04 
Table	  9:	  Mass	  spectrometry	  results	  from	  myc-­‐Immunoprecipitation	  of	  ZC3H32.	  	  The	   control	   sample	   (boiled	   beads	   from	   the	   IP	   done	   with	   wild	   type	   cells)	   was	   labeled	   with	  formaldehyde	  (“light”	  labeling),	  the	  sample	  of	  the	  IP	  done	  with	  the	  ZC3H32-­‐myc	  cell	  line	  in	  the	  presence	  of	  RNAse	   Inhibitor	  (“Inh.”)	  with	  deuterated	   formaldehyde	  (“medium”)	  and	  sample	  of	  the	   IP	   done	   with	   the	   ZC3H32-­‐myc	   cell	   line	   in	   the	   presence	   of	   RNAseA	   was	   labeled	   with	  deuterated	  and	  13C	  containing	  formaldehyde	  (“heavy”).	  	  Numbers	  indicate	  the	  enrichment	  of	  the	  protein	  in	  the	  respective	  sample	  (“Inh.”/”medium”)	  or	  (“RNAse”/”heavy”)	  as	  compared	  to	  the	  control	  (“light”).	  300	  indicates	  the	  maximum	  measurable	  level.	  The	   colour	   coding	   indicates	   the	   enrichment.	   red:	  300	   (maximum);	  dark	  orange:	  300-­‐20;	  salmon:	  20-­‐10;	  light	  orange:	  10-­‐5;	  light	  yellow:	  5-­‐2;	  white:	  <2	  (not	  significant	  or	  not	  enriched).	  	  Candidates	  shown	  in	  bold	  were	  tested	  by	  Co-­‐IP	  (see	  fig.	  53).	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Fig.	  53:	  The	  mass	  spectrometry	  results	  could	  not	  be	  verified	  with	  Co-­‐
Immunoprecipiations	  *	  marks	  the	  antibody	  which	  was	  used	  for	  the	  precipitation	  (here:	  α-­‐myc,	  α-­‐myc	  beads	  were	  used	  in	  all	  three	  IPs).	  The	  antibody	   recognizing	   the	   tagged	  ZC3H32	   (which	   is	   either	  V5	  or	  myc-­‐tagged)	   is	  written	   in	  bold	  S9	  was	  used	  as	  negative	  control	  in	  all	  three	  IPs.	  	  A:	  myc-­‐IP	  with	  Tb927.7.2780-­‐myc	  and	  V5-­‐ZC3H32.	  B:	  myc-­‐IP	  with	  DRBD2-­‐myc	  and	  V5-­‐ZC3H32	  	  C:	  myc-­‐IP	  with	  ZC3H32-­‐myc	  and	  V5-­‐eIF4E-­‐IP	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3.3.15	  Testing	  ZC3H32-­‐RNA	  interaction	  by	  CLIP	  In	   order	   to	   test	   whether	   ZC3H32	   binds	   directly	   to	   RNA,	   a	   CLIP	   (Crosslinking	  Immunoprecipitation)	   was	   done	   using	   ZC3H32-­‐myc	   cells,	   wild	   type	   cells	   as	   negative	  control	   and	   UBP-­‐1-­‐myc	   cells	   as	   positive	   control.	   For	   this	   experiment,	   the	   cells	   were	  crosslinked	  twice	  with	  UV-­‐light	  (Stratalinker,	  4000),	  then	  harvested	  and	  stored	  in	  liquid	  nitrogen.	  The	  cells	  were	  lysed	  in	  a	  buffer	  containing	  0.5%	  IP-­‐40.	  Then,	  the	  RNA	  that	  was	  not	   bound	   to	   any	  protein,	  was	  digested	  with	  RNAseT1.	  The	   Immunoprecipitation	  was	  done	  using	  myc-­‐beads.	  After	  the	  IP,	  the	  RNA	  in	  the	  precipitates	  was	  labelled	  with	  γATP	  and	  the	  RNA-­‐protein	  complexes	  were	  separated	  on	  a	  NuPAGE	  Bis-­‐TRIS	  gel.	  The	  gel	  was	  then	  exposed	  using	  a	  Phosphoimager	  film	  (see	  fig.	  54	  A	  and	  C).	  	  	  On	  the	  gel	  of	  the	  first	  CLIP	  experiment,	  a	  huge	  band	  was	  seen	  for	  the	  positive	  control	  at	  approximately	   50kDa.	   UBP1	   has	   a	   size	   of	   24.3kDa	   (plus	   appr.	   2kDa	   for	   the	  myc-­‐tag),	  however,	  as	  this	  is	  an	  RNA-­‐protein	  complex,	  it	  is	  expected	  to	  run	  higher.	  The	  same	  was	  observed	  in	  the	  CLIP	  experiments	  done	  by	  B.	  Jha	  (Jha,	  Fadda	  et	  al.	  2014).	  	  	  A	  faint	  band	  was	  seen	  at	  100kDa	  in	  the	  ZC3H32-­‐precipitate.	  This	  could	  possibly	  be	  the	  band	   for	   the	   RNA-­‐protein	   complex,	   as	   ZC3H32	   has	   a	   size	   of	   72	   kDa,	   and	   a	   difference	  between	   the	   molecular	   weight	   of	   the	   protein	   and	   the	   protein-­‐RNA	   complex	   of	   appr.	  25kDa	  was	  also	  observed	  for	  UBP-­‐1.	  However,	  the	  same	  band	  was	  also	  observed	  in	  the	  positive	  control,	  meaning	  that	  it	  is	  probably	  a	  contamination.	  	  The	  experiment	  was	  repeated	  twice,	  however,	  in	  both	  repetitions	  no	  band	  was	  observed	  in	  the	  ZC3H32	  precipitate.	  	  These	  experiments	  show	  that,	  if	  ZC3H32	  interacts	  directly	  with	  the	  RNA,	  this	  interaction	  might	  be	  too	  transient	  to	  be	  observed	  using	  this	  method.	  Another	  possibility	  is	  that	  the	  RNA	  binding	  site	  might	  be	  too	  small	  to	  offer	  protection	  against	  RNAseT1.	  	  	  	  




Fig	  54:	  ZC3H32-­‐RNA	  interaction	  cannot	  be	  detected	  using	  iCLIP	  	  A:	  1st	  CLIP	  experiment,	  NuPAGE	  gel	  with	  γATP	  labeled	  RNA.	  B:	  Western	  blot	  with	  samples	  from	  1st	  CLIP.	  I:	  Input,	  U:	  unbound,	  beads:	  protein	  bound	  to	  the	  beads.	  ZC3H32	  was	  pulled	  down	  using	  myc-­‐beads.	  C	  and	  D:	  2nd	  CLIP	  experiment,	  NuPAGE	  gel	  and	  Western	  blot	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4.	  Discussion	  
4.1	  Mass	  Spectrometry	  of	  free	  and	  membrane	  bound	  polyribosomes	  In	   order	   to	   determine	   the	   function	   of	   a	   putative	   RNA	   binding	   protein,	   polyribosome	  association	  is	  an	  important	  indication,	  especially	  if	  the	  candidate	  protein	  is	  supposed	  to	  be	   stabilizing	   its	   target	   RNAs.	   However,	   sucrose	   gradient	   centrifugation,	   followed	   by	  fractionation,	   has	   one	   big	   disadvantage:	   abundant	   proteins,	   like	   trypanothione	  reductase,	   trail	   down	   the	   gradient,	   which	   leads	   to	   false	   positives.	   This	   fact	   makes	   it	  difficult	   to	   determine	   whether	   an	   RNA	   binding	   protein	   really	   associates	   with	  polyribosomes,	  especially	  if	  this	  protein	  is	  abundant	  and/or	  has	  only	  a	  few	  RNA	  targets.	  Non-­‐abundant	   proteins	  might	   not	   be	   visible	   on	   a	  Western	   blot	   or	   detectable	   by	  mass	  spectrometry.	  	  Therefore,	  in	  order	  to	  test	  on	  a	  large	  scale	  which	  of	  the	  putative	  RNA	  binding	  proteins	  in	  
T.	  brucei	  genuinely	  bind	  to	  RNA,	  other	  methods	  might	  be	  better.	  One	  alternative	  method	  would	  be	  a	  precipitation	  with	  oligo-­‐dT	  beads.	  	  	  Also,	  it	  is	  very	  likely	  that	  the	  majority	  of	  RNA	  binding	  proteins	  is	  present	  in	  abundance,	  as	   it	   is	   the	   case	   for	   PABP	   (Gorlach,	   Burd	   et	   al.	   1994).	   This	   is	   a	   problem	   when	  polyribosome	  association	  is	  tested	  by	  Western	  blot.	  Because,	  if	  a	  protein	  is	  present	  with	  1x105	   copies/cell	   and	   would	   bind	   5%	   of	   the	   cells	   total	   mRNA,	   only	   1%	   of	   the	   total	  protein	   pool	   would	   be	   bound	   to	   RNA,	   while	   99%	   would	   be	   unbound	   and	   thus	   not	  associated	  with	  polyribosomes	  (for	  calculation	  see	  3.1.6).	  	  Also,	   an	   RNA	   binding	   protein’s	   association	   with	   its	   target	   RNAs	   could	   be	   transient,	  especially	   if	   its	   role	   destabilizing.	   This	   might	   be	   the	   case	   for	   ZC3H32	   or	   PUF2.	   A	  transient	  interaction	  would	  lead	  to	  a	  larger	  percentage	  of	  unbound	  protein	  and	  decrease	  the	  chance	  to	  proof	  a	  polyribosome	  association.	  	  Therefore,	  sucrose	  gradient	  centrifugation,	  whether	   followed	  by	  mass	  spectrometry	  or	  Western	   blotting,	   is	   still	   more	   suitable	   to	   determine	   the	   polyribosome	   association	   of	  more	  common	  RNA	  regulators,	   like	  PABP,	  DHH1	  and	  MKT1,	  than	  of	  more	  specific	  RNA	  binding	  proteins.	  	  Another	  problem	   is	   that	   the	  mass	   spectrometry	  data	   contains	  not	  only	   false	  positives,	  but	   also	   false	   negatives.	   For	   example,	   the	   translation	   initiation	   factor	   eIF4G3	  was	   not	  found	   in	   the	  mass	   spectrometry	   results	   of	   the	   bloodstream	   free	   polyribosomes,	  while	  eIF4G4	  was	  not	  found	  in	  the	  results	  of	  the	  membrane-­‐bound	  polyribosomes.	  However,	  Western	  blots	   from	  different	  gradients	   showed	   that	   these	   two	  proteins	  are	  present	   in	  both	  free	  and	  membrane-­‐bound	  polyribosomes	  to	  the	  same	  extent	  (see	  figure	  17).	  	  However,	   the	   obtained	   data	   gives	   an	   indication	   whether	   a	   protein	   is	   associated	   with	  polyribosomes	  or	  not.	  If	  the	  candidate	  protein	  in	  question	  is	  not	  very	  abundant	  but	  still	  found	   in	   the	   mass	   spectrometry	   results	   the	   polyribosome	   association	   is	   likely	   to	   be	  genuine.	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Also,	  a	  protein	  found	  in	  more	  than	  one	  of	  the	  mass	  spectrometry	  results	  is	  very	  likely	  to	  be	  a	  candidate:	  the	  five	  RNA	  binding	  proteins	  that	  were	  present	  in	  three	  of	  the	  five	  mass	  spectrometry	   data	   sets	   were	   all	   proven	   to	   be	   polyribosome	   associated.	   For	   DRBD3,	  however,	   crosslinking	   the	   cells	   is	   necessary	   in	   order	   to	   detect	   this	   protein	   in	   the	  polyribosomes.	  Thus,	  the	  data	  is	  still	  useful,	  especially	  in	  combination	  with	  the	  data	  obtained	  by	  other	  screens,	  e.g.	  the	  tethering	  screen	  developed	  by	  E.	  Erben.	  This	  screen	  gives	  an	  indication	  whether	  a	  protein	  is	  stabilizing	  or	  destabilizing	  mRNAs.	  If	  an	  RNA	  binding	  protein	  is	  found	  in	  my	  mass	  spectrometry	  results	  and	  is	  identified	  as	  stabilizing	   by	   the	   tethering	   screen,	   this	   information	   would	   strongly	   suggest	   that	   the	  protein	  is	  associated	  with	  polyribosomes	  and	  stabilizes	  its	  targets.	  
4.2	  VSG	  mRNP	  pull	  down	  	  I	  tried	  to	  isolating	  the	  VSG	  mRNP	  by	  first	  isolation	  polyribosomes	  and	  then	  pulling	  down	  the	   mRNP	   via	   the	   nascent	   polypeptide	   using	   Protein	   A	   beads	   and	   a	   VSG	   antibody.	  However,	  this	  did	  not	  work,	  the	  VSG	  mRNA	  was	  not	  enriched	  on	  the	  beads.	  	  If	   this	  method	   is	   repeated,	   the	   first	   thing	  needed	   is	  a	   cell	   line	   that	  expresses	  a	  certain	  VSG	  variant	  under	  drug	  control.	  This	  can	  be	  achieved	  with	  the	  Mark	  Carrington	  vector	  3850	  (pHD	  2606)	  or	  a	  completely	  new	  construct.	   	  Otherwise,	  the	  efficiency	  of	  the	  pull-­‐down	  cannot	  be	  tested	  by	  Northern	  blot,	  which	  makes	  it	   impossible	  to	  adjust	  the	  pull-­‐down	   conditions.	   However,	   there	   are	   several	   problems	   that	   remain:	   the	   procedure	  remains	   lengthy,	  which	   can	   lead	   to	  RNA	  binding	  proteins	   falling	  of	   the	  VSG	  RNA.	  This	  could	  be	  prevented,	  or	  at	  least,	  decreased,	  by	  UV-­‐crosslinking.	  	  A	  more	  important	  problem	  is	  the	  mature	  VSG	  protein.	  As	  already	  mentioned,	  abundant	  proteins	  trail	  down	  the	  gradient,	  VSG	  being	  no	  exception.	  The	  mature	  VSG	  can	  block	  the	  antibody	  and	  thus	  prevent	  the	  nascent	  polypeptide	  from	  binding.	  It	  is	  not	  unlikely	  that	  the	  mature	  protein	  binds	  the	  antibody	  with	  higher	  affinity	  than	  the	  nascent	  polypeptide.	  While	   it	   is	   surely	   possible	   to	   get	   rid	   of	   some	   of	   the	  mature	   VSG,	   e.g.	   by	   adding	   GLP-­‐transaminases	  to	  the	  cells	  prior	  to	  lysis,	   it	   is	  unlikely	  that	  all	  of	  the	  mature	  VSG	  can	  be	  removed	   from	  the	   IP.	  This	  would	   increase	   the	  amount	  of	  antibodies	  and	  poly-­‐A	  beads	  needed	  for	  the	  IP,	  which	  in	  turn	  would	  lead	  to	  a	  higher	  background.	  	  The	   high	   background	   is	   another	   problem:	   while	   it	   is	   possible	   to	   decrease	   the	  background,	  e.g.	  by	  blocking	  the	  beads	  and	  washing	  the	  IP	  stringently,	  a	  negative	  control	  is	   still	   necessary	   in	   order	   to	   sort	   out	   proteins	   that	   bind	   unspecifically	   to	   the	   beads.	  Especially	   if	   quantitative	   mass	   spectrometry	   is	   chosen	   for	   protein	   identification,	   an	  appropriate	  negative	  control	  is	  crucial.	  	  Empty	  beads	  are	  not	  suitable,	  as	  this	  would	  not	  sort	  out	  proteins	  binding	  unspecifically	  to	  the	  VSG	  antibody.	  It	  might	  be	  possible	  to	  use	  another	  antibody	  as	  a	  control,	  e.g.	  anti-­‐tubulin.	  However,	  this	  would	  pull	  down	  tubulin	  mRNPs	  and	  that	  would	  be	  a	  completely	  different	  IP,	  with	  completely	  different	  results.	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Using	   a	   cell	   line	   expressing	   another	   VSG,	   e.g.	   a	   VSG222	   cell	   line	   for	   the	   VSG118	   pull	  down,	  is	  also	  not	  an	  option,	  as	  it	  is	  likely	  that	  an	  antibody	  against	  one	  VSG	  binds	  another	  VSG	  variant	  as	  well.	  	  Therefore,	   it	   should	   be	   considered	   to	   use	   a	   different	   approach	   before	   working	   on	  adjusting	   this	   method.	   An	   alternative	   would	   be	   the	   method	   developed	   by	   D.	  Inchaustegui,	  in	  which	  the	  3’UTR	  of	  the	  protein	  of	  interest	  is	  cloned	  behind	  the	  CAT	  ORF,	  which	   carries	   three	   tags,	   with	   eight	   streptavidin	   binding	   peptides	   each,	   on	   its	   N-­‐terminus.	  	  In	   order	   to	   get	   rid	   of	   the	   mature	   protein,	   the	   immunoprecipitation	   is	   done	   with	   the	  polyribosomal	   fractions,	   using	   anti-­‐streptavidin	   beads,	   which	   bind	   to	   the	   nascent	  polypeptide.	   As	   the	   streptavidin	   binding	   peptides	   are	   on	   the	   N-­‐terminus,	   they	   are	  translated	   first	   and	   thus	   it	   is	   assured	   that	   the	   nascent	   polypeptide	   can	   bind	   to	   the	  streptavidin	  beads.	  	  It	   has	   already	   been	   shown	   that	   a	   97nt	   long	   sequence	   at	   the	   3’	   end	   of	   the	  VSG	  mRNA	  (containing	   the	   last	  10	  codons	  of	   the	  VSG	  ORF	  and	   the	  3’UTR)	  can	  stabilize	  a	   reporter	  RNA	  in	  the	  bloodstream	  form	  (Berberof,	  Vanhamme	  et	  al.	  1995).	  A	  conserved	  8mer	  and	  a	  conserved	  14mer	  have	  shown	  to	  be	  important	  for	  the	  stage-­‐specific	  regulation.	  	  Knowing	   this,	   two	   constructs	   could	   be	   made:	   One	   construct	   containing	   the	   entire	  sequence	  and	  a	  control	  construct,	  which	  does	  not	  contain	  the	  14mer	  and	  the	  8mer.	  The	  first	  construct	  should	  be	  stabilized	  in	  the	  bloodstream	  form	  and	  destabilized	  in	  the	  procyclic	   form,	  while,	  according	   to	   the	  result	  of	   (Berberof,	  Vanhamme	  et	  al.	  1995)	   the	  second	  one	  should	  show	  no	  stage-­‐specific	  regulation.	  A	  CAT	  assay	  can	  be	  used	  to	  verify	  that.	  	  This	  approach	  would	  have	  several	  advantages	  over	  the	  method	  I	  tried	  to	  develop:	  	  For	   once,	   this	   method	   is	   already	   developed	   and	   has	   been	   applied	   successfully	   by	   D.	  Inchaustegui.	  Secondly,	  with	  deleting	  the	  conserved	  regions,	  a	  suitable	  control	  construct	  can	  be	  made.	  If	  this	  does	  not	  work,	  a	  control	  construct	  without	  the	  streptavidin	  tags	  can	  be	  made.	  Thirdly,	   the	  CAT	   construct	   is	   inducible.	  This	  means,	   if	   the	   expression	   is	  not	   leaky,	   the	  cells	  can	  be	  harvested	  a	  few	  hours	  after	  induction,	  which	  would	  mean	  lower	  levels	  of	  the	  mature	  protein.	  A	  CAT	  assay	  can	  be	  used	  to	  determine	  how	  long	  it	  takes	  for	  the	  protein	  to	  be	  induced.	  A	  Northern	  blot	  of	  the	  polyribosomes	  can	  determine	  when	  the	  CAT	  RNA	  is	  translated.	   Thus,	   the	   ideal	   harvest	   time	   can	   be	   determined,	   at	   which	   the	   CAT	   RNA	   is	  already	  being	  translated,	  while	   there	   is	  still	  a	   low	  level	  of	  CAT	  protein.	  But	  even	   if	   the	  expression	  of	  the	  CAT	  construct	  were	  leaky	  the	  levels	  of	  the	  mature	  protein	  would	  still	  be	  lower	  than	  the	  levels	  of	  mature	  VSG.	  	  Thus,	  this	  method	  would	  probably	  be	  a	  better	  approach	  in	  order	  to	  find	  proteins	  binding	  to	  the	  VSG	  3’UTR.	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4.3	  The	  role	  of	  ZC3H32	  	  	  
4.3.1	  ZC3H32	  is	  a	  putative	  destabilizing	  C3H	  zinc	  finger	  protein	  Tethering	  of	  ZC3H32	   to	  a	   reporter	  RNA	   leads	   to	   the	  RNA’s	  degradation.	  This	   suggests	  that	  ZC3H32	  destabilizes	  its	  targets.	  	  Tethering	  of	  different	  ZC3H32	   fragments	  showed	   that	   the	   first	  145,	  as	  well	  as	   the	   last	  293	  amino	  acids	  are	  sufficient	  to	  decrease	  the	  levels	  of	  the	  CAT	  reporter.	  This	  suggests	  that	   at	   least	   one	   of	   these	   domains	   is	   responsible	   for	   the	   RNA	   degrading	   activity.	   The	  putative	   MKT1	   binding	   motif,	   the	   HNPY	   motif,	   which	   is	   found	   at	   position	   538	   (117	  amino	  acids	  away	  from	  the	  C-­‐terminus),	  seems	  to	  be	  necessary	  for	  the	  activity	  of	  the	  C-­‐terminal	  fragment.	  This	  indicates	  that	  MKT1	  plays	  a	  role	  in	  the	  activity	  of	  ZC3H32.	  	  The	  middle	   part	   of	   the	   protein	   shows	  no	   activity	   in	   the	   tethering	   screen.	   As	   this	   part	  contains	  the	  three	  zinc	  fingers,	  it	  is	  very	  likely	  that	  it	  is	  responsible	  for	  the	  binding	  to	  the	  RNA	  targets,	  while	  either	  the	  N-­‐	  or	  the	  C-­‐terminal	  part	  (or	  both)	  are	  responsible	  for	  the	  target’s	  degradation.	  	  Tethering	   of	   λN-­‐ZC3H32-­‐myc	   also	   decreased	   the	   translation	   of	   the	   CAT	   RNA:	   After	  induction	  of	  λN-­‐ZC3H32-­‐myc,	   the	  CAT	  RNA	  with	   the	  BoxB,	  which	   the	  λN-­‐ZC3H32-­‐myc	  fusion	  protein	  binds	  to,	  tended	  localize	  to	  the	  lower	  polyribosomal	  fractions,	  as	  well	  as	  the	  pre-­‐ribosomal	  fractions.	  CAT	  RNA	  without	  the	  BoxB,	  on	  the	  other	  hand,	  was	  mostly	  found	  in	  the	  high	  polyribosome	  fraction.	  Thus,	  when	  ZC3H32	  is	  tethered	  to	  the	  CAT	  RNA,	  the	  CAT	  RNA	  is	  bound	  by	  fewer	  ribosomes.	  This	  indicates	  that,	  if	  ZC3H32	  interacts	  with	  an	  mRNA,	  this	  mRNA	  is	  translated	  less.	  	  These	   results	   suggest	   that	   ZC3H32	   might	   degrade	   RNA	   by	   relocating	   it	   from	   the	  polyribosomes,	  which	  subsequently	  leads	  to	  its	  degradation.	  	  	  
4.3.2	  Putative	  ZC3H32	  mRNA	  targets	  	  High-­‐throughput	   sequencing	   revealed	   20	   RNAs	   that	   are	   up-­‐regulated	   upon	   ZC3H32	  knock-­‐down	  (see	  3.3.11).	  As	  ZC3H32	  is	  very	  likely	  a	  destabilizing	  RNA	  binding	  proteins	  these	  mRNAs	  are	  putative	  ZC3H32	  targets.	  The	  majority	  of	  these	  mRNAs	  show	  stage-­‐specific	  regulation,	  15	  out	  of	  these	  20	  are	  up-­‐regulated	   in	   the	   procyclic	   form	   (Fadda,	   Ryten	   et	   al.	   2014),	  while	   3	  more	   of	   them	   are	  slightly	  up-­‐regulated	  (less	  than	  two	  fold	  but	  more	  than	  1.5	  fold).	  This	  upregulation	  was	  confirmed	  for	  five	  proteins	  (see	  fig.	  48	  and	  49).	  	  Opposite	   to	   these	   20	   mRNAs,	   the	   RNA	   levels	   of	   ZC3H32	   are	   up-­‐regulated	   in	   the	  bloodstream	   form,	   suggesting	   that	   this	   protein	   is	   enriched	   in	   this	   life	   cycle	   stage	   (see	  3.3.1).	   ZC3H32	   is	   essential	   for	   the	   survival	   of	   the	   bloodstream	   form	   of	   Trypanosoma	  
brucei,	  which	  was	   shown	  by	  both	  RNAi	   and	   knock-­‐out	   studies	   (3.5	   and	  3.6),	  while	   an	  RNAi	  screen	  indicated	  that	  this	  protein	  is	  not	  essential	  in	  procyclics	  (Alsford,	  Glover	  et	  al.	  2005).	  
	   4.	  Discussion	  
130	  
ZC3H32	  is	  up-­‐regulated	  and	  essential	  in	  the	  bloodstream	  form,	  while	  its	  putative	  targets	  are	  down-­‐regulated	  in	  this	  life	  cycle	  stage.	  Also,	  the	  tethering	  screen	  shows	  that	  ZC3H32	  can	   induce	   a	   reporter	   RNA’s	   degradation	   (see	   3.3.8	   –	   3.3.10).	   Together,	   these	   results	  suggest	  that	  ZC3H32	  might	  be	  involved	  in	  the	  degradation	  of	  procyclic	  specific	  proteins.	  	  Moreover,	  12	  of	  the	  putative	  targets	  are	  involved	  in	  energy	  metabolism.	  Ten	  of	  them	  are	  found	  in	  the	  mitochondrion,	  two	  in	  the	  glycosomes.	  These	  proteins	  include	  enzymes	  of	  the	  TCA	  cycle	  as	  well	  as	  components	  of	  the	  respiratory	  chain,	  two	  pathways	  that	  are	  not	  active	   in	   the	   bloodstream	   form	   trypanosome.	   The	   glycosomal	   proteins	   (pyruvate	  phosphate	   dikinase	   and	   glycosomal	   malate	   dehydrogenase)	   are	   involved	   in	  glyconeogenesis	   and	   their	   protein	   levels	   are	   also	   down-­‐regulated	   in	   the	   bloodstream	  form	  (Urbaniak,	  Guther	  et	  al.	  2012),	  which	  is	  not	  surprising	  considering	  the	  high	  glucose	  level	  of	  the	  mammalian	  bloodstream.	  	  Out	   of	   the	   six	   tested	   candidates,	   five	   showed	  upregulation	   in	   upon	   ZC3H32	   reduction	  (either	  by	  RNAi	  or	  by	  stopping	  the	  expression	  of	  ZC3H32-­‐myc	  in	  the	  double	  knock-­‐out	  cell	  line).	  	  However,	   high-­‐throughput	   sequencing	   of	   RNAi	   cell	   lines	   has	   shown	   to	   have	   some	  drawbacks.	  For	  once,	   it	   remains	  unclear	  whether	   the	  observed	  upregulation	   is	   caused	  directly	  by	  ZC3H32,	  as	  many	  RNA	  binding	  proteins,	  for	  example	  PUF2,	  MKT1	  and	  XRNA,	  are	  down-­‐regulated	  upon	  ZC3H32	  RNAi	   induction.	  Thus,	   the	  stabilization	  of	   the	   target	  proteins	  could	  be	  caused	  by	  the	  absence	  of	  any	  of	  these	  proteins.	  	  Another	  problem,	  which	  has	  already	  been	  described	   in	  (Jha,	  Fadda	  et	  al.	  2014),	   is	   that	  the	  high-­‐throughput	   sequencing	   results	   of	  many	  RNAi	   cell	   lines	   (PUF2,	  MKT1,	  RRP45,	  CTR9,	  CAF1	  and	  ZC3H32)	  show	  a	  bias	  towards	  RNAs	  with	  short	  coding	  sequences.	  This	  means	   that	   RNAs	  with	   short	   coding	   sequences	   are	  more	   likely	   to	   be	   up-­‐regulated,	   as	  compared	  to	  the	  wild	  type,	  than	  RNAs	  with	  long	  coding	  sequences.	  	  This	  might	  be	  due	   to	   an	   effect	   on	   transcription,	   because,	   if	   transcription	  were	   slowed	  down,	   long	   RNAs	   would	   be	  more	   strongly	   affected	   than	   short	   ones,	   leading	   to	   lower	  levels	  of	  long	  RNAs	  (Jha,	  Fadda	  et	  al.	  2014).	  The	   correlation	   (0.42)	   between	   the	   ZC3H32	   sequencing	   result	   and	   the	   CDS	   length	  clearly	   shows	   that	   this	   effect	   also	   influences	   the	   ZC3H32	   sequencing	   result.	  However,	  out	   of	   the	   20	   up-­‐regulated	   RNAs	   only	   4	   have	   a	   short	   open	   reading	   frame	   (meaning	  coding	   sequences	   that	   are	   shorter	   than	   the	   coding	   sequences	   of	   three	   quarters	   of	   the	  sequenced	   mRNAs).	   Also,	   two	   of	   them	   are	   not	   up-­‐regulated	   in	   any	   of	   the	   other	  sequencing	  results	  (one	  encodes	  cytochrome	  c	  oxidase	  assembly	  protein	  and	  the	  other	  one	  a	  hypothetical	  protein),	  which	  does	  not	  suggest	  an	  unspecific	  upregulation,	  despite	  their	  short	   length.	  The	  other	  two,	  however,	  are	  up-­‐regulated	  in	  other	  data	  sets	  as	  well	  and	  are	  probably	  false	  positives.	  Another	   problem	   is	   the	   stress	   response,	   as	   some	   RNAs	   could	   simply	   be	   up-­‐regulated	  because	   the	   cell	   is	   stressed.	   The	   samples	   were	   collected	   after	   24	   hours	   of	   induction.	  After	  this	  time,	  the	  growth	  of	  the	  cells	  has	  already	  been	  arrested.	  However,	  in	  order	  to	  see	   when	   this	   effect	   occurs,	   RNA	   was	   collected	   at	   earlier	   timepoints	   as	   well	   and	   the	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levels	  of	   three	  candidates	  were	   tested	  by	  Northern	  blotting	   (see	  3.3.12,	   fig.	  48).	  While	  the	   RNA	   of	   glycosomal	   malate	   dehydrogenase	   (gMDH)	   was	   up-­‐regulated	   after	   eight	  hours,	   the	   RNA	   levels	   of	   isocitrate	   dehydrogenase	   (IDH)	   and	   succinyl-­‐CoA	   synthetase	  (SCS)	  were	  already	  up-­‐regulated	  after	   four	  and,	  respectively,	   two	  hours.	  This	   indicates	  that	   these	   RNAs	   are	   not	   up-­‐regulated	   because	   the	   cell	   is	   stressed.	   Also,	   although	   the	  high-­‐throughput	   sequencing	   results	   show	   that	   the	   mRNA	   of	   pyruvate	   dehydrogenase	  (PDH)	  seems	  to	  be	  up-­‐regulated	  upon	  PUF2	  knock-­‐down,	  IDH	  seems	  to	  be	  up-­‐regulated	  in	   the	  MKT1	  RNAi	  cell	   line	  and	  SCS	  is	  up-­‐regulated	   in	  both	   the	  PUF2	  and	  RRP45	  RNAi	  cell	  line,	  none	  of	  the	  tested	  RNAs	  a	  generally	  up-­‐regulated	  in	  RNAi	  cell	  lines.	  	  Whether	  the	  stabilization	  of	  these	  RNAs	  is	  caused	  by	  a	  direct	  interaction	  with	  ZC3H32	  or	  by	  an	   indirect	  effect	   is	  unclear.	   It	  was	  not	  possible	   to	  show	  whether	  ZC3H32	   interacts	  with	  RNA	  by	  CLIP	  (see	  3.3.14,	  fig.	  52),	  probably	  because	  this	  RNA	  destabilizes	  its	  targets.	  Thus,	   any	   interaction	  would	   be	   rather	   short.	   This	  makes	   it	   very	   hard	   to	   determine	   a	  direct	   interaction.	   Another	   problem	   is	   that	   the	   RNA	   levels	   of	   the	   putative	   candidate	  genes	  in	  the	  bloodstream	  forms	  are	  rather	  low.	  I	  made	  an	  Immunoprecipitation	  with	  UV-­‐crosslinked	   ZC3H32-­‐myc	   cells	   and	   myc-­‐beads,	   followed	   by	   Northern	   and	   Western	  blotting.	  While	   the	  Western	  blot	   showed	   that	   the	   IP	  worked	  well,	   the	   candidate	  RNAs	  (PPDK,	  PDH	  and	  gMDH)	  could	  not	  be	  detected	  in	  the	  pellet	  and	  also	  the	  signals	  from	  the	  input	  and	  the	  supernatant	  were	  not	  very	  strong	  (results	  not	  shown),	  suggesting	  that	  this	  approach	  is	  not	  very	  likely	  to	  succeed.	  	  Another	  possibility	  would	  be	  to	  repeat	  the	  sequencing	  of	  the	  procyclic	  ZC3H32-­‐myc	  cell	  line,	   in	  which	  ZC3H32	   is	   overexpressed.	  The	  main	  advantage	  of	   this	   cell	   line	   is	   that	   it	  shows	  no	  growth	  defect.	  Also,	  the	  sequencing	  results	  did	  not	  correlate	  with	  the	  length	  of	  the	  coding	  sequence,	  showing	  that	  this	  side	  effect	  is	  irrelevant	  in	  this	  case.	  The	  problem	  is	  that	  the	  overexpression	  in	  procyclic	  cells	  did	  not	  cause	  an	  opposite	  effect	  as	  compared	  to	  the	  ZC3H32	  knock-­‐down	  in	  the	  bloodstream	  form:	  While	  the	  results	  did	  not	   correlate,	   they	   are	   also	   not	   opposite	   (R	   is	   approximately	   0).	   Also,	   only	   one	   of	   the	  putative	   ZC3H32	   targets	   seemed	   to	   be	   destabilized	   upon	   ZC3H32	   overexpression	   in	  procyclics.	   As	   already	   mentioned,	   ZC3H32	   overexpression	   does	   not	   cause	   a	   growth	  defect	   in	   procyclics.	   Together,	   these	   results	   suggest	   that	   the	   influence	   of	   ZC3H32	   is	  limited	   in	   the	  procyclic	   form.	  This	  might	  be	  caused	  by	   the	  presence	  other	   trans-­‐acting	  factors	   in	   this	   life	   cycle	   stage,	  which	  prevent	   ZC3H32	   from	  binding.	   It	   is	   also	  possible	  that	  ZC3H32	  needs	  one	  or	  more	  other	  proteins	  to	  function,	  which	  might	  not	  be	  present	  in	  this	  life	  cycle	  stage.	  	  Thus,	   a	   repetition	   of	   the	   high-­‐throughput	   sequencing	   of	   the	   procyclic	   overexpression	  cell	   line	   might	   only	   give	   limited	   information	   about	   the	   role	   of	   this	   protein	   in	   the	  bloodstream	  form.	  	  Another	  approach	  to	  further	  characterize	  the	  effect	  of	  ZC3H32	  on	  these	  proteins	  would	  be	   to	   test	  whether	   their	   translation	   is	   affected	  by	  ZC3H32	  knock-­‐down.	  This	   could	  be	  done	  by	   inducing	   the	  RNAi	  cell	   line	   for	  a	  short	   time,	  make	  a	  polyribosome	  profile	  and	  check	  whether	   the	   translation	  of	   the	   candidate	  RNAs	   increases	  as	   compared	   to	  a	  wild	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type	   cell	   line.	   The	   induction	   time	   should	   just	   be	   long	   enough	   to	   ensure	   a	   significant	  decrease	   in	   ZC3H32	   protein	   levels	   but	   also	   not	   too	   long,	   so	   that	   the	   cells	   are	   still	   be	  growing.	   The	   same	   experiment	   can	   also	   be	   done	  using	   the	   double	   knock-­‐out	   cell	   line,	  this	  would	   have	   the	   advantage	   that	   each	   result	   would	   be	   verified	   using	   a	   completely	  different	  cell	  line.	  What	  is	  more,	  this	  would	  rule	  out	  any	  side	  effect	  caused	  by	  unspecific	  RNAi	  targets.	  While	  this	  would	  still	  not	  prove	  beyond	  doubt	  that	  an	  interaction	  with	  ZC3H32	  causes	  the	   stabilization	   of	   these	   candidate	   RNAs,	   this	   experiment	  might	   at	   least	   support	   the	  results	   of	   the	   tethering	   assay,	  which	   showed	   that	   ZC3H32	   can	   lower	   the	   translational	  efficiency	  of	  a	  reporter	  RNA.	  It	   is	   also	   possible	   to	   do	   high-­‐throughput	   sequencing	   of	   the	   low	   ribosomal	   fractions	  (monosomes	   and	   up	   to	   4	   ribosomes)	   and	   the	   high	   polyribosomal	   fractions	   using	   the	  RNAi	  or	  the	  knock-­‐out	  cell	  lines.	  This	  would	  show	  which	  RNAs	  are	  translated	  with	  low	  efficiency	   (low	   ribosomal	   fractions)	   and	   which	   one	   with	   a	   high	   efficiency	   (high	  ribosomal	  fractions).	  Comparison	  with	  a	  the	  sequencing	  results	  from	  the	  same	  fractions	  made	  using	  wild	  type	  cells	  would	  then	  tell	  us	  for	  which	  mRNAs	  the	  translation	  efficiency	  changes	  upon	  ZC3H32	  knock-­‐down.	  	  
4.3.3	  Interaction	  partners	  of	  ZC3H32	  	  It	  was	  already	  suggested	  by	  a	  yeast-­‐two	  hybrid	  screen,	  as	  well	  as	  a	  TAP-­‐purification,	  that	  ZC3H32	  interacts	  with	  MKT1	  (Singh,	  Minia	  et	  al.	  2014).	  This	  interaction	  was	  confirmed	  by	   Co-­‐Immunprecipitation	   (see	   3.3.4,	   fig.	   34).	   However,	   only	   a	   small	   fraction	   of	   the	  ZC3H32	  pool	  seems	  to	  interact	  with	  MKT1.	  A	  Co-­‐IP	  in	  the	  presence	  of	  RNAseA	  showed	  that	  this	  interaction	  is	  not	  dependent	  on	  RNA	  binding.	  This	  also	  shows	  that	  ZC3H32	  and	  MKT1	  really	  interact	  and	  not	  just	  bind	  to	  different	  binding	  sites	  of	  the	  same	  mRNAs.	  An	   interaction	   between	   ZC3H32	   and	  members	   of	   the	   degradation	  machinery	   (CAF40,	  XRNA,	   RRP45,	   NOT2,	   CAF1)	   could	   not	   be	   confirmed.	   A	   yeast-­‐two-­‐hybrid	   screen	  suggested	   that	   MKT1	   interacts	   with	   NOT2,	   a	   member	   of	   the	   CAF-­‐NOT	   deadenylase	  complex	   (Singh,	   Minia	   et	   al.	   2014).	   This	   interaction	   could	   not	   be	   confirmed	   by	   co-­‐immunoprecipitation	  as	  well.	  A	  possible	  reason	  might	  be	  that	  these	  interactions	  are	  too	  transient	  to	  be	  observed	  by	  these	  methods.	  Thus,	  it	  stays	  unclear	  how	  ZC3H32	  degrades	  its	  target	  RNAs.	  	  There	   are	   two	  methods	   that	   can	  be	  used	   to	  determine	  ZC3H32’s	   interaction	  partners.	  One	  would	  be	  a	  yeast-­‐two-­‐hybrid	  screen.	  This	  method	  has	  the	  disadvantage	  that	  it	  has	  a	  high	   rate	   of	   false	   positives.	   Another	   possibility	   is	   a	   pull-­‐down	   followed	   by	   mass	  spectrometry.	   This	   was	   already	   tried	   (see	   3.3.14)	   but	   without	   success.	   One	   possible	  reason	  is	  that	  the	  quantitative	  mass	  spectrometry	  failed.	  Maybe	  	  too	  much	  material	  was	  given	  for	  the	  analysis	  and	  only	  very	  abundant	  proteins	  were	  detected.	  Another	  possible	  reason	  might	  have	  been	  that	  the	  myc-­‐tag	  purification	  was	  only	  a	  one-­‐step	  purification.	  Thus,	   the	  background	  might	  have	  been	  too	  high.	   If	   this	  experiment	   is	  repeated,	  a	   two-­‐step	  purification,	  using	  a	  TAP-­‐tag	  for	  example,	  might	  be	  better.	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Once	   the	   interaction	   partners	   are	   known,	   it	   might	   be	   possible	   to	   deduct	   a	   possible	  mechanism	  for	  this	  RNA	  binding	  protein.	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found in 1st MS 
results? 




spec pc total  pc bs 
Protein name 
Accession 
numbers function free mb free mb   free mb free 
S-adenosylhomocysteine hydrolase Tb11.01.1350 
AA meta-
bolism 5   17 1 23 1     
heat shock protein HSP70 Tb927.10.12710 CHAP 8   23   31     1 
heat shock protein HSP70 Tb927.7.710 CHAP 4 5 12   21       
chaperone protein DNAj Tb927.2.5160 CHAP 4 7 2   13       
lipid metabolisim putative prefoldin Tb11.52.0006 CHAP   11     11       
heat shock protein HSP78 Tb927.2.3030 CHAP   4 4   8       
heat shock protein HSP84 Tb11.02.0250 CHAP   5 2   7     1 
 similarity to p23 (Hsp90 co-chaperone) Tb09.211.1690 CHAP 2 2     4     1 
chaperone protein DNAj Tb11.01.8480 CHAP   4     4       
heat shock protein HSP100 Tb927.2.5980 CHAP   4     4       
chaperone protein DNA Tb927.10.6610 CHAP   2     2       
heat shock protein HSP70 Tb09.211.1390 CHAP   2     2       
heat shock protein HSP70 Tb09.160.3090 CHAP   2     2       
chaperone protein DNAj Tb11.03.0110 CHAP   1     1       
heat shock protein binding, DnaJ Tb927.10.14740 CHAP   1     1       
heat shock protein HSP20 Tb927.7.4290 CHAP   1     1       
syntaxin Tb09.160.2420 CHAP   1     1       
co-chaperone GrpE Tb927.6.2170 CHAP 1       1       
stress-induced protein sti1 Tb927.5.2940 CHAP 1       1       
heat shock protein HSP70 Tb11.01.3110 CHAP 27 23 35 11 96       
heat shock protein HSP90 Tb927.10.10890 CHAP 19 13 26 4 62       
protein disulfide isomerase Tb927.10.8230 CHAP 12 5 5 1 23       
histone H2B Tb927.10.10460 Chromatin 6 3 6 5 20       
histone H4 Tb927.5.4170 Chromatin 4 4 4 4 16       
2-oxoglutarate dehydrogenase E2  Tb11.01.3550 TCA 4 3 10 2 19       
no domains FL-CYSK-MEMB Tb11.02.0210 CYSKEL 14 12     26       
C-terminal motor kinesin Tb927.10.14890 CYSKEL 7 15     22       
Ca-dependent membrane targeting 
domain Tb927.4.2080 CYSKEL   16     16       
stomatin-like protein Tb927.5.520 CYSKEL 2 13     15       
paraflagellar rod component Tb11.01.5100 CYSKEL 4 10     14       
putative leucine rich repeat, outer arm 
dynein light chain 1 domain Tb11.01.8770 CYSKEL   1 11 1 13       
flagellar calcium-binding protein, 
calflagin Tb927.8.5460 CYSKEL 1 12     13       
microtubule-associated protein 2 Tb10.v4.0052 CYSKEL 8 5     13       
actin A  Tb09.211.0620 CYSKEL 5 5     10       
microtubule TRAF3 and DISC1 binding 
protein,  Tb927.10.450 CYSKEL 3 7     10       
cytoskeleton-associated protein CAP5.5 Tb927.4.3950 CYSKEL     8 2 10       
intraflagellar transport protein IFT81 Tb927.10.2640 CYSKEL   10     10       
flagellar transport protein Tb927.3.1110 CYSKEL 2 6     8       
paraflagellar rod component Tb927.8.6660 CYSKEL 2 6     8       
intraflagellar transport protein-like 
protein Tb927.7.3370 CYSKEL 4 3     7       
73 kDa paraflagellar rod protein,PFR1 Tb927.3.4290 CYSKEL 3 1 2   6       
intraflagellar transport complex B protein 
46 Ce Tb927.6.3100 CYSKEL 2 4     6       
Cytoskeletal protein with EF hand Tb927.7.3440 CYSKEL 2 2     4       
dynein light intermediate chain D1bLIC Tb11.01.8570 CYSKEL 2 2     4       
kinesin Tb927.8.4950 CYSKEL     4   4       
microtubule-associated protein Tb927.10.10280 CYSKEL     4   4       
intraflagellar transport protein IFT52 Tb927.10.14980 CYSKEL 1 2     3       
flagellum-adhesion glycoprotein Tb927.8.4060 CYSKEL   3     3       
trypanosoma specific. plasma 
membrane and cytoskeleton. no Tb927.3.1010 CYSKEL   3     3       
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domains 
flagellar attachment zone protein Tb927.4.3740 CYSKEL     3   3       
kinesin Tb927.8.2630 CYSKEL   2     2       
paraflagellar rod protein Tb11.01.6740 CYSKEL   2     2       
intraflagellar transport protein 
IFT55/IFT57 Tb927.10.11310 CYSKEL 2       2       
intraflagellar transport protein, Member 
of IFT complex A Tb09.160.5670 CYSKEL     2   2       
69 kDa paraflagellar rod protein,PFR2 Tb927.8.4970 CYSKEL   1     1       
BILBO1 flagellar protein essential for 
flagellar pocket biogenesis Tb11.01.3960 CYSKEL   1     1       
homology to vacuolar proteins Tb927.10.14320 CYSKEL   1     1       
Cytoskel. Fraction, flagellum Tb927.8.6920 CYSKEL   1     1       
intraflagellar transport protein IFT88 Tb11.55.0006 CYSKEL   1     1       
MORN repeat-containing 
protein,flagellar component Tb927.6.4670 CYSKEL   1     1       
Prefoldin domain, spectrin repeat, CYSK 
proteome Tb927.4.5340 CYSKEL   1     1       
dynein heavy chain Tb927.10.5350 CYSKEL 1       1       
beta tubulin Tb927.1.2330 CYSKEL 20 26 23 11 80       
alpha tubulin Tb927.1.2340 CYSKEL 18 20 18 7 63       
delta-1-pyrroline-5-carboxylate 
dehydrogenase Tb927.10.3210 ENZ 15   19 4 38       
aminopeptidase, putative,metallo-
peptidase, Clan MA(E) Family M1 Tb11.02.1070 ENZ     23   23       
Five SET domains - protein lysyl 
methyltransferase? Tb09.211.1620 ENZ     21   21       
calpain-like cysteine peptidase Tb927.8.8330 ENZ 4 13     17       
carboxypeptidase Tb11.02.0100 ENZ 2   14   16       
lipophosphoglycan biosynthetic protein,  
HSP90 Tb927.3.3580 ENZ 3 9 2   14       
cytosolic leucyl aminopeptidase Tb927.8.3060 ENZ 5   9   14       
aspartyl aminopeptidase Tb927.3.3410 ENZ 5   8   13       
prolyl oligopeptidase, putative,serine 
peptidase clan SC, family S9A Tb927.10.8020 ENZ     13   13       
dihydrolipoamide acetyltransferase E2 
subunit Tb927.10.7570 ENZ 4   8   12       
acidic phosphatase Tb927.5.630 ENZ 6 5     11       
phosphoglycerate kinase Tb927.1.710 ENZ     11   11       
tryparedoxin peroxidase Tb09.160.4250 ENZ 3   5 2 10       
tryparedoxin peroxidase Tb09.160.4280 ENZ 5 5     10       
cytosolic malate dehydrogenas Tb11.01.3040 ENZ 3 2 4   9       
nucleoside hydrolase Tb927.7.4570 ENZ 3 1 5   9       
cystathione gamma lyase Tb09.211.3330 ENZ     8   8 1     
trypanothione reductase Tb927.10.10390 ENZ 1   8   9       
arginine kinase Tb09.160.4590 ENZ     9   9       
thimet oligopeptidase A, 
putative,metallo- peptidase, Tb927.7.190 ENZ     9   9       
3-ketoacyl-CoA thiolase Tb927.8.2540 ENZ   2 6   8       
thioredoxin-like, lipocalin domain, cyskel 
flag proteome Tb11.01.1170 ENZ   6 2   8       
aminopeptidase, putative,metallo-
peptidase, Clan MF Tb11.02.0070 ENZ 4   4   8       
cytosolic nonspecific dipeptidase Tb927.10.12260 ENZ     8   8       
transketolase Tb927.8.6170 ENZ     6   6 1 1   
L-threonine 3-dehydrogenase Tb927.6.2790 ENZ     7   7       
hydroxymethylglutaryl-CoA synthase 
activity Tb927.8.6110 ENZ 1   5   6       
oligopeptidase b,serine peptidase, clan 
SC, family S9A-like protein Tb11.52.0003 ENZ     6   6       
peptidase, putative,metallo-peptidase Tb927.8.7020 ENZ     6   6       
arginine kinase Tb09.160.4570 ENZ 4 1     5       
protein phosphatase 2C Tb11.03.0390 ENZ 3 2     5       
thioredoxin Tb927.4.2450 ENZ 1 4     5       
mitogen-activated protein kinase Tb927.8.3770 ENZ   5     5       
orotidine-5-phosphate decarboxylase Tb927.5.3810 ENZ   5     5       
arginine N-methyltransferase Tb927.10.3560 ENZ     5   5       
carnitine O-palmitoyltransferase II Tb927.3.3900 ENZ     5   5       
N-acetyltransferase subunit Nat1 Tb927.10.5670 ENZ     5   5       
S-adenosylmethionine synthetase Tb927.6.4840 ENZ     5   5       
protease regulatory ATPase subunit 4 Tb927.10.3520 ENZ 2 2     4       
adenylyl cyclase Tb927.4.4470 ENZ   4     4       
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protein kinase Tb927.10.5140 ENZ   4     4       
phosphoinositide-binding protein Tb09.211.4240 ENZ   4     4       
phospholipase A1 Tb927.1.4830 ENZ   4     4       
creatinase, endopeptidase, histone 
chaperone, SPT6/FACT subunit Tb927.3.5620 ENZ     4   4       
threonine synthase Tb927.7.4390 ENZ     4   4       
guanosine monophosphate reductase Tb927.5.2080 ENZ     2   2 1 1   
calpain-like cysteine peptidase Tb927.7.4060 ENZ 1 2     3       
6-phosphogluconate dehydrogenase Tb09.211.3180 ENZ 1   2   3       
carbonic anhydrase-like protein Tb11.01.0290 ENZ   3     3       
protein kinase Tb927.10.14780 ENZ   3     3       
D-alanine aminotransferase Tb927.1.3950 ENZ 3       3       
tryparedoxin peroxidase Tb927.8.1990 ENZ 3       3       
aminopeptidase P, putative,metallo-
peptidase, Clan MG, Family M24 Tb09.211.4330 ENZ     3   3       
aminopeptidase P1, putative,metallo-
peptidase, Clan MG, Family M24 Tb927.3.2090 ENZ     3   3       
aminopeptidase, putative,metallo-
peptidase, Clan MG, Family M24 Tb927.10.14790 ENZ     3   3       
phosphoacetylglucosamine mutase Tb927.8.980 ENZ     3   3       
protein kinase Tb927.10.5930 ENZ     3   3       
pseudouridine synthase, Cbf5p Tb927.10.170 ENZ     3   3       
trypanothione synthetase Tb927.2.4370 ENZ     3   3       
3-oxo-5-alpha-steroid 4-dehydrogenase Tb927.3.1840 ENZ   2     2       
calpain-like protein fragment Tb927.1.2230 ENZ   2     2       
calpain-like protein fragment Tb927.1.2260 ENZ   2     2       
cysteine peptidase precursor Tb927.6.1000 ENZ   2     2       
glycogen synthase kinase 3 Tb927.10.13780 ENZ   2     2       
Methyltransferase type 11 putative Tb927.7.6890 ENZ   2     2       
methylthioadenosine phosphorylase Tb927.7.7040 ENZ 2       2       
peptidylprolyl isomerase-like protein Tb927.10.16100 ENZ 2       2       
serine carboxypeptidase III precursor Tb927.10.1040 ENZ   2     2       
serine/threonine-protein kinase Tb927.3.2440 ENZ   2     2       
uridine phosphorylase Tb927.8.4430 ENZ 2       2       
aminopeptidase, putative,metallo-
peptidase, Clan MA(E) Family M1 Tb927.3.4750 ENZ     2   2       
arginine N-methyltransferase Tb927.1.4690 ENZ     2   2       
cystathionine beta-synthase Tb11.02.5400 ENZ     2   2       
guanine deaminase Tb927.5.4560 ENZ     2   2       
peptidase t, putative,aminotripeptidase Tb927.7.6270 ENZ     2   2       
phosphoribosylpyrophosphate 
synthetase Tb927.5.2960 ENZ     2   2       
prostaglandin f synthase Tb11.02.2310 ENZ     2   2       
Putative phosphatase, DUF domain Tb927.7.5210 ENZ     2   2       
ribonucleoside-diphosphate reductase 
large chain Tb11.02.5720 ENZ     2   2       
metacaspase MCA4 Tb927.10.2440 ENZ   1     1       
phosphatic acid phsophatasetype-2 like 
domain Tb927.8.480 ENZ   1     1       
branched-chain amino acid 
aminotransferase Tb927.2.4590 ENZ 1       1       
lysine decarboxylase Tb927.5.1460 ENZ 1       1       
metalloprotease, FtsH homologue Tb11.01.6360 ENZ 1       1       




glycerol 27 22 5 3 57 1     
enolase Tb927.10.2890 
Glucose & 
glycerol 17 12 22 1 52 1     
hexokinase Tb927.10.2010 
Glucose & 
glycerol 16 17 8 2 43       
ATP-dependent phosphofructokinase Tb927.3.3270 
Glucose & 
glycerol 13 6 4   23 1 1 1 
glycerol kinase, glycosomal Tb09.211.3540 
Glucose & 
glycerol 3 6 9 4 22 1 1   
glycerol-3-phosphate dehydrogenase 
[NAD ], glycosomal Tb927.8.3530 
Glucose & 
glycerol 3 4 7 4 18 1 1   
pyruvate phosphate dikinase Tb11.02.4150 GLYC     23 8 31       
glyceraldehyde 3-phosphate 
dehydrogenase, glycosomal Tb927.6.4280 GLYC 4 10     14       
PEX14 Tb927.10.240 GLYC 2 12     14       
phosphoenolpyruvate carboxykinase, 
glycosomal  Tb927.2.4210 GLYC     7 3 10 1 1   
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phosphoglycerate kinase PGKC Tb927.1.700 GLYC 3 8     11       
glucose-6-phosphate isomerase, 
glycosomal Tb927.1.3830 GLYC 9 1     10       
glyceraldehyde 3-phosphate 
dehydrogenase, cytosolic Tb927.10.6880 GLYC 4   4   8       
PEX12 Tb927.10.15850 GLYC   8     8       
Gim5B protein,glycosomal membrane 
protein Tb09.211.2740 GLYC 2 2     4       
malate dehydrogenase, glycosomal  Tb927.10.15410 GLYC     2 2 4       
PEX11 Tb11.01.3370 GLYC   4     4       
PEX3 Tb927.3.2410 GLYC   3     3       
2,3-bisphosphoglycerate-independent 
phosphoglycerate mutase Tb927.10.7930 GLYC     3   3       
triosephosphate isomerase Tb11.02.3210 GLYC   2     2       
75 kDa invariant surface glycoprotein Tb927.5.360 MEMB 18 4     22       
glycosylphosphatidylinositol-specific 
phospholipase C Tb927.2.6000 MEMB 2 3     5       
transmembrane domain protein Tb927.5.309b MEMB 2 2     4       
75 kDa invariant surface glycoprotein Tb927.5.390 MEMB 4       4       
Signal pep. secrete/ER. Tb927.10.11140 MEMB   4     4       
64 kDa invariant surface glycoprotein Tb927.5.1410 MEMB   2     2       
antigenic protein, putative Tb927.4.2070 MEMB   2     2       
2 transmembrane domains,homology to 
ABC transporter  Tb927.7.470 MEMB 2       2       
N-myristoyltransferase Tb927.10.14240 MEMB     2   2       
FG-GAP repeat protein Tb927.7.6460 MEMB   1     1       
membrane-bound acid phosphatase 1 
precursor Tb11.01.4701 MEMB 1       1       
64 kDa invariant surface glycoprotein Tb927.2.3270 MEMB 1       1       
64 kDa invariant surface glycoprotein Tb927.2.3320 MEMB 1       1       
Signal peptide, 4 TM domains Tb927.4.2530 MEMB   1     1       
heat shock 70 kDa protein, mitochondrial 
precursor Tb927.6.3740 MITOS 17 14 22 3 56       
homologue to slingshot, isoforms of 
drosophila localised to putative 
mitochondrial RNA binding complex 1 Tb927.7.2570 MITOS 3 5 2   10 1     
2-oxoglutarate dehydrogenase E1 
component Tb11.01.1740 MITOS     36 1 37       
2-oxoglutarate dehydrogenase E1 
componen Tb11.47.0004 MITOS     27   27       
chaperonin Hsp60, mitochondrial Tb927.10.6400 MITOS 6 3 15   24       
adenylosuccinate synthetase Tb11.02.1120 MITOS 13 2 8   23       
pyruvate dehydrogenase E1 alpha 
subunit Tb927.10.12700 MITOS 7 1 12   20       
pyruvate kinase 1 Tb927.10.14140 MITOS 9 1 8   18       
pyruvate dehydrogenase E1 beta 
subunit Tb927.3.1790 MITOS 7   7   14 1 1   
succinyl-coA:3-ketoacid-coenzyme A 
transferase, mitochondrial Tb11.02.0290 MITOS 1   13   14       
dihydrolipoyl dehydrogenase Tb11.01.8470 MITOS     14   14       
malic enzyme Tb11.02.3120 MITOS     11 1 12       
ABC transporter domain, predicted 
ATPase, locates to mithcondrial RNA 
binding complex 1 Tb927.3.1590 MITOS 2   9   11       
aconitase Tb927.10.14000 MITOS     9   9       
kinetoplast DNA-associated protein Tb11.01.8090 MITOS 5 2     7       
succinyl-CoA ligase [GDP-forming] beta-
chain Tb927.10.7410 MITOS     7   7       
fumarate hydratase, class I Tb927.3.4500 MITOS     6   6       
NADH-dependent fumarate reductase Tb927.5.940 MITOS     6   6       
glycerol-3-phosphate dehydrogenase 
(FAD-dependent), mitochondrial Tb11.02.5280 MITOS 2 3     5       
2-amino-3-ketobutyrate coenzyme A 
ligase, putative,glycine acetyltransferase Tb927.8.6060 MITOS     5   5       
malic enzyme Tb11.02.3130 MITOS     5   5       
glutamine synthetase Tb927.7.4970 MITOS     3   3 1     
adenylosuccinate lyase Tb09.160.5560 MITOS     4   4       
succinyl-CoA synthetase alpha subunit Tb927.3.2230 MITOS     4   4       
mitochondrial processing peptidase, 
beta subunit Tb927.5.1060 MITOS     2   2 1 1   
3,2-trans-enoyl-CoA isomerase, 
mitochondrial precursor Tb927.4.4910 MITOS   3     3       
Mitochondrial TBRGG1 oligo-U binding Tb927.6.2230 MITOS   3     3       
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protein 
Ribosome binding factor A signature. 
Processing of 16S rRNA? similar to ring 
finger protein 127 [Gallus gallus]  Tb09.211.1240 MITOS   3     3       
glutamine hydrolysing carbomoyl 
phosphate synthase Tb927.5.3800 MITOS     3   3       
Assoc with F0F1 ATP synthase, 
essential for ATP synthesis Tb927.10.520 MITOS 1 1     2       
mit. Membrane protein Tb11.02.5660 MITOS   2     2       
universal minicircle sequence binding 
protein (UMSBP) Tb927.10.6060 MITOS   2     2       
glutamate dehydrogenase Tb09.160.4310 MITOS     2   2       
1-acyl-sn-glycerol-3-phosphate 
acyltransferase protein Tb11.01.6800 MITOS   1     1       
importin alpha subunit, putative Tb927.6.2640 NUC 4 5 4   13       
nucleosome assembly protein, putative Tb927.10.15180 NUC 4 4 3   11       
TbKap123 transport factor (importin) Tb11.01.7010 NUC   8 3   11       
splicing factor TSR1 Tb927.8.900 NUC 2 5     7 1     
predicted nuclear, no domains Tb11.01.6790 NUC   8     8       
prohibitin Tb10.v4.0045 NUC 3 2     5       
proliferative cell nuclear antigen (PCNA) Tb09.160.3710 NUC 3   2   5       
replication factor C, subunit 1 Tb11.02.3360 NUC   5     5       
DNA topoisomerase type IB small 
subunit Tb09.160.5070 NUC 2 2     4       
histone H2A Tb927.7.2820 NUC 1   3   4       
ruvB-like DNA helicase Tb927.4.1270 NUC     4   4       
ruvB-like DNA helicase Tb927.4.2000 NUC     4   4       
histone H3 Tb927.1.2430 NUC 1   2   3       
double-strand-break repair protein rad21 Tb927.7.6900 NUC   3     3       
GTP-binding nuclear protein rtb2 Tb927.3.1120 NUC   3     3       
replication Factor A 28 kDa subunit Tb927.5.1700 NUC   3     3       
SH3 domain protein, conserved Tb927.10.14720 NUC   3     3       
homology to tRNA ligase and zinc finger 
proteins Tb927.8.2080 NUC   2     2       
replication factor C, subunit  2 Tb927.6.3890 NUC   2     2       
replication factor C, subunit 3 Tb09.211.3310 NUC   2     2       
Nuclease and TUDOR domains 
=staphylococcal nuclease domain 
protein of H. sapiens Tb11.01.5780 NUC     2   2       
prohibitin 1 Tb927.8.4810 NUC     2   2       
spliceosome-associated protein, putative Tb927.6.2000 NUC   1     1       
transcription elongation factor s-II Tb927.2.3580 NUC   1     1       
TTAGGG binding factor. Tb927.10.12850 NUC   1     1       
DNA-directed RNA polymerase, alpha 
subunit Tb927.10.15370 NUC 1       1       
nucleolar RNA binding protein, snoRNA 
binding domain Tb09.160.3820 nucleolus 8   8   16 1     
nucleolar GTP-binding protein 1 Tb11.02.0620 nucleolus 3   6   9 1     
fibrillarin Tb927.10.7500 nucleolus 5 2 2   9       
S-adenosyl-methonine-dependent 
methyl transferase Tb927.4.3840 nucleolus     7   7       
homologies to Ribosomal RNA large 
subunit methyltransferase L of 
pseudomonas  Tb927.2.2230 nucleolus 2 2     4       
ribosome biogenesis protein Tb927.7.270 nucleolus 3 1     4       
nucleolar RNA-binding protein, truncated Tb927.8.740 nucleolus     2   2 1     
snoRNP protein GAR1 Tb927.4.470 nucleolus 2 1     3       
ENP1, rRNA processing protein Tb927.6.1900 nucleolus   3     3       
U3 small nucleolar ribonucleoprotein 
protein MPP10 Tb927.3.3590 nucleolus   2     2       
fibrillarin Tb927.10.14750 nucleolus 2       2       
rRNA processing protein EBP2 Tb09.244.2790 nucleolus 1       1       
inosine-5'-monophosphate 
dehydrogenase Tb927.10.16120 nucleotide 5 8 3 2 18       
nucleoside diphosphate kinase Tb11.01.7800 nucleotide 3 1 2 1 7       
Nucleoporin NUP98 Tb927.3.3180 NUP   4     4       
Nucleoporin NUP64 Tb927.4.4310 NUP   2     2       
NUP-1 protein Tb927.2.4230 NUP   2     2       
ATP synthase F1, beta subunit Tb927.3.1380 
Ox. 
phosphory
lation 12 6 15 7 40 1 1   
ATP synthase F1, alpha subunit Tb927.7.7420 Ox. 6 2 11 3 22 1     





peptidase, Clan M Tb11.02.4440 
Protease/p
eptidase 10   18 2 30 1   1 
calpain-like cysteine peptidase Tb927.1.2100 
Protease/p
eptidase 1   25 2 28 1     
40S ribosomal protein L14 Tb11.01.3020 Ribosome 7 8 6   21       
60S ribosomal protein L36 Tb09.244.2725 Ribosome 8 7     15 1   1 
40S ribosomal protein S25 Tb927.10.2840 Ribosome 5 6     11       
40S ribosomal protein S21 Tb11.02.4360 Ribosome 3 3 3   9       
60S ribosomal protein L32 Tb927.10.270 Ribosome 3 6     9       
60S ribosomal protein L31 Tb09.211.3270 Ribosome 3 3     6       
60S acidic ribosomal protein P2 Tb927.6.5120 Ribosome 4       4     1 
40S ribosomal protein S30 Tb927.6.2100 Ribosome 2 1     3       
40S ribosomal protein S15 Tb927.7.2340 Ribosome 2       2     1 
60S acidic ribosomal protein Tb927.5.1820 Ribosome 2       2       
60S ribosomal protein L38 Tb09.160.0815 Ribosome   1     1       
60S ribosomal protein L39 Tb927.8.5260 Ribosome   1     1       
60S Ribosomal protein L1 Tb927.10.8200 Ribosome 1       1       
60S ribosomal protein L4 Tb927.3.5050 Ribosome 21 20 23 8 72 1 1 1 
60S ribosomal protein L3 Tb927.4.1790 Ribosome 22 17 22 9 70 1 1 1 
40S ribosomal protein S4 Tb11.02.1085 Ribosome 19 15 18 12 64       
40S ribosomal protein S3A Tb927.10.3940 Ribosome 18 19 14 11 62       
60S acidic ribosomal subunit Tb11.46.0001 Ribosome 17 15 19 8 59 1 1   
60S ribosomal protein L13 Tb927.3.3310 Ribosome 14 17 9 4 44 1 1 1 
60S ribosomal protein L7a Tb927.8.1330 Ribosome 13 13 13 6 45       
60S ribosomal protein L5 Tb09.244.2730 Ribosome 16 10 12 6 44       
60S ribosomal protein L10 Tb09.211.0110 Ribosome 11 13 11 7 42       
40S ribosomal protein S3 Tb09.160.4450 Ribosome 11 13 10 6 40 1 1 1 
60S ribosomal protein L2 L8 Tb11.01.7960 Ribosome 13 12 10 5 40       
60S ribosomal protein L7 Tb927.7.1730 Ribosome 12 10 10 6 38     1 
40S ribosomal protein S18 Tb927.10.5330 Ribosome 12 15 6 4 37       
40S ribosomal protein S2 Tb927.10.14600 Ribosome 11 13 7 6 37       
60S ribosomal protein L21e Tb11.50.0005 Ribosome 8 12 9 5 34       
60S ribosomal protein L23a, or L25 Tb927.7.5170 Ribosome 10 11 8 5 34       
60S ribosomal protein L10a Tb11.01.1470 Ribosome 8 12 7 5 32 1   1 
60S ribosomal protein L13a Tb927.4.3550 Ribosome 7 10 8 6 31 1 1 1 
60S ribosomal protein L6 Tb927.10.11390 Ribosome 8 11 8 5 32       
40S ribosomal protein S7 Tb09.160.2550 Ribosome 8 9 6 7 30 1   1 
60S ribosomal protein L19 Tb927.7.5000 Ribosome 9 10 6 4 29 1 1 1 
60S ribosomal protein L23 Tb09.211.2630 Ribosome 9 9 6 5 29 1   1 
40S ribosomal protein S16 Tb927.7.1040 Ribosome 8 10 8 4 30       
40S ribosomal protein SA Tb11.01.2560 Ribosome 8 9 8 5 30       
60S ribosomal protein L35a Tb927.4.2180 Ribosome 7 7 8 5 27 1 1 1 
40S ribosomal protein S6 Tb927.10.190 Ribosome 12 11 4 1 28       
60S ribosomal protein L27 Tb11.01.7535 Ribosome 7 8 7 6 28       
60S ribosomal protein L18 Tb11.01.5720 Ribosome 6 8 8 3 25 1   1 
40S ribosomal protein S13 Tb927.10.15120 Ribosome 7 11 5 3 26       
40S ribosomal protein S17 Tb11.01.3675 Ribosome 8 9 5 4 26       
40S ribosomal protein S5 Tb11.02.4170 Ribosome 8 8 4 4 24 1 1 1 
40S ribosomal protein S6 Tb09.244.2630 Ribosome 3 3 11 7 24 1   1 
40S ribosomal protein S8 Tb927.8.6150 Ribosome 6 7 6 5 24 1 1 1 
40S ribosomal protein S9 Tb927.10.5610 Ribosome 6 7 7 5 25       
40S ribosomal protein S19 Tb927.4.1860 Ribosome 7 8 4 4 23 1   1 
60S ribosomal protein L28 Tb11.02.4050 Ribosome 6 8 5 4 23       
60S ribosomal protein L30 Tb927.10.4110 Ribosome 7 7 6 3 23       
60S ribosomal protein L9 Tb927.10.1100 Ribosome 5 5 8 5 23       
60S ribosomal protein L17 Tb11.02.2430 Ribosome 5 7 6 4 22       
40S ribosomal protein S10 Tb927.10.5360 Ribosome 6 7 3 4 20 1     
40S ribosomal protein S11 Tb927.10.560 Ribosome 4 5 5 6 20       
60S ribosomal protein L11 Tb09.160.5580 Ribosome 5 5 5 2 17 1     
60S ribosomal protein L18 Tb11.02.1840 Ribosome 5 6 4 3 18       
60S ribosomal protein L44 Tb11.02.0740 Ribosome 6 8 3 1 18       
40S ribosomal protein S14 Tb927.6.4980 Ribosome 4 5 4 3 16 1 1 1 
40S ribosomal protein S15A Tb11.02.4000 Ribosome 4 5 4 4 17     1 
40S ribosomal protein S26 Tb11.01.0355 Ribosome 4 5 3 3 15 1 1 1 
40S ribosomal protein S27 Tb11.01.1475 Ribosome 4 4 4 3 15 1 1 1 
40S ribosomal protein S24E Tb927.10.7330 Ribosome 5 6 3 2 16       
60S ribosomal protein L27a Tb09.211.2650 Ribosome 5 5 2 2 14 1 1 1 
40S ribosomal protein S12 Tb927.10.8430 Ribosome 3 4 4 2 13       
40S ribosomal protein S23 Tb927.10.1080 Ribosome 5 3 3 2 13       
60S ribosomal protein L12 Tb09.211.4550 Ribosome 5 3 2 3 13       
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60S ribosomal protein L15 Tb927.6.5040 Ribosome 3 2 4 2 11 1   1 
60S ribosomal protein L29 Tb11.01.1790 Ribosome 3 4 2 2 11 1 1 1 
60S ribosomal protein L26 Tb09.211.4850 Ribosome 2 4 3 3 12       
60S ribosomal protein L37a Tb927.10.220 Ribosome 3 5 2 1 11       
40S ribosomal protein S33 Tb927.7.230 Ribosome 3 4 2 1 10       
60S ribosomal protein L24 Tb927.10.5460 Ribosome 1 4 3 2 10       
60S ribosomal protein L35 Tb09.160.0700 Ribosome 3 4 2 1 10       
60S acidic ribosomal protein Tb09.160.4200 Ribosome 3 2 2 2 9       
60S ribosomal proteins L38 Tb927.10.3280 Ribosome 2 4 2 1 9       
40S ribosomal protein S27+ ubiquitin Tb927.10.5030 Ribosome 2 3 2 1 8       
60S ribosomal protein L22 Tb11.01.1920 Ribosome 2 3 2 1 8       
60S ribosomal protein L34 Tb11.01.1480 Ribosome 2 2 2 2 8       
60S ribosomal protein L37 Tb09.211.0865 Ribosome 2 2 2 1 7       
AGO1 Tb927.10.10850 RNA     21   21     1 
NOT5 Tb927.3.1920 RNA 4 9     13       
DHH1 Tb927.10.3990 RNA 2 4 6   12       
DRBD3 (PTB1) Tb09.211.0560 RNA 2 5 2   9       
DDX60 Tb927.3.2600 RNA     8   8 1     
Dbp2 Tb927.8.1510 RNA 3 4     7       
RBP42 Tb927.6.4440 RNA 3 1 2   6       
PUF2 Tb927.10.12660 RNA   6     6       
ZC3H41 Tb11.46.0009 RNA     5   5       
PUF6 Tb927.10.11760 RNA   4     4       
RPB29 Tb927.10.13720 RNA   3     3       
Dbp2/HEL64 Tb927.10.6630 RNA   2     2       
PUF1 Tb927.10.4430 RNA   2     2       
PUF3 Tb927.10.310 RNA   2     2       
ZC3H29 Tb09.211.1130 RNA   2     2       
NOT2 Tb927.6.850 RNA 2       2       
RBP11 Tb927.8.4450 RNA 2       2       
PUF10 Tb11.02.4570 RNA     2   2       
SUB2 Tb927.10.540 RNA   1     1       
PBP1 Tb927.8.4540 RNA   1     1       
ZC3H18 Tb927.7.2140 RNA   1     1       
ZC3H30 Tb927.10.1540 RNA   1     1       
ZC3H32 Tb927.10.5250 RNA   1     1       
MEX67 Tb11.22.0004 RNA   2     2       
ALBA4/ ALBA3  Tb927.4.2030 RNA 1 2 2 1 6       
MKT1 Tb927.6.4770 RNA 3 2 2   7       
PARN-3 Tb09.211.4350 RNA     2   2       
LA protein Tb927.10.2370 
RNA, 
putative 2   2   4       
cytoplasmic RNA-binding protein or 
Prp46p splicing factor Tb09.160.5620 
RNA, 
putative 1 2     3       
CCCH zinc finger PS50103, up slightly 
in PC.  Tb11.02.1470 
RNA, 
putative   2     2       
hypothetical protein, conserved has two 
RBDs Tb11.01.5680 
RNA, 
putative 2       2       
P-loop nucloside phosphate hydrolase, 
PH domain-like Tb927.3.2490 
RNA, 
putative     2   2       
NRBD2 Tb11.01.5590 
r/tRNA 
processing 12 11 12 6 41 1   1 
NOP86 Tb09.160.1160 
r/tRNA 
processing 5 25 9 2 41       
nucleolar protein, NOP5 domain Tb927.8.3750 
r/tRNA 
processing 3 1 11   15 1   1 
T-complex protein 1, theta subunit Tb927.10.8190 TRANS 2   17   19 1     
T-complex protein 1, alpha subunit Tb11.01.8510 TRANS     18   18 1     
T-complex protein 1, delta subunit Tb927.10.1060 TRANS     17 2 19       
T-complex protein 1 gamma subunit Tb927.8.3150 TRANS   2 17   19       
T-complex protein 1, beta subunit Tb11.42.0003 TRANS     16   16 1     
T-complex protein 1, epsilon subunit Tb11.01.5860 TRANS     15   15 1     
T-complex protein 1, zeta subunit Tb11.02.0750 TRANS 1   14   15       
T-complex protein 1, eta subunit Tb09.211.2570 TRANS     11   11 1     
Dbp1 Tb927.10.14550 TRANS 3 9 3   15       
Ded1 Tb09.211.3510 TRANS   9 5   14       
EIF3a Tb927.7.6090 TRANS 8   16   24       
EIF4G3 Tb927.8.4820 TRANS 14   5   19 1     
EIF4A1 Tb09.160.3270 TRANS 6 6 8   20     1 
EIF3c Tb927.10.8270 TRANS 1   13   14       
Bfr1, polysome component. loc in ER of 
Sc. Interacts RF1, AP3.  2x higher in BF Tb927.10.14150 TRANS 3 6     9       
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EIF5 Tb927.10.2770 TRANS   5 4   9       
EIF3 7 eukaryotic translation initiation 
factor 3 subunit 7 Tb927.6.4370 TRANS     7   7       
EIF eukaryotic translation initiation factor Tb11.01.3420 TRANS     6   6       
EIF3b Tb927.5.2570 TRANS     6   6       
eIF3L Tb927.10.4640 TRANS     6   6       
ERF1 eukaryotic release factor 1 Tb11.22.0012 TRANS   1 4   5       
EF1 beta Tb927.4.3570 TRANS 2   3   5       
EIF3g Tb927.4.1930 TRANS 5       5       
EIF3 eukaryotic translation initiation 
factor 3 Tb11.01.1370 TRANS     5   5       
EIF4E3 Tb11.01.3630 TRANS 1 3     4       
EIF4G4 Tb11.01.2330 TRANS   3     3       
GTP-binding protein RBG1 (yeast) Tb927.10.6800 TRANS   3     3       
EIF2 gamma eukaryotic translation 
initiation factor 2 gamma Tb11.01.4830 TRANS     3   3       
ERF3 eukaryotic release factor 3 Tb11.02.4030 TRANS     3   3       
elongation factor Tu Tb927.10.13360 TRANS     2   2       
elongation initiation factor 2 alpha 
subunit Tb927.3.2900 TRANS     2   2       
IF2 Tb927.2.3780 TRANS     2   2       
EIF3c Tb927.10.8290 TRANS 1       1       
PABP2 Tb09.211.2150 TRANS 28 21 24 6 79 1 1 1 
PABP1 Tb09.211.0930 TRANS 24 11 25 4 64 1 1 1 
EF2 Tb927.10.4560 TRANS 10   45 8 63       
TbRACK1, associated with ribosomes Tb11.01.3170 TRANS 15 14 15 8 52 1 1 1 
EF1 alpha Tb927.10.2100 TRANS 9 10 9   28 1     
EF1 gamma Tb11.01.4660 TRANS 4 1 10 2 17 1     
EIF4E4 Tb927.6.1870 TRANS 10 3 2   15 1   1 
threonyl-tRNA synthetase Tb927.5.1090 tRNAsynth     17   17       
glycyl-tRNA synthetase Tb11.01.1400 tRNAsynth 2   13   15       
seryl-tRNA synthetase Tb11.02.5020 tRNAsynth 4   8 1 13       
isoleucyl-tRNA synthetase Tb927.10.9190 tRNAsynth     13   13       
cysteinyl-tRNA synthetase Tb927.6.950 tRNAsynth     12   12       
lysyl-tRNA synthetase Tb927.8.1600 tRNAsynth 6   5   11       
leucyl-tRNA synthetase Tb11.02.1210 tRNAsynth     9   9       
arginyl-tRNA synthetase, putative Tb11.46.0008 tRNAsynth     8   8       
valyl-tRNA synthetase, putative Tb927.6.4480 tRNAsynth     8   8       
phenylalanyl-tRNA synthetase (beta 
subunit) Tb11.22.0005 tRNAsynth 3   3   6       
glutamyl-tRNA synthetase Tb927.6.4590 tRNAsynth     6   6       
tyrosyl-tRNA synthetase Tb927.7.2400 tRNAsynth   5     5       
asparaginyl-tRNA synthetase Tb927.4.2310 tRNAsynth     3   3       
glutaminyl-tRNA synthetase Tb09.160.3730 tRNAsynth     3   3       
methionyl-tRNA synthetase Tb927.10.1500 tRNAsynth     3   3       
tyrosyl-tRNA synthetase Tb927.7.3620 tRNAsynth     3   3       
alanyl-tRNA synthetase Tb927.6.700 tRNAsynth     2   2       
aspartyl-tRNA synthetase Tb927.6.1880 tRNAsynth     2   2       
proteasome regulatory non-ATPase 
subunit 11 Tb927.10.2980 Ubi 3 1     4       
polyubiquitin Tb11.01.1680 Ubi     2   2 1 1   
proteasome beta 6 subunit,20S 
proteasome beta 6 subunit Tb927.7.4790 Ubi 2 1     3       
proteasome regulatory non-ATPase 
subunit 8 Tb927.10.14530 Ubi 2 1     3       
proteasome regulatory ATPase subunit 
3 Tb927.6.1090 Ubi   1 2   3       
proteasome beta-1 subunit Tb927.6.1260 Ubi 1   2   3       
ubiquitin-like protein Tb11.02.1600 Ubi   3     3       
proteasome regulatory non-ATPase 
subunit 6 Tb927.2.2440 Ubi     3   3       
proteasome regulatory ATPase subunit 
5 Tb927.7.2550 Ubi   2     2       
proteasome regulatory non-ATP-ase 
subunit 10 Tb927.8.570 Ubi   2     2       
ubiquitin-conjugating enzyme e2 Tb11.01.5790 Ubi   2     2       
proteasome alpha 2 subunit Tb927.10.290 Ubi 2       2     1 
proteasome regulatory non-ATP-ase 
subunit 2 Tb11.01.0960 Ubi     2   2       
ubiquitin-conjugating enzyme Tb927.7.6960 Ubi   1     1       
proteasome alpha 3 subunit Tb927.7.4420 Ubi 1       1       
proteasome alpha 5 subunit, 20S Tb927.10.230 Ubi 1       1       
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proteasome 
V-type ATPase, A subunit Tb927.4.1080 VAC   3 5   8       
vacuolar ATP synthase subunit d Tb927.10.3760 VAC   5     5       
vacuolar ATP synthase subunit c Tb927.10.14040 VAC   2     2       
vacuolar ATP synthase, subunit C or D Tb927.5.550 VAC   2     2       
vacuolar ATP synthase subunit b Tb11.01.3560 VAC     2   2       
vacuolar protein sorting-associated 
protein 4 Tb927.3.3280 VAC   1     1       
vacuolar proton translocating ATPase 
subunit A Tb927.5.1300 VAC   1     1       
Golgi/lysosome glycoprotein 1 Tb927.8.1870 VES 6 6     12       
adaptin complex 1 subunit, beta-adaptin Tb927.10.8040 VES 3 8     11       
clathrin heavy chain Tb927.10.6050 VES   3 5   8       
Sec13, putative,cytosolic coat protein,  Tb927.10.14180 VES 3 4     7       
ADP-ribosylation factor-like protein 3A Tb927.3.3450 VES 1 3     4       
lysosomal/endosomal membrane protein 
p67 Tb927.5.1810 VES 1 3     4       
major sperm protein or PapD domain. 
PM-FLAG-CYSK proteomes, Tb11.01.4810 VES   4     4       
SNF7  protein transport Tb11.18.0015 VES   4     4       
ERV46, membrane fusions, Cop11 
vesicles Tb11.02.5080 VES 2 1     3       
Translocon-associated protein alpha Tb927.7.2190 VES 1 2     3     1 
vesicle-associated membrane protein, 
putative Tb927.5.3560 VES 1 2     3       
ADP-ribosylation factor, putative Tb09.211.4460 VES   3     3       
clathrin coat assembly protein Tb11.02.2410 VES   3     3       
endoplasmic reticulum oxidoreductin Tb927.8.4890 VES   3     3       
GPI transamidase GPI16 Tb927.4.1920 VES   3     3       
GPI transamidase TTA1 Tb11.01.7400 VES   3     3       
RAB1 Tb927.8.890 VES   3     3       
translocon-associated protein beta Tb927.6.4500 VES   3     3       
vesicle protein SN7 family protein. Tb11.01.1390 VES   3     3       
calreticulin, putative Tb927.4.5010 VES 3       3       
GRAM domain Glucosyltransferases Tb09.160.5200 VES 3       3       
ADP-ribosylation factor-like protein Tb09.160.5300 VES   2     2       
GPI inositol deacylase precursor Tb927.10.4780 VES   2     2       
GPI-anchor transamidase subunit 8 
(GPI8) Tb927.10.13860 VES   2     2       
Rab-like 5, small G protein Tb11.01.8590 VES   2     2       
ras-like small GTPase, 
evidence=traceable author statement  Tb11.02.0240 VES   2     2       
ras-related protein rab-5,small GTPase, 
putative  Tb927.10.12960 VES   2     2       
small GTP-binding protein 
Rab11,Rab11A Tb927.8.4330 VES   2     2       
small GTP-binding protein, 
putative;evidence=traceable author 
statement Tb927.3.5550 VES   2     2       
translocon-associated protein gamma 4 
transmembrane domains Tb927.7.4470 VES   2     2       
SRP68 Tb927.4.1850 VES 2       2       
RAB GDP dissociation inhibitor alpha Tb927.3.4680 VES     2   2       
ADP-ribosylation factor GTPase 
activating protein Tb09.244.2540 VES   1     1       
COP protein Tb09.244.2760 VES   1     1       
low homology to syntaxin Tb11.01.1960 VES   1     1       
SNF7-related domain Tb09.211.1770 VES   1     1       
14-3-3-like protein Tb11.01.1290 VES 1       1       
glucose-regulated protein 78, 
putative,luminal binding protein 1 (BiP) Tb11.02.5450 VES 26 34 15 5 80       
dynamin, putative,vacuolar sortin protein 
1 Tb927.3.4720 VES 12 8 12   32 1   1 
Valosin-comtaiing protein homologue, 
transitional ER Tb927.10.5770 VES 1 2 15 1 19       
VSG Tb08.27P2.220 VSG 7 6     13       
VSG Tb927.5.4820 VSG 1 1 2 1 5       
VSG Tb927.1.05 VSG 2 1     3       
VSG Tb09.v4.0136 VSG   2     2       
VSG Tb10.v4.0241 VSG   1     1       
VSG Tb05.5K5.540 VSG 1       1       
low homology to EIF-3.H of C. elegans, Tb927.8.1170   1   2   3       
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none in yeast 
C2 calcium/lipid-binding region, CaLB,  Tb927.7.3550   22 25 9   56       
prefoldin domain, Spectrin repeat low 
homologies,  CYSK proteome Tb927.8.6980     26     26       
hypothetical, mRNA up in BS Tb927.7.2650   12 11     23     1 
ubiquitin-activating enzyme e1 Tb09.211.3610       13   13       
hypothetical protein, no matches in yeast 
or human Tb927.4.1300       11   11 1     
FtsJ cell division protein, putative Tb927.2.4550   6 2 2   10       
brucei-congo speciific. no domains Tb927.10.2930   1 9     10       
low homology to RNA helicase of 
toxoplasma gondii, trypanosoma-specific Tb927.3.3300     10     10       
WD40 domains, nuclear? slightly up BS, 
medium homology to plectin Tb927.10.840     10     10       
orthologues have ARM repeat Tb927.7.2240   4 5     9       
FY-rich domain IPR003889 Tb927.7.1060   2 5     7       
hypothetical protein Tb927.1.4310     7     7       
down in stat phase. no matches Tb927.10.14700   3 3     6       
low homology to coiled-cooil proteins 
and hook proteins (cytoskeletal linkers) Tb11.02.4300   4 2     6       
hypothetical protein Tb927.8.1960     3 3   6       
homology (medium) to cox4 neighbour, 
predicted mito. UPF0172 family  Tb927.8.1570     6     6       
hypothetical protein Tb927.6.1470   3 2     5       
low homology to a CPSF-like protein but 
no domains,  possibly nuclear Tb927.4.3540   1 4     5       
hypothetical protein Tb11.39.0004   5       5       
orthologues have SMAD/FHA domain, 
no homologies found Tb09.211.4170   5       5       
telomere repeat dimerization domain Tb927.7.2170       5   5       
hypothetical protein,clow homology to 
syntaxin of giardia lamdia Tb927.4.3060   2 2     4       
no domains, no clear location Tb11.02.0010   1 3     4       
no homologies, possibly nuclear Tb927.3.5370   1 3     4       
nuclear? Tb09.211.1150   1 3     4       
homology to imilar to NSP5beta3beta 
[Gallus gallus]. And other DNA binding 
proteins Tb927.10.5450     4     4       
hypothetical protein Tb11.47.0020     4     4       
hypothetical protein Tb927.1.4280     4     4       
low homology to dynactin Tb927.5.2500     4     4       
low homology to WD-repeat protein, 
putative [Toxoplasma gondii] Tb927.10.5870     4     4       
homologies to hypotheticasl proteins Tb927.6.5070   4       4       
predicted WD40 repeat  Tb11.02.4620       2   2 1     
homology to hyp. Proteins, none in yeast Tb927.8.1500   1 2     3       
LisH dimerisation motif orthologue Tb09.211.1800   1 2     3       
homology to zinc finger proteins (low) Tb927.8.2260     3     3       
hypothetical protein Tb927.10.15250     3     3       
hypothetical protein Tb927.2.2940     3     3       
Proteophosphoglycan Tb927.10.5880     3     3       
Trypanosoma-specific no matches Tb927.7.5030     3     3       
Up in BS. no domains Tb927.10.13790     3     3       
up in PC. no matches. Tb11.01.2550     3     3       
low homology to 26S proteasome 
domain Tb927.3.1680   3       3       
 ARF-like 2 binding protein BART Tb927.10.5810   3       3     1 
cAMP-specific phosphodiesterase 
PDEB2 Tb09.160.3630       3   3       
hypothetical protein, conserved Tb11.02.2520       3   3       
major vault protein Tb927.10.6310       3   3       
major vault protein Tb927.5.4460       3   3       
ubiquitin-activating enzyme e1 Tb927.8.2640       3   3       
3 transmembrane regions Tb09.211.1050     2     2       
brucei-specific, higher in BS, no matches Tb11.02.0350     2     2       
C3H4 zinc finger Tb927.10.12940     2     2       
C3H4 zinc finger Tb927.10.6380     2     2       
GTP binding protein Tb927.2.5060       2   2       
homology to a porin of toxoplasma 
gondii  Tb927.2.2510     2     2       
hypothetical protein Tb927.10.3780     2     2       
low homologies, no domains Tb927.5.3190     2     2       
	   6.	  Supplemental	  data	  
153	  
low homology to mitochondrial 
phenylalanyl-tRNA synthetase 
[Schizosaccharomyces pombe] Tb927.7.5240     2     2       
low homology to 
phosphatidylserinsynthase Tb927.4.2170     2     2       
low homology to toxoplasma gondii zinc 
finger proteins, Tb11.01.4400     2     2       
LysM domain (peptidoglycan binding). 
trypanosoma-specific Tb927.5.3460     2     2       
no clear location, no domains, no hits Tb11.01.1090     2     2       
Trypanosoma-specific, SSF52047 RNI-
like Tb09.211.0160     2     2       
hypothetical protein, Tb11.50.0001   2       2       
low homology to heat shock protein 
SSC1, mitochondrial precursor [Candida 
albicans WO-1] Tb927.10.8940   2       2       
low homology to d tRNA 
methyltransferase of s: cerevisiae Tb927.10.15760   2       2       
 small homology to ATP-dependent DNA 
helicase II subunit 1 Tb927.2.3800   2       2       
major vault protein Tb927.10.1990       2   2       
Ribosome recycling factor domain Tb927.7.2640       2   2       
Breast cancer type I susceptibility 
protein domain  Tb09.211.1310     1     1       
CS domain, HCP-like domain, medium 
homology to sel-1 homolog 2 precursor 
[Mus musculus] Tb11.01.3290     1     1       
homology to  kintoun isoform 2 [Homo 
sapiens]               Tb927.10.12860     1     1       
homology to nuclear factor of activated 
T-cells 5 isoform a [Homo sapiens] Tb09.211.0200     1     1       
homology to RhoGAP domain-containing 
protein  Tb927.10.4070     1     1       
homology to UBX domain-containing 
protein 7 [Homo sapiens]  Tb927.3.5320     1     1       
Hypothetical conserved in trypanosoma, 
Leish match not syntenic Tb927.10.12670     1     1       
hypothetical protein Tb09.160.0400     1     1       
hypothetical protein Tb11.02.4290     1     1       
hypothetical protein Tb927.10.3810     1     1       
hypothetical protein, conserved Tb927.10.16110     1     1       
low homology to dynactin, only brucei, 
BS specific. Tb927.4.1230     1     1       
mannose-specific lectin, putative  Tb11.02.1680     1     1       
no domains Tb11.01.4570     1     1       
no domains, low homology to 
proteasome beta 10 subunit proprotein 
[Homo sapiens] Tb11.01.4890     1     1       
SAP domain (helix-loop-helix) Tb927.10.4440     1     1       
signal anchor sequence, transmembrane 
domain Tb11.01.2460     1     1       
signal anchor, low homology to actin 
regulating protein Neurabin2 Tb927.8.7720     1     1       
signal peptide low homology to zinc 
finger transcription factor TRPS1 [Mus 
musculus] Tb927.3.3820     1     1       
signal peptide, no homologies Tb927.5.1990     1     1       
Tetratricopeptide repeat domain Tb927.6.4800     1     1       
low homology to CAP-Gly domain-
containing linker protein 1 isoform b 
(H.Sapiens) Tb09.211.2700   1       1       
no homologues Tb11.01.6835   1       1       
replication factor C subunit 4 
[Plasmodium vivax SaI-1] low homology Tb11.02.4120   1       1       
     Total           1507     1859      2123    423        
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6.2	  High-­‐throughput	  RNA	  sequencing	  results	  
6.2.1	  mRNAs	  down-­‐regulated	  in	  the	  bloodstream	  ZC3H32	  RNAi	  cell	  line	  (as	  compared	  to	  
WT)	  	  





Tb927.11.16720 cyclin 6,mitotic cyclin (CYC6) Cell cycle 0.32 0.44 
Tb927.11.2490 kinesin, putative,Unc104-like kinesin, putative Cytoskeleton 0.49 0.47 
Tb927.6.3150 Hydin,flagellar component Cytoskeleton 0.48 0.32 
Tb927.4.870 dynein heavy chain, putative Cytoskeleton 0.40 0.30 
Tb927.2.5270 dynein heavy chain, putative Cytoskeleton 0.48 0.42 
Tb927.11.11220 dynein heavy chain, putative Cytoskeleton 0.42 0.38 
Tb927.11.8160 dynein heavy chain, putative Cytoskeleton 0.49 0.38 
Tb927.11.2430 dynein heavy chain, putative (DHC1b) or DYNC2H2 Cytoskeleton 0.48 0.36 
Tb927.8.3250 dynein heavy chain, putative Cytoskeleton 0.42 0.27 
Tb927.3.930 dynein heavy chain, putative Cytoskeleton 0.46 0.23 
Tb927.11.3250 dynein heavy chain, putative Cytoskeleton 0.50 0.19 
Tb927.9.13610 helicase, putative DNA helicase 0.39 0.48 
Tb927.1.5080 ESAG9, putative ESAG 0.50 0.15 
Tb927.6.2850 ESAG8-associated protein, putative (PIE8) ESAG 0.29 0.11 
Tb927.7.2420 glycogen synthase kinase-3 alpha, putative 
Glycan synthesis & 
metabolism 0.07 0.35 
Tb927.10.4050 serine palmitoyltransferase, putative Lipids & fatty acids 0.26 0.40 
Tb927.2.3080 fatty acid desaturase, putative,oleate desaturase, putative Lipids & fatty acids 0.45 0.48 
Tb927.1.3320 leucine-rich repeat protein (LRRP) LRRP 0.35 0.41 
Tb927.2.1380 leucine-rich repeat protein (LRRP) LRRP 0.04 0.22 
Tb927.3.1490 leucine-rich repeat protein (LRRP) LRRP 0.40 0.42 
Tb927.11.6890 DNA repair and recombination helicase protein PIF1 Mitochondrial DNA 0.12 0.48 
Tb927.9.14600 iron/ascorbate oxidoreductase family protein, putative Mitochondrial pathway 0.00 0.48 
Tb927.5.3620 dual specificity phosphatase, putative Phosphatase 0.15 0.38 
Tb927.7.7160 dual specificity phosphatase, putative Phosphatase 0.38 0.49 
Tb927.2.4280 dual specificity phosphatase, putative Phosphatase 0.31 0.46 
Tb927.11.7010 protein kinase, putative Protein kinase 0.21 0.49 
Tb927.6.2030 protein kinase, putative Protein kinase 0.04 0.43 
Tb927.8.870 serine/threonine kinase, putative,protein kinase, putative Protein kinase 0.31 0.27 
Tb927.7.6310 polo-like protein kinase,protein kinase (PLK) Protein kinase 0.41 0.40 
Tb927.9.6560 protein kinase, putative Protein kinase 0.43 0.34 
Tb927.11.4610 protein kinase A regulatory subunit (PKA-R) Protein kinase 0.34 0.18 
Tb927.10.14270 TFIIF-stimulated CTD phosphatase, putative Protein phosphatase 0.15 0.34 
Tb927.6.640 kinetoplastid-specific phospho-protein phosphatase, putative Protein phosphatase 0.11 0.28 
Tb927.5.4380 kinetoplastid-specific phospho-protein phosphatase, putative Protein phosphatase 0.48 0.44 
Tb927.10.12760 ZC3H36 RNA binding 0.11 0.39 
Tb927.10.5150 ZC3H31 RNA binding 0.11 0.42 
Tb927.8.6650 DRBD12 RNA binding 0.13 0.21 
Tb927.7.5380 RNA-binding protein, putative, RBD RNA binding 0.09 0.37 
Tb927.10.12780 ZC3H37 RNA binding 0.39 0.37 
Tb927.11.16550 ZC3H46 RNA binding 0.08 0.27 
Tb927.10.12800 ZC3H38 RNA binding 0.44 0.31 
Tb927.6.3480 DRBD5 RNA binding 0.36 0.11 
Tb927.6.3490 ZFP1 RNA binding 0.03 0.17 
Tb927.6.820 PUF4 RNA binding 0.06 0.43 
Tb927.9.9520 ZC3H29 RNA binding 0.38 0.45 
Tb927.10.5250 ZC3H32 RNA binding 0.09 0.12 
Tb927.7.2140 ZC3H18 RNA binding 0.42 0.43 
Tb927.10.11760 PUF6 RNA binding 0.39 0.45 
Tb927.10.12660 PUF2 RNA binding 0.06 0.25 
Tb927.3.3940 DRBD11 RNA binding 0.09 0.11 
Tb927.1.2600 PUF9 RNA binding 0.06 0.33 
Tb927.8.710 DRBD17 RNA binding 0.24 0.19 
Tb927.8.4540 PBP1 RNA degradation 0.24 0.38 
Tb927.7.4900 
5'-3' exonuclease XRNA, putative,exoribonuclease 1, 
putative (XRNA) RNA degradation 0.43 0.35 
Tb927.10.1510 NOT complex subunit NOT1 RNA degradation 0.39 0.34 
Tb927.2.3880 heterogeneous nuclear ribonucleoprotein H/F, putative + RNA processing 0.17 0.10 
Tb927.8.900 splicing factor TSR1 (TSR1) RNA processing 0.29 0.36 
Tb927.2.3580 transcription elongation factor s-II, putative (TFIIS2-1) RNA synthesis II 0.42 0.27 
Tb927.1.1930 TbTOR4 = TOR-like 2 Signalling 0.40 0.32 
Tb927.2.2260 PIK-related Signalling 0.38 0.33 
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Tb927.10.14550 ATP-dependent DEAD/H RNA helicase, DED1-1 Translation 0.06 0.14 
Tb927.9.12510 ATP-dependent DEAD/H RNA helicase, DED1-2 Translation 0.49 0.35 
Tb927.5.2400 ubiquitin carboxyl-terminal hydrolase, putative Ubiquitin & proteasome 0.38 0.42 
Tb927.8.1590 ubiquitin-protein ligase, putative (upl3) Ubiquitin & proteasome 0.35 0.34 
Tb927.10.3410 hypothetical protein   0.02 0.25 
Tb927.6.1790 hypothetical protein   0.02 0.49 
Tb927.9.4130 hypothetical protein, conserved   0.04 0.48 
Tb927.7.2090 hypothetical protein, conserved   0.14 0.37 
Tb927.5.2480 hypothetical protein, conserved   0.38 0.43 
Tb927.10.480 hypothetical protein, conserved   0.23 0.16 
Tb927.9.9370 hypothetical protein, conserved   0.36 0.22 
Tb927.6.3880 hypothetical protein, conserved   0.47 0.40 
Tb927.10.12650 hypothetical protein, conserved   0.02 0.25 
Tb927.2.3090 hypothetical protein, conserved   0.47 0.48 
Tb927.1.1470 hypothetical protein, conserved   0.34 0.33 
Tb927.6.690 hypothetical protein, conserved   0.05 0.38 
Tb927.5.2360 hypothetical protein, conserved   0.26 0.48 
Tb927.10.11630 hypothetical protein, conserved   0.30 0.34 
Tb927.11.16820 hypothetical protein, conserved   0.39 0.37 
Tb927.4.710 hypothetical protein, conserved   0.23 0.26 
Tb927.11.4620 hypothetical protein, conserved   0.39 0.13 
Tb927.8.7820 hypothetical protein, conserved   0.02 0.47 
Tb927.5.2010 hypothetical protein   0.46 0.41 
Tb927.2.2340 hypothetical protein, conserved   0.21 0.29 
Tb927.10.3400 hypothetical protein, conserved   0.03 0.20 
Tb927.11.15160 hypothetical protein, conserved   0.49 0.43 
Tb927.5.2620 hypothetical protein, conserved   0.27 0.48 
Tb927.4.1910 hypothetical protein, conserved   0.06 0.24 
Tb927.11.6600 hypothetical protein, conserved   0.02 0.46 
Tb927.8.3820 hypothetical protein, conserved   0.42 0.41 
Tb927.7.3970 hypothetical protein, conserved   0.16 0.33 
Tb927.1.1500 hypothetical protein, conserved   0.06 0.23 
Tb927.8.910 hypothetical protein, conserved   0.04 0.11 
Tb927.2.2770 hypothetical protein, conserved   0.43 0.41 
Tb927.11.2860 hypothetical protein, conserved   0.08 0.48 
Tb927.5.3290 hypothetical protein, conserved   0.40 0.50 
Tb927.11.14220 hypothetical protein, conserved   0.07 0.14 
Tb927.7.5340 hypothetical protein, conserved   0.21 0.19 
Tb927.10.9330 hypothetical protein, conserved   0.41 0.45 
Tb927.5.2000 hypothetical protein   0.35 0.32 
Tb927.8.7850 hypothetical protein, conserved   0.48 0.42 
Tb927.8.5110 hypothetical protein, conserved   0.09 0.24 
Tb927.8.1290 hypothetical protein, conserved   0.10 0.31 
Tb927.9.7520 hypothetical protein, conserved   0.30 0.42 
Tb927.9.4080 hypothetical protein, conserved   0.05 0.46 
Tb927.11.6860 hypothetical protein   0.27 0.35 
Tb927.8.880 hypothetical protein   0.15 0.38 
Tb927.9.15290 hypothetical protein, conserved   0.46 0.45 
Tb927.7.6690 hypothetical protein   0.19 0.31 
Tb927.3.4270 hypothetical protein, conserved   0.42 0.50 
Tb927.4.4580 hypothetical protein, conserved   0.45 0.37 
Tb927.6.620 hypothetical protein, conserved   0.46 0.47 
Tb927.10.15730 hypothetical protein, conserved   0.48 0.35 
Tb927.11.6440 hypothetical protein, conserved, often in TAP MS   0.37 0.31 
Tb927.8.5580 hypothetical protein, conserved   0.40 0.44 
Tb927.1.880 hypothetical protein, conserved   0.44 0.42 
Tb927.10.7230 hypothetical protein, conserved   0.49 0.47 
Tb927.1.4310 hypothetical protein, conserved   0.26 0.14 
Tb927.9.1750 hypothetical protein, conserved   0.36 0.36 
Tb927.7.3550 hypothetical protein, conserved   0.40 0.22 	  
6.2.2	  mRNAs	  up-­‐regulated	  in	  the	  procyclic	  ZC3H32-­‐myc	  cell	  line	  (as	  compared	  to	  WT)	  
Gene ID Annotation Class 
ZC3H32-
myc 
Tb927.8.6060 2-amino-3-ketobutyrate coenzyme A ligase, putative Amino acid metabolism 2.14 
Tb927.11.2230 carnitine O-acetyltransferase, putative (CAT) Amino acid metabolism 2.63 
Tb927.10.11970 kynurenine aminotransferase, putative Amino acid metabolism 4.46 
Tb927.11.6680 amino acid permease/transporter, putative Amino acid transporter 2.70 
Tb927.11.9790 calmodulin, putative Calcium 2.13 
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Tb927.4.3330 hyp. protein Calcium 2.20 
Tb927.10.370 calcineurin B subunit, putative Calcium 2.55 
Tb927.6.5020 cyclin 7, putative,CYC2-like cyclin, putative (CYC7) Cell cycle 3.31 
Tb927.11.5710 chaperone protein DNAj, putative Chaperone 2.00 
Tb927.2.5980 heat shock protein 104 (HSP104) Chaperone 2.06 
Tb927.10.15600 FKBP-type peptidyl-prolyl cis-trans isomerase, putative Chaperone 2.12 
Tb927.7.1320	   10	  kDa	  heat	  shock	  protein,	  putative	  (HSP10)	   Chaperone	   2.87 
Tb927.6.3850 chaperone protein DNAj, putative Chaperone 2.90 
Tb927.3.4500 fumarate hydratase, class I (FHc) Citric acid cycle 2.30 
Tb927.11.900 isocitrate dehydrogenase, putative (IDH) Citric acid cycle 2.90 
Tb927.10.14000 aconitase (ACO) Citric acid cycle 3.37 
Tb927.10.13430 citrate synthase, putative Citric acid cycle 6.59 
Tb927.11.4660 kinesin family member 6, putative (Kif13-2) Cytoskeleton 2.02 
Tb927.4.870 dynein heavy chain, putative Cytoskeleton 2.03 
Tb927.10.4690 dynein light chain, putative Cytoskeleton 2.06 
Tb927.10.1110 kinesin, putative Cytoskeleton 2.11 
Tb927.8.4840 kinesin, putative Cytoskeleton 2.13 
Tb927.11.11220 dynein heavy chain, putative Cytoskeleton 2.14 
Tb927.10.13330 paraflagellar rod protein PFC20 Cytoskeleton 2.16 
Tb927.2.3660 paraflagellar rod protein PFC10 Cytoskeleton 2.19 
Tb927.11.2430 dynein heavy chain, putative (DHC1b) or DYNC2H2 Cytoskeleton 2.19 
Tb927.2.5270 dynein heavy chain, putative Cytoskeleton 2.34 
Tb927.3.930 dynein heavy chain, putative Cytoskeleton 2.52 
Tb927.11.3250 dynein heavy chain, putative Cytoskeleton 2.54 
Tb927.8.3250 dynein heavy chain, putative Cytoskeleton 2.69 
Tb927.11.8160 dynein heavy chain, putative Cytoskeleton 2.88 
Tb927.11.320 unspecified product Cytoskeleton 2.90 
Tb927.11.16310 myosin, putative,myosin heavy chain, putative Cytoskeleton_Actin 2.03 
Tb927.10.10600 ARP2/3 complex 16kDa subunit, putative Cytoskeleton_Actin 2.32 
Tb927.2.2900 ARP2/3 complex subunit, putative Cytoskeleton_Actin 2.50 
Tb927.5.3760 meiotic recombination protein spo11, putative DNA synthesis, modification, repair 2.01 
Tb927.10.5490 hyp. protein,predicted HORMA domain protein DNA synthesis, modification, repair 2.10 
Tb927.2.5190 hyp. protein DNA synthesis, modification, repair 2.37 
Tb927.8.2210 pteridine reductase (PTR1) Folate 2.21 
Tb927.1.2820 pteridine transporter, putative Folate 2.70 
Tb927.8.3530 glycerol-3-phosphate dehydrogenase [NAD ], glycosomal Glucose & glycerol 2.19 
Tb927.10.4780 GPI inositol deacylase precursor (GPIdeAc) GPI anchors & metabolism 2.07 
Tb927.3.2610 GPI inositol deacylase 2 (GPIdeAc2) GPI anchors & metabolism 2.08 
Tb927.11.580 lipid-like atypical dual specificity phosphatase, putative Lipids & fatty acids 2.06 
Tb927.10.690 palmitoyl acyltransferase 3, putative Lipids & fatty acids 2.56 
Tb927.1.4490 acetyltransferase, putative Lipids & fatty acids 3.48 
Tb927.8.480 phosphatidic acid phosphatase protein, putative Lipids & fatty acids 23.26 
Tb927.5.1830 lysosomal/endosomal membrane protein p67 (p67) Lysosome 2.20 
Tb927.10.3760 vacuolar ATP synthase subunit d, putative Lysosome 2.39 
Tb927.4.1400 vacuolar transport protein 4A, putative Lysosome 2.41 
Tb927.11.10740 vacuolar sorting-associated protein-like, putative Lysosome 2.61 
Tb927.11.1470 65 kDa invariant surface glycoprotein (ISG65) Membrane protein 2.17 
Tb927.9.11640 hyp. protein, predicted GPI anchor Membrane protein 2.67 
Tb927.9.7830 mitochondrial tRNA import complex, putative Mitochondrial biogenesis 4.17 
Tb927.10.8950 kinetoplast DNA-associated protein, putative Mitochondrial DNA 2.15 
Tb927.11.11800 DNA repair and recombination helicase protein PIF3 Mitochondrial DNA 2.37 
Tb927.11.14790 DNA repair and recombination helicase protein PIF4 Mitochondrial DNA 3.44 
Tb927.11.15550 NADH-cytochrome b5 reductase, putative (B5R) Mitochondrial electron transport 2.07 
Tb927.11.6640 cytochrome b5, putative (CYB5) Mitochondrial electron transport 4.83 
Tb927.9.12500 hyp. protein Mitochondrial membrane 2.12 
Tb927.7.3590 Complex II subunit, putative Mitochondrial pathway 2.04 
Tb927.3.2180 Mitochondrial ATP synthase subunit, putative Mitochondrial pathway 2.08 
Tb927.10.5050 Mitochondrial ATP synthase epsilon subunit, putative Mitochondrial pathway 2.13 
Tb927.9.13580 hyp. protein Mitochondrial pathway 2.17 
Tb927.2.3610 Mitochondrial ATP synthase subunit, putative Mitochondrial pathway 2.42 
Tb927.5.510 hyp. protein Mitochondrial pathway 2.75 
Tb927.11.9800 serine peptidase, Clan SP, family S59, putative Nucleoporin Nucleo-cytoplasmic transport 2.05 
Tb927.5.1360 nucleoside 2-deoxyribosyltransferase (NDRT) Nucleotides 2.42 
Tb927.7.1790 Adenine phosphoribosyltransferase, putative Nucleotides-Purines 2.58 
Tb927.3.590 adenosine transporter, putative Nucleotides-Purines 5.56 
Tb927.8.4430 uridine phosphorylase;with=PDB:3BJE Nucleotides-Pyrimidines 2.94 
Tb927.11.14600 procyclin-associated gene 2-like protein, putative PAG 4.23 
Tb927.11.11740 membrane-bound acid phosphatase, putative Phosphatase 2.27 
Tb927.11.7320 dual specificity phopshatase, putative Phosphatase 2.38 
Tb927.10.3490 kinetoplastid-specific dual specificity phosphatase, putative Phosphatase 2.39 
Tb927.4.2670 pyroglutamyl-peptidase I (PGP), putative,cysteine peptidase Protease or peptidase 2.03 
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Tb927.10.14300 protein kinase, putative,serine/threonine protein kinase, putative Protein kinase 2.18 
Tb927.11.11110 protein kinase, putative,serine/threonine kinase, putative Protein kinase 2.73 
Tb927.9.1500 protein kinase, putative Protein kinase 2.86 
Tb927.11.4990 kinetoplastid-specific phospho-protein phosphatase, putative Protein phosphatase 2.43 
Tb927.9.6090 PTP1-interacting protein, 39 kDa PIP39 Protein phosphatase 3.71 
Tb927.3.5090 tryparedoxin, putative Redox pathways 2.44 
Tb927.11.1370 glutaredoxin, putative Redox pathways 2.53 
Tb927.11.3230 60S ribosomal protein L44 Ribosome 2.35 
Tb927.10.3380 60S acidic ribosomal protein P2 Ribosome 2.38 
Tb927.10.4120 60S ribosomal protein L30 Ribosome 2.60 
Tb927.9.15210 60S ribosomal protein L36 Ribosome 2.94 
Tb927.5.1820 60S acidic ribosomal protein Ribosome 3.35 
Tb927.11.5850 RBP38 RNA binding 2.27 
Tb927.6.4050 ZC3H14 RNA binding 2.30 
Tb927.7.4730 PUF5 RNA binding 2.38 
Tb927.9.4560 RBP32 RNA binding 4.66 
Tb927.10.5250 ZC3H32 RNA binding 13.29 
Tb927.10.2220 piwi-like protein 1 RNA degradation 2.49 
Tb927.10.16140 Adenylate/guanylate cyclase, putative Signalling 2.10 
Tb927.10.12170 RAB-interacting protein, putative Signalling 2.24 
Tb927.2.2260 PIK-related Signalling 3.00 
Tb927.7.5230 lanosterol synthase Sterols 2.05 
Tb927.8.2480 3-oxo-5-alpha-steroid 4-dehydrogenase-like, putative Sterols 2.20 
Tb927.4.4080 C-5 sterol desaturase, putative Sterols 2.24 
Tb927.11.9700 nascent polypeptide associated complex alpha subunit, putative Translation 2.55 
Tb927.4.2710 ubiquitin-conjugating enzyme e2, putative Ubiquitin & proteasome 2.16 
Tb927.11.12340 predicted Zinc finger, C3HC4 type (RING finger) protein Ubiquitin & proteasome 2.44 
Tb927.11.13940 ubiquitin-conjugating enzyme e2, putative Ubiquitin & proteasome 2.92 
Tb927.8.3660 protein transport protein Sec23 (SEC23.1) Vesicular transport 2.06 
Tb927.11.10270 golgi SNARE protein-like, putative Vesicular transport 2.07 
Tb927.2.5120 vesicle-associated membrane protein, in Tc vacuolar proteome Vesicular transport 2.11 
Tb927.9.10010 Sec63 homologue, chaperone protein DNAj Vesicular transport 2.17 
Tb927.9.14080 vesicle-associated membrane protein, putative Vesicular transport 2.18 
Tb927.8.7050 mu-adaptin 4, adaptor complex AP-4 medium subunit, putative Vesicular transport 2.21 
Tb927.7.3160 dynein heavy chain, cytosolic, putative Vesicular transport 2.22 
Tb927.11.14240 hyp. protein Vesicular transport 2.24 
Tb927.11.5490 synaptojanin (N-terminal domain), putative Vesicular transport 2.35 
Tb927.7.6440 hyp. protein Vesicular transport 2.37 
Tb927.9.12870 hyp. protein Vesicular transport 2.61 
Tb927.10.580 hyp. protein   2.01 
Tb927.2.5970 hyp. protein   2.01 
Tb927.11.13630 hyp. protein   2.01 
Tb927.7.1700 hyp. protein   2.01 
Tb927.9.12390 hyp. protein   2.01 
Tb927.4.4890 hyp. protein   2.02 
Tb927.7.5830 hyp. protein   2.02 
Tb927.8.7480 hyp. protein   2.02 
Tb927.8.5590 hyp. protein   2.02 
Tb927.11.14540 hyp. protein   2.03 
Tb927.10.7830 hyp. protein   2.03 
Tb927.10.4140 hyp. protein   2.04 
Tb927.7.5510 hyp. protein   2.04 
Tb927.4.1260 hyp. protein   2.05 
Tb927.11.8900 hyp. protein   2.05 
Tb927.11.520 hyp. protein   2.05 
Tb927.11.12620 hyp. protein   2.05 
Tb927.3.4480 hyp. protein   2.05 
Tb927.3.1550 hyp. protein   2.06 
Tb927.11.5620 hyp. protein   2.06 
Tb927.11.16330 hyp. protein   2.06 
Tb927.8.2110 hyp. protein   2.06 
Tb927.11.7090 hyp. protein   2.06 
Tb927.5.1590 hyp. protein   2.07 
Tb927.7.7190 hyp. protein   2.07 
Tb927.11.5640 hyp. protein   2.07 
Tb927.3.4870 hyp. protein   2.07 
Tb927.10.7000 hyp. protein   2.08 
Tb927.1.1300 hyp. protein   2.09 
Tb927.10.9690 hyp. protein,predicted C2 domain protein   2.11 
Tb927.8.5050 hyp. protein   2.11 
Tb927.8.4340 hyp. protein   2.11 
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Tb927.3.3600 hyp. protein   2.12 
Tb927.7.4750 hyp. protein   2.12 
Tb927.5.3260 hyp. protein   2.12 
Tb927.8.7990 hyp. protein   2.13 
Tb927.11.15610 hyp. protein   2.13 
Tb927.11.5660 hyp. protein   2.13 
Tb927.7.4230 hyp. protein   2.13 
Tb927.3.2380 hyp. protein   2.14 
Tb927.8.3390 hyp. protein   2.14 
Tb927.11.2190 hyp. protein   2.15 
Tb927.8.5160 hyp. protein   2.16 
Tb927.3.2360 hyp. protein   2.18 
Tb927.2.1790 hyp. protein   2.18 
Tb927.2.4680 hyp. protein   2.18 
Tb927.11.6100 hyp. protein   2.18 
Tb927.4.1830 hyp. protein   2.19 
Tb927.7.490 hyp. protein   2.19 
Tb927.11.2930 hyp. protein   2.19 
Tb927.9.1750 hyp. protein   2.19 
Tb927.10.11060 hyp. protein   2.20 
Tb927.3.1870 hyp. protein   2.20 
Tb927.8.5550 hyp. protein   2.20 
Tb927.9.10360 hyp. protein   2.20 
Tb927.7.3130 hyp. protein   2.21 
Tb927.10.15730 hyp. protein   2.22 
Tb927.8.1700 hyp. protein   2.22 
Tb927.9.12950 hyp. protein   2.23 
Tb927.4.2570 hyp. protein   2.24 
Tb927.6.2870 hyp. protein   2.24 
Tb927.10.9270 hyp. protein   2.24 
Tb927.8.5190 hyp. protein   2.24 
Tb927.8.5870 hyp. protein   2.26 
Tb927.5.1290 hyp. protein   2.27 
Tb927.9.1360 hyp. protein   2.27 
Tb927.8.5580 hyp. protein   2.28 
Tb927.11.12840 hyp. protein   2.28 
Tb927.11.5790 hyp. protein   2.28 
Tb927.10.1810 hyp. protein   2.29 
Tb927.3.5390 hyp. protein   2.29 
Tb927.8.2190 hyp. protein   2.31 
Tb927.5.1220 hyp. protein   2.32 
Tb927.11.4510 hyp. protein   2.32 
Tb927.4.1390 hyp. protein   2.33 
Tb927.4.2380 sarcoplasmic reticulum glycoprotein, putative   2.34 
Tb927.7.3600 hyp. protein   2.34 
Tb927.7.3530 hyp. protein   2.34 
Tb927.3.650 hyp. protein   2.35 
Tb927.8.7550 hyp. protein   2.36 
Tb927.8.1970 hyp. protein   2.36 
Tb927.9.13070 hyp. protein,predicted heat shock factor binding protein   2.37 
Tb927.5.3790 hyp. protein   2.37 
Tb927.9.10160 hyp. protein   2.37 
Tb927.10.1650 hyp. protein   2.38 
Tb927.11.1170 hyp. protein   2.38 
Tb927.10.4660 hyp. protein   2.38 
Tb927.1.1040 hyp. protein   2.38 
Tb927.3.5080 hyp. protein   2.39 
Tb927.9.7040 hyp. protein   2.39 
Tb927.3.1260 hyp. protein   2.40 
Tb927.10.2850 hyp. protein   2.40 
Tb927.10.3530 hyp. protein   2.41 
Tb927.4.370 hyp. protein   2.41 
Tb927.8.6890 hyp. protein   2.42 
Tb927.1.1880 hyp. protein   2.42 
Tb927.8.5270 hyp. protein   2.43 
Tb927.11.390 hyp. protein   2.44 
Tb927.10.12080 hyp. protein   2.45 
Tb927.8.5850 hyp. protein   2.45 
Tb927.11.15410 hyp. protein   2.48 
Tb927.1.780 hyp. protein   2.48 
Tb927.9.8330 hyp. protein   2.49 
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Tb927.10.2340 hyp. protein   2.49 
Tb927.1.1640 hyp. protein   2.50 
Tb927.4.520 hyp. protein   2.51 
Tb927.3.2460 hyp. protein   2.51 
Tb927.8.5320 hyp. protein   2.52 
Tb927.5.2350 hyp. protein   2.53 
Tb927.2.3340 hyp. protein   2.53 
Tb927.4.2420 hyp. protein   2.54 
Tb927.8.3990 hyp. protein   2.54 
Tb927.4.3520 hyp. protein   2.54 
Tb927.11.12990 hyp. protein   2.56 
Tb927.11.5540 hyp. protein   2.57 
Tb927.11.3460 hyp. protein   2.57 
Tb927.10.2820 hyp. protein   2.58 
Tb927.7.860 hyp. protein   2.58 
Tb927.9.9810 hyp. protein   2.58 
Tb927.10.6560 hyp. protein   2.59 
Tb927.11.7550 hyp. protein   2.61 
Tb927.10.14450 hyp. protein   2.62 
Tb927.4.3340 hyp. protein   2.63 
Tb927.7.7000 hyp. protein   2.66 
Tb927.10.2920 hyp. protein   2.68 
Tb927.10.2400 hyp. protein   2.69 
Tb927.9.3750 hyp. protein   2.70 
Tb927.8.5900 hyp. protein   2.70 
Tb927.11.15510 hyp. protein   2.72 
Tb927.10.1300 hyp. protein   2.79 
Tb927.4.3500 hyp. protein   2.80 
Tb927.11.1330 hyp. protein   2.83 
Tb927.3.2940 hyp. protein   2.84 
Tb927.10.440 hyp. protein   2.84 
Tb927.11.15670 hyp. protein   2.88 
Tb927.10.14350 hyp. protein   2.94 
Tb927.9.8320 hyp. protein   2.97 
Tb927.4.4320 divalent cation tolerance protein, putative   3.02 
Tb927.7.3660 hyp. protein   3.04 
Tb927.10.14370 hyp. protein   3.10 
Tb927.9.4550 hyp. protein   3.10 
Tb927.11.9120 hyp. protein   3.12 
Tb927.8.6100 hyp. protein   3.16 
Tb927.11.16260 hyp. protein   3.17 
Tb927.10.9300 adiponectin receptor protein 1   3.20 
Tb927.3.2920 hyp. protein   3.28 
Tb927.9.12740 hyp. protein   3.29 
Tb927.11.13610 hyp. protein   3.29 
Tb927.11.9860 hyp. protein   3.31 
Tb927.10.10770 hyp. protein   3.34 
Tb927.4.4390 hyp. protein   3.35 
Tb927.9.10510 hyp. protein   3.36 
Tb927.11.15660 hyp. protein   3.37 
Tb927.4.390 hyp. protein   3.38 
Tb927.10.9510 hyp. protein   3.40 
Tb927.10.2970 hyp. protein   3.42 
Tb927.10.300 hyp. protein   3.43 
Tb927.4.500 hyp. protein   3.43 
Tb927.4.4780 hyp. protein   3.47 
Tb927.5.4020 hyp. protein   3.63 
Tb927.9.8030 hyp. protein   3.64 
Tb927.9.8760 hyp. protein   3.78 
Tb927.4.3480 hyp. protein   3.89 
Tb927.10.780 hyp. protein   4.14 
Tb927.11.5720 hyp. protein   4.20 
Tb927.9.10930 hyp. protein   4.41 
Tb927.11.2460 hyp. protein   4.47 
Tb927.9.15690 hyp. protein   4.61 
Tb927.10.3360 hyp. protein   4.90 
Tb927.11.15200 hyp. protein   5.08 
Tb927.7.2180 hyp. protein   6.45 
Tb927.9.11910 hyp. protein   11.84 
Tb927.9.15350 hyp. protein   28.87 
Tb927.9.15100 hyp. protein   237.48 
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6.2.3	  mRNAs	  down-­‐regulated	  in	  the	  procyclic	  ZC3H32-­‐myc	  cell	  line	  (as	  compared	  to	  WT)	  	  
Gene ID Annotation Class 
ZC3H32
- myc 
Tb927.8.6340 CYC2-like cyclin, putative (CYC10) Cell cycle 0.14 
Tb927.9.10950 chaperone protein DNAj, putative Chaperone 0.22 
Tb927.10.2620 HSP20 cold-shock domain (p23-like) Chaperone 0.35 
Tb927.10.12380 chaperone protein DNAj, putative Chaperone 0.48 
Tb927.10.2290 chaperone protein DNAj, endoplasmatic reticulum Chaperone 0.49 
Tb927.3.3490 high mobility group protein, putative (TDP1) Chromatin 0.41 
Tb927.11.2690 succinyl-coA:3-ketoacid-coenzyme A transferase, putative Citric acid cycle 0.35 
Tb927.10.2560 mitochondrial malate dehydrogenase (mMDH) Citric acid cycle 0.38 
Tb927.10.5960 engulfment and cell motility domain 2, putative cytoskeleton 0.35 
Tb927.11.12180 kinesin, putative Cytoskeleton 0.41 
Tb927.10.2640 intraflagellar transport protein IFT81, putative Cytoskeleton 0.45 
Tb927.7.3000 kinesin, putative Cytoskeleton 0.45 
Tb927.10.12490 kinesin, putative Cytoskeleton 0.47 
Tb927.10.450 hyp. protein Cytoskeleton 0.47 
Tb927.11.7820 endonuclease/exonuclease/phosphatase, putative DNA synthesis, modification, repair 0.04 
Tb927.4.1330 DNA topoisomerase IB, large subunit DNA synthesis, modification, repair 0.42 
Tb927.9.14120 hyp. protein, phosphatase domain enzyme 0.31 
Tb927.7.5450 lipin, putative Enzyme 0.41 
Tb927.8.3970 oxidoreductase, putative Enzyme 0.43 
Tb927.5.2650 L-galactonolactone oxidase (GAL/ALO) Enzyme 0.43 
Tb927.10.9560 oxidoreductase, putative Enzyme 0.48 
Tb927.7.1930 nucleoside diphosphatase, putative5 Enzyme 0.49 
Tb927.10.2020 hexokinase (HK2) Glucose & glycerol 0.18 
Tb927.7.2420 glycogen synthase kinase-3 alpha, putative Glycan synthesis & metabolism 0.07 
Tb927.10.2570 lysosomal alpha-mannosidase precursor, putative Glycan synthesis & metabolism 0.37 
Tb927.5.2760 UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase, putative Glycan synthesis & metabolism 0.44 
Tb927.10.12290 UDP-Gal or UDP-GlcNAc-dependent glycosyltransferase, putative Glycan synthesis & metabolism 0.45 
Tb927.6.1140 
dolichyl-P-Man:GDP-Man5GlcNAc2-PP-dolichyl alpha-1,2-
mannosyltransferase, putative Glycan synthesis & metabolism 0.49 
Tb927.9.15460 calcium motive p-type ATPase, putative Ion channel or pump 0.50 
Tb927.10.4050 serine palmitoyltransferase, putative Lipids & fatty acids 0.25 
Tb927.11.3350 phospholipid-transporting ATPase 1-like protein, putative Lipids & fatty acids 0.31 
Tb927.2.3080 fatty acid desaturase, putative,oleate desaturase, putative Lipids & fatty acids 0.46 
Tb927.6.3550 phospholipid-translocating P-type ATPase (flippase), putative Lipids & fatty acids 0.47 
Tb927.10.8900 Choline phosphotransferase Lipids & fatty acids 0.47 
Tb927.10.2410 MSP-C, putative Membrane protein 0.40 
Tb927.11.15040 chaperonin HSP60, mitochondrial precursor Mitochondrial biogenesis 0.46 
Tb927.6.4090 chaperonin HSP60, mitochondrial precursor Mitochondrial biogenesis 0.48 
Tb927.1.4010 TbPRI2, primase 2, kDNA replication Mitochondrial DNA 0.26 
Tb927.11.6890 DNA repair and recombination helicase protein PIF1 Mitochondrial DNA 0.36 
Tb927.1.3800 hyp. protein Mitochondrial membrane 0.39 
Tb927.5.520 stomatin-like protein, putative Mitochondrial pathway 0.37 
Tb927.7.7080 mitochondrial glycoprotein-like protein Mitochondrial pathway 0.49 
Tb927.10.10830 RGG2, MRB complex component Mitochondrial RNA 0.29 
Tb927.6.2140 Mitochondrial RNA binding complex I component, putative Mitochondrial RNA 0.36 
Tb927.3.1820 mitochondrial RNA binding complex 1 subunit Mitochondrial RNA 0.40 
Tb927.9.13780 Mitchondrial SSU ribosomal protein Mitochondrial translation 0.06 
Tb927.6.4080 Mitchondrial LSU ribosomal protein Mitochondrial translation 0.37 
Tb927.9.14050 Mitchondrial LSU ribosomal protein Mitochondrial translation 0.49 
Tb927.11.3380 Ran-binding protein 1, putative Nucleo-cytoplasmic transport 0.40 
Tb927.6.1970 nuclear cap binding protein, putative (CBC20) Nucleo-cytoplasmic transport 0.45 
Tb927.6.4740 importin-alpha re-exporter protein, putative Nucleo-cytoplasmic transport 0.46 
Tb927.6.2640 importin alpha subunit, putative (TbKap60) Nucleo-cytoplasmic transport 0.46 
Tb927.10.2530 adenylate kinase, putative Nucleotides-Purines 0.29 
Tb927.6.220 purine nucleoside transporter (TbNT9) Nucleotides-Purines 0.37 
Tb927.9.7470 purine nucleoside transporter (TbNT10) Nucleotides-Purines 0.43 
Tb927.11.3650 adenylosuccinate synthetase, putative Nucleotides-Purines 0.43 
Tb927.10.16120 inosine-5'-monophosphate dehydrogenase,IMP dehydrogenase Nucleotides-Purines 0.49 
Tb927.7.4570 inosine-guanine nucleoside hydrolase (IG-NH) Nucleotides-Purines 0.49 
Tb927.10.10810 adenosine deaminase-like protein Nucleotides-Purines 0.49 
Tb927.5.3620 kinetoplastid-specific dual specificity phosphatase, putative Phosphatase 0.34 
Tb927.6.4540 HMG-CoA reductase Prenylation 0.47 
Tb927.6.400 peptidase M20/M25/M40, putative Protease or peptidase 0.35 
Tb927.10.9600 protein kinase, putativ Protein kinase 0.03 
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Tb927.6.2030 protein kinase, putative Protein kinase 0.03 
Tb927.11.16790 mitogen-activated protein kinase (ECK1) Protein kinase 0.05 
Tb927.3.1630 casein kinase 1, putative (CK1) Protein kinase 0.08 
Tb927.2.1820 protein kinase, putative Protein kinase 0.14 
Tb927.8.870 serine/threonine kinase, putative,protein kinase, putative Protein kinase 0.21 
Tb927.11.14070 protein kinase, putative Protein kinase 0.22 
Tb927.7.6220 protein kinase, putative Protein kinase 0.26 
Tb927.1.1380 serine/threonine protein phosphatase 2A reg. subunit, putative Protein kinase 0.26 
Tb927.7.6680 protein kinase, putative Protein kinase 0.27 
Tb927.11.7010 protein kinase, putative Protein kinase 0.30 
Tb927.2.4200 protein kinase, putative Protein kinase 0.30 
Tb927.7.3650 protein kinase, putative Protein kinase 0.31 
Tb927.10.10870 protein kinase, putative Protein kinase 0.35 
Tb927.2.2720 protein kinase, putative Protein kinase 0.38 
Tb927.7.5770 Nuclear Dbf2-related kinase (PK53) Protein kinase 0.39 
Tb927.11.4610 protein kinase A regulatory subunit (PKA-R) Protein kinase 0.41 
Tb927.10.3340 protein kinase, putative Protein kinase 0.42 
Tb927.10.10350 protein kinase, putative Protein kinase 0.42 
Tb927.6.4970 serine/arginine-rich protein specific kinase SRPK, putative Protein kinase 0.48 
Tb927.10.15020 protein kinase, putative Protein kinase 0.49 
Tb927.6.640 kinetoplastid-specific phospho-protein phosphatase, putative Protein phosphatase 0.09 
Tb927.10.14270 TFIIF-stimulated CTD phosphatase, putative Protein phosphatase 0.11 
Tb927.6.1800 protein phosphatase 2C, putative Protein phosphatase 0.20 
Tb927.10.8050 TFIIF-stimulated CTD phosphatase, putative Protein phosphatase 0.27 
Tb927.7.4020 protein phosphatase 2C, putative Protein phosphatase 0.35 
Tb927.4.3680 protein phosphatase 2C, putative Protein phosphatase 0.48 
Tb927.6.2050 ribosome biogenesis regulatory protein (RRS1), putative Ribosome 0.46 
Tb927.11.530 RBP3 RNA binding 0.03 
Tb927.6.820 PUF4 RNA binding 0.03 
Tb927.6.3490 ZFP1 RNA binding 0.04 
Tb927.10.12660 PUF2 RNA binding 0.07 
Tb927.11.8470 ZC3H45 RNA binding 0.08 
Tb927.8.2780 RBP10 RNA binding 0.11 
Tb927.10.5150 ZC3H31 RNA binding 0.12 
Tb927.11.16550 ZC3H46 RNA binding 0.12 
Tb927.3.1910 hyp. protein RNA binding 0.14 
Tb927.3.5250 ZC3H8 RNA binding 0.16 
Tb927.1.2600 PUF9 RNA binding 0.17 
Tb927.4.4230 RBP31 RNA binding 0.17 
Tb927.7.3730 RBP26 RNA binding 0.17 
Tb927.7.5380 RNA-binding protein, putative, RBD RNA binding 0.23 
Tb927.10.14930 ZC3H39 RNA binding 0.25 
Tb927.10.12330 ZC3H34 RNA binding 0.30 
Tb927.9.9520 ZC3H29 RNA binding 0.35 
Tb927.8.6650 DRBD12 RNA binding 0.39 
Tb927.5.760 cell cycle sequence binding phosphoprotein (RBP33), CSBP2 RNA binding 0.40 
Tb927.9.13280 DRBD10 RNA binding 0.40 
Tb927.3.3670 TRRM3 RNA binding 0.42 
Tb927.10.12760 ZC3H36 RNA binding 0.43 
Tb927.9.13990 DRBD2 RNA binding 0.44 
Tb927.8.710 DRBD17 RNA binding 0.46 
Tb927.5.810 ZC3H11 RNA binding 0.49 
Tb927.3.1030 RPB28 RNA binding 0.49 
Tb927.6.600 NOT complex subunit CAF1 deadenylase RNA degradation 0.15 
Tb927.6.4770 MKT1 RNA degradation 0.26 
Tb927.11.550 SCD6 RNA degradation 0.30 
Tb927.8.900 splicing factor TSR1 (TSR1) RNA processing 0.30 
Tb927.2.3880 heterogeneous nuclear ribonucleoprotein H/F, putative (HNRNPH) RNA processing 0.30 
Tb927.2.4710 TRRM1 RNA processing 0.33 
Tb927.6.2700 small nuclear ribonucleoprotein Sm-E RNA processing 0.37 
Tb927.2.5240 PRP19-like protein, putative (TbPRP19) RNA processing 0.48 
Tb927.3.3590 U3 small nucleolar ribonucleoprotein protein MPP10, putative RNA processing 0.48 
Tb927.3.3160 poly(A) polymerase,polynucleotide adenylyltransferase (PAP) RNA processing 0.49 
Tb927.11.10420 DNA-directed RNA polymerase, putative (RPA12) RNA synthesis I 0.47 
Tb927.2.3580 transcription elongation factor s-II, putative (TFIIS2-1) RNA synthesis II 0.39 
Tb927.4.470 snoRNP protein GAR1, putative rRNA-tRNA processing 0.22 
Tb927.11.3070 hyp. protein rRNA-tRNA processing 0.45 
Tb927.8.2500 ribosomal RNA methyltransferase, putative rRNA-tRNA processing 0.48 
Tb927.10.7190 D-tyrosyl-tRNA deacylase, putative rRNA-tRNA processing 0.49 
Tb927.10.14550 ATP-dependent DEAD/H RNA helicase, DED1-1 Translation 0.05 
Tb927.5.1490 eukaryotic initiation factor 4G, eIF4G1 translation 0.19 
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Tb927.9.11050 4E-interacting protein, putative Translation 0.34 
Tb927.6.3870 SGN1 Translation 0.37 
Tb927.11.2260 eukaryotic translation initiation factor 4e, eIF4E1 Translation 0.46 
Tb927.9.12510 ATP-dependent DEAD/H RNA helicase, DED1-2 Translation 0.46 
Tb927.5.2570 translation initiation factor, putative (EIF3B) Translation 0.48 
Tb927.6.700 alanyl-tRNA synthetase, putative Translation tRNA 0.43 
Tb927.6.2060 histidyl-tRNA synthetase Translation tRNA 0.45 
Tb927.6.4590 glutamyl-tRNA synthetase, putative Translation tRNA 0.45 
Tb927.5.2430 membrane transporter protein, putative Transporter 0.18 
Tb927.2.5410 ABC transporter, putative. multidrug resistance protein Transporter 0.44 
Tb927.5.2400 ubiquitin carboxyl-terminal hydrolase, putative Ubiquitin & proteasome 0.25 
Tb927.9.13430 ubiquitin carboxyl-terminal hydrolase, putative Ubiquitin & proteasome 0.34 
Tb927.6.1260 proteasome beta-1 subunit, putative (TbPSB1) Ubiquitin & proteasome 0.48 
Tb927.6.440 haptoglobin-hemoglobin receptor (HpHbR) Vesicular transport 0.19 
Tb927.8.4770 small GTP-binding protein Rab18 (TbRAB18) Vesicular transport 0.29 
Tb927.6.4670 MORN repeat-containing protein,flagellar component (TbMORN1) Vesicular transport 0.33 
Tb927.6.3650 ADP-ribosylation factor, putative Vesicular transport 0.38 
Tb927.5.2660 hyp. protein Vesicular transport 0.45 
Tb927.10.6230 hyp. protein,MORN repeat containing protein Vesicular transport 0.49 
Tb927.6.350 hyp. protein Zinc finger 0.29 
Tb927.8.910 hyp. protein   0.02 
Tb927.11.2820 hyp. protein   0.02 
Tb927.11.16780 hyp. protein   0.02 
Tb927.6.690 hyp. protein   0.03 
Tb927.10.15310 hyp. protein   0.03 
Tb927.8.7820 hyp. protein   0.03 
Tb927.10.3400 hyp. protein   0.04 
Tb927.6.2520 hyp. protein   0.05 
Tb927.11.6600 hyp. protein   0.06 
Tb927.11.14220 hyp. protein   0.06 
Tb927.10.9610 hyp. protein   0.06 
Tb927.4.4520 hyp. protein   0.06 
Tb927.11.3720 hyp. protein   0.06 
Tb927.11.2860 hyp. protein   0.07 
Tb927.9.4080 hyp. protein   0.07 
Tb927.8.4200 hyp. protein   0.07 
Tb927.7.6300 hyp. protein   0.07 
Tb927.4.1910 hyp. protein   0.09 
Tb927.1.1500 hyp. protein   0.10 
Tb927.8.5110 hyp. protein   0.10 
Tb927.7.3970 hyp. protein   0.11 
Tb927.2.2340 hyp. protein   0.11 
Tb927.10.9630 hyp. protein   0.14 
Tb927.6.3880 hyp. protein   0.15 
Tb927.7.6340 hyp. protein   0.16 
Tb927.5.2620 hyp. protein   0.19 
Tb927.11.16820 hyp. protein   0.19 
Tb927.6.860 hyp. protein   0.20 
Tb927.4.1010 hyp. protein   0.20 
Tb927.3.4590 hyp. protein   0.21 
Tb927.5.2360 hyp. protein   0.21 
Tb927.4.1000 hyp. protein   0.22 
Tb927.10.11630 hyp. protein   0.23 
Tb927.5.2390 hyp. protein   0.25 
Tb927.10.15040 hyp. protein   0.26 
Tb927.11.12690 hyp. protein   0.26 
Tb927.10.8730 hyp. protein   0.26 
Tb927.6.2160 hyp. protein   0.27 
Tb927.5.2300 formin, putative   0.28 
Tb927.3.600 hyp. protein   0.28 
Tb927.7.5340 hyp. protein   0.28 
Tb927.10.2580 hyp. protein   0.29 
Tb927.10.12430 hyp. protein   0.29 
Tb927.11.2870 hyp. protein   0.29 
Tb927.9.7520 hyp. protein   0.29 
Tb927.6.2530 hyp. protein   0.29 
Tb927.11.11880 hyp. protein   0.30 
Tb927.3.3060 hyp. protein   0.30 
Tb927.8.7290 hyp. protein   0.31 
Tb927.10.12060 hyp. protein   0.32 
Tb927.11.13110 hyp. protein   0.32 
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Tb927.4.3970 hyp. protein   0.33 
Tb927.10.12270 hyp. protein   0.33 
Tb927.10.12390 hyp. protein   0.34 
Tb927.6.2090 hyp. protein   0.34 
Tb927.7.4680 hyp. protein   0.34 
Tb927.7.5270 hyp. protein   0.34 
Tb927.9.9370 hyp. protein   0.35 
Tb927.10.2460 hyp. protein   0.35 
Tb927.1.4020 hyp. protein   0.36 
Tb927.2.3090 hyp. protein   0.37 
Tb927.7.6700 hyp. protein   0.37 
Tb927.10.2700 hyp. protein,predicted WD40 repeat protein   0.37 
Tb927.8.1270 hyp. protein   0.38 
Tb927.5.2730 hyp. protein   0.38 
Tb927.10.14940 hyp. protein   0.38 
Tb927.7.6210 hyp. protein   0.38 
Tb927.5.2530 hyp. protein   0.38 
Tb927.8.1290 hyp. protein   0.38 
Tb927.11.12540 hyp. protein   0.38 
Tb927.6.2120 hyp. protein   0.38 
Tb927.1.1470 hyp. protein   0.39 
Tb927.11.3300 hyp. protein   0.39 
Tb927.6.4380 hyp. protein   0.40 
Tb927.11.11760 hyp. protein   0.40 
Tb927.10.12410 hyp. protein   0.40 
Tb927.6.4320 hyp. protein   0.40 
Tb927.5.2500 hyp. protein   0.40 
Tb927.4.1900 hyp. protein   0.41 
Tb927.8.1150 hyp. protein   0.41 
Tb927.3.1010 hyp. protein   0.41 
Tb927.5.2310 hyp. protein   0.41 
Tb927.7.4720 hyp. protein   0.41 
Tb927.6.4520 hyp. protein   0.41 
Tb927.5.2520 hyp. protein   0.42 
Tb927.5.2630 hyp. protein   0.42 
Tb927.5.2640 hyp. protein   0.42 
Tb927.6.410 hyp. protein   0.42 
Tb927.11.5810 hyp. protein   0.43 
Tb927.10.1560 hyp. protein   0.43 
Tb927.10.5730 hyp. protein   0.43 
Tb927.7.3380 hyp. protein   0.43 
Tb927.1.740 hyp. protein   0.43 
Tb927.9.13320 hyp. protein   0.43 
Tb927.6.4360 hyp. protein   0.43 
Tb927.5.4100 hyp. protein   0.43 
Tb927.5.2670 hyp. protein   0.44 
Tb927.8.5670 hyp. protein   0.44 
Tb927.6.2620 hyp. protein   0.44 
Tb927.11.12300 hyp. protein   0.44 
Tb927.5.600 hyp. protein   0.44 
Tb927.6.3700 hyp. protein   0.44 
Tb927.7.4780 hyp. protein   0.44 
Tb927.6.3180 hyp. protein   0.44 
Tb927.6.1470 hyp. protein   0.44 
Tb927.1.4680 hyp. protein   0.44 
Tb927.5.840 hyp. protein   0.45 
Tb927.11.780 hyp. protein   0.45 
Tb927.1.4710 hyp. protein   0.45 
Tb927.5.2600 hyp. protein   0.46 
Tb927.3.2780 hyp. protein   0.46 
Tb927.5.1260 hyp. protein   0.46 
Tb927.11.13570 hyp. protein   0.46 
Tb927.11.16450 hyp. protein   0.46 
Tb927.5.2320 hyp. protein   0.46 
Tb927.6.1830 hyp. protein   0.46 
Tb927.10.11600 hyp. protein   0.46 
Tb927.5.2770 hyp. protein   0.46 
Tb927.1.2210 hyp. protein   0.47 
Tb927.2.3420 hyp. protein   0.47 
Tb927.7.6690 hyp. protein   0.47 
Tb927.4.2160 hyp. protein   0.47 
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Tb927.10.5090 hyp. protein   0.47 
Tb927.10.2930 hyp. protein   0.47 
Tb927.1.2750 hyp. protein   0.47 
Tb927.8.6670 hyp. protein   0.47 
Tb927.3.3260 hyp. protein   0.47 
Tb927.2.3400 hyp. protein, copurified with splicing complex   0.47 
Tb927.10.7720 hyp. protein   0.48 
Tb927.9.13460 hyp. protein   0.48 
Tb927.6.3710 hyp. protein   0.48 
Tb927.7.2450 hyp. protein   0.48 
Tb927.8.2600 hyp. protein   0.48 
Tb927.5.2110 hyp. protein   0.48 
Tb927.11.1690 hyp. protein   0.48 
Tb927.11.5200 hyp. protein   0.48 
Tb927.8.1320 hyp. protein   0.48 
Tb927.10.14150 hyp. protein   0.48 
Tb927.6.630 hyp. protein   0.49 
Tb927.4.710 hyp. protein   0.49 
Tb927.7.4440 hyp. protein   0.49 
Tb927.8.5300 hyp. protein   0.49 
Tb927.7.180 hyp. protein   0.49 
Tb927.5.2440 hyp. protein   0.49 
Tb927.10.8640 hyp. protein   0.49 
Tb927.11.12720 hyp. protein   0.49 
Tb927.8.4310 hyp. protein   0.49 
Tb927.11.12940 hyp. protein   0.49 
Tb927.11.820 hyp. protein   0.49 
Tb927.8.3950 hyp. protein   0.49 
Tb927.10.3330 hyp. protein   0.49 
Tb927.1.1700 hyp. protein   0.49 
Tb927.5.2840 hyp. protein   0.49 
Tb927.5.770 hyp. protein   0.49 
Tb927.10.13800 hyp. protein   0.50 
Tb927.11.1420 hyp. protein   0.50 
Tb927.10.4790 hyp. protein   0.50 
Tb927.10.14330 hyp. protein   0.50 
Tb927.7.1360 hyp. protein   0.50 	  
